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Abstract 
Protein ubiquitination is a key regulator of both protein stability and activity, and is 
involved in the regulation of a vast variety of cellular pathways. The ubiquitination 
system therefore provides an exciting target for drug development aiming to regulate 
the function of specific proteins. Our understanding of ubiquitin signalling is far 
from complete; and if we are to exploit this system for the benefit of human health, it 
is important to gain a better understanding of this complex posttranslational 
modification system as well as the effect of ubiquitination on the target protein. The 
E3 ligases MDM2 and CHIP were implicated in the control of the two transcriptional 
activators (TAs) IRF-1 and p53, that normally function to maintain health at the 
cellular and organismal level. Research carried out as part of my PhD has focused on 
gaining a mechanistic understanding of the ubiquitination process in particular the 
relationship between the E3 ligase and its substrate. Broadly, the mechanisms of E3 
ligase regulation have been linked to substrate specificity and then to the 
physiological outcome of site-specific ubiquitination of the DNA binding domain of 
the TAs IRF-1 and p53. More specifically I have; (i) identified a mechanism by 
which the E3 ligase activity of the CHIP U-box can be allosterically regulated by 
ligand binding to its TPR domain. (ii) Residues on IRF-1 that are targeted by MDM2 
and CHIP have been mapped, revealing that both ligases modify sites exclusively in 
IRF-1's DNA binding domain (DBD). Furthermore, I showed that, in its DNA bound 
conformation, IRF-1 is neither bound nor ubiquitinated by the ligases, suggesting a 
mechanism by which IRF-1 ubiquitination and possibly degradation can be regulated 
through its DNA binding state. And lastly, (iii) I have shown that both IRF-1 and 
p53, which have ubiquitin acceptor lysines in their DBD, bind DNA more stably 
when ubiquitinated. Modelling suggests that interactions between a positively 
charged surface area of ubiquitin and the negatively charged DNA can stabilises the 
TA-ubiquitin complex. DBD ubiquitination sites are required for full transactivation 
potential of both TAs, supporting a role of ubiquitin in their activation. p53 is 
ubiquitinated in response to activation by IR or Nutlin-3 and these ubiquitinated 
forms of p53 are localised in the cell nucleus associated with chromatin and do not 
lead to protein degradation. Taken together, the data imply that p53 and IRF-1 DNA 
binding ability, and thereby activity, can be modulated by ubiquitin modification. 
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1. Introduction  1 
Chapter 1: Introduction 
 
1.1 Ubiquitination 
Protein ubiquitination, first discovered in 1975 by Aaron Ciechanover, Avram 
Hershko and Irwin Rose [1, 2], was shown to play a major role in proteasomal 
degradation of proteins. One or several ubiquitin molecules, a protein consisting of 
76 amino acids, are attached to a lysine on a target substrate. A chain of a minimum 
of four ubiquitin molecules is recognised by the 26S subunit of the proteasome and 
subsequently unfolded and degraded [3]. Degradation of proteins by the 
ubiquitin/proteasome pathway (UPS) is the most prevalent mechanism of controlled 
protein degradation in cells. Levels of many proteins are tightly controlled to ensure 
their function and enable a quick and controlled response to stresses or stimuli. This 
is especially important for proteins involved in mechanisms ensuring cellular 
homeostasis, e.g. proteins that play a role in the cell stress response, cell cycle and 
cell death pathways. In addition to these functions, the UPS plays an important role 
in the elimination of misfolded and aggregated proteins from the cell. However, 
although ubiquitination as a signal for degradation is the best-studied function for 
this modification, since its discovery almost endless roles for ubiquitination in the 
regulation of all kinds of cellular pathways have emerged. For example, 
ubiquitination has been shown to be involved in endocytosis, signal transduction, 
DNA repair, autophagy, cell death pathways and more (Table 1-1) [4-8]; thus it is, as 
it's name suggests, ubiquitously involved in most cellular processes. Ubiquitination is 
not only the most common but also the most diverse posttranslational modification. 
This is due to the complexity of the system. As mentioned above, a chain of at least 
four ubiquitins attached to a target protein can lead to its degradation, however this is 
only one of many possibilities for the outcome of an ubiquitination reaction. Chains 
of up to three ubiquitins are common and in most cases do not lead to degradation of 
the substrate, but can alter its function or localisation. Ubiquitin chains are linked 
through any of the seven lysines in the molecule (K6, K11, K27, K29, K33, K48, 
K63) [9], or less commonly through the N-terminal methionine residue of ubiquitin 
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(M1;[10]). Different chain linkages have been shown to be involved in different 
cellular processes and, additionally, chains can consist of a mix of different linkages 
or can even be branched [11, 12]. Branched chains do not associate with the 
proteasome and therefore do not signal substrate degradation [11, 12].  
Adding even more complexity to the system, other ubiquitin like proteins (Table 1-1) 
have been identified and can be used separately or as part of a mixed ubiquitin chain. 
This results in almost endless possibilities of protein modification by this system 
[13], inevitably leading to the question of how such a complex system of 
modification is controlled. In recent years advances have been made in 
understanding the regulation of ubiquitination for many proteins, however, many 
details of how the system is controlled remain elusive. 
Considering the complexity of the ubiquitin system, it is not surprising that up to 5% 
of the human genome encodes proteins involved in ubiquitination pathways [14]. 
There are two main ubiquitin E1 enzymes, around 30-40 E2s and hundreds of E3 
ligases with more being characterised all the time [14]. Protein ubiquitination 
exclusively appears in eukaryotes, where it is highly conserved from yeast to human, 
with only three conservative changes in the ubiquitin protein [5]. Although, no 
ubiquitination like modification system has been identified in prokaryotes, homology 
searches have identified enzymes in the sulphur pathway of Escherichia coli that 
have similarity to the E1 enzyme of the ubiquitination cascade. This protein, MoeB, 
is involved in the biosynthesis of the molybdenum cofactor, Moco [15]. Moreover, 
other proteins involved in the moco and thiamine pathways of different bacteria 
species have been shown to have similarity to E1 and also E2 enzymes. These 
proteins are believed to be evolutionarily more ancient than the ubiquitin pathway in 
eukaryotes, suggesting that they might have formed the origin from which the 
ubiquitin system has evolved [5, 16, 17]. 
 
As ubiquitination is involved in the control of many cellular processes at different 
levels, it is not surprising that its dysregulation plays a major role in the development 
of a wide range of diseases, including cancers, neurodegenerative disorders such as 
Parkinson’s disease, Huntington’s disease and Alzheimer’s disease, type 2 diabetes 
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and in certain severe types of mental retardation (such as Angelman syndrome) [5, 
18]. Thus, a large effort is being made to study this system, its regulation and 





1.1.1 Ubiquitination reaction 
The ubiquitination cascade comprises three enzymes E1, E2 and E3 (Fig 1-1). In an 
initial step, the ubiquitin-activating enzyme (E1) activates ubiquitin by adenylating 
the C-terminus and forming a thioester bond between a cysteine residue in its active 
site and the C-terminal glycine of ubiquitin. This step is ATP dependent. For full 
activity of the E1, it has to non-covalently bind to and adenylate another ubiquitin 
molecule [19, 20]. In the second step, the ubiquitin linked to the E1 is transferred to 
the E2, where it is again linked to an active cysteine via a thioester bond. The 
ubiquitin 'charged' E2 binds an E3 ligase, and in a last step, the E3 catalyses the 
transfer of ubiquitin from the E2 onto a substrate [21]. There are three classes of E3 
ligases the RING-, U-Box and the HECT- domain proteins. HECT domain E3 ligases 
bind to specific E2 enzymes and contain an active site cysteine residue that forms a 
thioester bond with ubiquitin in an intermediate step, the ubiquitin then transfers 
directly from the E3 to the substrate [6, 22, 23]. U-box and RING domain E3 ligases, 
on the other hand, are unusual enzymes as they lack a catalytic site and are believed 
to act as a scaffold, positioning the substrate, E2 and ubiquitin and thereby allowing 
transfer of ubiquitin to the substrate. One round of this cascade leads to addition of 
one ubiquitin to a lysine of the substrate protein, in many cases not only one, but a 
chain of ubiquitins is attached to a target protein. Different theories have been 
proposed to explain how these chains are formed. It has been suggested that 
preformed ubiquitination chains are attached to the substrate; this is supported by the 
fact that free, unanchored ubiquitin chains are present in the cell [24]. However, no 
evidence has been given for this concept and in vitro,where addition of ubiquitin to a 
protein appears to be sequential. The most likely mechanism seems to be several 
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rounds of the reaction described above, where one of the lysines in the ubiquitin 
already attached to the substrate serves as the ubiquitin acceptor in the second round, 
and therefore the chain is elongated round by round [24]. This model raised the 
question of the need for a so-called E4 enzyme, which is responsible for chain 
elongation after an E3 ligase has facilitated the transfer of the first ubiquitin to a 
substrate [25]. It is clear that the formation of an ubiquitin chain would require  
major conformational changes in the enzymes or enzyme complex involved in the 
process, allowing the machinery to build and move along an ubiquitin chain. It is 
thus possible that an E3 ligase can also act as an E4. Multi-protein E3 complexes and 
E3 oligomerisation has been observed in cells, and these could be involved in the 
formation of ubiquitination chains. In this case, a different protein or a different 
molecule of the same E3 in a complex could act as the E4 [25-28]. As discussed 
later, interplay between distinct E3-E2 pairs appears to be important in controlling 
chain linkages and length.  
 
In most cases ubiquitin is attached to a lysine of a target protein, however, ubiquitin 
linked via the formation of esters or thioesters to threonine and serine or cysteine 
residues respectively has also  been observed. Additionally, ubiquitin can be 
conjugated to the N-terminal α-NH2 group of protein. These atypical linkages have 




1. Introduction  5 
 
Figure 1-1 Ubiquitination cascade (adapted from Passmore and Barford, 2004 [28]) 
Overview of the ubiquitination reaction involving three enzymes, E1 (ubiquitin activating 
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1.1.1.1 Chain linkages 
Ubiquitin chains linked via K48 and K11 in ubiquitin are the most common; 
however, chains linked via any of the 7 lysine residues and the N-terminal 
methionine have been observed in vivo and a chain of at least 4 ubiquitins linked by 
either residue have been shown to associate with the proteasome [9]. A proteomic 
study in budding yeast revealed the relative abundance of the different chain linkages 
in the following order K48 (29%), K11 (28%), K63 (17%), K6 (11%), K27 (9%), 
K29 (3%) and K33 (3%) [32]. Remarkably, the most studied K48 linkage was as 
abundant as linkage via K11. Roles of ubiquitin chains linked by K11 are less well 
understood, however, it is has been the focus of intensive research over the past 
years, and its roles are now increasingly better understood. Additionally, it has to be 
noted, that the ratio of chain linkages may vary in different species, under stress 
conditions or during disease. Little is known about the abundance of linear 
ubiquitination chains, where the C-terminus of one chain is attached to the N-
terminus of another by a 600 kDa E3 ligase complex called the linear ubiquitin chain 
assembly complex (LUBAC), which consists of HOIL-1, HOIP and Sharpin [10]. 
Modification of proteins by linear ubiquitination chains has been shown to be 
involved in different cell signalling pathways [33]. Chains are not always linked by 
only one residue on ubiquitin; mixed chains have been observed, as well as branched 
chains, where one ubiquitin molecule is linked to two further ubiquitins molecules 
(Fig 1-2) [11, 12]. This raises questions regarding the control, function and 
specificity of the different chain types. It has been suggested that in many cases, 
ubiquitination is unspecific and that lysines on the substrate are targeted randomly. If 
this is the case, it is difficult to imagine that chain elongation could be more specific, 
targeting specific lysine residues on ubiquitin. However, more and more evidence is 
being found that specific linkages signal for specific events, for example linkages via 
K63, have been shown to play a major role in cell signaling/kinase activation [34, 
35]; and it is thus widely accepted that ubiquitin chain linkages are generated 
specifically. Furthermore, in many cases ubiquitination of lysine residues has been 
shown to be specific to either a certain residue or domain of a protein [8]. This 
illustrates how the system must be controlled on several levels to ensure correct 
substrate modification with the right length and linkage of the chain. Not only one, 
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but many lysines within one substrate can be modified by either one ubiquitin or an 
ubiquitin chain, resulting in multi-mono or multi polyubiquitination (Fig 1-2).  
 
 
1.1.1.2 Ubiquitin Structure  
The 76 amino acid containing protein ubiquitin is folded in a compact β-grasp fold 
[36], which is conserved among all ubiquitin like (UBL) proteins, and contains a 6 
amino acid long flexible C-terminal tail (Fig 1-3). Ubiquitin is extremely stable, 
tolerating temperatures up to 100°C and has a half life of about 10 hours in cultured 
cells [4]. Overall ubiquitin adopts a very rigid conformation, with only certain 
residues within its binding pockets displaying limited flexibility to allow protein-
protein interactions [8]. Ubiquitin contains seven lysine residues, which are involved 
in chain formation. All ubiquitin lysines are exposed and scattered over the surface 
of the protein (Fig 1-3a). Ubiquitin has three hydrophobic patches, which mediate 
interactions with its binding partners and the proteasome (see Fig 1-3b) [8]. The 
hydrophobic patch around Ile44, Leu8, Val70 and His68 is involved in the majority of 
interactions with ubiquitin binding proteins (UBP) and the proteasome [37-39]. 
Another hydrophobic surface lies around the residues Ile36, Leu71 and Leu73 and is 
important for recognition by some HECT E3 ligases and involved in the interaction 
of ubiquitin molecules within an ubiquitin chain [40-42]. The hydrophobic patch 
around Gln2, Phe4 and Thr14 has been identified as being required for cell division in 
yeast [39], and interacts with certain proteins including the ubiquitin-specific 
protease (USP) domain of some DUBs [41]. The TEK box, which is required for 
K11 linked chain elongation by the anaphase promoting complex (APC/C) and 
UbcH10, and mitotic degradation in higher eukaryotes, consists of the residues Thr12, 
Thr14, Glu34, Lys6 and Lys11[8, 43]. X-Ray and NMR structures of ubiquitin chains 
reveal significant differences in the three-dimensional structure and exposed surface 
of chains with different linkages  (Fig 1-3c) [8, 44-46]. While chains linked by K48 
or K11 have a closed and compactly packed conformation, chains linked by K63 and 
M1 exhibit a more open conformation and expose surface residues that are buried in 
the K48 and K11 chains, with no contact points of the ubiquitin molecule besides the 
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linkage site. This more open conformation gives the ubiquitin chains flexibility and 
allows them to adjust their conformation despite the very rigid structure of ubiquitin 
[4, 8].  
 






Figure 1-2 Types of ubiquitination 
Protein ubiquitination can result in an array of outcomes. If a single ubiquitin molecule is 
attached to a substrate, it is described as mono-ubiquitination and this generally does not lead 
to proteasomal degradation. Several ubiquitin molecules can be attached to a protein as a 
chain, resulting in polyubiquitination. Often multiple ubiquitin molecules or chains are 
linked to different lysine residues on a target protein, resulting in multi- mono or multi-
polyubiquitination. Ubiquitin chains can consist of different linkages or even different types 
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Figure 1-3 Structure of ubiquitin and ubiquitin chains 
(a) Ubiquitin structure (PDB: 1ubq [36]) as ribbon with linkage sites indicated by sticks. 
Residues for chain elongation are in orange and C-terminal glycine in blue. (b) Ubiquitin 
surface with patches involved in protein-protein interactions highlighted. (c) Structures of 
ubiquitin chains linked by K48 (PDB:1aar [45]), K11 (PDB:2xew [44]), K63 (PDB:2jf5 
[47]) and M1 (PDB:2w9n [47]). Tetra ubiquitin chains were modelled using the respective 
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1.1.2  E2 - E3 interaction 
The endless possibilities of ubiquitination events show that the mechanisms leading 
to ubiquitination have to be controlled tightly to ensure creation of the right 
molecular signal. Many details about the exact regulation, and how specificity is 
controlled, remain unknown. It appears that the E3 ligase is mainly responsible for 
substrate specificity, while chain linkage and length are achieved through the 
interplay of specific E2-E3 pairs [12, 48]. It has been shown that many E3 ligases 
can interact with a set of different E2 enzymes resulting in the formation of different 
types of ubiquitin chains or mono-ubiquitination of the substrate. The E3 ligase 
complex of BRCA1 and BARD1 for examples has been shown to interact with at 
least 10 different E2 enzymes. Some of these E3-E2 pairs are required for attachment 
of the first ubiquitin while other pairs result in the formation of various chain 
linkages [49, 50]. In this case, the E2 determines whether a certain E3 ligase has the 
ability to act as an E4 ligase and promote polyubiquitin chain formation or is 
restricted to act as a monoubiquitination ligase. Some E2s are connected to a certain 
chain specificity e.g. Ube2G2 has been shown to assemble K48 linked chains while 
Ube2S is specific to forming K11 linked chains [8]. HECT E3 ligases seem to play a 
bigger role in determining chain specificity when compared to RING E3 ligases, 
because they directly bind to and transfer ubiquitin to the substrate. RING E3 ligases 
on the other hand act as a building block forming a complex of E3, E2, ubiquitin and 
substrate and facilitating the transfer of ubiquitin from the loaded E2 onto the target 
residue [12, 24, 48]. 
Recently the crystal structure of a charged E3-E2-ubiquitin complex has been solved 
[46] (Fig 1-4). The structure gives insight into the packing of the complex leading to 
ubiquitination. It shows that the E3 interacts not only with the E2, but also with the 
E2 bound ubiquitin, resulting in a tightly packed complex of the three molecules. The 
E3 now directs the ubiquitin to a target lysine, which can be on the E3 ligase itself 
resulting in autoubiquitination, a lysine on a target substrate or a different ubiquitin 
molecule. A distinct set of E2-E3 enzymes can, in many cases not only lead to 
ubiquitination of one specific lysine, but several different residues in one protein. 
While the static crystal structure does not reveal the degree of flexibility of the 
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complex, analysis of the UbcH5c–ubiquitin complex by both NMR and SAXS 
(small-angle X-ray scattering) [39] has shown that the E2-ub conjugate is very 
flexible and can exhibit a range of conformations in solution. Taken together these 
experiments suggest that even though all members of the complex interact with each 
other, the complex is not static and can adopt different conformations, explaining 








Figure 1-4 Structure of the E3 ligase RNF bound to ubiquitin charged UbcH5a  
Crystal structure of the E3 ligase RNF4 (green) in complex with the E2 UbcH5a (blue) and 
ubiquitin (pink) (PDB:4AP4 [46]). The complex is an intermediate of the ubiquitination 
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1.1.3 Ubiquitin binding proteins 
Apart from being recognised and bound by the proteasome, ubiquitin and ubiquitin 
chains can interact with a variety of different proteins, which have an ubiquitin-
binding domain (UBD). These proteins recognise the ubiquitin modification and act 
as effector molecules that transduce the signal to downstream cellular events. Around 
200 proteins in the cell are estimated to contain a UBD with which they can bind 
ubiquitin, either when it is attached to a protein or free as a single molecule or chain 
[37]. The different UBDs differ greatly and so far, 16 distinct tertiary structures have 
been identified that bind to ubiquitin. The domains differ in size from 30-150 
residues and are specific to either a certain surface region of ubiquitin or a specific 
chain linkage [51]. Some UBDs are specific to one of the three hydrophobic patches 
of ubiquitin (see Fig 1-3) and can therefore only bind ubiquitin, if this patch is not 
buried by protein interactions with the ubiquitin substrate or a different ubiquitin 
molecule in a chain. Detailed information of how UBD can distinguish between 
different linkages is still missing. One example of how chain specificity can be 
achieved is through the repeat of several UBDs in one ubiquitin binding protein [52]. 
Consequently some ubiquitin interacting proteins consist of tandem repeats of the 
ubiquitin interacting motif (UIM), which recognises the patch around the Ile44 
residue on ubiquitin. Since packing of the ubiquitination chains differs remarkably 
(see Fig 1-3c) and the distance between two ubiquitin molecules is distinctive for a 
specific chain linkages, two UIM motifs separated by a spacer of a specific length 
can recognise different types of chains [8, 51]. Ataxin-3 for example has two repeats 
of this motif connected by a small spacer, these two UIM can recognise ubiquitin 
molecules that are connected by a K48 linkage and are therefore packed tightly [53]. 
A sub-unit of the BRCA1-E3 ligase Rap80, on the other hand, has two UIM 
separated by a longer spacer; these domains can recognise ubiquitin molecules in an 
extended conformation for example in K63 linked chains [54]. Another mechanism 
by which UBDs can recognise specific chain linkages is by contacting two ubiquitin 
molecules at the same time. In this case, the patches on ubiquitin bound by the UBD 
are only exposed in a conformation next to each other in chains with a certain linkage 
[55, 56]. Interestingly, residues around the linkage site itself are, in most cases, not 
involved in the interaction of the ubiquitin binding domain and ubiquitin. The 
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linkage rather is important to predict the packing and orientation of the ubiquitin 
molecules, which is recognised by the UBDs [8]. 
 
1.1.4 Deubiquitination enzymes 
Ubiquitination is a reversible modification and around 100 deubiquitinating enzymes 
(DUBs) have been identified so far, with human cells containing around 55 DUBs [8, 
57]. These enzymes remove ubiquitin conjugates from substrates and depolymerise 
ubiquitin chains. This is an important mechanism to ensure that the ubiquitin signal 
can be controlled carefully in response to stresses or stimuli. DUBs are divided into 
five main classes, one metalloprotease class and four Cys protease classes [58]. One 
main function of a subset of DUBs is to protect ubiquitin from degradation by the 
proteasome; these DUBs are associated with the proteasome and remove ubiquitin 
from the substrate before it can itself be unfolded and degraded [38]. The cell thereby 
recycles ubiquitin, ensuring that cellular levels of the protein remain high, 
saveguarding cellular resources. The other important function of DUBs is to 
specifically deubiquitinate certain substrates and thereby control the ubiquitination 
state of certain proteins in response to stimuli [8]. These DUBs tend to be linkage 
unspecific and act on a certain set of substrates. An example of fine control of the 
activation state of a protein by E3 and DUB activity is NF-κB. Activation of NF-κB 
relies on ubiquitination of different proteins by K63 linked chains while deactivation 
of NF-κB is achieved by deubiquitination of these proteins and ubiquitination of NF-
κB by K48 linked chains leading to its proteasomal degradation. Strikingly, the same 
protein, A20, is responsible for both events; it has both DUB and E3 ligase activity 
and removes the K63 chains responsible for NF-κB activation with its DUB activity 
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1.1.5 Ubiquitin like modification 
Ubiquitin is the leading member of a class of small molecules that modify proteins, 
which are collectively called ubiquitin like (UBL) proteins. All UBL proteins contain 
a β-grasp fold as their three dimensional core structure and are attached to substrates 
via a similar cascade to ubiquitin. So far nine classes of UBL proteins have been 
identified; these are SUMO, NEDD8, ISG15, FUB1, FAT10, Atg8, Atg12, Urm1, 
and Ufm1 (Table 1-2) [62]. It is likely that additional UBL molecules will be 
identified in the future. Despite sharing the same three-dimensional structure, UBL 
proteins have a low sequence similarity, but are believed to have evolved from a 
common ancestor (Table 1-2) [5]. UBL proteins are involved in regulation of DNA 
replication, signal transduction, cell cycle control, embryogenesis, cytoskeletal 
regulation, metabolism, stress response, homeostasis and mRNA processing and 
others [62]. UBL modification can inhibit ubiquitination by targeting the same lysine 
residue, and also can work hand in hand with ubiquitination by forming mixed chains 
that contain different UBL modifiers [5, 13, 62].  
Additionally, ubiquitin like domains (ULD) within bigger polypeptides have been 
identified. These domains fold in the same way as other UBL proteins but are not 
processed or attached to other proteins. These ULD can be recognised by proteins 
with UBD and, similarly to other ubiquitin like modifiers, ULDs can trigger the 
interaction with ubiquitin binding proteins [5].  
1.1.5.1 SUMO  
SUMOylation is the best-studied UBL modification apart from ubiquitination. Like 
ubiquitin, SUMO can form polymers and is involved in a variety of cellular 
pathways, including the control of genome stability, signal transduction, targeting to, 
and formation of, nuclear compartments, cell cycle and meiosis [62-66]. SUMO 
chain formation is achieved mainly through SUMO residue K11 [67]. Three isoforms 
have been confirmed in humans; these are SUMO-1, SUMO-2 and SUMO-3. SUMO 
binding proteins containing a so called SUMO-interaction motif (SIM) have been 
identified and shown to have a higher affinity for SUMO than ubiquitin binding 
proteins for ubiquitin [65]. SUMO and ubiquitin both target lysine residues and are 
therefore two mutually exclusive modifications. Nevertheless, both have been shown 
 
1. Introduction  17 
to work in synergy, e.g. some proteins were shown to be SUMOylated in a first step, 
which in turn serves as a signal for ubiquitination in a second step leading to 
proteasomal degradation [5, 65, 67]. 
SUMOylation can affect the activity of its target proteins by changing their affinity 
for their binding partners. One example of this is the DNA glycosylase (TDG), which 
when SUMOylated undergoes conformational changes that decrease its DNA 
binding affinity [68, 69]. 
1.1.5.2 NEDD8 
NEDD8 is another UBL protein with 55% sequence identity to ubiquitin. Only 
limited substrates have been identified for NEDDylation, however, it has become the 
focus of more intense research in recent years. The transcription factor p53 has been 
shown to be modified by NEDD8, via a mechanism that is dependent on its E3 ligase 
MDM2 and leads to transcriptional inactivation of this transcription factor [70]. 
Another important role of NEDDylation is the activation of the superfamily CRL E3 
ligases [71]. NEDDylation of CRL ligases is essential for their activation. Many of 
these CRL ligases are involved in development of cancers and other diseases. The 
NEDDylation pathway, including NEDD8-activating enzyme, NAE and the two 
NEDD8 E2 enzymes UBC12 and UBE2F therefore provide an interesting protein for 
research aiming to identify novel drug targets [72-74].  
1.1.5.3 ISG15 
ISG15 was the first ubiquitin like protein identified after ubiquitin in the late 1980s 
and has been shown to play a role in the innate immune response to viruses. ISG15, 
its E1 (ISG15-activating) and its E2 (ISG-conjugating) enzymes are strongly induced 
by type I interferon. Despite being the first UBL protein to be identified, details 
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18 Nuclear transport, DNA replication and  
repair, mitosis and signal transduction. 
 
NEDD8 (Rub1) 55 Cell cycle control and embryogenesis. May be 
involved in the formation of aggresomes. 
 
ISG15 32 and 37 * Modifies STAT1, SERPINA3G/SPI2A, 
JAK1, MAPK3/ERK1, PLCG1, 
EIF2AK2/PKR, MX1/MxA, and RIG-1. 
Displays antiviral activity. 
 
FUBI (MNSF-β or 
FAU) 
38 Translation Gene expression. Viral infectious 
cycle. Endocrine pancreas development. 
Cellular protein metabolic processes. 
 
FAT10 32 and 40* Protein degradation. Activation of innate 
immunity. Mediates mitotic non-disjunction 
and chromosome instability in cancers. 
Caspase-dependent apoptosis. 
 
Atg8 ND Expression of kappa-type opioid receptor. 
Intra-Golgi traffic and transport. Intracellular 
transport of GABA (A) receptors. Apoptosis. 
Formation of autophagosome. 
 
Atg12 ND Autophagic vacuole assembly. Negative 
regulation of type I interferon production. 
Urm1 ND Unknown 
 
UFM1 ND Ufmylation, unknown function 
* Values listed for both two ubiquitin-related domains within the protein. ND=not detectable 
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1.1.6 Ubiquitin Function 
1.1.6.1 Degradation  
As describe previously, the best-studied function of ubiquitination is its role in 
proteasomal degradation. Ubiquitin chains are used as a molecular tag, marking 
proteins to be recognised and degraded by the proteasome. In the majority of cases, a 
chain of four ubiquitin molecules linked by either K48 or K11 is both necessary and 
sufficient for proteasomal degradation. Longer ubiquitination chains increase the 
affinity for the proteasome and thereby the probability of binding and degradation [8, 
75].  
Interestingly, tetra-ubiquitin chains of K48 and K63 linkage show the same affinity 
for the proteasome [76], but while proteins tagged with K48 linked tetra ubiquitin are 
degraded, proteins attached to a chain linked by K63 are usually not degraded. This 
has been explained by the structural differences of the chains. As described above 
K48 chains have a more compact conformation compared to K63 linked chains, and 
this affects the affinity of the chains for different DUBs. Consequently, K63 chains 
are deubiquitinated at a faster rate compared to K48 chains, releasing the substrate 
before the proteasome has unfolded and cleaved it, K48 linked chains, on the other 
hand, have a slower conversion rate by DUBs and thereby longer residency at the 
proteasome, favouring degradation [51, 77]. Strikingly, a study by Pickart et al 
showed that chains linked via any of the lysines in ubiquitin bind to the proteasome 
in vitro, suggesting a role in degradation for all of them. In vivo chains linked via 
K11, K29, K48 and K63 have been shown to be involved in signalling protein 
degradation in different studies [9, 78]. However, the presence of mixed chains 
makes the investigation of effects of a particular type of chain experimentally 
challenging, and more work is necessary to confirm the exact roles of different 
linkages in the degradation of proteins. In certain cases, interactions of the E3 with 
the proteasome are required for efficient degradation of a protein, suggesting a role 
of the E3 ligase in delivering the substrate to the proteasome [79]. Other studies 
suggested that in certain cases mono-ubiquitination is sufficient to signal 
proteasomal degradation [80-82]. Taken together these studies highlight the fact that 
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no rigid rule can be applied to the system and that many, often unknown factors, are 
involved in determining the fate of a protein modified with ubiquitin.  
In addition to being the key player in proteasomal degradation, ubiquitination has 
now been identified as playing a role in autophagy and lysosomal degradation. 
Accordingly ubiquitin chains, predominantly linked by K63, have been shown to 
target mainly membrane proteins for degradation via the lysosome [83, 84]. 
Additionally, mono-ubiquitination of plasma membrane proteins e.g. receptor 
tyrosine kinases lead to recruitment of members of the endocytic pathway and 
thereby triggering endocytosis and lysosomal degradation of the kinase [38, 85-88]. 
Autophagy is important in removal of harmful protein aggregates from the cell, as 
these aggregates can often be too bulky to be processed by the proteasome. 
Autophagy receptors that can bind to ubiquitin and autophagy specific ubiquitin like 
modifiers have been identified, e.g. p62/SQSTM1 and NBR1 [89]. These findings 
link ubiquitin to the autophagy system, highlighting the role of ubiquitination in the 
elimination of protein aggregates from the cell. 
 
1.1.6.2 Protein-protein interactions 
Ubiquitination can affect protein-protein interactions through four mechanisms (Fig 
1-5). (i) It can function indirectly by leading to a conformational change in the 
protein allowing or inhibiting binding of a binding partner [5]. (ii) The most common 
mechanism by which ubiquitin mediates interactions between two proteins is by 
directly being involved in the interaction, providing or extending the molecular 
surface for the interaction [5, 82]. (iii) Ubiquitin can inhibit binding of another 
protein by occupying the binding site, and thereby sterically preventing an 
interaction. However, there are only a few examples of this mechanism in vivo. Or 
(iv) free ubiquitin chains, that are not attached to either of the proteins, can mediate 
or disrupt interactions [5, 82]. 
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Figure 1-5 Effect of ubiquitin on protein-protein interactions [5] 
(a) Ubiquitination of a protein can lead to allosteric changes that allow or inhibit interaction 
with a binding partner. (b) Ubiquitin can extend the binding surface of a protein interaction 
and thereby increase the binding affinity of two proteins. (c) Ubiquitin can be attached to a 
binding interface on a protein and thereby sterically inhibit binding to other proteins. (d) Free 
ubiquitination chains present in the cell can act as a scaffold in building a protein complex of 
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1.1.6.3 Cellular localisation 
Ubiquitination has been shown to affect protein localisation. This happens either 
through ubiquitin binding to a surface important for localisation thereby masking it, 
or ubiquitin mediating conformational changes leading to unmasking of a protein 
surface area e.g. a nuclear export signal [5]. Additionally, ubiquitination can affect 
protein interactions that are important for localisation of a protein. Not only the 
localisation of ubiquitin substrates are affected by ubiquitin, but also the localisation 
of the E2 can be effected. Localisation of Ube2E3/UbcM2, for example, has been 
shown to be dependent upon its ubiquitin binding state; only when the E2 is charged 
with ubiquitin through a thioester bond, is it recognised by the transport factors of the 
importin family and shuttled into the nucleus [90]. 
1.1.6.4 Protein activity 
A combination of any of the above can result in a change in protein activity, for 
example activity of a transcription factor can be suppressed or terminated by its 
polyubiquitination and subsequent degradation, as occurs in the control of p53 levels 
through its E3 ligase MDM2. In other cases ubiquitination can lead to a 
conformational change in a protein that can, for example, affect the catalytic site of 
an enzyme or its ability to bind other proteins. Moreover, ubiquitin can be directly 
involved in protein-protein interactions and trigger the formation of large multi 
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1.2  Transcription  
Transcription, the process of enzymatic RNA synthesis from a DNA template, is the 
first step of all gene expression. Its proper function and regulation is critical for 
homoestasis, cell growth and differentiation, and consequently dysregulation of this 
process is involved in the development of numerous kinds of diseases. A brief 
outline of the transcription event is shown in Fig 1-6. In order for transcription to 
occur, Pol II (RNA Polymerase II) has to associate with DNA upstream of an open 
reading frame and synthesise a complementary strand of RNA. However, other than 
in bacterial cells, where the RNA polymerase can initiate promoter specific 
transcription, eukaryotic Pol II is dependent on general transcription factors (GTFs) 
to start transcription [91, 92]. Transcriptional activators (TAs) that contain a domain 
with specific DNA binding ability are recruited to their specific consensus sequence 
at a gene promoter. In addition to the DNA binding domain, TAs comprise a 
transactivation domain (TAD) which binds other components of the transcription 
machinery, including cofactos, GTFs and Pol II, consequently bringing these factors 
together at the chromatin to form a preinitiation complex. Next transcription is 
initiated and Pol II moves along the gene and synthesises an RNA transcript in a 
process called elongation. During transcriptional elongation, transcription factors can 
either stay bound to the promoter sequence and another Pol II can be recruited to this 
pre-assembled recruitment platform, initiating another round of transcription or the 
transcription factor dissociates from the DNA and terminates transcriptional 
initiation [91]. 
During elongation other factors involved in chromatin modification, RNA chain 
synthesis and RNA processing and export associate with Pol II. As the DNA is 
tightly packed into nucleosomes these have to be removed or remodelled in order for 
the Pol II to move along a certain DNA sequence (Fig 1-6b) [91, 93, 94]. After Pol II 
has moved along and transcribed a DNA sequence, DNA repacked into a chromatin 
structure. Components of the RNA processing (RnP) machinery associate with the 
Pol II complex and conduct pre-messenger RNA maturation [91, 92]. Transcription 
is terminated when Pol II associates with the termination machinery and the newly 
synthesised mRNA is exported out of the nucleus for translation (Fig 1-6c) [91, 92].  
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Figure 1-6 Simplified overview of transcription (adapted from Geng et al., 2012)[91] 
(a) Binding of a transcription factor to its target promoter leads to the recruitment of 
coactivators (CA), general transcription factors (GTFs) and RNA Polymerase II (Pol II) that 
form a complex at the promoter and initiate transcription. (b) During the elongation phase, 
RNA is synthesised by Pol II, which is processed by Pol II associated components of the 
RNA processing (RnP) machinery. During elongation, histones have to be repositioned to 
allow sliding of the Pol II complex along the gene. (c) Transcription is terminated by 
association of the Pol II with the termination machinery (Tm) and transcription-coupled 
chromatin marks stay on the newly transcribed gene. Newly synthesised mRNA is exported 
out of the nucleus. 
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1.3 The UPS in control of transcription 
Degradation of proteins by the UPS and transcription as the first step in protein 
expression appear to be two entirely contradictory events. However, an important 
role of the UPS in the control of several parts of the transcription machinery has 
become apparent in recent years. Strikingly a study by Auld et al. [95]  showed that 
almost all transcriptional active genes in yeast are associated with one or several 
parts of the proteasome. The exact role and mechanism by which the proteasome is 
involved in transcriptional regulation remain unclear, however, different studies have 
suggested roles of the proteasome in almost every phase of the transcription process 
[91]. It has been proposed that the proteasome is required to regulate transcription by 
degrading components of the pre-initiation complex when no longer required thereby 
allowing transcription to progress, furthermore the 19S subunit was shown to be 
required for transcriptional elongation [91, 96, 97], while the 20S subunit is required 
for termination [91, 98].  
One interesting example of how the UPS is involved in the control of the 
transcription machinery is ubiquitination dependent degradation of the Polymerase II 
(Pol II) in response to DNA damage. This is a very important process as it allows 
other proteins to access the site of DNA damage in order to repair the active genes or 
alternatively trigger a cells death response. When an active Pol II encounters a place 
of DNA damage it first recruits the NER (nucleotide excision repair) machinery to 
the site of DNA damage as part of the TCR (transcription-coupled DNA repair) 
pathway [99-102]. If DNA repair by this pathway fails, however, the stalled 
polymerase is recognised and polyubiquitinated by the E2/E3 complex Rsp5 and 
UbcH5 leading to Rpb1 ubiquitination and Pol II degradation. It has been suggested 
that the ubiquitin chain formation acts as a 'molecular clock', only if the DNA 
damage cannot be repaired by the TCR pathway is the Pol II stalled long enough for 
the ubiquitin chain to be elongated and thus recognised by the proteasome [99]. 
Removal of the Pol II complex allows components of the global genome repair 
(GGR) pathway to be recruited to the site of DNA damage and to repair the damage 
[103].  
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It has been proposed that the ubiquitination/degradation model to remove stalled Pol 
II from the site of transcription is a more general mechanism by which Pol II can be 
removed from the DNA and can not only work as part of the TCR pathway, but also 
when for example factors like TFIIS are unable to resume an arrested transcription 
complex [99, 103]. 
Interestingly, the Rsp5/UbcH5 complex can only recognise Pol II in a specifically 
phosphorylated state. The Pol II binds to the promoter it is in its non-phosphorylated 
form and is phosphorylated at residue serine 5 within its CTD repeats during 
transcriptional initiation, this phosphorylation inhibits binding of Rsp5 (E3) to Pol II. 
Only when Pol II is further phosphorylated at serine residue 2 during elongation is it 
recognised by Rsp5, this ensures that no DNA unbound Pol II is targeted for 
ubiquitination and destruction by the E3 ligase [99, 104-106].  
In addition to targeting stalled Pol II the Rsp5/UbcH5 complex also specifically 
binds to and ubiquitinates Pol II during the elongation phase. This is achieved by 
binding of UbcH5 (E2) to the 'switch  domain' of pol II [107], strikingly this 
domain is unstructured unless Pol II is present in complex with DNA and RNA, 
allowing recognition of this domain by UbcH5 only when in its structured and thus 
DNA bound, active conformation [99].    
Besides Pol II numerous other factors involved in transcription were shown to be 
regulated by the UPS system. A link between the transactivation and degron domain, 
for example, has been made in a number of transcription factors and this phenomena 
is conserved in prokaryotes (which do not have a UPS system) [91], demonstrating 
the significance of the connection between TA activity and stability (see 5.1 for 
detail of how transcription factor function is regulated by the UPS).  
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1.4 Interferon regulatory factor -1  
Interferon regulatory factor-1 (IRF-1) is the founding member of the IRF family, a 
class of transcription factors consisting of ten members in vertebrates (with IRF-10 
being non-functional in human and mice [108]). IRF-1 was the first member 
identified from this family in the late 1980s as a protein that binds to the virus-
inducible enhancer element of the IFNβ gene [109]. All members of this family share 
a structurally similar N-terminal DNA binding domain (DBD), which forms a helix-
turn-helix structure and possesses five invariant tryptophan repeats that are essential 
for their DNA binding ability (Fig 1-7) [110]. All IRF DBDs recognise a 
characteristic IFN-stimulated response element (ISRE) with the consensus sequence 
5'-AAN NGA AA-3' [111]. Even though members of the IRF family share the same 
ISRE element, the specific binding site, often consisting of a repeat of this consensus 
site, differ between the different factors. The C-terminus of the IRFs is less well 
conserved and often functions as an interface for protein-protein interactions [112].  
Members of the IRF family were identified through their role as transcriptional 
regulators in the type I interferon pathway and play an important role in the cells 
antiviral response. Recently a close connection between the innate and adaptive 
immune system has been established, and numerous IRFs were shown to play an 
important role in the development and regulation of several types of immune cells. 
Additionally, some IRFs including IRF-1, have been linked to the cellular response 
to oncogenesis and the development of certain cancers [113]. IRF-1 is involved in 
the DNA damage response, apoptosis, cell cycle control and tumour suppression 
[113-115]. This is in addition to its role in immunity where it is important for the T-
cell response, regulation of IFN and IFN-responsive genes and the antiviral response 
[116, 117]. IRF-1 was shown to be required for NK (natural killer) cell development 
in bone marrow stroma cells, by leading to transcription of IL-15 [118]. Accordingly, 
studies IRF-1 -/- mice demonstrated a severely abrogated number of NK cells [119, 
120]. 
Additionally, IRF-1 is required for the TH1 immune response and IRF-1 -/- mice have 
a deficiency of IL-12 which is required for TH1 differentiation and are thus more 
vulnerable to infection by e.g. Listeria monocytogenes and Leishmania major [121, 
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122]. Moreover, IRF-1 -/- mice display a reduced incidence and severity of 
inflammatory disorders and allergies, implicating a role of IRF-1 in the control of 
inflammation and autoimmunity as IRF-1 -/- mice [123]. (See 1.4.3 for details of 
IRF-1's role in cancer development).  
 
1.4.1 Structure  
IRF-1 consists of three main-domains and several sub-domains. The main domains 
are the DNA-binding domain, the transactivation domain and the enhancer domain 
(Fig 1-8). So far only the structure of the N-terminal DBD has been solved [124], and 
the structure of the central and C-terminal region remains elusive. Sequence analysis 
suggests that the central and C-terminus of IRF-1 are intrinsically disordered. The 
relatively new concept of protein disorder predicts that certain proteins remain 
unstructured or do not form a distinctive three-dimensional structure spontaneously, 
until they form complexes with other proteins [125]. This contrasts the 'structure–
function paradigm’, which predicts that after translation, all proteins fold into a 
specific shape and that this shape is essential for a protein to be able to perform its 
function. It is now believed that disorder can be essential to the function of a protein, 
allowing it to interact with a range of different binding partners [126]. Programs 
predict that 40% of all human proteins contain such disordered sequences and that 
25% are completely disordered [125]. This is supported by the fact that thousands of 
structures in the PDB databank are known to contain disordered chains or motifs, 
which only become structured in the presence of binding proteins or ligands [126]. In 
the case of IRF-1, its C-terminal disordered regions could allow it to interact with a 
range of different regulatory proteins that affect its function in response to an array 
of stimuli [127]. 
1.4.1.1 DNA-binding domain  
IRF-1's N-terminal DNA binding domain (aa 1-120) is highly conserved not only 
across the IRF family, but also across different species. It was crystallised bound to 
the natural positive regulatory domain I (PRD I), a binding element from the 
interferon-β promoter (Fig 1-7) [124]. This was the first crystal structure of an IRF 
DBD and revealed the characteristic helix-turn-helix motif, with conserved 
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tryptophan repeats contacting the DNA. The structure shows that the main DNA 
interactions are with a short GAAA core sequence, explaining the occurrence of 
repeats of this sequence in the IRF response elements. The main residues contacting 
the major groove in the GAAA sequence are Arg82, Cys83, Asn86 and Ser87, with 
Arg82 being completely conserved along the IRF family members. Mutants with 
either a single mutation from Trp11 to Arg or residues Tyr109, Leu112 and Pro113 
mutated to Ala are unable to bind to DNA; however it is not clear if this is due to 
direct interactions of these residues with the DNA or if these mutations lead to a 
gross change in the DBD conformation that prevents binding [124]. Although IRF-1 
was crystallised bound to DNA as a monomer, footprinting studies by Spink and 
Evans [128] showed that after initially binding as a monomer, two IRF-1 molecules 
are present at one IRF-1 binding site of the inducible nitric-oxide synthase (iNOS) 
promoter. The product of this gene is important for nitric oxide production under 
different inflammatory conditions. Binding of a second IRF-1 molecule to the 
promoter extends occupancy on the DNA in both the 5' and 3' direction in 
footprinting studies, suggesting that binding of the second molecule leads to 
conformational changes of the DNA-DBD interaction of the first monomer. 
Additionally, binding of the second IRF-1 monomer was shown to be dependent on 
the first protein, suggesting cooperative binding of the two molecules [128]. A model 
of the two IRF-1 monomers, based on the findings of this study, is shown in Figure 
1-7 and does not suggest that the DBDs of the two monomers have any points of 
contact. This implies that the binding cooperativity is not due to dimerisation of the 
two molecules, but rather that IRF-1 induced conformational changes in the DNA, 
which were observed in the IRF-1 crystal structure [124], increases the affinity of the 
IRF-1 DBD for the second binding site on the promoter. However, as the C-terminal 
region of IRF-1 is not present in the crystal structure, the possibility of dimer 
formation through the contact of residues in this part of the protein cannot be 
excluded. 
Adjacent to IRF-1 DBD lies its nuclear localisation signal (aa 117-141) [129]. It is 
predicted to be located within an exposed surface area and is required for the import 
of IRF-1 into the nucleus, where IRF-1 binds DNA and acts as a transcriptional 
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regulator. Deletion of this region leads to localisation of IRF-1 mainly in the 
cytoplasm and thus its inactivation [129]. 
1.4.1.2 Mf2 domain 
Recently, residues 106–140 have been identified to serve as a multi protein binding 
interface for IRF-1 and named multi-functional domain 2 (Mf2) [127]. The sequence 
of this domain suggests that it is strongly disordered and proteins binding to this 
domain differ in their amino acid specificity. Thus, this domain appears to be a bona 
fide example of how the flexibility of a highly disordered domain can allow 
interaction with an array of different interaction partners. Proteins that interact with 
this domain include the IRF-1 E3 ligase CHIP, NPM1, TRIM28, and YB-1 [127, 
130].  
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Figure 1-7 IRF-1 DBD bound to its consensus sequence 
(a) Crystal structure of the IRF-1 DBD in complex with DNA, with tryphtopan repeats 
shown as sticks. (b) Model of cooperative binding of two IRF-1 monomers to the iNOS 
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1.4.1.3 Transactivation domain 
The transactivation domain of IRF-1 was mapped to a region between residues 185-
256. Deletions and fusion studies showed that this region is both required and 
sufficient for transactivation i.e. a GAL-4 protein fused to this region shows higher 
activity in a CAT-reporter assay when compared to wild type GAL-4 [129, 131].  
No structural information is available for this domain of the protein, however, it is 
predicted to be more ordered than the central region of IRF-1 and to form a loop-
helix-loop-sheet [132]. Interestingly, a mutant lacking this domain acts as a dominant 
negative in cells, similar to the IRF-2 protein, which shares high homology with the 
IRF-1 DBD, but lacks a sequence similar to IRF-1's transactivation domain.  
1.4.1.4 Enhancer Domain 
Studies on the C-terminal region of IRF-1 demonstrated that even though it is neither 
required for transactivation nor able to promote transactivation on its own, it is able 
to 'enhance' IRF-1's transactivation activity. Further studies revealed several distinct 
functions of this domain. It carries a repressor domain, which is important for IRF-1 
dependent Cdk2 repression that is mainly dependent on an LXXLL coregulator 
signature motif at residues 306-310 [133]. Additionally, molecular chaperones of the 
Hsp70 family that play an important role in maintaining IRF-1's cellular function, 
bind to the LXXL motif [112]. The enhancer domain is required for efficient growth 
inhibition by IRF-1, and deletion or mutation of this region results in a loss of growth 
suppressor activity [133]. It further encompasses a binding site for p300; IRF-1 
binding to p300 leads to acetylations and thus activation of p53. Thereby p53 and 
IRF-1 synergise to regulate expression of p21, in a mechanism that is independent of 
IRF-1's DNA binding ability and merely relies on its ability to bind to p300 [134]. 
  
Furthermore, the enhancer domain has been shown to play an important role in the 
control of IRF-1 degradation by the ubiquitin proteasome pathway; it contains both 
the ubiquitination and degradation signal, but, interestingly, is not subject to 
modification by ubiquitin itself.  Surprisingly, the two signals can be uncoupled, and 
removal of the last 25 amino acids of IRF-1 leads to inhibition of its degradation 
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whilst it is still polyubiquitinated. Only removal of the last 70 amino acids leads to 
inhibition of both ubiquitination and degradation [135]. 
A study by the Ball group has shown that the activity of the enhancer can be 
activated by binding of nanobodies to the 25 C-terminal residues of IRF-1 (301-325), 
also called the multi functional domain 1 (Mf1). Binding of nanobodies to this region 
results in an up to 8-fold increase in expression of IRF-1 responsive promoter, which 
is accompanied by an increase in the rate of IRF-1 degradation [136]. This link 
between activity and degradation is noteworthy, as several transcription factors were 
shown to be most active when least abundant and it would therefore be interesting to 
study how this link between activation and degradation is mediated in the case of 
IRF-1 [137]. 
1.4.1.5 Dimerisation domains 
IRF-1 has been shown to heterodimerise with IRF-8 leading to repression of IRF-1 
transcriptional activity [138, 139]. The interface between IRF-1 and IRF-8 has been 
mapped to residues 164-219 on IRF-1 using deletion mutants [129].  
The physiological relevance and occurrence of IRF-1 homodimers remains unclear. 
A study by Kirchhoff et al. suggest that IRF-1 forms homodimers in vivo through a 
dimerisation motif at residues 91-114 [140]. However, in vitro IRF-1 is present as a 
monomer in solution, as shown by density gradient centrifugation and native PAGE 
(unpublished data, Ball group). Furthermore, IRF-1 was crystallised in its monomeric 
form, however as mentioned earlier, footprinting studies suggest cooperative binding 
at the iNOS promoter, which could be due to an additional homodimersiation domain 
outside the IRF-1 DBD. 
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Figure 1-8 Functional domains of human IRF-1  
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1.4.2 Activation 
IRF-1 is activated in response to a number of inhibitory cytokines, as well as by 
dsRNA, interferons (IFNs), and genotoxic stress [141, 142]. Upon activation, IRF-1 
can stimulate the expression of a wide range of target genes; this is dependent on 
several factors including cell type, stage of development and stimulus [143]. The 
best-studied pathway of IRF-1 activation is through IFN-γ treatment or viral attack. 
IFN-γ is a cytokine, which is produced by activated T cells or NK cells. IRF-1 
activation by IFN-γ is dependent on the JAK/STAT pathway and stimulates 
expression of IFN-β [109, 144], 2-5A synthetase [145, 146], and RNA dependent 
protein kinase [147, 148] along with other proteins. IFN-γ binds to the IFN-γ receptor 
or IFNGR on the outer cell membrane. Binding to the receptors leads to activation of 
the Janus protein kinase 1 or 2 (JAK1 or JAK2), which is associated with the 
intracellular part of the trans membrane receptor. After auto- and/or trans 
phosphorylation of specific residues within JAK, the kinase phosphorylates the 
downstream targets signal transducers and activators of transcription (STAT) 1 and 
2. The activated STATs trigger the formation of a transcriptional activator complex 
called IFN-γ-activated factor (GAF - also termed IFN-α-activated factor AAF), 
consisting of a homodimer of tyrosine-phosphorylated STAT1 [149, 150]. This 
complex translocates into the nucleus, where it binds a specific DNA sequence, 
called the GAS element, which in turn facilitates transcription of several IFN-
stimulated genes, including IRF-1 [149].  
 
A study by Pamment et al.[141] showed that activation of IRF-1 in response to DNA 
damage is dependent on the ATM-kinase. Further, induction of IRF-1 protein and 
mRNA after radiation is defective in ATM deficient cells; however, the response to 
viral mimics remains intact. This suggests that the ATM-signalling pathway plays a 
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1.4.3 IRF-1 in cancer   
IRF-1 has been identified as playing a role in the development of different cancers 
and has thus been classified as a tumour suppressor protein. The first study 
connecting IRF-1 with the regulation of oncogenesis was from Harada et al. (1993) 
and demonstrated that the phenotype of NIH3T3 cells, which underwent 
transformation by IRF-2 overexpression, could be reverted by over expression of 
IRF-1 [151]. Later studies in mouse embryonic fibroblasts (MEFs) showed that IRF-
1 -/- cells were defective in DNA damage-induced cell cycle arrest [152].  
 
IRF-1 is involved in apoptosis and thereby helps elimination of pre-cancerous cells. 
In activated matured T lymphocytes IRF-1, and not p53, is required for DNA damage 
induced cell death [153], while in thymocytes apoptosis is dependent on p53 and not 
IRF-1. Furthermore, IRF-1 has been implicated in apoptosis that is triggered by 
factors other than DNA damage, like IFN-γ [154-156]. The exact IRF-1 target 
proteins involved in apoptosis remain elusive, but factors like caspases and tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL), are believed to play an 
important role [120, 157].  
 
In an oncogenic transformation assay, introduction of activated c-Ha-Ras leads to 
transformation of IRF-1 -/- MEFs but not wild-type cells (where at least two 
oncogenes are required for transformation) [158]. In mouse studies, IRF-1 deficiency 
does not have a substantial effect on tumour formation, however in combination with 
expression of c-Ha-Ras or deletion of p53 the incidence of tumour development 
increases dramatically in vivo. Together these studies demonstrate a tumour 
suppressor activity of IRF-1. Consistent with these observations, defects in IRF-1 
activity, through loss or mutation of the IRF-1 gene or through overexpression of 
IRF-1 repressors e.g. Y-box protein (YB-1) or tripartite motif-containing 28 (TRIM-
28), have been linked to the development and progression of different cancers, 
including leukaemia, myelodysplastic syndrome (MDS), oesophageal, gastric and 
breast cancers [159-163]. The IRF-1 gene maps to chromosome 5q31.1 [161] and 
cytogenetic abnormalities in this region have been found in several diseases, e.g. 
11% of sporadic breast cancers show a loss of chromosome 5q12-31 [164]. A study 
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by Doherty et al. showed that 30% of neo-plastic breast tissues lack IRF-1 [159]. 
Furthermore, several point mutations in the IRF-1 gene were identified in cancer 
samples. The COSMIC (Catalogue of somatic mutations in cancers) lists 23 
mutations in the IRF-1 gene (from 7859 samples), 14 of these are missense mutation, 
with 7 affecting residues in the highly conserved DBD of IRF-1 [165].   
Taken together the biochemical and clinical studies indicate that IRF-1 is an 
important regulator of cellular growth control and cell death, and that its loss or 
dysregulation can play a role in the formation and progress of different malignancies.  
 
1.4.4 Ubiquitination of IRF-1 
IRF-1, like most other transcriptional regulators, has a very short half-life of 20-30 
minutes in cultured cells. Thus, levels of IRF-1 are controlled very tightly to ensure 
proper function in vivo. IRF-1 is ubiquitinated leading to degradation by the 
proteasome, a pathway important in controlling cellular levels of IRF-1 [135, 166]. 
However, many details of this pathway and how it is controlled remain unknown. 
The Ball group has shown that the rate of IRF-1 ubiquitination and degradation is 
mainly mediated through its C-terminal enhancer domain. As mentioned earlier the 
enhancer comprises a degradation and an ubiquitination signal (Fig 1-8) and these 
two processes can be uncoupled as demonstrated by a mutation study by Pion et al. 
[135]. The only E3 ligase that has been identified for IRF-1 is C-terminus of Hsc70 
interacting protein (CHIP) [130]. CHIP is a U-box E3 ligase that binds to Hsp70 and 
targets misfolded proteins for degradation, thereby linking the ubiquitin pathway to 
the chaperone machinery in cells. Recently CHIP has also been shown to act as a 
'direct' E3 ligase binding to substrates and promoting their ubiquitination directly in 
the absence of Hsp70. Under unstressed conditions, CHIP has a positive effect on 
IRF-1 steady state levels in cells. However, under stress conditions, including heat or 
heavy metal stress, CHIP was shown to directly bind to and ubiquitinate IRF-1, 
leading to its degradation. A basal E3 for IRF-1 turnover remains unidentified. 
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1.5 p53 
The transcription factor p53 was first described in 1979 and has since been shown to 
play a major role in the cell's response to oncogenic stresses and in tumour 
suppression [167-169]. It is one of the most commonly mutated proteins in human 
cancers, with around 50 % of all malignancies carrying a mutation in the p53 gene. 
p53 is crucial in the prevention of cancer development as it has been found to control 
over 100 target proteins involved in regulation of growth control, DNA repair, cell-
cycle, apoptosis, angiogenesis, metastasis, nitric oxide production and also protein 
degradation, in response to oncogenic and other cellular stress signals [170-173]. 
p53 activity is tightly controlled by the rate of its degradation through the ubiquitin – 
proteasome pathway. In unstressed cells p53 proteins is constantly ubiquitinated and 
degraded by the UPS leading to low level of the protein in the cell. Only in response 
to a wide variety of stresses e.g. DNA damage, hypoxia, nitric oxide, nutrition 
deprivation, heat/cold shock and or oncogene activation, is degradation of p53 
inhibited and its level increase dramatically leading to up-regulation of its target 
genes. Many of these gene products are involved in the prevention of cancer 
development by either leading to growth arrest or cell death [171]. How the exact 
p53 response is determined and regulated (i.e. apoptosis vs. growth arrest and 
senescence) has not been completely understood yet. Recently, the importance of p53 
in the control of the cellular metabolism has become apparent, the tumour suppressor 
was shown to be involved in control of glycolysis, oxidative phosphorylation, 
glutaminolysis, insulin sensitivity, nucleotide biosynthesis, mitochondrial integrity, 
fatty acid oxidation, antioxidant response, autophagy and mTOR signalling [174]. 
p53, for example, inhibits the glucose transporter GLUT1 and GLUT4 and insulin 
receptors leading reduced uptake of glucose into the cell. p53 furthermore activates 
transcription of TIGAR and stimulates degradation of phosphoglycerate mutase 
(PGM) , together this contributes to reduced glycolysis and opposes the Warburg 
effect, which described a high rate of glycolysis followed by lactic acid fermentation 
in the cytosol of cancerous cells. [174]. Strikingly, a study by Li et al. [175] showed 
that p53 function in metabolism is sufficient for its function as a tumour suppressor 
protein, the study utilised transgenic mice with mutations in the p53 core domain that 
avert its ability to activate transcription of genes involved in apoptosis and growth 
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arrest, the mutants protein, however, is still able to regulate metabolic genes and its 
tumour suppressive function is unaffected. This is an intriguing observation and 
suggests that the relatively recently discovered role of p53 in the adaptation of the 
cells metabolism under stress conditions plays a crucial part in p53's role in the 
prevention of oncogenesis. 
The importance of p53 as a tumour suppressor has been demonstrated in several 
studies with either p53 -/- or +/- mice or mice carrying different mutant p53 genes. 
Transgenic mice lacking either one or both p53 genes or carrying a mutation that 
renders the protein transcriptionally inactive are prone to tumour formation and have 
a dramatically reduced life expectancy [176-180].  
MDM2 (murine double minute 2) is the main and best-studied E3 ligase involved in 
p53 turnover. Under normal conditions, p53 levels are controlled by a complex 
feedback regulated system and dysregulation can lead to excessive p53 
ubiquitination and degradation, thereby inhibiting its function as a tumour suppressor 
protein. This can result in uncontrolled cell growth and cancer development. 
Therefore, inhibiting MDM2 mediated ubiquitination of p53 and thus stabilising p53 
levels is a major interest for research aiming to reactivate the p53 pathway in cancer 
cells. 
Like IRF-1, p53 has several intrinsically disordered domains; this equips the 
transcription factor with conformational plasticity and allows it to adopt a wide range 
of different structures in response to different binding partners. Motifs on p53 have 
been shown to interact with more than three hundred different proteins in the cell 
[181]. p53 thereby interconnects different signalling pathways and acts as an 
important hub protein. The list of p53 interactions partners consists of p53 activators, 
inhibitors and effectors of its function. p53 is a multi-domain protein and consists of 
a DNA binding domain, a transactivation domain, a tetramerisation domain and 
several other sub-domains and motifs that are important in controlling p53 activity 
and degradation.  
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1.5.1 Structure  
1.5.1.1 DNA binding domain  
The structure of the p53 core domain (DNA binding domain) has been studied 
extensively, it was first crystallised in 1994 in complex with DNA [182] and several 
others structures, either free, bound to domains of signalling proteins or in complex 
with DNA have been solved since. The p53 DBD can be subdivided into two motifs, 
one binding the major and the other one the minor groove of p53's target DNA. The 
binding site of the minor groove is stabilised through a zinc ion, which is 
tetrahedrally coordinated by the residues Cys176, His179, Cys238 and Cys242. The zinc 
ion stabilises the interactions between p53 and DNA and loss of this ion leads to a 
decrease in thermodynamic stability and an increase in aggregation and fluctuation in 
neighbouring loops, in turn resulting in a decrease of p53 DNA binding specificity 
[183, 184].  A p53 tetramer specifically recognises a repeat of the consensus 
sequence: 5'-RRRCWWGYYY-3' (R=A,G; W=A,T; Y=C,T), which can be 
separated by a spacer of 0-13 base pairs [185]. Crystallographic studies showed that 
binding of a p53 tetramer to a repeat of this sequence leads to a twisting and bending 
of the DNA molecule [186]. The main residues on p53 involved in DNA-protein 
interactions include Lys120, Ser241, Arg248, Arg273, Ala276, Cys277 and Arg280 [182, 
187]. Several residues within the DBD of p53 are subject to posttranslational 
modifications, which can have an effect on p53 activity and/or DNA binding 
specificity. One example is acetylation of Lys120 by the acetyltransferases hMOF and 
TIP60 in response to DNA damage. This modification reportedly leads to specific 
transcription of factors required for apoptosis like BAX and PUMA and initiates 
apoptosis. Mutation of Lys120 to Arg or depletion of the acetyltransferase inhibits the 
ability of p53 to activate BAX and PUMA, but does not have an effect on expression 
of other p53 target proteins that are involved in cellular growth arrest [188, 189]. 
Several missense mutations on the p53 DNA binding domain have been implicated 
in the development of human cancers, the most common mutations are Arg175, 
Tyr220, Gly245, Arg248, Arg249, Arg273, Arg 282 (Fig 1-8b) [170]. 
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Figure 1-9 Structure of p53s DBD 
(a) Tetrameric structure of the p53 core domain, monomers are presented in different colours 
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1.5.1.2 Transactivating domain  
The p53 transactivating domain is located at its extreme N-terminus and exhibits a 
natively unfolded region. It can be divided into two subdomains TAD1 (aa 1-40) and 
TAD2 (aa 40-61) [190, 191]. The TAD domains are followed by a proline rich 
region (aa 64-92), which contains five PXXP motifs [191]. PXXP motifs are known 
to mediate protein-protein interactions through binding of Src homology domains; 
however, the function of this motif in p53 is not understood well. Mutational studies 
on this domain suggest that rather than playing a role as a protein-docking site, the 
length of this domain is essential for p53's function as a tumour suppressor protein 
[134], implying that it plays a role as a molecular spacer that separates two functional 
domains [192]. 
The TAD motifs serve as a binding site for many p53 interacting proteins, including 
components of the transcription machinery [193-195] and coactivators such as p300 
and CREB-binding protein (CBP) [196, 197]. It also provides one of the two binding 
sites for MDM2 and the MDM4 binding site [198-201]. Interestingly, the binding 
site for the coactivator p300 and CBP, which is essential for proper p53 function 
partly overlaps with the binding site of MDM2, making binding of these two p53 
regulators mutually exclusive. p300 is believed to acetylate histones and thereby 
relax the chromatin structure, favouring binding of factors like p53 [202]. 
Additionally, it directly targets p53 for acetylation in its DNA binding domain, 
which leads to activation. MDM2 on the other hand inhibits p53 function by 
targeting it for degradation, in addition to blocking the binding site of the p53 
activator p300 (see section 5.1.2 for details about MDM2). The p53 N-terminus is 
subject to several posttranslational modifications in response to different stresses and 
these are important in p53 control. Several serine and threonine residues within the 
transactivation domain are targeted by different kinases, and phosphorylation of 
these sites can affect the affinity of proteins that compete for binding to this domain, 
and thereby affect p53 activity. For example, phosphorylation of Thr18 or Ser20 
decreases binding affinity of MDM2 to p53, and studies suggest that this same 
modification can increase the affinity of the interaction between p53 and p300 [134, 
201, 203, 204].  
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1.5.1.3 Tetramerisation domain  
p53 forms reversible tetramers through residues in its C-terminus (aa 326-356). The 
structure of a p53 tetramer (C-terminal domain only) was solved by NMR and 
crystallography studies [205-208]. The structure can be described as a dimer of 
dimers and in vitro studies on p53 biogenesis showed that dimers form during 
translation on the polysome while tetramers are formed in solution by dimerisation of 
the preformed dimers [209]. The tetramerisation domain is built of a short β-strand 
and an α-helix; upon dimerisation two monomers form an intermolecular β-sheet and 
an antiparallel helix. The main residues involved in formation of the intermediate 
dimer are Leu330, Ile332 and Phe341. Two of these dimers then associate, through their 
helices by mainly hydrophobic interactions, forming a four-helix bundle tetramer. 
p53 binds DNA in its tetrameric form and mutations of residues that are essential for 
tetramer formation lead to decreased or complete loss of p53 activity. 
   
1.5.1.4 C-terminal domain 
The C-terminal region of p53 is important for control of p53 activity and subject to 
several posttranslational modifications, including acetylation, ubiquitination, 
phosphorylation, SUMOylation, methylation, and NEDDylation. These 
modifications regulate p53 function and cellular protein levels [210-212]. 
Structurally, the C-terminus is intrinsically disordered, but several crystal structures 
of peptides from this domain bound to other proteins have been solved, suggesting 
that it can fold into a specific structure when interacting with binding partners. An 
example of this is a peptide consisting of p53 residues 367-388, which is 
unstructured in isolation, but takes up a helical conformation when bound to the 
calcium-dependent dimeric S100B(ββ) protein and a β-turn-like conformation when 
acetylated at Lys382 and associated with the bromodomain of CBP [213, 214]. One of 
many other proteins that bind to this region is HAUSP/USP7, a deubiquitinase that 
has been shown to deubiquitinate p53, thereby working together with different E3s in 
controlling the ubiquitination state of this transcription factor [215].  
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The C-terminus of p53 has additionally been shown to bind DNA non-specifically 
through electrostatic interactions of several lysine residues. These low affinity 
interactions inhibit binding of the core domain to specific p53 promoter sequences 
[216], and acetylation of the C-terminal lysines leads to a gradual loss of this non-
specific DNA binding capacity [217]. A mechanism has been proposed in which the 
C-terminal non-specific binding ability of p53 is involved in linear diffusion on 
DNA, a process where p53 slides along searching for its target sequence [218]. 
Consistent with these findings, it was shown that the last 30 amino acids of p53 are 
essential for efficient binding and transactivation of target genes in the context of 
chromatin or large molecules of DNA [218, 219]. 
 
 
1.5.2 p53 in Cancer  
The transcription factor p53 is part of a small protein family that consists of two 
other members p63 and p73. All three proteins share structural and functional 
homology, but while p63 and p73 play roles in normal cellular development, p53's 
most important role appears to be prevention of tumour development. Strikingly, it 
has been demonstrated that p53 is either non-functional or functions incorrectly in 
most human cancers [170, 172].  Under normal conditions levels of the protein are 
kept low, but in response to stresses like carcinogen-induced DNA damage, 
abnormal proliferative signals, hypoxia or loss of cell adhesion, p53 is activated and 
regulates different cellular processes to guard against tumorigenesis. p53 can trigger 
a range of cellular responses including cell-cycle arrest, senescence, DNA damage 
repair, inhibition of angiogenesis, differentiation and apoptosis. p53 functions either 
through its transactivation activity, leading to expression of specific target genes, or 
by binding to other regulatory proteins and thereby altering their function. The nature 
of the cellular response to p53 activation, depends on several factors like cell type, 
oncogenic cell composition, type of stress, level of p53 expression and interactions 
of p53 with specific proteins [170, 173]; however, the most common cellular 
response to p53 activation is growth arrest and apoptosis. p53 can activate the 
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expression of target genes that result in growth arrest of the cell either in the G1 
phase, before DNA replication, or before mitosis in the G2 phase. Growth arrest 
allows the cell to repair DNA damage. In other cases, presumably when DNA 
damage is beyond repair, p53 triggers apoptosis, by inducing the expression of a 
wide range of cell death effectors [173]. 
Consistent with the observations of p53 function, mouse models that are p53-
deficient develop multiple, spontaneous tumours at an early age [220-222]. As 
mentioned earlier, genetic alteration of the p53 gene is the most common mutation in 
human cancers. Most mutations occur in the core DNA binding domain, either in 
residues that directly contact DNA or are important for the structure of the domain. 
p53 mutants have been shown to be kinetically unstable and unfold spontaneously 
taking up a characteristic mutant conformation. These mutant proteins are often not 
degraded by the cell efficiently, either because they are not recognised effectively by 
the respective E3 ligase or because the degradation pathways are non functional due 
to loss of p53 wt function. This can lead to accumulation of mutant p53 in the cell. 
Since p53 is active in its tetrameric form, some p53 mutants have a dominant-
negative effect over wild type p53 as one mutant molecule in a mixed p53 tetramer 
can inhibit its function [170, 223].  
Activation of p53 in tumour cells in order to achieve cell death by apoptosis is a 
major interest in the development of drugs targeting cancerous cells. The approaches 
can be divided into three different groups, depending on the status of p53 used in the 
cell and are: (i) reactivation of mutant p53 [223, 224]; (ii) targeting negative 
regulator of p53 function by the development of antagonists or activating positive 
regulators of p53 [225], (iii) exogenous p53 expression, e.g. by adenovirus- mediated 
gene transfer [226]. Two studies in transgenic mice have independently shown that 
restoration of p53 function can lead to apoptosis of cancer cells and thus tumour 
regression in vivo. These results indicate that efforts to treat human cancers by 
reactivation of p53 are a promising therapeutic strategy [227, 228]. 
  
 




Figure 1-10 Overview of p53 function [229] 
Different stimuli like DNA breaks, UV, stress or oncogenes lead to p53 activation by 
different signalling pathways. p53 is either activated directly by phosphorylation or 
indirectly by blocking the negative regulators of p53, MDM2 and MDM4, thus leading to an 
increase in p53 activity. Activated p53 leads to transcription of a range of target genes 
including several genes that are involved in growth arrest, apoptosis, DNA repair, translation 
and prevention of angiogenesis. In addition to its role as a transcriptional activator, p53 has 
been shown to exhibit other non-transcriptional function in a range of cellular pathways (left 
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1.5.3 Ubiquitination of p53 
p53 levels and therefore its activity is tightly controlled by the rate of its degradation. 
Under normal conditions p53 is constantly transcribed and translated, however levels 
are kept low by almost immediate degradation of the protein. Thus, p53 has a very 
short half-life of only around 20 minutes under unstressed conditions. In response to 
stresses, e.g. oncogenic or genotoxic stresses, p53 degradation is inhibited and its 
half-life increases to several hours [230, 231].  
So far 15 E3 ligases have been implicated in p53 ubiquitination. Our understanding 
of the regulation and function of most of these, however, is limited. E3 ligases 
identified as targeting p53 include MDM2, Pirh2, ARF-BP1/MULE, E4F1, Trim24, 
CHIP, Cullin complexes and others that still await full validation.  
The best studied E3 for p53 ubiquitination is MDM2. This RING finger containing 
E3 ligase catalyses the ubiquitination of several lysine residues within p53 [232] and 
has been shown to be a very important factor in controlling p53 protein levels. 
MDM2 works in synergy with its homolog MDM4 (or MDMX), which shares 
structure and sequence homology with MDM2 but has no E3 ligase activity [200, 
233]. Different studies suggest that MDM2 and MDM4 can form heterodimers, 
which stabilise MDM2 and increase its inhibitory effect on p53 [234, 235]. 
In addition to controlling p53 activity by ubiquitination, which leads to proteasomal 
degradation, MDM2 also competes with the p53 activator p300 for binding to p53 
and thereby inhibits p300-mediated enhancement of p53 activity. Interestingly, 
MDM2 is also a direct transcriptional target of p53 [236, 237]. This results in a 
negative feedback loop, where p53 ubiquitination is inhibited in response to cell 
stress, leading to its activation and thus expression of MDM2, which in turn 
ubiquitinates p53 and thereby down regulates its levels and terminates the signal. 
Mass spectrometry analysis and mutational studies have identified several lysines in 
the C-terminal and core domain of p53 to be subject to modification by ubiquitin 
[232, 238], however, the exact molecular signals of ubiquitination at different lysine 
residues remain elusive. Studies on the effect of ubiquitination of different residues 
in its C-terminal domain have resulted in conflicting results. The initial study that 
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identified six C-terminal lysines as a target for ubiquitination suggested that these 
residues are essential for proteasomal degradation of p53 [238]. In contrast, results of 
a recent mutational study in mouse embryonic stem cells showed that the C-terminal 
lysines are not required for degradation of p53 under normal cellular conditions or 
during DNA damage [239]. Another study by Lohrum et al. suggested that 
monoubiquitination of the C-terminus of p53 serves as a nuclear export signal, 
resulting in shuttling of p53 out of the nucleus [240]. So far most studies have either 
used multiple site mutants or a p53 ubiquitin fusion protein; these artificial 
modifications of p53 could have effects on the protein e.g. conformational changes 
that affect the experimental outcome. In summary, more work is necessary to dissect 
and completely understand how p53 activity and degradation are controlled by 
ubiquitination at distinct lysine residues.  
Strikingly, MDM2 has also been shown to act as an activator of p53 following DNA 
damage. This effect is dependent on the ATM kinase, which phosphorylates MDM2 
at Ser395 promoting interaction of MDM2 with p53 mRNA [241]. Interaction 
between the MDM2 RING domain and p53 mRNA inhibits MDM2 E3 ligase 
activity and promotes p53 translation, leading to an increase in p53 levels [242]. 
Thus, MDM2 can act both as an inhibitor and activator of p53.  
In conclusion, MDM2 is viewed as the key regulator of p53 activity and its 
regulation has therefore been studied extensively. In addition to carrying mutations 
in the p53 gene itself, many cancers have a dysfunctional p53 degradation pathway, 
leading to excessive degradation of the p53 WT protein and thus loss of its tumour 
suppressor activity. Reactivating p53 by developing drugs that affect the regulation 
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1.5.4 CHIP  
The ubiquitin ligase CHIP (C-terminal of Hsp70-interacting protein) plays an 
important role in the protein quality control system of cells. This system recognises 
misfolded proteins, which are then either refolded by chaperones or degraded via the 
ubiquitin proteasome pathway. CHIP forms a link between the two pathways by 
functioning as a Hsp70 co-chaperone [243] that also interacts with Hsp90. CHIP 
facilitates ubiquitination of Hsp70/90 bound client proteins leading to their 
proteasomal degradation thereby tilting the machinery towards the degradation rather 
than the refolding pathway [244-246]. The protein quality control system forms a 
very important mechanism in the cell, ensuring healthy cellular functions, especially 
in stress situations. Malfunction of the cells degradation pathways can lead to the 
accumulation of misfolded proteins and these aggregates can cause diseases, like 
neurofibrillary tangles in Alzheimer’s disease and the Lewy bodies in Parkinson 
disease [247]. In addition to functioning as an E3 ligase for chaperone bound client 
proteins, a role of CHIP as a direct E3 ligase is emerging, where CHIP binds to 
substrates independently of Hsp70 and facilitates their ubiquitination [130]. Details 
of the control and regulation of these two distinct functions for CHIP are, however, 
largely unknown. In addition to its E3 ligase function, CHIP can also act as a 
molecular chaperone that promotes or maintains protein structures independently of 
Hsp70 [248, 249]. 
Structurally, CHIP is comprised of two distinct domains: (i) the catalytically active 
C-terminal U-box domain (aa 227-297), which is structurally related to the RING 
finger domain, but is stabilised through hydrogen bonds instead of by zinc binding 
[245, 250]. And (ii) the N-terminal tetratricopeptide repeat (TPR) domain (aa 25-
130), which is responsible for chaperone interactions [245] (Fig 1-11). TPR domains 
are multipurpose structural modules that are highly conserved from E.coli to human. 
These domains were shown to be involved in the assembly of multi-protein 
complexes and function in a wide array of cellular processes including transcriptional 
control, mitochondrial transport, kinase signalling, protein folding, immunity and 
viral replication [251-253]. The TPR and U-box domains are linked by a flexible 
linker region, also called charged or middle domain [254]. 
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The structure of mouse (aa 25-304, [254]) and zebrafish (aa 112-284,  [255]) CHIP 
was solved by two groups independently. Both structure confirm that CHIP forms a 
homodimer, however both structures differ significantly. While the zebrafish 
structure, which lacks the TPR domain, shows a symmetric dimer, the mouse 
structure, which was solved in complex with an TPR bound Hsp90 peptide, shows an 
asymmetric dimer with considerable differences in the orientation of the charged 
middle domains. These differences in the structures could be due to the fact that the 
zebrafish structure was solved in the absence of the N-terminal TPR domain, which 
could be important for the over all conformation of the protein. Additionally, an H/D 
exchange study on full length CHIP suggested that CHIP forms a symmetric dimer in 
solution [256]. The dimer interface encompasses the U-Box and central domain in 
both crystal structures [254, 255]. Several ubiquitin conjugating enzymes (E2s) are 
known to interact with the U-box of CHIP, and these can facilitate the formation of 
polyubiquitination chains linked by K48, K11 or K63, depending on the E2 [12, 
245]. CHIP was shown to negatively control p53 levels in cells and to act as an E3 
ligase for IRF-1 under specific stress conditions [130, 257].  
CHIP function was implicated in tumour suppression by studies showing that CHIP 
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1.5.5 MDM2  
The oncoprotein MDM2 (murine double minute) is the most important regulator of 
p53 function and was shown to regulate p53 activity on multiple levels. The best-
studied role of MDM2 in p53 control is its ability to target p53 for ubiquitination by 
its E3 ligase activity [258, 259]. However, MDM2 was shown to regulate p53 
through several other mechanisms, including blocking interactions between p53 and 
co-activators at target promoters [197, 260]. Moreover, MDM2 has been suggested 
to promote degradation of the ribosomal proteins L26 and L11 and thereby inhibiting 
p53 translation [261]. Interestingly, MDM2 was also shown to positively affect p53 
levels by binding to p53 mRNA, which stimulates p53 protein synthesis and inhibits 
MDM2 E3 ligase activity [242], furthermore, MDM2 can act as an ATP-dependent 
molecular chaperone towards p53 [262, 263]. 
MDM2 consists of several distinct domains that are involved in protein-protein 
interactions and exhibit different functions. The N-terminal hydrophobic pocket is 
required for interaction with several proteins, including p53, and binds to the peptide 
consensus sequence FxxxWxxL [199, 264]. The central region of MDM2 comprises 
of an acidic amino acid rich domain, which interacts with a number of enzymes 
involved in signalling that contain the general consensus sequence: SxxLxGxxxF 
[198, 265, 266]. At the MDM2 C-terminus lies its RING domain, which is, like other 
RING domains, stabilised by coordination of two zinc ions. In addition, the MDM2 
RING encompasses a P-Walker motif, which is essential for its ATP-dependent 
molecular chaperone function [262, 267]. MDM2 is believed to form heterodimers 
with its close homolog MDM4 (also called MDMX) in vivo [268], as well as 
homodimers. MDM4 also was shown to act as a negative regulator of p53 function, 
however, it does not exhibit E3 ligase activity and the exact mechanism by which it 
regulates p53 is unclear [234, 269-272]. MDM4 has been shown to act as a substrate 
for MDM2 mediated ubiquitination leading to its degradation [273-275].  
 
The structure of several MDM2 sub-domain have been analysed by NMR and/or 
crystallisation, i.e. the C-terminal RING domain as a heterodimer with the MDM4 
RING and as a homodimer [268], 276] , the zinc-finger domain [277]  and the N-
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terminal hydrophobic pocket [278, 279] . So far it has however not been possible to 
solve the structure of full length MDM2, the reason for this is most likely a high 
amount of intrinsically disordered regions that are difficult to analyse. 
 
MDM2 interacts with two distinct binding sites on p53, the higher affinity interaction 
between its hydrophobic pocket and the Box I motif on p53 leads to allosteric 
changes in MDM2 that stimulate binding of the acid domain to the second p53 
binding site within its core domain (Box V) with weaker affinity. This site is the 
"ubiquitination signal" on p53 and binding to this site is required for efficient p53 
ubiquitination by MDM2 [198, 265, 266, 280]. 
 
In addition to controlling p53 function, MDM2 can regulate the levels and activity of 
a number of other proteins both positively and negatively. So are IRF-2 and pRb 
(retinoblastoma protein) ubiquitinated and degraded in a MDM2 dependent manner 
[281, 282]. The activity of p65 and p73 are modulated by MDM2, without 
necessarily leading to protein destruction [283-288].  
MDM2 has become the focus of intensive research as a target for the development of 
drugs aiming to reactivate p53 function in cancer cells. Several small molecules have 
been identified that either disrupt the interactions between p53 and MDM2, modulate 
MDM2 protein expression or inhibits MDM2's E3 ligase function and at least one of 
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Figure 1-11 Functional domains of CHIP and MDM2  
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1.6 Objective of this thesis 
The scope of this thesis was to gain a better understanding of the regulation, 
mechanism and effects of p53 and IRF-1 ubiquitination. To do this, I studied three 
main areas: Firstly, the regulation of the two E3 ligases CHIP and MDM2, which 
have been implicated in the control of the tumour suppressors p53 and IRF-1. This 
was done by studying the structure/function relationship, as well as the effects of 
ligand binding to the E3 ligases (chapter 3). Secondly, I wanted to establish the 
mechanism of IRF-1 ubiquitination in more detail, therefore, I mapped the sites of 
ubiquitin modification in a first step and then went on to determine interplay between 
DNA binding and ubiquitination of the transcription factor (chapter 4). Lastly, I 
studied the non-proteolytic effect of ubiquitination on the activity of p53 and IRF-1 
to gain insight into how these transcription factors are regulated by modification with 
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Chapter 2: Materials and Methods  
2.1 Reagents, plasmids and centrifuges 
pET-15b-mod-CHIP and pGEx6MDM2‐WT was a kind gift from Alicja Zylicz; 
pcDNA3-IRF-1 WT and mutants (W11R) were from Emmanuelle Pion and Kathryn 
Ball; pcDNA3-p53, pcDNA3-MDM2, His-ubiquitin were from Susanne Pettersson, 
Ted Hupp and Kathryn Ball, FLAG-IRF-1, FLAG-IRF-1 ΔMf2, FLAG-empty 
vector, pDEST15-IRF-1 WT and W11R (codon optimised) were from Vikram 
Narayan, Emmanuelle Pion and Kathryn Ball, pT7‐7Hup53 was from Ted Hupp, 
ubiquitin-pHISTEV30a was a kind gift from Dr. Anna Plechanovova and Prof. Ron 
Hay (see Table 2-1 for details of plasmids). 
Table 2-1 List of Vectors 






























Chemicals and reagents were purchased from Sigma or BDH, unless otherwise 
indicated. Sorvall RC-5C plus and Eppendorf 5415R were used for all 
centrifugations, unless otherwise indicated. 
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2.2 Microbiological techniques 
2.2.1 Growth of bacterial cultures 
2.2.1.1 Over-night cultures 
For overnight cultures, 5‐250 ml of LB broth media with the appropriate antibiotic 
was inoculated with colonies from either a glycerol stock or a bacterial culture dish. 
The culture was incubated over-night at 37°C in a shaking incubator. 
Luria‐Bertani (LB) broth 
1% (w/v) Tryptone 
1% (w/v) NaCl 
0.5% (w/v) Yeast extract 
The media was sterilised by autoclaving at 121°C for 20 minutes and 50 µg/ml 
kanamycin (Gibco) or 100 µg/ml ampicillin (SIGMA) was added after autoclaving. 
2.2.1.2 Glycerol stocks 
For long time storage of the bacteria cultures glycerol stocks were prepared. 
Therefore, 850 µl of a liquid over-night culture was mixed well with 150 µl sterile 
glycerol, snap frozen in liquid N2 and stored at ‐80°C. 
 
2.2.2 Preparation of competent cells 
Bacterial cells from glycerol stock were inoculated into 2 ml of antibiotic free LB 
media and incubated overnight at 37°C in a shaking incubator.. The overnight culture 
was diluted 1:200 in 100 ml LB media and grown till the OD600nm has reached 0.6. 
The culture was pelleted for 20 minutes at 4000 g, re-suspended in 16 ml ice-cold 
buffer I and incubated for 10 minutes on ice. Cells were centrifuged again as above 
and the pellet was re-suspended in 2 ml ice-cold buffer II. After a 10 minutes 
incubation time, cells were aliquoted (30 µl) and snap frozen using liquid nitrogen. 





2. Materials and Methods  57 
Buffer I  
60 mM CH3COOK  
10 mM CaCl2  
40 mM MgCl2   
100 mM RbCl  
15% (v/v) glycerol  
Adjusted to pH 5.8 with CH3COOH and sterilised by filtration  
 
 
Buffer II  
10 mM MOPS  
75 mM CaCl2  
10 mM RbCl  
15% (v/v) glycerol  
Adjusted to pH 6.5 with NaOH and sterilised by filtration 
 
2.2.3 Heat shock transformation of E.coli 
30 µl of competent cells (stored at ‐80°C) were thawed on ice. Next, 50-200 ng of 
plasmid DNA was added to the cells and incubated for 20 minutes on ice. The 
bacteria were incubated at 42°C (water bath) for 45 seconds and subsequently 500 µl 
of LB broth media (antibiotic free) was added and bacteria cells were incubated for 1 
hour at 37°C while shaking. Cells (100 µl and 250 µl) were plated on agar plates and 
incubated at 37°C over-night. 
LB agar plates 
1% (w/v) tryptone 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
1.5% (w/v) agar, granulated 
 
Sterilised by autoclaving at 121°C for 20 minutes.  
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To prepare plates the agar was melted using a microwave, cooled down and 100 
µg/ml ampicillin or 50 µg/ml kanamycin (SIGMA and Gibco) was added after the 
agar had reached around 45°C. Next, the agar was poured into 90 mm petri dishes 
(Sterilin), allowed to cool down and dried in a 37°C incubator.  
 
2.2.4 Amplification, purification and quantification of plasmid 
DNA 
One distinct colony from a LB agar plate was inoculated in 5 ml (Mini-prep) or 250 
ml (Maxi-prep) of LB broth (with selective antibiotic) and incubated for 12-16 hours 
at 37°C shaking. Bacterial cells were collected by centrifugation at 4000 g and 
plasmid DNA was extracted using either the Qiagen HiSpeed Mini-prep or Maxi-
prep kit following supplier's instructions. DNA was eluted using 30 or 500 µl H2O 
respectively. DNA content was quantified using a NanoDrop ND-1000 
spectrophotometer following manufacturer’s instructions.  
 
2.2.5 Agarose gel electrophoresis of DNA 
DNA samples were analysed using agarose gel electrophoresis. Therefore, 1- 2% 
agarose (electrophoresis-grade - Invitrogen) was dissolved in 1X TAE by gentle 
heating in a microwave oven. After all the agarose had dissolved, the mixture was 
allowed to cool down slightly and ethidium bromide (0.5 µg/ml) was added to the gel 
prior to pouring into a gel chamber. DNA samples were mixed with 6X DNA loading 
dye and loaded onto the gel. Gels were run at 100 V for 45-60 minutes.  
 
1X TAE Buffer  
40 mM Tris-HCl  
1 mM EDTA  
Adjusted pH to 8 with glacial acetic acid  
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6X DNA Loading Dye  
0.25% bromophenol blue  




2.2.6 Site-directed mutagenesis  
Site-directed mutagenesis was carried out using the QuikChange Kit (Stratagene) 
according to the manufacturer’s instructions. Primers used for site-directed 
mutagenesis are listed in Table 2-2. 
PCR reaction mix for site-directed mutagenesis was prepared as follows:  
12.5 µl Pfu Master Mix (2X)  
2.5 µl Band Doctor  
50 ng Plasmid DNA template  
0.13 µl Forward Primer (100 µM stock)  
0.13 µl Reverse Primer (100 µM stock)  
Nuclease-free water to 25 µl  
 
Thermal cycling conditions were:  
95°C for 1 minute  
95°C for 50 sec  
55°C for 1 minute  
68°C for 12 minutes  
Repeat steps 2-4 for 15 cycles  
68°C for 30 minutes  
Hold at 4°C 
 
To remove the template DNA the reactions were digested with 1 µl DpnI (5 U/µl, 
Invitrogen) at 37°C for 90 minutes, followed by heating at 65°C for 10 minutes to 
inactivate the enzyme. Of the digested product 5-15 µl was transformed into 
competent DH5α cells. Two to three single colonies were picked and DNA was 
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prepared using the Qiagen Mini-prep kit (2.2.3 and 2.2.4). The isolated DNA was 
sequenced to confirm that it contained the respective mutation (Source BioScience). 
PCR was performed using DNA Engine Dyad peltier thermal cycler (Bio Rad) 
 
 
Table 2-2 Primer sets for site-directed mutagenesis (with sites of codon change 
indicated in red) 
 








































F: 5'TATTAACAGAGATGCGTGCC'3  
R: 5'GGCACGCATCTCTGTTAATA'3 
pDEST15-IRF-1 
(codon optimised)  
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2.3 Biochemical Techniques  
2.3.1 Separation of proteins by SDS-PAGE 
The Biorad System was used for gel preparation and running. First the separation gel 
was poured (70% of gel) and overlaid with H2O to obtain an even surface and to 
exclude oxygen from the gel. After the separation gel had polymerised, the water was 
thoroughly removed and the stalking gel was poured on top. Immediately a comb (10 
or 15 wells) was inserted and the gel was left to polymerise. After solidifying, the gel 
was placed in a tank with running buffer and the comb was removed. Samples were 
prepared by addition of sample buffer (2 x) and heating for 2-5 minutes at 95°C. In 
the first lane 5 µl of pre‐stained protein standard (Bio‐Rad) was loaded as a size 
marker. The gel was run at 120 V (constant) until the proteins left the stalking gel 
and then at 170‐200 V (constant) until the bromophenol blue dye had reached the 
bottom of the gel. 
Running Buffer       2 x sample buffer 
192 mM glycine       5% (w/v) SDS 
25 mM Tris-HCl (pH 6.8)  125 mM Tris-HCl (pH 6.8)  
0.1% (w/v) SDS   25% (v/v) glycerol) 
     200 mM DTT 
     bromophenolblue (as required) 
 
Separation Gel 0.75 mm   Stalking Gel 0.75 mm  
8-15% acrylamide mix  5% acrylamide mix 
0.39 M Tris-HCl (pH 8.8)   0.13 M Tris-HCl (pH 6.8)  
0.1% (w/v) SDS    0.1% (w/v) SDS  
0.1% (w/v) APS    0.1% (w/v) APS 
0.04% (v/v) TEMED    0.04% (v/v) TEMED  
 
SDS-PAGE was carried out using the Biorad Protean II mini-gel system. 
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2.3.2 Invitrogen precast gel system 
All ubiquitination assay samples were run on gradient precast gels (4‐12% Bis‐ Tris 
Gels, Invitrogen) with 1 x MOPS running buffer (Invitrogen). The gels were run at 
175 V (constant) for around 60 minutes. 
 
2.3.3 Colloidal Blue Staining  
After the proteins were separated by SDS‐PAGE the gel was transferred into 20 ml 
fix solution for 10 minutes and subsequently into 20 ml stain solution (Invitrogen). 
After 10 minutes in the stain solution 1 ml of Stainer B (Invitrogen) was added and 
the gel was stained for at least 3 hours or over-night. To destain, the gel was 
transferred into H2O and a ball of tissue paper was added to the petri dish to absorb 
the dye and fasten destaining. Subsequently, gels were dried onto chromatography 
paper using a heated vacuum gel dryer (Gel Master Model 1426, Welch Rietschle 
Thomas). 
Fix Stain 
10 ml methanol 11 ml H2O 
2 ml acetic acid 4 ml methanol 
8 ml H2O 4 ml Stainer A (Invitrogen) 
 
2.3.4 Coomoassie Blue Stain  
For Coomassie blue staining polyacrylamide gels were incubated for 10 minutes in 
the Coomassie Stain and subsequently placed in destain until bands had reached the 
desired intensity (for 4-16 hours). Gels were dried as above (2.3.3).  
Coomassie stain     Destain 
5% Coomassie blue R-450 (Sigma)   7.5% (v/v) methanol 
10% (v/v) acetic acid     10% (v/v) acetic acid 
50% (v/v) methanol 
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2.3.5 Immuno blotting 
After separation by SDS‐PAGE, proteins were transferred electrophoretically from 
the gel onto a nitrocellulose membrane (Whatman) by western blotting. The gel was 
placed on the membrane (pre‐wetted in transfer buffer) and filter paper and a sponge 
was placed on either side. The blot was placed in a tank and the transfer was carried 
out either for 1 hour at 100 V (with an ice block to control the temperature) or at 30 
mA overnight. After the transfer, the membrane was ink stained (Pelikan; diluted 
1:1000 in PBST) for 10 minutes and then washed 3 times for 5 minutes in PBST. To 
block any nonspecific binding sites for the antibody, the membrane was blocked in 
PBST + 5% (w/v) dried skimmed milk (PBST5M; Marvel) for 1 hour or over-night. 
The membrane was then incubated with the primary antibody in PBST5M for 1 hour 
at room temperature (24°C) or overnight at 4°C. The membrane was washed with 
PBST as previously and incubated with the secondary antibody diluted 1:2000 in 
PBST5M for 1 hour at room temperature (24°C), subsequently the membrane was 
washed again and incubated in 2 ml of a 1:1 mix of ECL solution 1 and 2. Then the 
membrane was dried with a tissue paper, exposed to X‐Ray Film (SLS) or Hyperfilm 
ECL (Amersham) and the film was developed using a Konica Medical Film 
Processor (SRX-101A).  
10x PBS     Transfer Buffer 
1.37 M NaCl    192 mM glycine 
0.1 M Na2HPO4    25 mM Tris 
27 mM KCl     20% (v/v) methanol 
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Table 2-3 Primary Antibodies 
 
 
Target  Clonality Name Supplier  Dilution  
IRF-1 mouse monoclonal 20/IRF-1 BD 1:1000 
IRF-1  rabbit polyclonal C20 Santa Cruz 1:1000 
p53 mouse monoclonal DO1 Moravian 
Biotechnology 
1:5000 
p53  rabbit polyclonal CM1 Moravian 
Biotechnology 
1:1000 
CHIP  mouse monoclonal v3.1 Gift from 
B.Vojtesek 
1:30 
CHIP  rabbit polyclonal N-ter SIGMA 1:1000 
MDM2  mouse monoclonal 2A10 Moravian 
Biotechnology 
1:1000 
MDM2  mouse monoclonal 4B2 Moravian 
Biotechnology 
1:1000 
ubiquitin  mouse monoclonal sc-8017 Santa Cruz 1:1000 
ubiquitination  mouse monoclonal FK2 Enzo Life 
Sciences 
1:1000 
polyubiquitination  mouse monoclonal FK1 Enzo Life 
Sciences 
1:0000 
His tag mouse monoclonal  Novagen 1:1000 
FLAG M2 mouse monoclonal  SIGMA 1:1000 
p21 mouse monoclonal OP64 Calbiochem 1:1000 
GAPDH mouse monoclonal  Abcam 1:30000 
b-actin mouse monoclonal  SIGMA 1:5000 
HP1 mouse monoclonal  Upstate 1:5000 
Histone 3 rabbit polyclonal  Abcam 1:1000 
GST mouse monoclonal GST-2 SIGMA 1:1000 
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PBST 
1x PBS + 0.1% (v/v) Tween 20 
 
ECL Solution 1    ECL Solution 2 
100 mM Tris-HCl (pH 8.5)   100 mM Tris-HCl (pH 8.5) 
2.5 mM luminol stock   0.02% (v/v) H2O2 
0.4 mM p‐coumaric acid 




2.4 Cell culture, cell lines and media 
All tissue culture disposables such as culture plates, flasks and pipettes were from 
TPP or Greiner-Cellstar unless otherwise indicated. Media was obtained from Gibco. 




Cell line Media  C02 Origin 
A375 DMEM 10% Human malignant 
melanoma 
Mcf7 DMEM 5% Human breast 
adenocarcinoma  
HCT-116 (p53 wt)  McCoy's 5% Human colon 
carcinoma 
HCT-116 (p53 -/-) McCoy's 5% Human colon 
carcinoma 
H1299 RPMI 5% Human non-small 
cell lung carcinoma 
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2.4.1 Sub-culturing of cells 
Cells were grown in 10 cm diameter culture dishes and sub-cultured when cells 
reached 100% confluency (depending on cell type 2-3 times a week). To sub-culture, 
cells were washed once with 10 ml of sterile PBS and then incubated with 2 ml of 
Trypsin-EDTA until the monolayer had detached from the plate. Then 8 ml of fresh 
media was added to the cells and mixed. From the cell suspension 1 ml was placed 
into a new dish containing 9 ml of fresh media (1:10 dilution), to use as stock plate to 
maintain the cell line. The remaining cells were used to seed cells in different dish 
sizes and cell dilutions to be used in experiments as required.  
 
2.4.2 Freezing and recovery of cells  
To freeze cells for storage a cell dish at 80-100% confluence was washed and 
trypsinised as above (2.4.1). Once fresh media had been added, the cell suspension 
was transferred into a 15 ml falcon tube and centrifuged for 3 minutes at 200 g. 
Subsequently cells were re-suspended in 3 ml of freezing media and divided in 1 ml 
aliquots in cryotubes (NunC). To freeze cells, the aliquots were stored in a NalgeneTM 
Cryo freezing container at -80°C overnight and then placed in liquid nitrogen for 
long term storage.  
To recover cells the cryotubes were removed from liquid nitrogen and warmed up 
immediately. Once cells had thawed they were mixed with 10 ml warm full media 
and placed in the incubator overnight to allow cells to attach. Next, the media was 
exchanged to remove any residual DMSO. 
Freezing media 
10% DMSO  
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2.4.3 Transient transfection of DNA 
For transfection, cells were grown to approximately 70-80% confluency and 
transfected with the amounts of DNA indicated in the figure legends using Attractene 
(Qiagen) following the supplier's instructions. DNA levels were normalised using the 
corresponding empty vector and cells were harvested 16-24 hours post transfection. 
2.4.4 Cell irradiation  
Cells were irradiated in tissue culture dishes without a lid, with 5 Gray (Gy) using a 
Faxitron cabinet X-ray system, 43855D (Faxitron X-ray Corporation) at 2 Gy/min. 
2.4.5 Drug treatment  
In several experiments described in this thesis, cells were treated with various drugs 
prior to harvest and lysis. Table 2-5 summarizes drugs, concentration and times used 
for the treatments; details are indicated in the relevant figure legends.  
Table 2-5 Drugs treatments 
Drug  Supplier Concentration  Time  
Nutlin-3 Enzo Life Sciences 10 µM 2-24 hours  
KU-55933 (ATM 
Inhibitor) 
Merck 10 µM 4 hours 
Cycloheximide Suelco 30 µg/ml 20-150 minutes 
MG-132 Calbiochem  10 µM 4 hours  





2.4.6 Harvesting cells 
Cell containingdishes were placed on ice and culture media was removed. The cell 
monolayer was washed with ice-cold PBS. Then 1 ml of ice-cold PBS was added to 
the cells and they were scraped off carefully using a cell scraper and transferred into 
an eppendorf tube. Cells were centrifuged for 5 minutes at 5000 g at 4°C and 
supernatants were discarded. The cell pellet was snap-frozen in liquid nitrogen and 
stored at -80°C until cell lysis. 
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2.4.7 Cell lysis 
For cell lysis, approximately two volumes (with respect to the size of the cell pellet) 
of lysis buffer was and mixed thoroughly with the pellet by pipetting. Cells were 
incubated on ice for 20 minutes, followed by centrifugation at 15 000 g for 15 
minutes at 4°C. The supernatant was transferred to a new eppendorf tube and total 
protein concentration was determined using the bradford protein quantification assay. 
0.4% Triton X-100 Lysis Buffer  Urea Lysis Buffer 
50 mM HEPES (pH 7.5)   8 M Urea 
0.4% (v/v) Triton X-100   50 mM HEPES (pH 7.6) 
150 mM NaCl    5 mM DTT 
10 mM NaF     1 mM benzamidine 
2 mM DTT     50 nM NaF 
0.1 mM EDTA    120 nM okadaic acid 
1X PIM (see below)  
 
 
PIM- Protease Inhibitor Mix (10X stock)  
200 µg/ml leupeptin  
10 µg/ml aprotinin  
20 µg/ml pepstatin  
10 mM benzamidine  
100 µg/ml soybean trypsin inhibitor  
20 mM pefabloc  
10 mM EDTA 
 
2.4.8 Protein quantification  
Protein concentrations were estimated using Bradford’s reagent (Bio-Rad), according 
to the manufacturer’s instructions. Absorbance (595 nm) was determined using the 
Victor 3 plate reader (Perkin Elmer). 
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2.5 Protein Purification from E.coli 
All proteins were expressed in E.coli BLR21‐A1 cells (Invitrogen, genotype 
Genotype: F- ompT hsdSB(rB- mB-) gal dcm araB::T7RNAP-tetA). This E.coli 
strain contains a firmly regulated arabinose-inducible araBAD promoter upstream of 
a T7 RNA polymerase gene and can be used with all T7 promoter-based vectors.  
2.5.1 Purification of His-tagged CHIP 
25 ml of an overnight culture of BLR21‐A1 cells containing the PET15b‐CHIP 
plasmid were transferred into 500 ml LB broth with ampicillin (50 µg/ml). Bacteria 
cells were incubated at 37°C shaking until the OD600 had reached 0.4 (U‐2800 
Spectrophotometer, Digilab Hitachi), then protein expression was induced by the 
addition of 0.2% arabinose and the cells were incubated for another 3 hours at room 
temperature (24°C) with shaking. Subsequently, the bacteria were spun down at 6000 
g for 15 minutes at 4°C and the supernatant were discarded. The cell pellet was re-
suspended in 15 ml lysis buffer and kept on ice for 20 minutes. To help cell lysis the 
cells were snap frozen and thawed twice, then sonicated 3 times for 15 seconds on 
ice with 30 seconds cooling intervals. The lysate was next centrifuged at 10 000 g for 
10 minutes at 4°C to remove cell debris. In the meantime, Ni2+ beads (Qiagen) were 
prepared, 1 ml of agarose (50% slurry) solution were transferred into a Falcon tube 
and washed 3 times with lysis buffer. To wash the beads 5 ml of lysis buffer was 
added, mixed well and removed again after separation from the beads by gentle 
centrifugation at 500 g. The lysate was added to the washed beads and incubated for 
1 hour at 4 °C on a rotating table. Subsequently, the beads were washed to remove 
any unbound protein, the wash steps were performed as before, 2 x with wash buffer 
1 and 3 x with wash buffer 2. Then the proteins were eluted for 30 minutes at 4°C on 
a rotating table using 5 ml elution buffer. The beads were separated from the proteins 
by gentle centrifugation at 500 g and the protein concentration was determined using 




2. Materials and Methods  71 
Lysis buffer     Wash buffer 1 
20 mM Tris-HCl (pH 8)   20 mM imidazole 
150 mM NaCl    150 mM NaCl 
0.1% (v/v) IGEPAL    20 mM Tris-HCl (pH 8) 
10 mM NaF     2 mM benzamidine 
2 mM DTT     0.1% (v/v) IGEPAL 
1x PIM 
20 mM imidazole 
10 mg/ml lysozyme 
 
Wash buffer 2     Elution buffer 
40 mM imidazole    20 mM Tris-HCl pH 8 
150 mM NaCl    150 mM NaCl 
20 mM Tris-HCl (pH 8)   150 mM imidazole 
2 mM benzamidine    1x PIM 
0.1% (v/v) IGEPAL 
 
2.5.2 Purification of GST-tagged proteins 
25 ml of an over-night culture of BLR21‐A1 cells containing pDEST15‐GST‐ IRF‐1 
or pGEx6MDM2‐WT plasmid were transferred into 1 l LB broth with ampicillin 
(50 µg/ml). The cells were incubated at 37°C shaking until the OD600 had reached 
0.4, then protein expression was induced by the addition of 0.2% arabinose and the 
bacteria were incubated for another 3 hours at room temperature (24°C) in a shaker. 
Subsequently the bacteria were spun down at 6000 g for 15 minutes at 4°C and the 
supernatant was discarded. To lyse the cells, the pellet was re-suspended in 20 ml 
lysis buffer and sonicated 2 x for 10 seconds on ice with 30 seconds cooling 
intervals. To remove cell debris, the lysate was spun down at 6000 g for 10 minutes 
at 4°C. Glutathione‐sepharose 4B (Amersham/GE) columns were prepared by 
transferring 1 ml of beads (50% slurry) to a falcon tube. The beads were washed 
three times with 10 ml PBS, therefore PBS was added to the beads and mixed well, 
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then the beads were separated from PBS by gentle centrifugation at 1000 g at 4 °C. 
In a final wash step beads were washed with TNEN in the same way as before and 
then re-suspended in TNEN. The entire lysate was added to the beads and incubated 
rotating for 60 minutes at 4°C. After incubation the beads were washed five times 
with TNEN as previously to remove any unbound protein. Then the GST tagged 
proteins were eluted with 5 ml elution buffer for 30 minutes at 4°C on a rotating 
table. The protein was separated from the beads by centrifugation at 1000 g, 
aliquoted, snap frozen and stored at ‐80°C. The protein concentration was determined 
using the Bradford assay. 
 
Lysis Buffer     TNEN 
20 mM Tris-HCl (pH 8)   2 mM benzamidine 
150 mM NaCl    20 mM Tris-HCl (pH 8) 
1 mM EDTA     1 mM EDTA 
0.5% (v/v) IGEPAL    0.5% (v/v) IGEPAL 
1x PIM     10 mM NaF 
10mg/ml lysozyme    2 mM DTT 




100 mM Tris-HCl (pH 8) 
20 mM reduced glutathione 
120 mM NaCl 
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2.5.3 Removal of GST tag using Prescission Protease  
To remove the GST-tag from GST-MDM2 protein, after the last wash step, instead 
of addition of elution buffer, beads were washed and then suspended in 1 ml 
Prescission buffer. Prescission protease (30 µl, GE Healthcare) was added to the 
beads and incubated over-night at 4°C on a rotating table. Beads were removed by 2 
minutes centrifugation at 1000 at 4°C and the supernatant, which contained the 
purified and cleaved MDM2 protein was aliquoted, snap frozen in liquid nitrogen 
and stored at -80°C. 
 
Precission buffer 
50 mM Tris-HCl (pH 8) 
1 mM EDTA 
120 mM NaCl 
1 mM DTT 
 
 
2.5.4 p53 Purification 
25 ml of an overnight culture of BLR21‐A1 cells containing the pT7‐7 Hup53 
plasmid were transferred into 1 l LB broth with ampicillin (50 µg/ml). The cells were 
incubated at 37°C in a shaker until the OD600 had reached 0.6, then protein 
expression was induced by the addition of 0.2% arabinose and the bacteria were 
incubated for another 3 hours at room temperature (24°C) in a shaker. Next, cells 
were harvested by centrifugation at 6000 g for 15 minutes at 4°C, the supernatant 
was discarded and the cell pellet was re-suspended in 5 ml re-suspension buffer. For 
cell lysis, the cell suspension was snap‐frozen and thawed on ice, then sonicated 4 
times for 15 seconds with 30 seconds incubation periods on ice between pulses. The 
lysate was cleared by centrifugation at 10 000 g for 15 minutes at 4°C. Subsequently, 
the lysate was loaded onto a Heparin HiTrap 5 ml column (Amersham) and the 
column was attached to a FPLC (UPC_900/P‐920, Amersham). The proteins were 
eluted with 15 x column volume (75 ml) using a salt gradient from 100% Buffer A 
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with 0 M KCl to 100% Buffer B with 1 M KCl. The eluent was collect in 1 ml 
fractions. Every second fraction collected (90 in total), was analysed by SDS-PAGE 
followed by either Coomassie Brilliant Blue staining or western blotting with an anti‐
p53 (DO1) antibody to identify fractions containing p53 protein. 
The fractions containing the majority of p53 protein were identified (0.4‐0.6 M KCl), 
pooled and further cleaned using p11 cellulose. Therefore, 2 g of p11 cellulose 
(Whatman) was incubated in 5 ml 0.5 M NaOH for 5 minutes. The cellulose was 
subsequently washed with water until the pH had reached 11, incubated in 5 ml 
0.5 M HCl for another 5 minutes and washed again until the pH had reached 3. The 
equilibrated P11 cellulose was washed two times in 10x Buffer A, diluted 1:1 in 
Buffer A and incubated at 4°C over-night. To wash the cellulose, the respective 
washing solution was added, mixed well and then removed by gentle centrifugation 
at 500 g for 4 minutes at 4°C. 15 ml of pooled fractions from the heparin column 
purification (0.4‐0.6 M KCl) were diluted in 135 ml Buffer C to give a final salt 
concentration of 50 mM KCl. Then, the samples were added to the equilibrated P11 
cellulose, mixed at 4°C for 1 hour and loaded onto a column. The column was 
washed with 1 ml of Buffer A and then the proteins were eluted using 1 ml Buffer A 
with increasing salt concentrations (100 mM, 200mM … 1M KCl). The fractions 
were separated by SDS‐PAGE and then visualised using Coomassie Brilliant Blue 
stain. 
Re-suspension buffer    Buffer A 
10% (w/v) sucrose    25 mM HEPES (pH 7.4) 
10 mM HEPES (pH 7.4)   10% (v/v) glycerol 
25mM NaCl     5 mM benzamidine 
1 PIM tablet (Roche)    5 mM DTT 
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Buffer B     10 x Buffer A w/out glycerol 
25mM HEPES (pH 7.4)   250 mM HEPES (pH 7.4) 
10% (v/v) glycerol    50 mM benzamidine 
5 mM benzamidine    50 mM DTT 
5 mM DTT     1% (v/v) Triton X-100 
0.1% (v/v) Triton X-100 
1 M KCl 
 
Buffer C 
25 mM HEPES (pH 7.4) 




2.6.1 In vitro protein-protein binding assay (ELISA) 
A white 96 well microtiter plate (Fisher) was coated with 100 ng of protein 1 (His-
CHIP, MDM2, p53, GST-IRF-1, His-UbcH5 or His UbcH13/Mms2 (Boston 
Biochem) per well in 50 µl 0.1 M NaHCO3 and incubated over-night at 4°C. Then, 
the plate was washed three times with 200 µl PBST and any free binding sites on the 
plate were blocked using 3% BSA in PBS for 1 hour at room temperature (24°C). 
The plate was washed as previously and 50 µl ELISA buffer with a titration (0-100 
ng) of protein 2 (His-CHIP, MDM2, p53 or GST-IRF-1) was added to each well and 
again incubated for 1 hour at room temperature (24°C). The plate was washed as 
previously and 50 µl anti-protein 2 mAb diluted 1:1000 in 3% BSA in PBS was 
added to the wells and incubated for 1 hour at room temperature (24°C). The plate 
was washed again and a secondary anti‐mouse antibody was added diluted 1:1000 in 
3% BSA (w/v) in PBS and incubated for 1 hour. Subsequently the wells were washed 
again and 50 µl of a mixture of ECL1/ECL2 (1:1) was added to the wells and 
incubated for 1 minute. Then electrochemical luminescence was measured using a 
luminometer (Labsystems; Flousoskan Ascent FL). 
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ELISA buffer 
25 mM HEPES (pH7.5) 
50 mM KCl 
10 mM MgCl2 
5% (v/v) glycerol 
0.1% (v/v) Tween‐20 
2 mg/ml BSA 
 
2.6.2 Competition ELISA  
Competition assays were carried out similar to in vitro protein-protein binding assays 
(2.6.1), with His-CHIP, NPM, Kap-1, MDM2 or His-Set as protein 1 (NPM, His-
SET and Kap-1 was a kind gift from Vikram Narayan). Instead of a titration, 100 ng 
of protein 2 with a titration of peptides or oligonucleotides (as detailed in figure 
legends) was added to the plate in PBS. Washing and detection was carried out as 
detailed in 2.6.1. 
2.6.3 In vitro peptide binding assay (peptide ELISA) 
A white 96 microtiter well plate was coated with 50 µl Streptavidin (1 µg per well in 
PBS) and dried in a 37°C incubator over-night. Next, wells were washed three times 
with 200 µl PBST and incubated with saturating amounts of biotin tagged peptides 
(~60 pmol; 0.25 µl of 5 mg/ml stock) in 50 µl PBS for 1 hour at room temperature 
(24°C). Peptides were obtained from Chiron Mimotopes and contain a Ser-Gly-Ser-
Gly spacer between peptide and N-terminal Biotin tag. Plates were washed again as 
above and incubated with 3% BSA (w/v) in PBS for 1 hour at room temperature 
(24°C), to block any free binding sites on the plate. After another wash step a 
titration of protein was added to the plate (0-100 ng or as indicated in the figure 
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Table 2-6 IRF-1 peptides 
1.	   WLEMQINSNQMPITRMRMRP 12.	   PALSPTQDLEVEQALVPGYM 
2.	   EMIFQINSNQIPGLIWINKE 13.	   TLPDWHIPVEPALSPCAVSS 
3.	   AAKHGWDINKEMIFQIPWKH 14.	   QVSNFSDLYVVPDSTHIPVE 
4.	   YTGRHIDACLFRSWAWDINK 15.	   DEDEETTAESNFQVSPMPST 
5.	   EPDPKTWKANHTGRYKAGEK 16.	   LEQSELGKLPEDIMKDEDEE 
6.	   IEEVKFRCAMNSLPDTWKAN 17.	   VDGKGYLLNELEQSEWQPTN 
7.	   GSSAVRVYRKIEEVKDQSRN 18.	   DFSCKPGVQPTSVYGYLLNE 
8.	   SERKKRMLPPLTKNQVRVYR 19.	   DSPGGDIGLSEEPEIKCSFD 
9.	   CKRKSAAKSKERKSKSSRDK 20.	   MDATWNLQRVFTDLKDIGLS 
10.	   GLSSSGDSSPDTFSDKRKSC 21.	   AQISPLRVPTMDATWLDSLL 
11.	   HSSYTVPGYMGLSSSTLPDD 22.	   PIPCALDSLLTPVRLPSIQA 
 
2.6.4 Immunoprecipitation (IP) 
A375 cells were treated with 10 µM Nutlin-3 or an equivalent volume of DMSO for 
8 hours. Then cells were scraped into 1 ml IP lysis buffers, incubated for 20 minutes 
and lysate was collected by centrifugation at 4°C for 20 minutes at 500 g. Lysates 
were pre-cleared by 40 minutes incubation with 100 µl of sepharose CL 4B (Sigma-
Aldrich, washed 4 times in PBS) at 4°C with rotation. Pre-cleared lysate was 
collected by centrifugation at 1000 g for 2 minutes and concentration of total protein 
was quantified using Bradford. Subsequently, 1 µg of CM1 (p53 pAb) was added to 
2 mg of total protein in the pre-cleared lysate and, in a final volume of 1 ml, 
incubated for 1 hour at 4°C with gentle rotation. Then, 15 µl of protein G-
SepharoseTM 4 FastFlow (GE Healthcare; washed 4 times in PBS) was added to the 
above samples and incubated over-night at 4°C with gentle rotation. Beads were 
washed four times with 500 µl of IP buffer. Samples were then eluted by addition of 
50 µl of SDS sample buffer and incubation at 95°C for 5 minutes. The eluate was 
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IP buffer 5 
0.3 M NaCl 
1% (v/v) Triton X-100 
50 mM HEPES pH 7.6 
	  
	  
2.6.5 Flag -IP 
A375 were transfected with either 2 µg FLAG-IRF-1 WT, FLAG-IRF-1 ΔMf2 or 
FLAG empty vector. 24 hours post transfections, cells were scarped into 0.5% Triton 
lysis buffer and lysate was prepared and pre-cleared as in 2.6.3. Then, 2.5 mg of pre-
cleared lysate was mixed with 35 µl (50% slurry) FLAG-M2-agarose beads 
(SIGMA, washed 4 times in PBS) and incubated for 1 hour at 4°C. Next, beads were 
washed 4 times with 500 µl wash buffer and 2 times with PBS and then samples 
were eluted by incubation with 15 µg 3X FLAG peptide in 70 µl PBS for 30 minutes 
at 4°C on a rotating table. Samples were collected by centrifugation at 1000 g for 2 
minutes and eluate and lysate were analysed by SDS-PAGE/Immunoblot. 
Wash buffer 
PBS 
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2.6.6 In vitro ubiquitination assay 
First the ubiquitination mix for 16 reactions was prepared as follows:  
366 µl H2O 
10 µl HEPES (pH 8) 
2.4 µl MgCl2 
2 µl 10% Triton X-100 
6 µl 0.2 M ATP 
0.2 µl 1M DTT 
0.4 µl benzamidine 
3.2 µl 10 mg/ml ubiquitin (Boston Biochem) 
0.7 µl E1 (UBE1, Boston Biochem) 
0.4 µl E2 (His-UbcH5a) 
 
The mix was aliquoted into 22 µl reactions. Next, 25 ng (unless otherwise indicates) 
substrate (p53, GST- IRF-1 or Bag-1s) and 50 ng CHIP or MDM2 (unless otherwise 
indicated) was added to each reaction. Where specified peptides or other proteins 
were added, the reactions were normalised by either DMSO or the respective protein 
buffer. The reactions were carried out at 30°C for 15 minutes, unless otherwise 
indicated. To stop the reaction 22 µl of 2x sample buffer was added and the samples 
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2.6.7 Discharge Assay 
First the mix for 16 reactions was prepared as follows: 
Mix (for 16 tubes) 
366 µl H2O 
10 µl HEPES (pH 8) 
2.4 µl MgCl2 
2 µl 10% Triton X-100 
5 µl 20 µM ATP  
0.2 µl 1M DTT 
0.4 µl benzamidine 
3.2 µl 10 mg/ml ubiquitin  (Boston Biochem) 
0.7 µl E1 (UBE1, Boston Biochem) 
0.4 µl E2 (His-UBch5a) 
 
The mix was aliquoted to 22 µl and incubated at 30°C for 5 minutes to allow the E2 
to be charged by the E1. Then, the reaction was incubated on ice for 30 minutes and 
an E3 ligase was added to the reactions (amounts indicated in figure legends). E2 
discharge was either monitored over time and aliquots were taken after 5, 10, 15 and 
20 minutes, or a titration of the E3 ligase (as indicated in figure legends) was added 
and all reactions were terminated after 15 minutes. To stop the reaction 22 µl of 2x 
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2.6.8 In vivo ubiquitination assay 
H1299 or A375 cells were seeded onto a 6-well plate and transfected with His-tagged 
ubiquitin, IRF-1 (WT or W11R), MDM2 and CHIP as indicated in the figure 
legends. Cells were treated as indicated in figure legends and harvested 24 hours post 
transfection into 1 ml of ice cold PBS. 20% cell suspension was removed for direct 
lysis and the remaining 80% were used to for a His-pull down. Both samples were 
pelleted by centrifugation at 2000 g for 5 minutes at 4°C, the supernatant was 
discarded and the samples were lysed. For the His-pull down samples were lysed in 1 
ml lysis buffer by mixing and passing the cells through a needle and syringe, to break 
up the cells, 10-15 times. The lysate was mixed with further 4 ml of lysis buffer and 
75 µl Ni2+-NTA agarose beads (Qiagen, washed in PBS) and incubated on a rotating 
table over-night in a 15 ml falcon tube. Subsequently, beads were collected by 
centrifugation at 1000 g, for 5 minutes at 4°C. To wash, cells were re-suspended in 
750 µl buffer A and transferred to a 1.5 ml eppendorf tube, incubated for 5-15 
minutes on a rotating table at room temperature (24°C) and pelleted by centrifugation 
as above. Beads were washed in the same way 4 more times using buffer B-D. Then, 
75 µl elution buffer was added to the beads and incubated for 30 minutes at room 
temperature (24°C) on a rotating table. Beads were pelleted by centrifugation as 
before, the supernatant was transferred to a new tube, mixed with an equal volume of 
SDS sample buffer and analysed using a 4-12% NuPAGE gel (Invitrogen). 
Ubiquitinated protein was detected using anti-IRF-1, anti-p53 or anti –CHIP mAb. 
For direct lysis, the second aliquots (20%) were lysed in 25 µl of triton X-100 lysis 
buffer. Samples were analysed on a 10% SDS-polyacrylamide gel using the indicated 
antibodies.  
Buffer	  A	   	   	   	   Lysis	  buffer	  
6 M Guanidinium-HCl  Buffer A + 5 mM imidazole 
95 mM Na2HPO4 
5.3 mM NaH2PO4 
10 mM Tris-HCl, pH 8.0 
10 mM β-mercaptoethanol 
Adjusted to pH 8.0 
 
2. Materials and Methods  82 
Buffer B    Buffer C 
8 M Urea    8 M Urea 
95 mM Na2HPO4   22.5 mM Na2HPO4 
5.3 mM NaH2PO4   77.5 mM NaH2PO4 
10 mM Tris-HCl, pH 8.0  10 mM Tris-HCl, pH 6.3 
10 mM β-mercaptoethanol  10 mM β-mercaptoethanol 
Adjusted to pH 8.0   Adjusted to pH 6.3 
Buffer D    Buffer E 
Buffer	  C	  +	  0.2%	  Triton	  X-­‐100	   Buffer	  C	  +	  0.1%	  Triton	  X-­‐100	  
Elution buffer 
0.2 M Imidazole 
5% SDS 
150 mM Tris-HCl (pH 6.8) 
10% glycerol 
0.72 M β-mercaptoethanol 
 
2.6.9 Dual Luciferase reporter assay 
Cells, either H1299 or HeLa, were seeded in 24 well plates and transfected with 
pCMVRenillaLuc (60 ng per well) and the indicated reporter constructs (120 ng per 
well). Cells were harvested 16-24 hours post-transfection and the Dual Luciferase 
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2.6.10 Electrophoretic mobility shift assay (EMSA)  
The ability of p53 and IRF-1 to bind to specific promoter sequences from their target 
genes was determined using EMSAs. In a first step the oligonucleotides containing 
the binding sequence of either IRF-1 or p53 was labelled using γ-32P ATP.  
 
Therefore, the following reaction was assembled: 
0.6 µl Forward Primer (stock: 1 mg/ml, SIGMA) 
0.6 µl Reverse Primer (stock: 1 mg/ml, SIGMA) 
1 µl of T4 DNA kinase buffer (New England Biolabs) 
0.4 µl of T4 DNA kinase (New England Biolabs) 
0.4 µl of 10 mCi/ml γ-32P ATP (Perkin Elmer) 
	  
The mixture was incubated for 2 hours at 37°C. Then, 15.5 µl TE and 4.5 µl KCl was 
added and the reaction was heated to 95°C for 2 minutes and cooled down slowly 
inside the metal heat block to assist proper annealing of the oligonucleotides. To 
remove any γ-32P ATP that was not incorporated into the oligonucleotide, the sample 
was purified using a 1.5 ml micro-spin column (Biorad), following supplier's 
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p21 F:  5'TTTAAAAGCAAAACTGCAAATGTTTCAGGCACA3' 
R:  5'TGTGCCTGAAACATTTGCAGTTTTGCTTTTAAA3' 
Hupp and Lane, 
1994 [290] 
Bax F:   5'GGGCTCACAAGTTAGAGACAAGCCTGGGCG3' 
R:   5'CGCCCAGGCTTGTCTCTAACTTGTGAGCCC3' 
Patel et al., 2008 
[291] 
MDM2 F:   5'GGTCAAGTTGGGACACGTCCGGCGTCGGCTGTC   
GGAGGAGCTAAGTCCTGACATGTCT3' 
R:    5'AGACATGTCAGGACTTAGCTCCTCCGACAGC 
CGACGCCGGACGTGTCCCAACTTGACC3' 
Kaku et al., 2001 
[292] 
PUMA F:    5'CGCGCCTGCAAGTCCTGACTTGTCCGCGGC3' 
R:    5'GCCGCGGACAAGTCAGGACTT GCAGGCGCG3' 
Patel et al., 2008 
[291] 
C1 F:    5'GGGCATCGGTCGAAGTGAAAGTGAAAGTGAAA 
GTGAG ACTCTAGAGGATCCGCT3' 
R:   5'AGCGGATCCTCTAGAGTCTCACTTTCACTTTCAC 
TTTCACTTCGACCGATGCCC3' 
Fujita et al., 
1989 [144] 
TRAIL  F: 5'TCAGTGAGGAAATGAAAGCGAATGAGTTGT3' 
R: 5'ACAACTCATTCGCTTTCATTTCCTCACTGA3' 
Clarke et al., 
2004 [293] 
ISG15 F: 5'GATCCTCGGGAAAGGGAAACCGAAACTGAAGCC3' 
R: 5'GGCTTCAGTTTCGGTTTCCCTTTCCCGAGGATC3' 
Lace et al., 2009 
[294] 
ISG20 F: 5'TTGATAACAAACTAGAAACTGAAACAGGGTCG3' 
R: 5'CGACCCTGTTTCAGTTTCTAGTTTGTTATCAA3' 
Gongora et al., 
2000 [295] 
Caspase 8 F: 5'CACAAGGTGAAACAGAAACCGGGGCGATC3'  
R: 5'GATCGCCCCGGTTTCTGTTTCACCTTGTG3' 
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Separating gel  %    TBE 
5% acrylamide mix     90 mM Tris-HCl (pH 8.3)  
1 x TBE      80 mM Boric Acid, 
0.1% (w/v) APS     2.6 mM EDTA. 
0.1% (v/v) Triton- X100  
44.2 ml H20 
Volume for one gel: 70 ml 
 
The gel mixture was prepared as described above. Then 2 ml was removed, 3% (v/v) 
TEMED was added and it was quickly poured into the sides of the gel chamber to 
form a seal. Then 0.1% (v/v) TEMED was added to the remaining mixture, the gel 
was poured and a comb was inserted. Prior to loading the samples, gels were pre-run 
at 35 mA for 30 minutes at 4 ºC. 
The reaction was prepared as a multiple of the following (1,2 or 3 x): 
2 µl of 6x reaction buffer 
p53 or IRF-1 (as indicated in figure legend) 
0.5 µl (10 mg/ml) Salmon Sperm DNA (Invitrogen) 
1 µl (1 mg/ml) poly DI/DC (SIGMA) 
1 µl probe (γ-32P labelled) 
1 µl anti-IRF-1 or anti-p53 mAb (as indicated in figure legend)  
Adjusted to 12 µl with water 
 
6x reaction buffer 
120 mM HEPES pH 7.5 
300 mM KCl 
30% Glycerol 
2.4 mM DTT 
0.6 mg/ml BSA 
0.03% TritonX-100 
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The reactions were incubated for 30 minutes at room temperature (24°C), mixed with 
6X DNA loading buffer (2.2.5) and loaded onto the pre-run 5% polyacrylamide gel. 
The gel was run at 35 mA for 150 minutes at 4°C and then transferred onto 3 mm 
chromatography paper (Whatman), dried in a vacuum gel dryer and covered with a 
phosphoimager screen over-night. Radiolabelled bands were detected using a 
Storm840 phosphoimager (GE Healthcare). 
 
2.6.11 In vitro DNA binding assay 
A white 96 microtiter well plate was coated with 50 µl Streptavidin (1 µg per well in 
PBS) and dried in a 37°C incubator over-night. Next, wells were washed 3 times 
with 200 µl PBST and incubated with saturating amounts of biotin tagged C1 
oligonucleotides (25 ng/well, SIGMA) in 50 µl PBS for 1 hour at room temperature 
(24°C). Only the forward primer contained a biotin tag and was annealed with the 
reverse primer prior to addition to the well by heating to 95°C and then allowing to 
cool down to room temperature (24°C) slowly. Plates were washed again as above 
and incubated with 3% BSA (w/v) in PBS for 1 hour at room temperature (24°C) to 
block any free binding sites on the plate. After another wash step a titration of 
ubiquitinated IRF-1 protein (in ubiquitin reaction mix, 2.6.6) was added to the plate 
and bound protein was detected as detailed in 2.6.4. 
 
2.6.12 Cell Fractionation  
To fractionate cells into soluble and insoluble fractions, cells were washed in ice-
cold PBS, and then lysed on the plate in gentle lysis buffer (PBS + 0.5% Triton-X 
100, 5 mM EDTA, 20 mM DTT, 0.05 mM Pefabloc) for 20 minutes with shaking. 
Cells were scraped and centrifuged at 6000 g for 5 minutes. Pellet and supernatant 
was taken and re-suspended in 2x SDS sample buffer, sonicated and heated (95°C). 
Subcellular Fractionations was carried out using the Proteo Extract Kit 
(Calbiochem), following supplier’s instructions.  
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2.6.13 Nuclei Fractionation 
A375 cells were grown in 15 cm dishes and treated as indicated in the figure legend. 
Cells were harvested using 2 ml Trypsin-EDTA and taken up in further 10 ml 10% 
FBS in PBS plus 20 mM DTT, pelleted by centrifugation at 500 g for 4 minutes and 
re-suspended in 3 ml NBA. Then 3 ml of NBB was added, cells were incubated for 3 
minutes on ice and centrifuged for 4 minutes at 1000 g. The supernatant was 
discarded and nuclei were washed in 10 ml NBR and then re-suspended in 500 µl 
NBR. In order to prepare soluble chromatin, nuclei were digested using 10 units of 
micrococcal nuclease for 10 minutes at room temperature (24°C) in the presence of 
5 µl per ml RNaseA/T1 (Ambion). The reaction was stopped by addition of EDTA to 
a final concentration of 10 mM. Then samples were pelleted for 30 seconds at 2000 
g, re-suspended in 500 µl Teep80 and incubated on ice over-night for cells lysis. To 
remove cell debris samples were centrifuged for 5 minutes at 5000 g at 4°C and 
soluble chromatin was fractionated using 10-50% (w/v) isokinetic sucrose gradients 
in TEEP80 by centrifugation for 110 minutes at 50 000 rpm in a MLS 50 Beckman 
rotor at 4°C. Gradients were fractionated in 500 µl fractions by upward displacement 
with continuous monitoring of the absorbance profile. Half the fractions were used to 
analyse the protein content by ethanol precipitation, followed by intense washing to 
remove all sucrose and then re-suspension in SDS-sample buffer. DNA was 
extracted from the other half of the fractions using phenol/chloroform and enriched 
by ethanol precipitation. DNA pellets were washed, re-suspended in H2O and 
analysed on a 1% agarose gel.  
NBA       NBB 
85 mM KCl     NBA + 0.1% (v/v) IGEPAL 
10 mM Tris-HCl (pH 7.6)  
5.5% (w/v) sucrose  
0.5 mM spermidine  
0.2 mM EDTA 
0.05 mM Pefabloc  
20 mM DTT 
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NBR       Teep 80 
85 mM KCl     10 mM Tris-HCl (pH 7.6) 
5.5%  (w/v) sucrose    1 mM EDTA  
10 mM Tris-HCl (pH 7.6)   1 mM EGTA  
1 mM CaCl2     0.1 mM pefabloc  
1 mM MgCl2     80 mM NaCl 








2.6.14 Mass Spectrometry  
2.6.14.1 Sample preparation for mass‐spectrometry 
When handling samples for mass spectrometry analysis the utmost care was taken to 
avoid contamination of the samples by keratin. The solutions used for the reactions 
were filtered before use where possible, gloves and a lab coat were worn at all times 
and most of the work was preformed in a fume hood. Five in vitro ubiquitination 
reactions with 1 µg substrate (GST-IRF-1, GST-MDM2, or His-CHIP) and 1.6 µg 
E3-ligase (for IRF-1) were pooled and a GST‐ or His- pulldown was preformed to 
remove reaction partners. The samples were separated on a 4-12% NuPAGE and 
protein‐peptides were isolated from the gel by in gel trypsin digestion. 
2.6.14.2 GST‐ and His-pulldown 
To isolate GST‐IRF‐1, GST-MDM2 or His-CHIP from the other components in the 
reaction a GST or His- pulldown was performed. First the glutathione sepharose 
beads 4B (Amersham, GE) or Ni2+ beads (Qiagen) were prepared by washing 3 times 
with sterile PBS. Next, five in vitro ubiquitination reactions were pooled, added to 
75 µl beads (50% slurry) and rotated at 4°C for 1 hour. To remove any unbound 
proteins the beads were washed 5 times with TNEN (2.5.1) or 2 times with His-
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washing buffer I and 3 times with His-washing buffer 2 (2.5.2). Then 40 µl of sterile 
4x LDS sample buffer (NuPage, Invitrogen) was added to the beads and heated for 4 
minutes at 85°C. The beads were separated from the solution by centrifugation and 
the samples were loaded onto a gel. The gel was stained using colloidal blue and 
sealed well. 
 
2.6.14.3 Microwave‐assisted in gel trypsin digestions for mass 
spectrometry 
Destaining 
Bands to be analysed by mass spectrometry were cut out of the gel and transferred to 
a separate petri‐dish. The bands were cut further in pieces of around 1 mm2 and 
transferred to LoBind Eppendorf tubes. 1 ml of H20 was added to the gel pieces, 
which were then vortexed for 15 minutes, spun down at 1000 g for one minute (as all 
following centrifugation steps) and the water was carefully removed by pipetting. To 
destain, 750 µl 50 mM ammonium bicarbonate (ABC) in 50% ammonium 
bicarbonate (ACN) was added and the samples were microwaved in a water bath for 
ten minutes on full power (700 W). The temperature of the water bath was not 
allowed to exceed 80°C in this step. The tubes were inverted, spun down and the 
liquid was removed. Then the gel pieces were dehydrated by addition of 200 µl 
100% ACN and vortexed for 5 minutes (gel pieces shrunk and turned white). The 
liquid was removed and samples were left open in the fume hood to dry for 20 
minutes. 
Reduction and alkylation 
For reduction, 200 µl of 10 mM DTT in 100 mM ABC was added to the samples and 
microwaved for 10 minutes on half power (350 W). The temperature of the water 
bath was not allowed to exceed 55°C. Samples were spun down and all liquid was 
removed. Next, the gel pieces were washed by addition of 750 µl ABC, mixed well, 
spun down and all liquid was removed. To alkylate the samples and thereby inhibit 
interactions of the peptide's cysteine residues, 200 µl of iodoacetamide was added to 
the samples and incubated for 30 minutes vortexing in the dark. Then the samples 
 
2. Materials and Methods  90 
were washed twice, first with 750 µl 100 mM ABC and next with 750 µl 20 mM 
ABC in 50% ACN. Therefore, the washing solution was added, the samples were 
vortexed for 15 minutes, spun down and the solution was carefully removed. The gel 
pieces were dehydrated by addition of 200 µl of 100% ACN and vortexed for 5 
minutes. The gel pieces shrank and turned white. The liquid was removed and 
samples were left open in the fume hood to dry for 20 minutes. 
Trypsin digestion 
The gel pieces were rehydrated in 45-60 µl of 12.5 mg/mL trypsin in 20 mM ABC in 
9% ACN, further 10‐50 µl 20 mM ABC in 9% ACN was added until the gel pieces 
were just covered with liquid. The pieces were left for 10 minutes to fully dehydrate. 
The total amount of liquid added to each sample was written on the lid of the tube. 
The samples were digested by microwaving twice for 10 minutes on half power 
(350 W) while the temperature in the water bath did not exceed 55 °C. The samples 
were incubated at room temperature (24°C) over-night in the dark.   
Peptide extraction 
An equivalent of the amount written on the lid of 100% ACN was added to each 
sample and incubated for 30 minutes while vortexing. The pieces were spun down 
and the liquid containing peptides was transferred to new LoBind eppendorf tubes. 
Another equivalent of the amount written on the lid of 5% formic acid (FA) in 50% 
ACN was added to the samples and vortexed for 10 minutes. The gel pieces were 
spun down and the liquid was transferred to the new LoBind eppendorf tubes. This 
step was repeated. Next, the gel pieces were dehydrated by addition of 50‐100 µl 
100% ACN, incubated for ten minutes, then spun down and the liquid was again 
transferred to the new eppendorf tubes. The liquid was evaporated in a gyrovap 
(Eppendorf) at 60°C for 2.5 hours. Subsequently, the peptides were re-suspended in 
35 µl of 1% FA by vortexing for 10 minutes. Then the samples were spun down for 
10 minutes at 10 000 g at room temperature (24°C) and 17 µl of the samples was 
analysed by mass‐spectrometry (FingerPrints Proteomics Facility, College of Life 
Sciences, University of Dundee). 
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2.7 Microscopy  
2.7.1 Dual-Link 
Cells were grown onto glass coverslips in a 6 well dish until they reached around 
50% confluency. After treatment (as indicated in the figure legends), cells were fixed 
by addition of 4% formaldehyde solution for 10 minutes and then permeabilised 
using 1% Triton X-100 in PBS. Next Duolink® II (red) assay from Olink® 
Bioscience was carried out following suppliers instructions. Briefly, any unspecific 
antibody binding sites were blocked using 3% BSA (w/v) in PBS for 1 hour at room 
temperature (24°C), next primary antibodies, anti-ubiquitin (mouse, 1:50, Santa 
Cruz) and anti-p53 (CM1, rabbit, 1:100) were diluted in the supplied antibody 
diluent and added to cells and incubated over-night at 4°C. As a control one slide 
was incubated with only anti-ubiquitin mAb and no second primary antibody. Next 
PLA probes conjugated to secondary antibodies anti- mouse and anti-rabbit 
respectively were added to the cells for 1 hour at 37 °C and ligation and 
amplification was carried out as detailed by the supplier. In the last step an 
amplification reaction produces a fluorescent signal that can be detected using a 
fluorescent microscope with a Texas Red filter (Ex 644 nm, Em 669nm). Results 
were visualised using an Axioplan2 (Zeiss) fluorescent microscope with Plan-
neofluar objectives, a 100W Hg source (Carl Zeiss, Welwyn Garden City, UK) and 
Chroma #89014ET single emission filters (Chroma Technology Corp., Rockingham, 
VT) using a 100x magnification Zeiss lense and a Hamamatsu Orca AG CCD camera 
(Hamamatsu Photonics (UK) Ltd, Welwyn Garden City, UK).The single excitation 
and emission filters are installed in motorised filter wheels (Prior Scientific 
Instruments, Cambridge, UK). Image capture and analysis were performed using in-
house scripts written for IPLab Spectrum (Scanalytics Corp, Fairfax, VA). 
4% formaldehyde solution   
4% (v/v) formaldehyde  
100 mM PIPES (pH) 
10 mM EDTA  
1 mM MgCl2  
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2.8 Modelling Techniques  
2.8.1 Generation of IRF-1/p53 - ubiquitin models 
The ‘Easy Interface’ of the HADDOCK web server [271, 297] was used to generate 
models of the IRF-1 and p53 DBD conjugated to ubiquitin. For p53, the C-terminus 
of the p53 DBD crystal structure (PDB:1TUP, resolved at 2.2 Å; [182]) was 
extended from residue 291 by grafting residue 292 from 2AHI  (resolved at 1.85 
Å;[187]) onto 1TUP. For the model, the C-terminal glycine residue of ubiquitin 
(Gly76) was selected as the active residue on ubiquitin (PDB :1UBQ, resolved at 1.8 
Å;[36]) and Lys 292 on p53 or  Lys39, Lys50 and Lys78 on IRF-1 (PDB:1IF1, resolved 
at 3 Å;[124]), were chosen as the active residue in the p53 or IRF-1 crystal structure, 
respectively. No passive residues were selected. The best four structures in the three 
clusters with the best HADDOCK score were analysed. After the models were 
generated the DBD:ubiquitin complex was superimposed back onto the respective 
crystal structure to obtain a model of the DBD:ubiquitin:DNA complex. Electrostatic 
surface analysis of the IRF-1/p53 DBD:monoubiquitin complex were carried out 
using APBS (Adaptive Poisson-Boltzmann Solver;[298] in PyMOL v1.4.1 
(http://www.pymol.org).  
 
2.8.2 Molecular Simulations 
To model the interactions of DNA with p53 or IRF-1 in its ubiquitinated or 
unmodified forms, the (extended) crystal structures of the p53 DBD (PDB: 1TUP, 
2AHI) or IRF-1 DBD (PDB: 1IF1) and the model of monoubiquitinated p53 or IRF-1 
DBD in complex with DNA as generated above were used. The N- and C- termini of 
the p53 DBD were capped with acetyl (ACE) and N-methyl (NME) respectively to 
keep them neutral. Molecular dynamics simulations were performed with the 
SANDER module of the AMBER (Assisted Model Building Refinement) 9 package 
(http://ambermd.org/) together with the ff99SB forcefield. The antechamber and 
LEaP modules were used to set up the simulation. Systems were solvated in a TIP3P 
water box with walls at least 8 Å away from any protein atom and net charges on the 
protein were neutralized using counter ions as required (20-26 Na+). To simulate a 
 
2. Materials and Methods  93 
covalent linkage, a distance restraint between Gly76 of ubiquitin and Lys292 of p53 or 
Lys78 of IRF-1 (between 1.2 and 2Å) was created using a DISANG file in AMBER. 
A brief energy minimization was carried out followed by heating of the systems to 
300 K and subsequent MD simulations were performed under constant pressure (1 
atm) and temperature (300 K) using the Sander module. Structures were stored every 
2 ps a. The free energies of binding (ΔGbind) of the p53 DBD +/- ubiquitin to DNA 
were computed and visualizations were carried out using the ptraj modules in 
AmberTools1.5. Figures were prepared using PyMOL
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Chapter 3: Modulation of CHIP and MDM2 E3 
ligase activity by ligand binding: using MD 
simulations to inform experimental approaches  
3.1 Introduction 
3.1.1 Molecular Dynamic Simulations 
Very limited options are available to study dynamics of proteins in solutions. Most 
studies are based on the rigid crystal structure and neglect the dynamic nature of 
proteins, which are in a constantly changing conformation and can adjust particularly 
upon ligand binding. Molecular Dynamics simulations is an in silico technique that 
utilises the crystal structure of a protein as a starting point and then calculates the 
predicted motions of the protein over a given period of time using physical 
approximations. The crystal structure of specific protein serves as the starting 
structure, next the forces that act on each atom are calculated using an energy 
function. With the help of the position and force that acts on an atom at a given 
temperature and pressure, the velocity and direction of the movement of this atom 
can be predicted [299]. In the simulation the structure moves forward in 2 fs steps 
and then the energy function and forces are recalculated. Along with many other 
applications the technique can be used to compute binding energies between small 
molecules and receptor proteins; and additionally the effect of ligands or single point 
mutation of the overall structure and flexibility of a protein can be predicted [300]. 
 
3.1.2 CHIP and MDM2 autoubiquitination  
As discussed in detail in Chapter 1, protein ubiquitination is involved in the 
regulation of a vast variety of cellular processes, affecting both proteins stability and 
function. It is thus not surprising that components of the ubiquitin machinery 
themselves are regulated by ubiquitination. The majority of E3 ligases exhibit 
autoubiquitination activity in vitro, and this can be utilised to study the activity of a 
ligase in a substrate independent manner. In vivo ubiquitination of E3 ligases was 
shown to lead to E3 degradation, resulting in a decrease of their E3 ligase activity on 
heterologous substrates. Additionally, autoubiquitination can modulate the activity of 
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E3 ligases without leading to their degradation. Further, DUBs and E2 enzymes can 
also be regulated by ubiquitination, and there is at least one example of an E2 that 
can undergo autoubiquitination independent of any E3, leading to its destruction by 
the proteasome [301].  
Both MDM2 and CHIP were previously shown to autoubiquitinate in vitro and in 
vivo [302-305]. Whether ubiquitination occurs in cis or in trans or in a combination 
of both remains to be investigated. Autoubiquitination of MDM2, which is dependent 
on its RING finger activity leads to its degradation and is therefore one mechanism 
by which its activity can be controlled [304]. It is not known whether MDM2 
autoubiquitination has any non-proteolytic functions.  
In contrast to MDM2, autoubiquitination of CHIP has not been implicated in its 
degradation, but increased CHIP ubiquitination correlates with an increase of its E3 
ligase activity [244, 303]. The ubiquitin conjugating enzyme Ube2w leads to 
autoubiquitination of CHIP at Lys2 and this in turns activates CHIP dependent 
ubiquitination and degradation of its target substrate INOS [306]. Furthermore, 
ubiquitination of Lys2 initiates the recruitment of ataxin-3, a DUB enzyme with three 
UIMs that bind ubiquitin chains, ataxin-3 binding to CHIP restricts the length of its 
substrate's polyubiquitin chains and additionally, ataxin-3 deubiquitinates CHIP in 
response to substrate polyubiquitination [306]. CHIP autoubiquitination has also 
been implicated in recruitment of other cofactors that contain a UBDs like the 
Ubiquitin Interacting Motif (UIM)-containing proteasomal subunit S5a for instance. 
Association of S51 with CHIP inhibits the formation of forked ubiquitin chains and 
thus favours turnover of CHIP substrates (as forked ubiquitin chains do not lead to 
degradation by the proteasome [307]). Moreover, other E2 enzymes, e.g. are 
involved in CHIP autoubiquitination, however, the target lysines and the mechanism 
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3.2 Results 
3.2.1 TPR-domain can modulate CHIP E3-ligase activity 
3.2.1.1 CHIP activity is modulated by Hsp70 binding 
The best-understood role of the E3 ligase CHIP, is its function in the triage system of 
cells where it works in synergy with Hsp70 to target chaperone client proteins for 
degradation. In this pathway, Hsp70 is required to 'deliver' substrates to CHIP for 
ubiquitination. However, the Ball group has recently identified the tumour 
suppressor protein IRF-1 as an Hsp70 independent substrate for CHIP. CHIP 
facilitates IRF-1 ubiquitination under specific stress conditions (see 1.3.4). 
Interestingly, IRF-1 ubiquitination by CHIP is not only independent of Hsp70 in 
vitro and in cells, but furthermore Hsp70 protein (Fig 3-1a) or an Hsp70 peptide from 
the CHIP binding interface that is sufficient to mimic Hsp70 (data not shown, 
Narayan, Landré et al., submitted manuscript [368]), inhibit ubiquitination of IRF-1 
by CHIP. This is an intriguing observation, as CHIP 's E3 ligase activity is generally 
believed to be dependent on interactions with Hsp70. To test if this inhibitory effect 
of Hsp70 was specific for IRF-1 ubiquitination, in vitro CHIP assays were 
performed; using p53 as the substrate, in the presence of Hsp70/40. Strikingly, the 
ubiquitination of p53, like that of IRF-1, was inhibited in the presence of Hsp70 (Fig 
3-1b). Furthermore, autoubiquitination of CHIP was reduced by the addition of 
Hsp70, both in the presence of IRF-1 or p53 and in the absence of any added 
substrate (3.1a, b (lower panel), c). This is in contrast to the observation made by 
others, where Hsp70 has an activating effect on CHIP activity, most strikingly on 
CHIP dependent ubiquitination of Bag-1s [308]. In order to investigate this 
discrepancy further I asked, if the inhibition of CHIP activity by Hsp70 observed in 
the Ball laboratory was due to technical differences in the way the ubiquitination 
assay was performed. Thus, I expressed and purified Bag-1s and examined the effect 
of Hsp70/40 on Bag-1s ubiquitination. As shown in Figure 3-1d, ubiquitination of 
Bag-1s was indeed strikingly increased in the presence of Hsp70, while CHIP alone 
led to a faint monoubiquitination band. Thus, in the presence of Hsp70 CHIP can 
facilitate Bag-1s polyubiquitination under conditions were it inhibits IRF-1 and p53 
modification. Additionally, no inhibition of CHIP autoubiquitination can be seen in 
the presence of Bag-1s. Taken together these results suggest that CHIP can mediate 
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substrate ubiquitination through two distinct pathways, in one, which is dependent on 
Hsp70, CHIP does not directly bind to its substrate but forms a complex through 
binding to Hsp70. In the other pathway, CHIP binds directly to its substrate and 







3. Results  98 
 
Figure 3-1 Hsp70/40 modulates the E3 ligase activity of CHIP 
In vitro ubiquitination assays with all components of the ubiquitination cascade as purified 
components (10	  μM	  ubiquitin, 100 nM UBE1, 1	  μM	  UbcH5a and 4.5 mM ATP) using CHIP 
as the E3 ligase with a titration of Hsp70/40 (3, 6, 15 µM Hsp70 and 0.3, 0.6, 1.5 µM 
Hsp40). The highest Hsp70 concentration of 15 µM relates to a 1:10 ratio of CHIP:Hsp70 in 
the reaction and is the same ratio found in human cells [309] (the same concentration of 
ubiquitin, UBE1, UbcH5a and ATP was used in all in vitro ubiquitination assays in this 
chapter). The activity of CHIP as an E3-ligase using (a) GST-IRF-1, (b) p53, (d) GST-BAG-
1s as the substrate plus (c) CHIP autoubiquitination in the presence of Hsp70/40 was 
determined. Reactions were carried out for 15 (a,b,d) or 5 (c) minutes and analysed using 
western blot with mAb against the indicated proteins. (a+b were carried out in collaboration 
with Vikram Narayan). 
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3.2.1.2 The flexibility and conformation of CHIP is regulated through its 
TPR domain 
As part of a collaborative study with Vikram Narayan (Narayan, Landré et al., 
submitted manuscript, [368]), I revealed that a CHIP mutant with a single mutation 
from Lys to Ala in the TPR domain (K30A), which is unable to interact with the 
Hsp70 protein, renders the protein intrinsically less active for substrate and 
autoubiquitination in vitro (Fig 3-2a). This is a surprising observation as this mutant 
has in the past been extensively used to demonstrate the effects of Hsp70 binding on 
CHIP activity in a cellular environment even though it has not previously been 
characterised in vitro or in cells. Any loss of CHIP mediated substrate ubiquitination 
using the K30A mutant in cells has been explained by its inability to interact with 
Hsp70, however as shown here the mutant is intrinsically inactive when compared to 
wild-type CHIP in the absence of any Hsp70 protein. In a cell based ubiquitination 
assay, the TPR mutant is not only defective in IRF-1 ubiquitination, but also in 
autoubiquitination (Fig 3-2b). Further, both biochemical and biophysical 
characterisation of the mutant showed that it, in fact, has similar characteristics to 
Hsp70 bound CHIP and is very different from wild type CHIP. (i) CHIP K30A has a 
similar melting temperature (46°C) to Hsp70 peptide bound CHIP (45.5°C), which is 
different from CHIPWT (43.5°C) (data not shown). (ii) Limited proteolysis of ligand 
bound, K30A mutant and wild-type CHIP proteins show a striking similarity of the 
banding pattern observed in a time course for mutant and liganded CHIP, which 
appeared more resistant to cleavage and thus less flexible than the CHIPWT protein 
(data not shown). (iii) SAXS analysis suggested a similar conformation of CHIP 
K30A protein and CHIP that is in complex with an Hsp70 peptide, which is 
significantly different from the CHIP apo-protein (data not shown, see Appendix 1.2 
for manuscript). Taken together these observations suggest that the K30A CHIP 
mutant mimics its Hsp70 bound form and exhibits reduced E3 ligase activity. As 
both the site of mutation (K30) and the Hsp70 binding site are located in the TRP 
domain of CHIP, these results indicate that mutation or ligand binding to the N-
terminal TPR domain affects the C-terminal catalytic U-Box domain of CHIP. 
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Figure 3-2 CHIPK30A mimics Hsp70 bound CHIP and reduces CHIP mediated 
ubiquitination 
(a) CHIP structure (mouse) (b) In vitro ubiquitination assay comparing the activity of 
CHIPWT and CHIPK30A autoubiquitination (left panel) and GST-IRF-1 ubiquitination (right 
panel) in a time course. Reactions determining CHIP autoubiquitination were incubated for 
0, 2 and 5 minutes and reactions with GST-IRF-1 for 5 and 15 minutes. Reactions were 
analysed by SDS-PAGE/immunoblot. (c) H1299 cells were co-transfected with IRF-1, His–
ubiquitin (0.5 µg) and CHIP or CHIP K30A (0.5-2 µg) as shown. At 20 hours post-
transfection cells were treated with MG132 (50 µM) for 4 hours and histidine-labelled 
ubiquitinated protein was isolated using Ni-NTA chromatography and analysed by 
SDS/PAGE and immunoblot. Total amounts of IRF-1, CHIP and β-actin (bottom panel) and 
modified IRF-1 (top panel) are shown (c, data courtesy Vikram Narayan).	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3.2.1.3 CHIPK30A and Hsp70-bound CHIP exhibit similar dynamics in MD 
simulations 
To gain insight into the mechanism by which TPR modulation can change the 
activity of the CHIP U-box, I set up and carried out molecular dynamic simulations 
of wild-type, mutant and ligand bound CHIP structures. As a basis for the simulation, 
the crystal structure of mouse CHIP (aa 25-304) bound to an Hsp90 peptide was used 
(PDB code: 2C2L [254]). Using Pymol, five mutations were introduced into the 
crystal structure, prior to the simulation, to obtain human CHIP. This was done to 
better relate the modelling to experimental data, where human CHIP was used.  
Simulations were run on five different systems: dimeric CHIP wild-type protein with 
an Hsp90 or Hsp70 peptide bound to each TPR domain, with one CHIP protomer 
Hsp90 peptide bound and the other unbound, with unbound CHIP and on the Lys30 
mutant (Fig 3-3). The simulations were run in an explicit water system in a tip3p 
water box. Prior to the simulations, the systems were minimized, followed by a 
heating and equalisation step. The results of the simulation show that, similar to the 
experimental data obtained, liganded or mutant CHIP behave in a similar manner to 
each other, but are different to wild type CHIP. Unliganded CHIP undergoes big 
conformational changes in the simulation, resulting in a more linear and extended 
conformation while peptide bound or mutant CHIP appears less flexible and retains 
the closed conformation seen in the crystal structure. See Fig 3-3b for changes in the 
conformation of wild-type, mutant and ligand bound CHIP, compared to the starting 
structure and Fig 3-3c for comparison of the structure after 20 ns simulation between 
each other. It should be noted that the crystal structure was solved in a peptide bound 
form, and it is consequently not surprising that the liganded structure undergoes 
fewer changes in the simulation than the unbound form.  
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Figure 3-3 CHIPK30A and Hsp70-bound CHIP exhibit similar dynamics in MD 
simulations  
 (A) Crystal structure of murine CHIP dimer (monomers in shades of blue) in complex with 
Hsp90 peptide (pink sticks; adapted from PDB 2C2L). (B) Overlay of the CHIP dimer before 
(blue ribbon) and after (grey mesh) 20 ns MD simulations for unliganded CHIPWT (left), 
CHIPWT in complex with Hsp90 peptide (centre) and CHIP (right). (C) Overlaid snapshots of 
the CHIP dimer in apo and liganded forms and with Lys30 mutated to Ala after 20 ns MD 
simulations. All images were generated using PyMOL v.1.4.1. 
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In order to determine the overall dynamics and flexibility of CHIP in the different 
states, the root mean square fluctuation (RMSF) of each amino acid was computed 
and averaged over a stable period of the simulation (5 ns frames). The results of the 
analysis were colour coded and are presented on the crystal structure in Fig 3-4. To 
access if the obtained results are in agreement with the b-factor of the crystal 
structure, which is a readout of the fluctuation of the different atoms in the crystal, 
the b-factor of the mouse structure (2C2L) in complex with Hsp90 and the RMSF in 
the MD simulation of the same structure were compared (Fig 3-4a). The results of 
the analysis showed that the relative values for fluctuation in the simulation and the 
b-factor are comparable in the different domains of the protein, e.g. the tip of the 
charged domain showed high amount of fluctuation and has a high b-factor while the 
6th and 7th helix of the TPR domain had low values for both. This indicates that the 
calculation of the RMSF from the MD simulation gives relatively accurate 
information about the fluctuation of the protein, I next went on to compare the RMSF 
of CHIP in its wild-type, ligand bound and mutant form. This showed that wild type 
CHIP displayed larger and more widespread fluctuations than the ligand bound or 
mutant form. Interestingly, ligand binding or mutation of the TPR domain resulted in 
a loss of flexibility, not only in the TPR domain, but in all three domains of CHIP. In 
a simulation where only one protomer is bound to Hsp90 peptide, while the other one 
is in an unbound conformation, the unbound protomer exhibits more flexibility than 
the bound protomer, further confirming the stabilising effect of ligand binding to 
CHIP's TPR domain. This is in good agreement with a HX-MS study on CHIP, 
which showed that the  apo-CHIP protein is more flexible than the Hsp70 or Hsp90 
peptide-bound forms [256].  
Taken together, the MD data are in agreement with the Ball groups experimental 
observation, which shows that CHIP with a mutation at K30A or in a peptide bound 
conformation is less thermostable and more susceptible to limited proteolytic 
cleavage than wild type CHIP (Narayan, Landré et al., submitted manuscript, [368], 
Appendix 1.2). This shows that CHIPK30A, even though unable to interact with 
Hsp70, displays properties of an Hsp70 bound state of CHIP. A close look at the 
dynamic simulations, together with analysis of salt bridges formed during the 
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simulation using VMD, revealed that the side-chain of Lys30 does not form any 
hydrogen bonds with atoms of other CHIP residues during the MD simulations and is 
instead well hydrated. We can therefore speculate that, consistent with studies 
showing alanine residues favour the formation of ordered helical structures [310], 
mutation of Lys30 to the much smaller and hydrophobic Ala, will make this region 
less hydrated and more likely to fold into an ordered structure which is more similar 
to the peptide bound structure than to the flexible, less ordered structure described 
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Figure 3-4 CHIPK30A and Hsp70-bound CHIP exhibit similar flexibility in MD 
simulations  
(a) Comparison between b-factor putty of the CHIP structure in complex with Hsp90 and the 
calculated fluctuation (root mean square fluctuation RMSF) using the MD simulation and 
AMBER tools. The score of the positional fluctuation analysis averaged over a 5 ns time 
frame were colour coded and indicated on the crystal structure, the b factor was also colours 
coded and is shown in the crystal structure, additionally the cartoon of CHIP is thicker in 
areas that has been assigned a high b-factor and thinner in areas with a low b-factor. Both b-
factor and RMSF are in Å2. (b) RMSF of Cα obtained from trajectories of 20 ns simulations 
of CHIPWT ± peptide and the K30A mutant. The score of the positional fluctuation analysis 
averaged over a 5 ns time frame were colour coded and indicated on the crystal structure. 
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3.2.1.4 The TPR-domain is an allosteric modulatory site which affects 
U-box activity 
The results presented above indicate that modulation of the TPR, either by mutation 
or peptide binding, has an effect on the overall structure of CHIP and thus affects not 
only the TPR, but also the middle charged and catalytic U-box domain. To 
investigate if there are any correlated movements between different domains of 
CHIP, the distribution of cross correlation between the Cα atoms of each amino acid 
was plotted as a function of the distances between the atoms (Fig 3-5). A striking 
anti-correlated motion (motion occurring in the opposite phase) was seen between 
the TPR-domain of one CHIP wild-type protomer with the U-boxes of both dimer 
components (Fig 3-5; movement A). This motion was strongly suppressed upon 
peptide binding and almost completely lost in the Lys30 mutant.  Additionally, 
correlated motions (motion occurring with the same phase) were observed between 
the two U-box domains of the dimer in the wild-type conformation and again these 
were lost upon peptide binding or substitution of Lys30 (Fig 3-5; movement B).  
These results implicate a mechanism in which the flexibility of the TPR is passed on 
to the U-Box domain and where when the TPR domain is stabilised by peptide 
binding or mutation this inter-domain communication is blocked, resulting in a loss 
of flexibility in the U-Box domain. As K30A mutation and Hsp70 binding modulate 
the U-box activity of CHIP, we believe that this loss in flexibility may directly affect 
its E3 ligase function. Consequently, we conclude that the loss of anti-correlated 
motions upon peptide binding or mutation of Lys30 is evidence that the TPR-domain 
is acting as a binding site for allosteric effectors, which regulate CHIP activity. To 
explore this experimentally, I next set-up assays to determine the effect of TPR 
modulation on U-Box function.  
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Figure 3-5 Correlated motions between the TPR and U-box domains of CHIP 
Dynamic cross-correlation maps of Cα atoms for the CHIP dimer in the presence or absence 
of Hsp90 peptide and with a K30A point mutation (upper panels). Anti-correlated 
movements of the TPR domain with both U-boxes (A) and correlated movements of the two 
U-boxes with each other (B) can be seen for the wild-type CHIP protein, but are strongly 
decreased upon Hsp90 peptide binding and in the Lys30 mutant. Sections of CHIPWT dimer 
coloured in red or blue (lower panels) correspond to the respective regions that are 
highlighted in the correlation maps.  
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3.2.1.5 CHIP interacts with different E2 enzymes 
Previous studies have concluded that the CHIP dimer is asymmetric and that as a 
consequence, the U-box of one of the protomers is unavailable for E2 binding due to 
the location of its associated TPR-domain, whereas the U-box from the other 
protomer remains accessible to the E2 [254]. The MD simulations suggest that 
changes in TPR-domain and U-box motion would not affect the ratio of E2-binding 
as access of UbcH5 to the U-box of one CHIP protomer remains unaltered. Thus, in 
our model loss of anti-correlated motion would impact on the dynamic structure of 
the U-box rather than altering the accessibility of one, or the other, U-box at any 
given time.  
We were, therefore, interested to find out how changes in CHIP dynamics affect 
interactions of the U-Box with E2 enzymes. In a first step, an E2 library for enzymes 
that would interact with CHIP to result in IRF-1 ubiquitination and or the formation 
of free ubiquitin chains was screened (Fig 3-6). Results of the assays show that of the 
E2s screened, CHIP can interact with UbcH5 enzymes (a,b and c) and UbcH6 
resulting in IRF-1 ubiquitination (Fig 3-6a). When the assay was carried out in the 
absence of any substrate and probed with an anti-ubiquitin antibody to detect any 
complexes of higher molecular mass, corresponding to free ubiquitin chains or 
ubiquitin linked to CHIP itself, CHIP was seen to additionally interact with the 
UbcH13/Mms2 heterodimer resulting in abundant amounts of free ubiquitin chains 
(Fig 3-6b).  
Thus, interaction of CHIP with UbcH13/Mms2 does not lead to substrate 
ubiquitination in vitro, however, it efficiently catalyse the formation of free ubiquitin 
chains. In order to determine if interplay between UbcH13/Mms2 and CHIP can 
catalyse the elongation of monoubiquitin added to a substrate by CHIP in 
combination with UbcH5, I assembled in vitro ubiquitination assays, with limiting 
amounts of UbcH5 and a titration of UbcH13/Mms2. Results show that, while 
UbcH13/Mms2 on its own does not mediate CHIP autoubiquitination (Fig 3-7, lane 
2), in the presence of a low concentration of UbcH5, UbcH13/Mms2 leads to a 
striking increase in polyubiquitinated forms of CHIP (lane 3-8). This indicates that 
even though a CHIP-UbcH13/Mms2 complex cannot catalyse attachment of the first 
 
3. Results  109 
ubiquitin to a substrate, it can lead to ubiquitin chain elongation following UbcH5 
priming. The UbcH13/Mms2 heterodimer is believed to result in the formation of 
chains solely linked via K63, indicating a role of this complex in specific substrate 
ubiquitination that serve as a molecular signal in pathways distinct from proteasome 
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Figure 3-6 CHIP can interact with a specific set of E2 enzymes 
In vitro ubiquitination assays were assembled with E1, His-CHIP, ubiquitin, ATP and 
various E2 enzymes as indicated and either with (a) GST-IRF-1 or (b) in the absence of any 
substrate. Reactions were incubated for 15 minutes and ubiquitinated protein was analysed 
by SDS-PAGE/immunoblot, using anti-IRF-1or anti-ubiquitin antibody as indicated (a was 
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Figure 3-7 UbcH13/Mms2 can enhance CHIPs polyubiquitination in the presence of 
UbcH5  
In vitro ubiquitination assays with constant amounts of CHIP (50 ng) and UbcH5 (25 ng) and 
a titration of UbcH13/Mms2 (6-100 ng).  Samples were analysed by SDS-
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3.2.1.6 The TPR-domain regulates CHIP's ability to interact with 
ubiquitin conjugating enzymes 
To determine if loss of U-box flexibility seen by modulation of the TRP domain 
affects the ability of CHIP to interact with the two E2s UbcH5 and UbcH13/Mms2, 
protein-protein interaction assays were utilised. First, the amounts of purified CHIP 
wild type and CHIPK30A were normalised to ensure that any differences observed in 
binding to the E2 were due to the protein's ability to interact with each other and not 
to the amounts of CHIP used or the ability of the antibody to detect the different 
forms of CHIP. Increasing amounts of CHIPWT or CHIPK30A were therefore coated 
onto a microtiter plate and detected with a CHIP mAb (Fig 3-8, upper panel). 
Following normalisation, binding of CHIP to UbcH5 and UbcH13/Mms2 was 
determined. The E2 enzymes were immobilised on a microtiter plate and incubated 
with a titration of either CHIPWT or CHIPK30A. Results of the assay show a significant 
reduction in the ability of the mutant protein to bind both E2s, when compared to 
wild-type CHIP (Fig 3-8, middle and lower panel). This shows that the 
conformational changes initiated by TPR domain mutation reduce the ability of the 
U-Box to interact with these two E2 enzymes. To determine if this directly affects 
the ability of CHIP to mediate ubiquitin discharge from the E2, I set up an assay that 
measures the ability of an E3 ligase to stimulate E2~Ub discharge. The assay 
consists of two steps, in the first ‘Charge Step’ the E1 and E2 are incubated in the 
presence of ubiquitin and ATP, but without an E3 (Fig 3-9a; step 1). In this step, the 
E2 is loaded with ubiquitin by the E1 forming an active thioester bond between 
ubiquitin's C-terminal glycine and a cysteine in the E2's catalytic centre, in an ATP 
dependent manner. The charge of the E2 can be monitored over time using SDS-
PAGE/immunoblot analysis under non-reducing conditions (Fig 3-9b). In order to 
limit the E2 charge to approximately one round per molecule, the amount of ATP in 
the assay was titrated to the minimal amount needed for maximum charge of the E2 
(Fig 3-9c). In this way, once the E2 is discharged by an E3, it will not be recharged, 
and the discharge can be monitored under different conditions. Accordingly, the 
second step is the ‘Discharge Step’ (Fig 3-9a; step 2), where an E3 ligase is added to 
the reaction. The E3 catalyses the transfer of the E2 bound ubiquitin to a substrate or 
a free ubiquitin molecule in the reaction. This discharge can be monitored over time. 
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Because ubiquitin is attached to the E2 via a thioester bond, the charged E2 species is 
sensitive to reducing agents such as DTT, while if ubiquitin was attached to an E2 
residue via an isopeptide bond (E2 ubiquitination), the complex would be stable 
under reducing conditions. Thus, addition of DTT to the sample prior to analysis by 
SDS-Page can confirm that the double band detected with the antibody specific for 
the E2 is indeed a charged E2~conjugate and not ubiquitinated E2 (Fig 3-9c). 
To investigate the effect of Hsp70 binding and K30A mutation on CHIP's ability to 
discharge UbcH5, E2-discharge assays were assembled to follow the loss of 
ubiquitin from thioester-linked UbcH5-ubiquitin complexes in response to the 
addition of CHIP in the absence of added substrates (Fig 3-10). Whereas increasing 
amounts of wild-type CHIP stimulated ubiquitin discharge from UbcH5, the addition 
of Hsp70 peptide strongly suppresses the ability of CHIP to stimulate ubiquitin loss 
from the E2~Ub complex (Fig 3-10a). Similarly, when the ability of CHIPWT to 
discharge UbcH5 is compared to that of CHIPK30A, the mutant protein had a 
significantly reduced ability to discharge ubiquitin from UbcH5. In fact, the activity 
of the K30A mutant was intermediate between that of CHIPWT and a U-box mutant 
(H260Q) that can no longer interact with the E2. The experimental data on E2-
discharge and CHIP-UbcH5 binding thereby support a role for the TPR-domain of 
CHIP as an allosteric modulator site, and shows that its occupation can generate long 
range inter-domain changes in the affinity and activity of the U-box resulting in an 
inhibition of CHIP E3-ligase activity.  
 
To determine if discharge of UbcH13/Mms2 by CHIP was also impaired by mutation 
of the TPR domain, discharge assays using UbcH13/Mms2 were carried out. 
Surprisingly, even though binding of CHIPK30A to the E2 dimer was reduced (Fig 3-
8), its ability to catalyse discharge of ubiquitin from the UbcH13/Mms2 heterodimer 
was increased when compared to CHIPWT (Fig 3-10a). I therefore wanted to know, if 
the K30A mutant was able to facilitate the formation of free ubiquitin chains in the 
presence of UbcH13/Mms2 and how its activity compared to that of the wild type 
protein. Ubiquitination assays with either CHIPWT or CHIPK30A as the E3 and either 
UbcH13/Mms2 or UbcH5 as the E2 component were assembled. As shown in Figure 
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3-11b, while CHIPK30A's ability to form ubiquitin chains is reduced when UbcH5 is 
present in the reaction (compare lane 2,3 to 7,8), in the presence of UbcH13/Mms2 
the mutant's ability to form ubiquitin-chains is increased compared to wild-type 
CHIP (compare lane 4,5 to 9,10). This suggest that the TPR domain can generate 
conformational changes in the U-box that inhibit its activity in combination with 
specific E2s, while its E3 ligase activity in combination with another subset of E2s is 
stimulated. Protein-protein interaction assays showed that binding of mutant CHIP to 
UbcH13/Mms2 is reduced when compared to wild type (Fig 3-8), it has to be 
investigated if this is because transient interactions between CHIP and 
UbcH13/Mms2 are sufficient for transfer of ubiquitin, or if CHIPK30A would bind 
more stably to the ubiquitin charged form of UbcH13/Mms2 and only its ability to 
interact with the uncharged E2 is impaired compared to wild-type CHIP. As a study 
from Plechanovova et al. (2012) [46] demonstrated, the E3 enzymes form 
interactions with residues from both the E2 and ubiquitin molecule. The E3 protein 
therefore exhibits a higher binding affinity for the E2~ubiquitin conjugate than for 
the E2 alone, thus once ubiquitin has been discharged from the E2, the complex is 
less stable and E2-E3 dissociate.  
Taken together the data presented in this section support a mechanism where ligand 
binding to the TPR domain of CHIP leads to conformational changes within the 
protein that alters its catalytic activity. Hence, we propose that the TPR domain can 
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Figure 3-8 CHIPK30A binds the two E2 enzymes UbcH5 and UbcH13/Mms2 with lower 
affinity when compared to CHIPWT  
First amounts of CHIPWT and CHIPK30A recombinant protein were normalised using an anti-
CHIP mAb, a titration (0-50 ng) of CHIP protein was coated onto a micotiter plate and 
detected using a CHIP mAb (upper panel). Binding was detected using chemiluminescence 
and is expressed as relative light units (RLU). Binding of the wild-type and mutant CHIP to 
UbcH5 (middle panel) and UbcH13/Mms2 (lower panel) was determined, E2 (100 ng) were 
coated onto a micotiter well and incubated with increasing amounts of CHIPWT or CHIPK30A 
(0-30 ng or 0-50 ng as indicated) in the mobile phase. CHIP binding was analysed using a 
CHIP pAb (N-ter) and detected as above. The data represents the mean of technical duplicate 
binding assays, additionally the assay was carried out at least twice in biological replicates.  


























































































3. Results  116 
 
Figure 3-9 Schematic illustration of the discharge assay 
(a) Step 1: the E2 is charged by the E1 in an ATP dependent reaction using purified 
components. The charge can be monitored over time using western blot analysis and an anti-
His antibody detecting His-UbcH5 (b and c). Importantly, this first charge step is limited by 
the amounts of ATP present in the reaction. The amount of ATP was titrated to a 
concentration, which only allows each E2 molecule to be charged with ubiquitin roughly one 
time (c). (a) Step 2: After the E2 is charged an E3 is added to the reaction, the E3 binds to 
the charged E2 and catalyzes ubiquitin transfer to either itself resulting in autoubiquitination, 
to free ubiquitin forming free ubiquitin chains or to a substrate. (d) UbcH5 was charged with 
ubiquitin in an in vitro reaction and subsequently analysed under reducing (abolishing the 
thioester linkage between ubiquitin (Gly76) and UbcH5 (Cys85)) and non reducing-conditions 
(leaving the thioester linkage intact) on SDS-Page/immunoblot.  
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Figure 3-10 Hsp70 peptide binding or TPR mutation reduces CHIPs ability to 
discharge UbcH5  
Discharge assays with UbcH5 and CHIP, E1, ubiquitin, E2 and ATP were incubated for 10 
minutes to charge the E2. Then discharge of the E2 by CHIP was monitored with either (a, b) 
a titration of CHIP (6-50 ng) or (c) over a time (5-20 minutes), in (a) the presence of Hsp70 
wt peptide, D641A mutant peptide (3 mM) or DMSO control; or (b, c) with CHIPWT, 
CHIPK30A or the E2-binding-defective mutant H260Q. The reactions were analysed by SDS-
Page/western blot under non-reducing conditions with an anti-His antibody that detects His-
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Figure 3-11 CHIP K30A exhibits increased E3 ligase activity compared to CHIPWT 
when interacting with UbcH13/Mms2 
(a) Discharge assays with UbcH13/Mms2 and CHIP, E1, ubiquitin, E2 and ATP were 
incubated for 10 minutes to charge the E2. Then discharge of the E2 by a titration of CHIPWT 
or CHIPK30A (6-50 ng) was monitored. The reactions were analysed by SDS-Page/western 
blot under non-reducing conditions with an anti-His antibody that detects His-UbcH5 and 
His-CHIP. (b) In vitro ubiquitination assay with a titration of CHIPWT or CHIPK30A (25 or 50 
ng) and UbcH5 or UbcH13/Mms2 as indicated. The reactions were incubated for 15 minutes 
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3.2.2 CHIP is autoubiquitinated at multiple residues in its 
functional domains 
Data presented in this chapter demonstrates how CHIP E3 ligase activity can be 
modulated by its TPR domain. Additionally, CHIP activity has previously been 
shown to be controlled by autoubiquitination. Interaction of CHIP with Ube2w leads 
to CHIP autoubiquitination at Lys2, and this activates its E3 ligase function [306]. To 
further our understanding of the regulation of CHIP activity by autoubiquitination, I 
was interested to investigate, if there are any additional lysine residues within CHIP 
that are targeted by its autoubiquitination activity when interacting with the E2 
enzyme UbcH5. In particular, I asked if any sites within the TPR are modified, and 
how this modification could affect its dynamics and activity.  
To identify lysine residues in CHIP that are subject to modification by ubiquitin as a 
result of its interaction with UbcH5, the ubiquitination sites on CHIP were mapped 
using mass spectrometry. Recombinant His-CHIP protein was allowed to 
autoubiquitinate in an in vitro ubiquitination reaction with UbcH5, E1, ubiquitin and 
ATP, then the samples were analysed by SDS-PAGE and Colloidal Blue Stain. The 
ubiquitinated forms of CHIP were identified, bands excised, and the samples were 
prepared for mass spectrometry analysis. Briefly, gel slices were first destained, 
followed by reduction, alkylation and digestion using the endopeptidase trypsin, 
subsequently peptides were extracted and analysed by mass spectrometry. Ubiquitin-
modified lysine residues are protected from trypsin cleavage, resulting in a distinct 
cleavage pattern for the ubiquitinated protein. Furthermore, ubiquitin that is attached 
to the protein is cleaved off at its C-terminal arginine residue leaving a di-glycine 
peptide remnant that adds 114.043 Da to the ubiquitinated peptide. The modified 
cleavage pattern, together with the mass additions, facilitates identification, by MS, 
of peptides that have been ubiquitinated (Fig 3-12). 
The results of the mass spectrometry analysis identified seven lysines within CHIP 
that were linked to ubiquitin (Fig 3-13). Two of these are located in or adjusted to the 
U-box domain, while the other five lie in or around CHIP's TPR domain. None of the 
lysines in the extreme N-terminus or its charged middle domain were subject to 
ubiquitination. Stable forms of ubiquitinated CHIP have been observed in cells [306] 
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(unpublished observation by the Ball group), suggesting that at least under some 
conditions CHIP ubiquitination does not signal its degradation but serves a different 
function. The observation that CHIP autoubiquitination is concentrated on its 
catalytic U-box and regulatory TPR domain, indicates that ubiquitination of these 
residues could affect its function. Addition of the 8-kDa protein ubiquitin to a 
molecule of CHIP could have an effect on the accessibility of surface residues that 
are involved in interaction with other proteins, e.g. E2 enzymes binding to its U-box 
or chaperones and other substrates that interact with its TPR domain. In fact, two of 
the lysine residues within the TPR, Lys30 and Lys72, which are involved in the 
interaction with Hsp90, are subject to autoubiquitination by CHIP (as shown in the 
crystal structure, Fig 3-14). This is an interesting observation and raises two 
questions (i) would ubiquitination of residues in the chaperones binding cleft 
sterically inhibit binding of proteins to this site and (ii) as the data in this chapter 
demonstrate that modulation of the TPR domain affects the overall dynamics of 
CHIP, how would ubiquitination of lysines in the TPR, especially Lys30, affect the 
flexibility and structure of this domain and could this possibly alter the activity of 
CHIP's U-box? Further studies are necessary to address these questions and to fully 
evaluate the physiological relevance of CHIP TPR and U-box ubiquitination.  
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Figure 3-12 Schematic illustration of the procedure used to map ubiquitination sites.  
First the protein of interest is ubiquitinated in an in vitro ubiquitination reaction including all 
the components of the reaction as purified recombinant proteins. The ubiquitinated protein is 
then isolated using a tag‐system and separated by SDS-PAGE. Bands corresponding to 
ubiquitinated proteins are excised and digested with the endopeptidase Trypsin. Trypsin 
cleaves proteins after either lysine or arginine residues, however, ubiquitinated lysine 
residues are protected from cleavage. Ubiquitin is also cleaved, and only a glycine dipeptide 
remains on the ubiquitinated peptide. This glycine dipeptide leads to a mass addition of 
114.043 Da. Peptides are analysed using mass spectrometry and ubiquitinated peptides are 















              .......K ........K..............K..........K ..........R...
RG




3. Results  122 
 
Figure 3-13 Auto-ubiquitination sites on CHIP mapped by MS analysis 
(a) Western blot of in vitro ubiquitinated His-CHIP (0.5 µg), after isolation of CHIP from the 
reaction using Ni-NTA chromatography. The in vitro ubiquitination reaction was incubated 
for 0, 10 or 45 minutes. (b) Results of MS analysis, showing modified peptides in CHIP. 
Lysine residues that were shown to be modified by ubiquitin are highlighted in red. (c) 
Modified lysine residues indicated above and total CHIP lysine residues indicated 
underneath a schematic CHIP domain structure. (Unfortunately, data on peptide coverage of 






Peptide  Sequence   Modified  Lysine   Mascot  Score     Domain  
GGGSPEKSPSAQE   K22   54.71   -­  
PSAQELKEQGNRL   K30   69.62   TPR  
RLFVGRKYPEAAA   K41   43.82   TPR  
RALCYLKMQQHEQ   K72   22.78   TPR  
RAYSLAKEQRLNF   K125   31.52   -­  
FSQVDEKRKKRDI   K221,223,224    26.25   U-­Box  
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Figure 3-14 The two ubiquitination sites Lys30 and Lys72 are involved in interactions 
with Hsp90  
Structure of CHIP TPR (cartoon) in association with Hsp90 peptide (highlighted). 
Autoubiquitination sites Lys30 and Lys72 are indicated as purple sticks and interactions 
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3.2.3 Inhibition of MDM2 activity by aptamer binding 
3.2.3.1 Identification of a MDM4 C-terminal peptide that inhibits MDM2 
E3-ligase activity  
The E3 ligase MDM2 is the main regulator of p53 activity and a significant amount 
of research is being invested to identify drugs that could inhibit its suppressive 
activity on p53 function. The Ball group has previously identified a peptide from the 
N-terminal RING domain of MDM4, T-apt, that binds to the MDM2 RING domain 
and inhibits its E3 ligase activity in vitro and in cells (Fig 3-15, data courtesy 
Susanne Pettersson). The MDM2 RING domain forms homodimers, and 
heterodimers with the MDM4 RING. When the T-apt peptide on MDM4 was 
mapped onto the available crystal structure of the MDM2/MDM4 dimer (PDB: 2VJF 
[268]), we found that the peptide lies within the dimer interface of the two proteins, 
indicating that T-apt binding could disrupt MDM2 dimer formation with either 
another MDM2 protomer or a MDM4 molecule. The MDM2 RING domain interacts 
with E2 enzymes leading to substrate ubiquitination. We were interested to establish, 
if MDM2's inability to ubiquitinate p53 in the presence of T-apt is due to a failure to 
discharge ubiquitin from the E2 or whether E2 discharge is unaffected. An UbcH5 
discharge assay was therefore assembled that tested the ability of MDM2 to 
discharge this E2 in the presence of either T-apt or a control peptide with a C-
terminal truncation that renders it less active. As shown in Figure 3-16, in the 
absence of any E3 ligase the UbcH5~ubiquitin complex is stable over the time of the 
assay, upon addition of MDM2 however, ubiquitin is quickly discharged (Fig 3-16a, 
compare lane 1 with 2-4, b compare lanes 1-3 to 4-9). If MDM2 was pre-incubated 
with T-apt, MDM2 mediated E2 discharge was completely abolished, while a control 
peptide did not have any effect on the ability of MDM2 to facilitate E2 discharge (a, 
compare lanes 5-7 with 8-10 and b, lanes 10-12 and 13-15). This shows that T-apt 
binding inhibits MDM2's ability to discharge UbcH5 and therefore, its catalytic 
activity, this implies that T-apt does not specifically inhibit p53 ubiquitination, but 
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Figure 3-15 T-apt binds to the MDM2 and inhibits its E3 ligase activity in vitro and in 
cells 
(a) Biotin tagged, overlapping peptides of the C-terminus of MDM4 were used to generate 
peptide aptamer affinity columns, which were incubated with cell lysate from H1299 cells. 
Eluates from the peptide aptamer affinity chromatography columns were analyzed by SDS-
PAGE/immunoblot and probed with an anti-MDM2 mAb. (b) T-apt-biotin 
(KEIQLVIKVFIA) or a control peptide (KEIQLVIKVF) were immobilized on a microtitre 
plate and incubated with a titration (0–100 ng) of MDM2. Protein binding was detected 
using an anti-MDM2 mAb and the protein amount against binding is expressed as relative 
light units (RLU). (c) In vitro ubiquitination assay with MDM2 as the E3 ligase, p53 as 
substrate and a titration of T-apt (1.5 and 10 µM). (d) H1299 cells were transfected with p53 
(0.5 µg), His- ubiquitin (0.5 µg) and EGFP-T-apt or EGFP alone as detailed. Post 
transfection (24 hours) cells were treated with MG132 (50 µM) for 4 hours. Ubiquitinated 
protein was isolated using affinity chromatography and immunoblots show total p53, EGFP 
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Figure 3-16 T-apt inhibits E2 discharge by MDM2 
(a) E2 (His-UbcH5) discharge assays with a titration of MDM2 and constant amounts of T-
apt, a control peptide with a C-terminal truncation or DMSO. The discharge reaction was 
incubated for 10 minutes and analysed by SDS-PAGE under non-reducing conditions 
followed by immunoblot with an anti-His antibody that detected His-UbcH5. (b) E2 
discharge assay carried out as in (a), but with constant amounts of MDM2 and the discharge 
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3.2.3.2 Dynamics of the MDM2 RING-domain in association with T-apt 
In order to get an insight into the binding dynamics and the residues involved in the 
interaction between T-apt and the MDM2 RING, I carried out molecular dynamic 
simulations on the MDM2 RING in complex with T-apt. The starting structure of the 
simulation was obtained from the MDM2/MDM4 heterodimer (PDB:2VJF [268]), 
with only the residues of the MDM4 molecule, which resemble T-apt, retained in the 
structure (Fig 3-17). After a 50 ns simulation, residues involved in contacts between 
the two molecules were computed using ptraj modules. Results from the analysis 
showed that the C-terminal residues (Phe-Ile-Ala) of the peptide form the most stable 
and energetically favourable interactions with the MDM2 molecule, this is supported 
experimentally by Dr. Pettersson using alanine scans of the peptide (data not shown). 
Strikingly, all interactions were hydrophobic and no salt bridges between the peptide 
and the RING were formed. Figure 3-18a (left panel) illustrates contacts between 
these three residues and the RING surface. The T-apt peptide contains a C-terminal 
cap, which neutralises its otherwise negative charged terminus; simulations show that 
this cap itself is involved in hydrophobic interaction with the MDM2 residues Val439 
and Met459. Modelling results are confirmed by experimental data, which show a 
reduction in binding between MDM2 and T-apt/OH (uncapped with a natively 
charged C-terminus) when compared to T-apt (Fig 3-18b, left panel). Furthermore, 
T-apt/OH displays a lower ability to inhibit MDM2 E3 ligase activity in an in vitro 
ubiquitination assay (right panel). These results suggest that the hydrophobic 
interactions between the cap and the MDM2 RING stabilise binding of the peptide, 
and additionally, the de-solvation energy of the free terminus is higher than that of 
the neutralised peptide and it is therefore less prone to form a complex with MDM2.  
A snapshot of the simulation, after the structure has stabilised (7 ns), revealed that in 
addition to the interface between the C-terminal region of the peptide, which also 
forms part of the interface between MDM2 and MDM4 in the crystal structure, the 
N-terminal part of the peptides folds onto the surface of MDM2 forming additional 
interactions (Fig 3-19a, compare position of orange to green peptide; b compare left 
to right panel). As these do not form part of the natural interface, we reasoned that 
substitution of residues of this part of the peptide could increase its affinity for 
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MDM2. For example, the N-terminal lysine is in proximity to a positively charged 
surface area on MDM2 (Fig 3-20a), and we predicted that substitution with either a 
hydrophobic or negatively charged residue could increase the peptides binding 
affinity for MDM2. In a first step, the three N-terminal residues Lys-Glu-Ile were 
mutated in silico and short simulations (4 ns) were run on a complex between the 
MDM2 RING and the amended peptides. The binding energy between MDM2 and 
the different peptides was computed and compared to T-apt wild-type (Fig 3-20b). 
Several peptides exhibited higher negative binding energies than the wild type T-apt 
peptide, suggesting that these peptides might bind to MDM2 with a higher affinity. 
To exam the modelling results experimentally, synthetic peptides were obtained and 
binding between MDM2 and the peptide series was tested using a protein-peptide 
interaction assays. Specifically, biotin labelled peptides were immobilised by capture 
onto a streptavidin coated on a microtiter plate and incubated with MDM2 in the 
mobile phase. Results show that one of the novel peptides, T-apt 4, with a single 
mutation from the N-terminal Lys to Trp, showed a strong increase in affinity for 
MDM2 (Fig 3-20b). Further binding assays with titrations of MDM2 confirmed that 
the amended peptide interacts with MDM2 more stably than the T-apt peptide. A 
snapshot of the simulation with the T-apt 4 peptide after 4 ns demonstrates that the 
substituted tryptophan fits well onto the MDM2 surface (Fig. 3.20e). 
Taken together, we have identified and optimised a small peptide derived from the 
interface of the MDM2/MDM4 dimer, which binds to MDM2 with a high affinity 
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Figure 3-17 Structure of MDM2 in complex with MDM2/T-apt  
(a) MDM2/MDM4 heterodimer shown as surface with the position of the T-apt peptide 
indicated by sticks (PDB:2VJF). (b) MDM2 RING domain associated with T-apt. The 
structure of T-apt was adapted from the conformation of the peptide in the MDM2/MDM4 
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Figure 3-18 Hydrophobic interactions between the T-apt peptide cap and the RING 
surface stabilise binding of the two molecules. 
(a) Contact analysis of the T-apt residues with the MDM2 RING domain in 50 ns molecular 
dynamic simulation was carried out using ptraj modules. Contacts identified by the analysis 
are indicated as dotted lines between atoms of RING and peptide residues. (b) Biotin-tagged 
T-apt wt or T-apt/OH (without a C-terminal cap) were immobilized on a microtiter plate and 
incubated with 100 ng of MDM2. MDM2 binding to the peptides was detected using an anti-
MDM2 mAb (left panel). An in vitro ubiquitination assay was carried out using p53 as the 
substrate, MDM2 as the E3 ligase and a titration of either T-apt wt or T-apt/OH and 
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Figure 3-19 Molecular Dynamic simulations reveal a second binding of T-apt on the 
MDM2 RING 
(a) Overlay of the starting structure of T-apt bound to the RING domain of MDM2, which 
was derived from the crystal structure of the MDM2/MDM4 heterodimer (orange) and a 
snapshot of the simulation after stabilisation (7 ns) (green). (b) The position of T-apt in the 
starting structure (left panel, as in a) and after 7 ns simulation (right panel) are shown with 
the MDM2 RING presented as surface with vacuum electrostatics and T-apt as yellow sticks.  
Lys - Glu - Ile
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Figure 3-20 Optimisation of T-apt by molecular modelling 
(a) Position of T-apt N-terminal (green sticks) on the surface of the MDM2 RING after 7 ns 
MD simulation. (b) T-apt residues were substituted in silico with the aim to obtain a peptide 
with higher affinity for MDM2. Short simulation of the amended peptide (4 ns) in complex 
with MDM2 were carried out and the free binding energy binding energies (ΔGbind) of T-apt 
1-5 was were computed using MM-GBSA (molecular mechanics/Generalized Born surface 
area) method using the GB module in Amber and are shown in in kcal/mol	  [311]. (c+d) 
Biotin-tagged T-apt like peptides (either wt or with N-terminal substitutions) were 
immobilized on a microtiter plate and incubated with (c) constant amounts (100 ng) or (d) a 
titration of MDM2 protein (0-400 ng). MDM2 binding to the peptides was detected using an 
anti-MDM2 mAb. (e) Position of T-apt 4's (K1W) N-terminal (yellow sticks) on the surface 
of the MDM2 RING after 4 ns MD simulation. Electrostatic surface was generated using the 
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T-­apt   KEIQLVIKVFIA   -­38.45  
T-­apt/1   EWIQLVIKVFIA   -­64.66  
T-­apt/2   EESQLVIKVFIA   -­66.95  
T-­apt/3   EEI    -­58.54  
T-­apt/4   KWIQLVIKVFIA   -­57.12  
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3.2.4 Several lysine residues in MDM2 are subject to 
autoubiquitination 
MDM2 has been reported to autoubiquitinate, which leads to its proteasomal 
degradation [304]. No additional functions of MDM2 autoubiquitination have been 
identified so far. To start investigating if there might be additional roles of MDM2 
ubiquitination, we set out to map lysine residues that are targeted by 
autoubiquitination using mass spectrometry (see Fig 3-14 for an outline of the 
experiment). Ubiquitinated forms of MDM2 were generated using an in vitro 
ubiquitination assay with UbcH5 as the E2 enzyme, samples were separated on a 
SDS-PAGE followed by Colloidal blue staining (3.23 a) and bands corresponding to 
ubiquitinated MDM2 were excised and prepared for MS evaluation. Analysis of the 
samples identified several lysine residues within the protein to be subject to 
autoubiquitination (Fig 3-23b and c). Several of these are located within or adjacent 
to the p53-binding interface and additionally several lysine residues in its catalytic 
RING domain were shown to be subject to ubiquitination (c). It would be interesting 
to determine how ubiquitination of these residues could affect binding of p53, E2 and 
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Figure 3-21 MDM2 autoubiquitinates at multiple sites 
(a) Blue stained gel of in vitro ubiquitinated GST-MDM2 (0.5 µg), after isolation of MDM2 
from the reaction using gluthathione beads. The in vitro ubiquitination reaction was 
incubated for 0, 10 or 45 minutes. (b) Results of MS analysis showing modified peptides in 
MDM2. Lysine residues that were shown to be modified by ubiquitin are highlighted in red. 
(c) Modified lysine residues are indicated above and total MDM2 lysine residues indicated 
underneath a schematic MDM2 domain structure. (Unfortunately, data on peptide coverage 
of the analysis could not be obtained).  
Peptide  Sequence   Modified  Lysine   Mascot  
Score  
Domain  
PKPLLLKLLKSVG   K  31,  36,  39   11.98     Hydrophobic  pocket
EGGSDQKDLVQEL   K136   14.82     
QELQEEKPSSSHL   K146   32.02     
EISEKAKLENSTQ   K334,336   43.68   (zinc  finger)
  
NWLPEDKGKDKGE   K  334,336,338   20.03     
FDVPDCKKTIVND   K  363,364   31.85     
CFTCAKKLKKRNK   K466,467,469,470   16.46   RING  
KLKKRNKPCPVCR   K467,469,470,  473   27.84   RING  
Hydrophobic  pocket RINGAcid  domain
Zinc  fingerNLS
NES
0    26                                  108                                                230                      274    289      331                                            437                          491  
K31,  K36,  K39 K136,  K146
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Lys              *  **    *  *      *    *          *  *        *  *          *  *                                                            *        ***  **          **        *      *  *      *  *    *****          
 
3. Results  135 
3.3 Discussion 
Several E3 ligases, including CHIP and MDM2, were shown to target a range of 
different substrates for ubiquitination, and furthermore to interact with more than one 
E2 enzymes resulting in ubiquitin chains of different length and linkages. However, 
only limited information is available on how the E3 is able to select different E2 
enzymes and substrates under specific cellular condition. Studying the regulation of 
E3 ligase activity by ligand binding can (i) give insight into regulation of E3 ligases 
by physiological binding partners, (ii) be used as a tool to study the effect of 
ubiquitination on specific substrates, (iii) can provide tools to study the molecular 
mechanism of cellular function of E3s relevant to disease, and,  (iv) can identify 
potential biologic drugs or drugable pathways, if the E3 ligase and/or its substrate 
has been implicated in the development of diseases. In this chapter, I have presented 
data on how the function of the E3 ligase CHIP can be modulated by allosteric 
regulation of its catalytic domain by mutation or ligand binding to the TPR domain. 
Furthermore, I characterised the binding dynamics of a novel MDM2 inhibitor and 
used this information to optimise the aptamer's binding affinity for the MDM2 RING 
domain. 
The E3 ligase CHIP was identified as an Hsp70/Hsp90 interacting protein and was 
later shown to facilitate ubiquitination of Hsp bound client proteins through its 
catalytic U-box domain [312]. CHIP thereby connects the chaperone mediated 
refolding pathway to the proteasomal degradation of misfolded proteins [29, 312, 
313]. In addition to this well-established role of CHIP, recently, another function of 
CHIP as an Hsp70 independent E3 ligase has emerged. Several proteins were 
identified that interact with CHIP in the absence of Hsp70. This suggests that, under 
some conditions, CHIP can act as direct E3 ligase, bypassing the need for chaperones 
to deliver their client proteins as substrates. Two CHIP substrates, death domain-
associated protein (Daxx) and Runx1 bind to CHIP independently of Hsp70 [244, 
314]. Furthermore, the Ball group has shown that binding and ubiquitination of IRF-
1 is not dependent on the presence of Hsp and that CHIP directly binds to and 
ubiquitinates folded substrates [130]. These observations, however, do not exclude, 
that in the Hsp70 dependent pathway, CHIP can mediate ubiquitination of these 
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proteins, if they are misfolded and presented by a chaperone. Here, we expand on 
previous observation from the Ball group, which showed that CHIP could facilitate 
IRF-1 ubiquitination in an Hsp70 independent manner, and demonstrate an additional 
role of Hsp70 in the regulation of CHIP activity. We show that Hsp70, in contrast to 
the classical model, inhibits CHIP as an E3 ligase for IRF-1 and p53 in vitro. 
Furthermore, Hsp70 binding reduced CHIP autoubiquitination in both the presence 
of p53 or IRF-1 and the absence of any substrate. Biophysical analysis of CHIP 
bound to an Hsp70 peptide revealed that ligand binding reduces overall flexibility of 
CHIP protein and further demonstrated that a CHIP mutant, which carries a single 
mutation from Arg to Ala in its TPR domain, structurally mimics the Hsp70 bound 
form of CHIP. This observation was unexpected as this mutant, which is unable to 
interact with Hsp70/90, is commonly used to study dependence of Hsp70/Hsp90 on 
CHIP [315]. As the mutant is unable to bind to Hsp proteins and at the same time 
shows reduced activity towards its substrate, it was concluded that CHIP activity is 
inevitably dependent on Hsp70 binding. Results from the Ball group presented here, 
however, demonstrate that this CHIP mutant is not only unable to bind to Hsp70 
(Narayan, Landré et al., submitted manuscript, [368], appendix 1.2), but also shows 
greatly reduced intrinsic E3 ligase activity when compared to the wild-type protein in 
the absence of any Hsp70 protein. Taken together the data suggest that, even though 
the mutant does not bind Hsp70, it adopts a conformation that is very similar to that 
of Hsp70 bound CHIP protein. The mutant is, therefore a structural mimic of ligand 
bound CHIP.  
Using molecular dynamic (MD) simulations, I confirmed the biophysical data; 
fluctuation measurements for individual residues in MD simulations of CHIP show a 
high degree of flexibility, which is significantly reduced upon ligand binding or the 
introduction of a structure stabilizing amino acid providing evidence for a model 
where the CHIP structure 'tightens' in response to TPR modulation by either Hsp70 
binding of mutation of K30A. This data is consistent with hydrogen exchange study 
on CHIP by Graf et al. [256], which suggest that the CHIP TPR and charged domain 
are highly flexible and that binding of Hsp70/90 to the TPR domain induces more 
stability to the TPR domain. And with SAXS data that suggested a similar 
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conformation of CHIP K30A protein and CHIP that is bound to  an Hsp70 peptide, 
which is significantly different from the CHIP apo-protein (Ball/Walkinshaw groups, 
unpublished observation). Analysis of the MD simulations further demonstrated 
correlated and anti-correlated motions between one TPR and the U-box domains of 
the CHIP dimer and anti-correlated motion (motion occurring in a opposite phase) 
between the two U-box domains. Correlated and anti-correlated motions are linked to 
mechanisms of enzyme catalysis and protein allostery. It is striking therefore that 
these motions in the CHIP TPR and U-box can be suppressed upon TPR-domain 
binding or mutation, and this indicates a key role of loss of coordinated motion and 
intrinsic flexibility in the allosteric regulation of CHIP by TPR-binding ligands such 
as Hsp70.  
Flexibility was shown to be essential for the function of several E3 ligases. As 
mentioned earlier, some E3s can function as both mono- and polyubiquitin ligases 
and target several lysine residues on one substrate. To achieve this range of 
outcomes, E3 ligases were shown to exhibit a high degree of flexibility. Cullin-RING 
E3 ligases complexes, for example, were shown to include flexible components that 
function by adapting the distance between E2 and substrate in order for the complex 
to initiate and then elongate ubiquitin chain formation [316]. In fact, flexibility in 
both substrate-binding proteins and Rbx subunits is required for efficient substrate 
polyubiquitination by cullin-RING E3-ligases. Similarly, we show here, that 
flexibility of CHIP is required for its activity as a direct E3 ligase. As described 
above, modulation of the CHIP TPR leads to a loss of inter domain communications 
and protein flexibility, resulting in tightening of the U-box domain. The U-box of 
CHIP interacts with different E2 enzymes to facilitate substrate ubiquitination. We 
demonstrate that TPR mediated allosteric regulation of CHIP's U-box affects its 
ability to interact with and discharge E2 enzymes. Strikingly, CHIP mediated 
substrate ubiquitination and E2 discharge is inhibited by mutation or ligand binding 
of CHIP's TPR in the presence of UbcH5. When interacting with UbcH13/Mms2, on 
the other hand, the ability of mutant CHIP to facilitate the formation of free ubiquitin 
chains and discharge the E2 is increased. Thus, demonstrating that modulation of 
CHIP's TPR can act as a 'molecular switch' favouring interactions with one E2 over 
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another. The E2 heterodimer UbcH13/Mms2 is mainly involved in the formation of 
K63 linked polyubiquitin chains when in complex with CHIP, however, it cannot 
facilitate transfer of the initial ubiquitin onto a substrate [254]. The observation that 
TPR modulation can favour E2 discharge from one E2 over an other provides an 
elaborate mechanism by which activity of an E3 ligase can be modulated to acting 
predominantly as an E4. We speculate that CHIP bound to Hsp70 prefers to interact 
with a specific set of E2s, while unbound CHIP interacts with other E2s, resulting in 
two distinct functions of the E3 ligase. The reduced flexibility of CHIP that is 
mediated by ligand binding to its TPR domain, could furthermore, narrow its 
interaction range and thus only allow ubiquitination of specific lysine residues on a 
substrate or ubiquitin, which are in proximity to the E2-CHIP complex. This can also 
explain why, in its rigid conformation, Hsp70 is required to deliver substrates to 
CHIP, as Hsp70 might be able to position the substrates closer to the E2/ubiquitin/U-
Box complex, thereby allowing ubiquitin transfer to the Hsp70 bound protein. While 
wild type CHIP exhibits higher flexibility and it consequently able to adopt different 
conformations allowing ubiquitination of different lysine residues in a single 
substrate or ubiquitin. Thus, the TPR-domain in CHIP appears to provide the 
plasticity it requires to act as a direct E3-ligase, but can also act as an ‘allosteric 
switch’ where the introduction of a more ordered, stable structure can modulate the 
ability of its U-box domain to discharge specific E2 enzymes.  
Interestingly, this study, in addition to giving insight into the control of CHIP 
function, demonstrates how a TPR domain can act as an allosteric modulator of a 
separate catalytic domain. This is in an intriguing observation and could shed light 
on an additional role of TPR structures, which have mainly been studied as protein 
binding domains that provide a scaffold for the assembly of multi-protein complexes. 
In fact, when studying effects of mutation or Hsp90 binding to the TPR domain of 
Cyclophilin 40 (Cyp40), an immunophilin cochaperone discovered in steroid 
receptor-Hsp90 complexes [317, 318], we found, that as for CHIP, ligand binding or 
mutation of the K30 equivalent K227 leads to a loss of protein flexibility and inter-
domain correlated motions (Appendix 1.1). This loss in protein dynamics correlates 
with an increase of the Cyp40 PPIase activity in vitro, suggesting that TPR mediated 
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changes in the structure of the Cyp40 catalytic domain can assist the formation of a 
more structured and hence active conformation. On the basis of our observations on 
the control of CHIP and PPIase activity by modulators of their TPR domain, we 
suggest a role of this domain in the regulation of protein activity by allosteric control 
of other discrete domains. Whilst writing this thesis a paper was published 
demonstrating that the TRP domain containing Rap protein from Bacillus subtilis 
undergoes gross conformational changes in response to ligand binding to its TPR 
domain, locking the protein in an inactive state [319]. This study gives further 
evidence for TPR domain mediated allosteric control of protein conformation and 
activity. As TPR-domains are involved in pathways, like proteostasis, that are 
fundamental to health and to healthy aging, improving our understanding of TPR 
function and regulation could lead to the development of allosteric regulators that 
modulate the activity of rate-limiting steps in different cellular pathways. 
The second part of this chapter addressed the characterisation and optimisation of an 
aptamer that binds to and inhibits MDM2's RING activity. Two main strategies are 
employed to identify drugs that lead to p53 (re-)activation in cancer cells. One is the 
reactivation of mutant p53 by peptides or small molecules that stabilise its active 
conformation and thus restore p53 DNA binding ability, potentially rescuing its wild- 
type activity [224, 229]. The other is inhibition of MDM2's repressive function on 
p53. MDM2 function towards p53 is targeted either by disruption of the MDM2-p53 
interaction or by inhibition of MDM2's E3 ligase activity in order to block p53 
degradation. A number of drug molecules that bind to MDM2 have been identified 
and are currently explored (reviewed by Wade et al., 2012 [289]). The Ball group has 
identified a C-terminal peptide of the MDM4 RING that inhibits MDM2 E3 ligase 
activity. The peptide was mapped to the MDM2/MDM4 dimer interface and is, 
consequently, likely to inhibit MDM2's dimerization ability. As MDM2 is only 
active as a homo- or heterodimer in complex with MDM4, dimer disruption results in 
decreased activity. The binding affinity and thus inhibitory potential of the natural 
occurring MDM4 peptide was increased through two modifications of the peptide. 
First the negative C-terminal charge was neutralised by the addition of a cap. 
Modelling data indicated that this favours hydrophobic interactions between the 
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peptide and RING surface and, additionally, decreases the de-solvation energy 
required for peptide binding. Second, on the basis of modelling results that suggested 
additional interactions between the N-terminus of T-apt and the MDM2 RING to 
those present in the MDM2/MDM4 crystal structure, the N-terminal lysine of the 
peptide was substituted with a tryptophan residue. The amended peptide displayed a 
strong increase in binding affinity for the MDM2 RING. This demonstrates how a 
peptide from a protein interaction partner can be utilised as a starting molecule for a 
regulatory aptamer and then optimised using modelling approaches combined with 
experimental testing. Further studies are necessary to reveal if the peptide could be 
translated into a potential drug that activates p53. Regardless of its therapeutic 
potential T-apt can be used as a tool to study MDM2 mechanism in vitro and the 
effects of E3 ligase inhibition in vitro and in cells.  
I have shown how E3 ligase activity could be modulated or inhibited by ligand 
binding to their functional domains. For the physiological regulation of E3 ligases, 
this implies that their activity could be altered by either binding of an interacting 
protein, as in the case of Hsp70 binding to CHIP, or by a post translational 
modification, which could either interfere with binding of interaction partners or 
affect protein conformation. For example, acetylation and phosphorylation neutralise 
or create a charge on a side-chain, and this could affect the conformation of a protein. 
Protein modification by ubiquitin can be described as an intermediate of the two. 
Ubiquitin is directly attached to a receptor residue in the target protein but is an 8-
kDa protein in itself. It can therefore be seen as a binding partner on its own that 
would be able to affect an E3 ligase in a similar way as binding of a peptide or 
protein. Interestingly, residues within the CHIP TPR domain, which we showed 
allosterically regulate the catalytic activity of its U-box domain, are subject to 
autoubiquitination. It would be interesting to determine how TPR ubiquitination 
affects the overall flexibly and activity of CHIP, and if TPR or U-box ubiquitination 
affect its ability to interact with specific E2 enzymes. Autoubiquitination site 
mapping on MDM2 shows that similar to CHIP, several functional domains in 
MDM2 are subject to ubiquitination. In addition to E2 interactions, 
autoubiquitination of substrate binding sites, i.e. the p53 binding site in MDM2s 
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hydrophobic pocket and the TPR domain of CHIP, could affect interactions with 
substrates, either blocking the binding site or changing the conformation of the 
E3:E2:ubiquitin:substrate complex. In this way, ubiquitin could amend the scaffold 
provided by the E3 and thereby change the conformation of the E3-E2-ubiquitin 
complex allowing ubiquitin transfer to specific residues on the substrate.  
The physiological relevance of the ubiquitination sites mapped by MS still require 
full validation, however, they indicate that ubiquitination could play a principal role 
in the regulation of E3 ligase activity and its ability to interact with substrates and E2 
enzymes. However, more work is necessary to investigate how and if E3 ligase self-
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Chapter 4: Interplay between IRF-1 
ubiquitination and DNA binding  
4.1 Introduction  
4.1.1 IRF-1 Interactome 
IRF-1 has been shown to be involved in numerous cellular pathways, yet information 
about its interactome is limited. Several proteins that are involved in posttranslational 
modifications of IRF-1 have been identified. The SUMO-E3 ligase PIAS3 binds to 
IRF-1 and, together with the SUMO E2 Ubc9, leads to SUMOylation of lysine 
residues 275 and 299 [320, 321]. IRF-1 is phosphorylated by CK2 at cluster sites 
between aa138-150 and 219-231 [322]. Further, a study in HEK cells showed that 
MyD88 (myelod differentiation primary response gene 88) binding induces IRF-1 
phosphorylytion and translocation, ultimately enhancing its transcriptional activity 
[323]. Additionally, IRF-1 was shown to be bound and acetylated by p300/CBP and, 
furthermore, IRF-1 binding to p300 leads to p53 acetylation and activation [134, 324, 
325]. Both PCAF (p300/CBP associated factor) and GCN5 (general control of amino 
acid synthesis 5) were suggested to enhance acetylation of IRF-1 and thereby be 
involved in its activation [326]. IRF-1 associates with the E3 ligase CHIP, which 
leads to its ubiquitination and degradation under specific stress conditions (see 
1.3.4). Moreover, a number of proteins were shown to bind to IRF-1 and either work 
synergistically to activate transcription e.g. NF-κB [327], HIV-Tat [328] and HPV 
E7 [329], or to repress its function like IRF-8/ICSBP [129] and NPM [330].  
The C-terminal domain of IRF-1 (Mf1 domain, Fig 1-8) directly binds to Hsp70 and, 
furthermore, inhibition of Hsp90 leads to loss of IRF-1 protein while Hsp90 over 
expression decreases IRF-1's rate of degradation [112]. Taken together these results 
indicate that IRF-1 is a client of the Hsp70/Hsp90 chaperone machinery and that this 
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A recent study by the Ball group, utilising affinity chromatography using 
overlapping IRF-1 peptides and subsequent mass spectrometry analysis, has 
identified a region adjacent to the DBD, which was named the Mf2 domain (aa 106-
140, see 1.3.1.2) and this region is involved in interactions with a large number of 
proteins [127]. Several of the known IRF-1 binding partners interact with this region 
e.g. NPM and CK2 and a great number of additional proteins were identified in the 
study, with most still awaiting validation as direct interaction partners of IRF-1. YB-
1 and TRIM28, which have been implicated in transcriptional regulation and cancer 
development, and SET were pulled out by the Mf2 peptides and have been validated 
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4.2 Results 
4.2.1 MDM2 can act as an E3 ligase for IRF-1 in vitro and in 
cells 
Even though, IRF-1 was shown to be regulated by the ubiquitin/proteasome system, 
many details of the mechanism and outcome of IRF-1 ubiquitination remain 
unknown. Results by the Ball group showed that ubiquitination and degradation of 
IRF-1 are signalled by two distinct motifs in the C-terminus of the transcription 
factor and that these two events can be uncoupled, indicating that there might be a 
function of IRF-1 ubiquitination that is separate from its degradation [135]. IRF-1 
was shown to be SUMOylated at residues Lys275 and Lys299 [331], and it was 
suggested that these lysine residues might also function as ubiquitin acceptor sites, a 
mutational study by the Ball group [135], however, found no evidence for an 
involvement of these residues in IRF-1 ubiquitination or degradation. I therefore, set 
out to identify the lysine residues on IRF-1 that are modified by ubiquitin in order to 
gain better insight into the mechanism and outcome of IRF-1 ubiquitination. We 
previously identified CHIP as an E3 ligase for IRF-1 under stress conditions [130]; 
however, an E3 for basal IRF-1 turnover remains elusive. The ball group published 
that the IRF family member IRF-2 is a substrate for MDM2 in vitro and in cells. 
However, IRF-2 is not subject to MDM2-mediated degradation leading us to 
speculate that MDM2 may be involved in the regulation of IRF-2 activity, rather than 
its turnover. Interestingly, the MDM2 binding sites in IRF-2 are conserved in IRF-1 
(Fig 4-1a) and binding site I overlaps with the binding site for CHIP, suggesting that 
the Mf2 domain may comprise a general E3 docking site. As a first step, I set out to 
determine if MDM2 was an E3 ligase that binds and ubiquitinates IRF-1, in order to 
use MDM2 as a tool to study IRF-1 ubiquitination. Therefore in vitro binding and 
ubiquitination assays were performed. When GST–IRF-1 was immobilized on a 
microtiter plate and incubated with a titration of MDM2 in the mobile phase, the 
results showed that MDM2 bound to IRF-1 in a dose-dependent manner (Fig 4-1b, 
left panel). To identify the binding interface between MDM2 and IRF-1, a peptide–
protein interaction assay was used. An overlapping IRF-1 peptide library (Table 2-6) 
was immobilized and incubated with a constant amount of MDM2 in the mobile 
phase; binding was then detected using an anti-MDM2 antibody. MDM2 bound to an 
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IRF-1 peptide from within the Mf2 domain (peptide 8, 
VRVYRMLPPLTKNQRKERKS; Fig 4-1b right panel) with homology to the 
MDM2-binding site-I of IRF- 2 (Fig 4-1a). This is the same interface where CHIP 
has been shown to interact with IRF-1, indicating that this could be a common 
docking site for multiple E3 ligases on IRF-1. To establish that IRF-1 can act as a 
direct substrate for MDM2 in vitro, I employed a minimal ubiquitination assay using 
only purified components, results of the assay showed that there was a positive 
correlation between the efficiency of IRF-1 ubiquitination and the concentration of 
MDM2 added to the assay (Fig 4-1c). To verify that the results obtained in the in 
vitro experiments are relevant in cells, I determined the interaction between IRF-1 
and MDM2 in HCT-116 cells. I asked whether MDM2 was detectable after isolation 
of IRF-1 complexes using a FLAG pull-down, and whether the loss of the Mf2 
domain affected binding. The results show that IRF-1 WT forms a complex 
containing MDM2 in cells (Fig 2a, lanes 2 and 5), whereas an IRF-1 Mf2 deletion 
mutant (Δ106–140) is not associated with MDM2 (lanes 3 and 6). In order to 
investigate, whether MDM2 is able to ubiquitinate IRF-1 in unstressed cells, in-cell 
ubiquitination assays using His–ubiquitin, IRF-1 and MDM2 (Fig 4-2b) were 
assembled in HCT-116 cells. After isolation and analysis of His-ubiquitinated 
proteins, an increase in the amount of ubiquitinated IRF-1 was seen in the presence 
of MDM2 (Fig 4-2b; compare lane 7 with lane 8), showing that under these 
conditions MDM2 can mediate ubiquitination of IRF-1 in cells. Whether 
ubiquitination of IRF-1 by MDM2 leads to its degradation and thus affects its half-
life was determined using HCT-116 cells transfected with MDM2 and treated with 
the protein synthesis inhibitor cycloheximide. The loss of endogenous IRF-1 protein 
was then monitored over time by immunoblot analysis (Fig 4-2c). The results show 
that MDM2 overexpression did not lead to a decrease in the half-life of IRF-1; rather 
it gave a slight, but reproducible, increase in its half-life. This result shows that even 
though MDM2 facilitates IRF-1 ubiquitination, this is not sufficient to signal its 
degradation, suggesting that MDM2 may be involved in the regulation of IRF-1 
activity rather than its rate of degradation as seen previously for IRF-2. 
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Figure 4-1 MDM2 binds and ubiquitinates IRF-1 in vitro 
(a) Alignment of the two MDM2-binding motifs on IRF-2 with the homologous regions from 
IRF-1. (b) GST–IRF-1 (100 ng) was immobilized on a microtiter plate and incubated with a 
titration (0–100 ng) of MDM2. Protein binding was detected using an anti-MDM2 mAb and 
the protein amount against binding is expressed as relative light units (RLU). Biotin-tagged 
IRF-1 peptides (60 pmol/well, 20 amino acids with a five amino acid overlap) were 
immobilized on a microtiter plate and incubated with 100 ng of MDM2. MDM2 binding to 
the peptides was detected using an anti-MDM2 mAb and is expressed in RLU. (c) An 
ubiquitination assay was carried out using GST–IRF-1 as the substrate, increasing amounts 
of MDM2 as the E3 ligase (0–160 ng), 10	  μM	  ubiquitin, 100 nM UBE1, 1	  μM	  UbcH5a and 
4.5 mM ATP and incubated for 15 minutes (the same concentration of ubiquitin, UBE1, 
UbcH5a and ATP was used in all in vitro ubiquitination assays in this chapter).  The samples 
were analysed using SDS/PAGE and immunoblot with an anti-IRF-1mAb. 	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Figure 4-2 MDM2 can act as an E3 ligase for IRF-1 in cells 
(a) HCT-116 cells were co-transfected with 2 µg of pcDNA3-MDM2 or pcDNA3-empty 
vector and 2 µg of FLAG–IRF-1WT, IRF-1ΔMf2 or empty vector. FLAG conjugates were 
immunoprecipitated using anti-FLAG-M2 agarose. After elution, samples and lysate (25 µg) 
were analysed by immunoblotting using an anti-MDM2 mAb and anti-FLAG mAb. (b) 
HCT-116 cells were co-transfected with pcDNA3-IRF-1 (0.5 µg), His–ubiquitin (0.5 µg) and 
pcDNA3-MDM2 (2 µg) as shown. Post-transfection (20 hours), cells were treated with 
MG132 (50 µΜ) for 4 hours and histidine-labelled ubiquitinated protein was isolated using 
Ni-NTA chromatography. Samples were analysed by SDS/PAGE and immunoblot using an 
anti-IRF-1 mAb. Total amounts of IRF-1 in the sample (bottom panel) and modified IRF-1 
(top panel) are shown (right panel, data courtesy of Emmanuelle Pion). (c) Immunoblot 
analysis of HCT-116 cells transfected with the indicated amounts of pcDNA3-MDM2 
following cycloheximide (30 µg/ml) treatment. Cells were harvested at the times shown and 
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4.2.2 MDM2 and CHIP mediate ubiquitination of IRF-1's DBD 
To investigate the role of E3 ligase docking to the Mf2 domain, I first asked whether 
the Mf2 binding E3 ligases, CHIP and MDM2, ubiquitinate common or distinct 
lysine residues by mapping sites of modification using mass spectrometry (MS). 
First, in vitro ubiquitination of IRF-1 by CHIP and MDM2 was characterised by 
performing a time course of ubiquitination in vitro. Results show a time dependent 
increase of IRF-1 ubiquitination by both CHIP (Fig 4-3a, left-hand panel) and 
MDM2 (right-hand panel). To examine if ubiquitination of IRF-1, facilitated by the 
two enzymes leads to mono- or polyubiquitination, a time course of in vitro IRF-1 
ubiquitination of up to 180 minutes was analysed using antibodies that detect only 
polyubiquitinated conjugates or both mono- and polyubiquitin conjugates (Fig 4-3b). 
This showed that CHIP generates both poly- and monoubiquitination of IRF-1; no 
signal at the size of IRF-1 was detected when MDM2 was used as the E3 ligase. 
Indicating that in vitro ubiquitination of IRF-1 by MDM2 was not as efficient as by 
CHIP under the utilised conditions. Both poly- and monoubiquitination can be 
observed at the top of the gel, at a size corresponding to MDM2 itself, indicating 
strong autoubiquitination of MDM2 in the assay.  
For the identification of ubiquitination sites by mass spectrometry, IRF-1 was 
ubiquitinated for either 10 or 45 minutes and discrete ubiquitinated intermediates 
were excised and subjected to in-gel digestion using trypsin and subsequent analysis 
by MS (Fig 4-4a; for an outline of the experimental procedure see Fig 3-14).  
Although there are a total of 23 lysine residues in the primary amino acid sequence 
of IRF-1, only a subset of those were detected by MS as being ubiquitin-acceptor 
sites for the Mf2-binding ligases CHIP or MDM2 (Fig 4-4b). Strikingly, IRF-1 was 
predominantly ubiquitinated in, or adjacent to, the DBD and no modified residues 
from within the C-terminal half of the protein were detected with either of the E3 
ligases. Although both MDM2 and CHIP modified Lys39, Lys50 and Lys117, no 
modification of IRF-1 at Lys95 was detected by CHIP, whereas this residue was 
modified when MDM2 provided the E3 activity. Similarly, Lys78 was detected only 
in the CHIP-ubiquitinated samples. Although this difference in specificity remains to 
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be confirmed using a second analytical technique, the existing data suggest that 
although Mf2-directed ubiquitination of IRF-1 is specific for the DBD, there could 
be subtle differences in the exact residues targeted by MDM2 and CHIP and thus in 
the molecular signal of the modification. 
 
4.2.3 Ubiquitination of IRF-1 residues Lys39, Lys50 and Lys78 
appears mutual exclusive 
In order to gain a structural insight in the effect of IRF-1's DBD ubiquitination on the 
overall shape and surface of the domain, models of the DBD in its ubiquitinated state 
were computed using the HADDOCK web server [271, 297]. The model was 
generated using the C-terminal glycine on ubiquitin and either one of the ubiquitin 
acceptor residues present in the crystal structure as docking sites (active residues 
Lys39, Lys50, Lys78 and Lys95) (Fig 4-5). Interestingly, modelling suggests that 
modification at three of the five ubiquitination sites (Lys39, Lys50 and Lys78) would 
result in ubiquitin occupying an overlapping three-dimensional space. Thus, 
ubiquitination at any one of these three sites could potentially block modification at 
the other two sites. To further investigate this model experimentally in vitro 
ubiquitination assays, using either WT ubiquitin or an ubiquitin mutant in which all 
of the lysine residues were mutated to arginine (NoK ubiquitin), were performed. For 
the majority of E3 ligases, NoK ubiquitin can only result in the formation of 
monoubiquitinated residues, as chain elongation is not possible (linear ubiquitin 
chain formation by M1 is an exception to this). I found that the ubiquitin mutant was, 
in general, a poor substrate for in vitro ubiquitination, with slower conversion of 
IRF-1 into its monoubiquitinated form, than was seen in the presence of WT 
ubiquitin. However, when assay conditions were adapted to facilitate ubiquitination I 
saw that monoubiquitination provided a maximum of three ubiquitins added per IRF-
1 molecule, and in the case of MDM2 a single ubiquitinated form predominanted 
(Fig 4-6a; compare lanes 3 and 5 with lanes 2 and 4), suggesting that a maximum of 
three out of the five ubiquitin-acceptor sites identified could be modified at any one 
time. If the modelling was correct it would predict that mutation of Lys39, Lys50 and 
Lys78 individually would not be sufficient to affect IRF-1 DBD monoubiquitination. 
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To complement the above approach a series of IRF-1 point mutant proteins were 
therefore generated in which Lys39, Lys50 and Lys78 were individually mutated to 
arginine. When the mutant proteins were used as substrates for CHIP in the presence 
of NoK ubiquitin, loss of Lys39 and Lys78 did not produce qualitative or quantitative 
changes in monoubiquitination of IRF-1, consistent with the idea that ubiquitination 
at either one of these residues produces a similar outcome and that ubiquitination at 
these two sites is mutually exclusive. Although mutation of Lys50 did have an effect 
on monoubiquitination, with loss of the slowest migrating ubiquitinated form of IRF-
1, this mutant was susceptible to cleavage during expression and the cleavage 
product was also a substrate for CHIP (Fig 4-6b faster migrating band in K50R 
sample), making these data difficult to interpret. When double or triple mutants were 
constructed to further study the role of specific residues, the resultant proteins were 
extremely susceptible to cleavage during expression and could consequently not be 
used in in vitro experiments. Taken as a whole, the data in this section support the 
modelling data and suggest that ubiquitination of Lys39 and Lys78, and potentially 
Lys50, are mutually exclusive and might, therefore, result in the generation of a very 
similar ‘molecular signature’. 
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Figure 4-3 Ubiquitination of IRF-1 by CHIP and MDM2 in vitro 
(a) Time course (0–30 min) of an in vitro ubiquitination assay of IRF-1 modified by His–
CHIP (50 ng) (upper panel) and MDM2 (80 ng) (lower panel), analysed with an anti-IRF-1 
mAb. (b) Time course (0–180 min) of an in vitro ubiquitination assay of IRF-1 modified by 
His–CHIP (50 ng) and MDM2 (80 ng), analysed with antibodies recognizing only poly- 
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Figure 4-4 IRF-1 is exclusively ubiquitinated in its DNA-binding domain 
 (a) GST–IRF-1 was ubiquitinated using an in vitro ubiquitination assay with CHIP or 
MDM2 as the E3 ligase and isolated from the reaction mix using glutathione beads. A 
Colloidal-Blue-stained gel before band excision for MS analysis (left-hand panel) and 
immunoblot analysis of the samples blotted for IRF-1 and CHIP (right-hand panel) are 
shown. CHIP was co-purified from the reaction with IRF-1 as a result of IRF-1–CHIP 
protein interactions. (b) Results of MS analysis of modified peptides in IRF-1. Lysine 
residues that were shown to be modified by ubiquitin are highlighted in red. (c) Modified 
lysine residues are indicated on a schematic IRF-1 domain structure. Lysine residues that are 
modified by only MDM2 or CHIP are shown in red, whereas residues that are modified by 
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IRF-­1  peptide        Modified  Lysine     Domain        Mascot  Score  
HAAKHGWDINKDACLFR   K39         DBD         18.91
HGWDINKDACLFR      K50         DBD         20.08
YKAGEKEPDPK      K70         DBD         6.48
YKAGEKEPDPKTWK     K78         DBD         12.75
MLPPLTKNQR                  K117         DBD/Mf2      23.96
  
CHIP
IRF-­1  peptide        Modified  Lysine     Domain        Mascot  Score  
HAAKHGWDINK      K39         DBD         18.49
HGWDINKDACLFR      K50         DBD         12.45
YKAGEKEPDPK      K70         DBD         7.26
CAMNSLPDIEEVKDQSR   K95         DBD         31.54
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Figure 4-5 Model of monoubiquitinated IRF-1 
(a) Ubiquitin was modelled on to the IRF-1 DBD at the ubiquitin receptor lysine residues 
present in the crystal structure (Lys39, Lys50, Lys78 and Lys95) using the HADDOCK web 
server (detailed in section 2.8.1). From the results obtained the four best structures from the 
three best clusters were analysed. The overlay of the ubiquitin position in respect to IRF-1 
for each lysine residue is shown, with ubiquitin in structures obtained from different clusters 
in different colours. (b) Model of ubiquitinated IRF-1. Ubiquitin was modelled on to the 
available crystal structure of the IRF-1 DBD (PDB:1IF1) (white) using the HADDOCK web 
server at Lys39 (green), Lys50 (yellow), Lys78 (red) and Lys95 (blue), the structure that 
obtained the highest score for each site (left-hand panel) and the three structures obtaining 
the highest score in one of the three best clusters for each site (right-hand panel) are shown. 
ubiquitin
  at  K95  
ubiquitin  at
K39,  K50  and    K78
ubiquitin
  at  K95  
ubiquitin  at
K39,  K50  and    K78
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Figure 4-6 Ubiquitination of lysine residues K39, K50 and K78 appears mutual 
exclusive 
 (a) In vitro ubiquitination of IRF-1 with CHIP and MDM2 as E3 ligases and either WT or 
NoK ubiquitin (in which all lysine residues are mutated to arginine). Reactions with WT 
ubiquitin were incubated for 10 minutes, whereas the reactions with no E3 ligase and NoK 
ubiquitin were incubated for 60 minutes. (b) In vitro ubiquitination assay with GST-IRF-1 
containing the indicated mutation at one of the ubiquitin-acceptor lysine residues, NoK 
ubiquitin and CHIP as the E3 ligase; the reactions were incubated for 45 minutes.  
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4.2.4 Ubiquitin receptor residues Lys78 and Lys95 are directly 
involved in DNA binding 
When the ubiquitin-modified residues were mapped on to the available IRF-1 DBD 
crystal structure (PDB:1IF1), we found that Lys39, Lys50 and Lys95 were located in 
exposed loops (L1, L2 and L3), whereas Lys78 was positioned within the α3-helix 
which forms the second helix of the HTH (helix–turn–helix) homologous motif (Fig 
4-7, upper panel). Strikingly, residues Lys78 and Lys95 lay very close/within the DNA 
binding interface (Fig 4-7, lower panels). To determine if these residues are actively 
involved in DNA-interactions between IRF-1 and its consensus sequence at the 
promoters, molecular dynamic simulation of the IRF-1 DBD in association with 
DNA were carried out and the binding energy between the protein and DNA was 
computed. Decomposition analysis of the residues involved in the interaction using 
MMGBSA (Ambertools) shows that Lys78 is one of the most important residues 
mediating IRF- 1 DNA interactions and an additional involvement in Lys95 in the 




4. Results  156 
 
Figure 4-7 Position of ubiquitination sites on the IRF-1 DBD crystal structure 
Crystal structure of the IRF-1 DBD (PDB code 1IF1) with lysine residues that were shown to 
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Figure 4-8 IRF-1 residues that are involved in DNA binding 
(a) Molecular simulations were carried out on IRF-1 DBD (PDB:1IF1) and residues involved 
in DNA interactions were identified by decomposition analysis. (b) Crystal structure of IRF-
1DBD shown as cartoon, with results identified as playing a major role in DNA interactions 
in the simulations indicated as sticks. 
 
Residue   DC  Score   Structure  
ARG  9     -­  8.52   N  –  terminal  
TRP  11   -­  6.34     1  
LEU  12     -­  3.22     1  
TRP  38   -­  3.15   L  1  
HIS  40     -­  5.8   L1  
ALA  41   -­  3.59   L1  
LYS  43   -­  7.55   L1  
ARG  64   -­  6.21     2  
LYS  75     -­  3.19     3  
LYS  78   -­  7.19     3  
ARG  82   -­  8.07     3  
LYS  95   -­  4.9   L  3  
ARG  99   -­  5.66   L  3  















4. Results  158 
4.2.5 DNA-bound IRF-1 is protected from ubiquitination in 
vitro 
As the ubiquitin-acceptor sites are all located within the DBD, with Lys78 and Lys95 
being at the DNA-binding interface and directly involved in interaction, we reasoned 
that modification might be affected by the sequence-specific DNA-binding activity 
of IRF-1. To test this, a consensus site DNA oligonucleotide (C1) was utilised, which 
I show can bind to GST–IRF-1WT (Fig 4-9, lanes 3–5) in an EMSA and is 
supershifted by an anti-IRF-1 mAb. To control for effects of DNA binding in 
subsequent experiments an IRF-1 DNA binding mutant with a single mutation from 
Trp to Arg was used (W11R). Analyses of the DNA binding ability of the mutant 
shows that binding to DNA is completely abolished (lanes 6–9), decomposition 
analysis of the binding energy between IRF-1 and DNA in molecular dynamic 
simulations shows that this residue is directly involved in and important for the 
interaction (Fig 4-8). To characterise this mutant further, molecular dynamic 
simulation of both IRF-1WT and IRF-1W11R were carried out in the absence of DNA. 
Results of the simulation, which are presented in Fig 4-10, suggest that a mutation at 
Trp11 to Arg has an effect on the overall shape of the IRF-1 DBD. The introduced 
arginine forms salt-bridges with side chains Glu13, Asp90 and additionally interacts 
with the backbone of Ser87. These interactions result in conformational changes, 
involving the positioning of loop 3 closer to the N-terminus of IRF-1 (Fig 4-10a). In 
turn, these changes lead to higher flexibility in loop 1, as shown by fluctuation 
analysis (Fig 4-10b), loop 1 is directly involved in DNA interactions, and it can be 
assumed that the changes in its dynamics, together with overall conformational 
changes in the DBD in the Arg mutant result in a strong decrease of its DNA binding 
ability.  
To examine the effects of DNA binding on IRF-1 ubiquitination, IRF-1 was pre-
incubated with C1 DNA or a control oligonucleotide that does not interact with IRF-
1 (p21c) (Fig 4-9, lanes 7– 10). Whereas control DNA (p21c) had no significant 
effect on the ubiquitination of IRF-1 by CHIP (Fig 4-11a, left-hand panel) or MDM2 
(right-hand panel), addition of IRF-1 consensus site DNA (C1) almost completely 
suppressed ubiquitination. To control for non-specific effects of DNA on IRF-1 the 
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non-DNA binding mutant IRF-1W11R was used and determined whether this was 
refractive to the effects of DNA. Figure 4-11a shows that whereas C1 
oligonucleotides inhibit the ubiquitination of wild-type IRF-1 (lanes 4 and 5) they 
had no significant effect on the ubiquitination of IRF-1W11R (lanes 9 and 10). As an 
additional control we showed that C1 DNA did not affect CHIP activity directly as 
there was no effect on the ability of CHIP to mediate autoubiquitination (Fig 4-11a, 
bottom left panel). Ubiquitination of p53, a second well characterized substrate for 
both CHIP (Fig 4-11b, left-hand panel) and MDM2 (Fig 4-11b, right-hand panel), 
was not affected by p53 binding to DNA from the p21 promoter (p21c DNA), 
suggesting that protection of IRF-1 from ubiquitination by DNA is a specific 
property of this transcription factor (Fig 4-11b). 
To expand on the observation described above, which used an optimized IRF-1 
consensus DNA oligonucleotide, a range of oligonucleotide probes based on 
naturally occurring binding elements from IRF-1 target gene promoters was 
examined. Elements from all IRF-1 target genes tested were able to inhibit CHIP- 
and MDM2-mediated ubiquitination, and there was good agreement between the 
ability of IRF-1 to bind DNA in an EMSA (Fig 4-12, bottom panel) and the ability of 
the oligonucleotide to inhibit ubiquitination of IRF-1 in an in vitro ubiquitination 
assay (Fig 4-12, top panels). For example, IRF-1 binds only weakly to an 
oligonucleotide based on the TRAIL promoter and this probe is a weak inhibitor of 
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Figure 4-9 IRF-1WT but not a W11R mutant specifically binds to the ISRE sequence in 
vitro 
EMSA showing binding of a titration (100 and 300 ng) of purified GST–IRF-1WT or of the 
DNA-binding mutant GST–IRF-1W11R to a 32P-labelled DNA probe of C1 DNA (left-hand 
panel) or binding of GST-IRF-1WT to the C1 probe compared with the non-binding control 
probe (p21c) (right-hand panel). When indicated an anti-IRF-1 mAb was added to the 
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Figure 4-10 Effect of W11R mutation on IRF-1 structure 
(a) Snapshot of molecular dynamic simulation of the IRF-1 DBD WT or W11R after 50 ns in 
the absence of DNA. Changes in the conformation of the DBD by substitution of Trp11 to 
Arg are indicated. (b) Averaged fluctuation of Cα atoms of all amino acids in the simulation 
after an initial stabilisation period. The corresponding three-dimensional is shown above the 
graph with α=α-helix, β=β-sheet and L=loop. Regions of higher flexibility in the mutant are 
indicated by yellow/orange bars.  
IRF-­1  WT                    IRF-­1  W11R
Interactions  of  Arg  with  
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ASP  90  
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Figure 4-11 DNA bound IRF-1 is protected from ubiquitination in vitro 
 (a) In vitro ubiquitination assay using GST–IRF-1WT and GST–IRF-1W11R as substrate with a 
titration of either C1 oligonucleotides or p21c DNA (0.25 and 1 µM) using CHIP (left-hand 
panel) or MDM2 (right-hand panel) as the E3 ligase. (b) In vitro ubiquitination assay with 
p53 as the substrate and a titration of p21 promoter DNA (10 nm–1 µM) or C1 DNA (500 
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Figure 4-12 The ability of oligonucleotides to inhibit ubiquitination correlates to their 
binding affinity for IRF-1 
The effects of oligonucleotides from promoters of different IRF-1-inducible genes (3 µM) 
were tested on the ubiquitination of IRF-1 by CHIP (top left-hand panel) and MDM2 (top 
right-hand panel) and compared with the ability of GST–IRF-1 (300 ng) to bind to the 
oligonucleotides in a band-shift assay (bottom panel). Where indicated, an anti-IRF-1 
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4.2.6 IRF-1 bound to DNA is unable to associate with proteins 
that interact with its Mf2 domain 
There are at least two possible mechanisms that could explain the loss of IRF-1 
ubiquitination when in its DNA-bound form; first the targeted lysine residues may be 
‘cryptic’ and consequently inaccessible to the ligases, or secondly, the ability of IRF-
1 to bind to CHIP or to MDM2 may be impaired. As the available structural data for 
the DBD of IRF-1 bound to its consensus DNA sequence [124] suggests that at least 
some of the required lysine residues are still available for ubiquitination (Fig 4-7; for 
example Lys50), I went on to investigate the second option, i.e. a change in the 
affinity of IRF-1 for Mf2-binding proteins. I therefore, studied the effects of IRF-1 
DNA binding on its ability to interact with MDM2 and CHIP. Protein-interaction 
assays were used to measure CHIP binding to IRF-1 protein that had been pre-
incubated with either C1 oligonucleotide or control DNA (p21c). Initial titrations 
demonstrated binding of native unliganded IRF- 1 in solution to immobilized CHIP 
in a dose-dependent manner (Fig 4-13a, left-hand panel). On the basis of this assay, a 
fixed amount of CHIP was immobilized and incubated with a constant amount of 
IRF-1 that had been pre-incubated with a titration of either C1 or p21c. Figure 4-13a 
(right-hand panel) shows that whereas IRF-1 binding to CHIP was largely unaffected 
by p21c, titration of C1 into the assay inhibited CHIP binding. The results of this 
assay suggest that stable binding of CHIP to IRF-1 is severely restricted when IRF-1 
is in its DNA-bound form. Similarly, when I tested binding of MDM2 to IRF-1 in its 
DNA-bound and -unbound form, MDM2 bound preferentially to the unbound form 
of IRF-1 (Fig 4-13b). The docking site of MDM2 and CHIP on IRF-1, the Mf2 
domain, is a multi-protein-binding site that interacts with a number of other IRF-1 
regulators [127], I was thus interested to investigate whether DNA binding also 
affects the interactions of other Mf2 domain interactions proteins with IRF-1. The 
effects of DNA binding on the interaction between IRF-1 and Kap-1, SET and NPM 
were tested individually. Figure 4-13b shows reduced binding of IRF-1 to all Mf2 
interacting proteins used in this assay when in its DNA-bound state. The crystal 
structure of the IRF-1 DBD in complex with its cognate promoter-binding element 
suggests that residues from within the Mf2 domain are not required for DNA 
binding; hence the results of the present study can be interpreted in two way's (i) that 
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access to the Mf2 interface is controlled through changes in the conformation of IRF-
1 rather than through direct competition or (ii) that even though the E3 ligases do not 
bind directly to the DBD, binding of DNA would sterically inhibit access of the 
proteins to the binding site. To test whether CHIP and MDM2 binding had a 
reciprocal effect on DNA binding I examined whether the ligases could compete 
with DNA for binding to IRF-1 using an EMSA (Fig 4-14). Neither CHIP nor 
MDM2 had any effect on the ability of IRF-1 to bind to DNA, suggesting that IRF-1 
has a higher affinity for DNA than for the Mf2-binding protein. 
In summary, the experiments presented here suggest that Mf2-domain-binding 
partners are likely to function only on the unliganded form of IRF-1. Furthermore, 
the observation that neither MDM2 nor CHIP is able to ubiquitinate IRF-1 unless 
they are bound to the protein, lends strong support for a direct relationship between 
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Figure 4-13 IRF-1 bound to DNA is unable to associate with proteins that interact with 
its Mf2 domain 
 (a) His–CHIP (100 ng) was immobilized on a microtiter plate and incubated with either a 
titration of purified GST–IRF-1 alone (0–100 ng) (left-hand panel) or with constant amounts 
of GST–IRF-1 (100 ng) and a titration of C1 DNA or p21c DNA (right-hand panel). (b) 
Different Mf2-domain-binding proteins, MDM2, SET, Kap-1 and NPM, were immobilized 
on a microtiter plate (100 ng) and incubated with GST–IRF-1 (100 ng) and C1 or p21c DNA 
(100 nM). Binding was detected using an anti-IRF-1 mAb. 
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Figure 4-14 MDM2 or CHIP do not affect the ability of IRF-1 to interact with DNA in 
vitro 
EMSA presenting binding of 300 ng of purified GST–IRF-1WT to a 32P-labelled DNA probe 
of C1 DNA in the presence of 0.3 or 1.5 µg of purified His–CHIP or MDM2 as shown. 
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4.2.7 Ubiquitination of IRF-1 in cells is enhanced in a DNA-
binding mutant 
Taken together, the above observations led us to hypothesize that IRF-1 is protected 
from ubiquitination, and therefore presumably from degradation, when it is in its 
transcriptionally active DNA-bound conformation. To study this hypothesis, I 
determined whether the W11R non-DNA-binding mutant of IRF-1 was more or less 
prone to ubiquitination than the wild type protein. I first confirmed that specific 
DNA did not inhibit binding of CHIP to IRF-1W11R in vitro using a protein– protein 
interaction assay. CHIP was coated onto a microtiter plate and incubated with IRF-1 
plus a titration of C1 DNA (Fig 4-15a). As expected, C1 DNA inhibited binding of 
IRF-1WT to CHIP, whereas binding of CHIP to IRF-1W11R was not affected by the 
presence of DNA. To determine if there were any intrinsic differences in the ability 
of W11R to act as a CHIP substrate, I compared the ubiquitination profile of wild-
type and W11R mutant IRF-1 in vitro. CHIP ubiquitinated both IRF-1WT and IRF-
1W11R to a similar extent in vitro (Fig 4-15b). Next in cell ubiquitination assays were 
carried out in HCT-116 cells using IRF-1WT and IRF-1W11R. When histidine-labelled 
ubiquitinated proteins were isolated from cells that had been transfected with either 
IRF-1WT or IRF-1W11R together with His–ubiquitin we found that the IRF-1W11R 
mutant was hyperubiquitinated when compared with the WT protein (Fig 4-15c, 
compare lanes 3 and 4). Thus all used experiments support the idea that IRF-1, which 
is not chromatin associated is more ‘available’ or susceptible to ubiquitination by 
endogenous Mf2-domain-interacting ligases. Thus, although CHIP ubiquitinates 
IRF–1WT and IRF-1W11R to a similar extent in vitro, in cells the Trp11 mutant is 
preferentially ubiquitinated, supporting the concept that free IRF-1 may be turned 
over more rapidly than the pool of IRF-1 that is bound, or able to bind, to DNA. 
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Figure 4-15 Ubiquitination of IRF-1 in cells is enhanced in a DNA-binding mutant 
(A) His–CHIP (100 ng) was immobilized on a microtiter plate and incubated with constant 
amounts of either GST–IRF-1WT or GST–IRF-1W11R (100 ng) and a titration of C1 or p21c 
probe. (B) In vitro ubiquitination assay using GST–IRF-1WT or GST–IRF-1W11R as substrate 
with a titration of His–CHIP (0–60 ng). (C) HCT-116 cells were co-transfected with 
pcDNA3-IRF-1WT or pcDNA3-IRF-1W11R (0.5 µg) and His–ubiquitin (0.5 µg) as shown. 
At 20 hours post-transfection cells were treated with MG132 (50 µM) for 4 hours and 
histidine-labelled ubiquitinated protein was isolated using Ni-NTA chromatography and 
analysed by SDS/PAGE and immunoblotting. Total amounts of IRF-1 in the sample (bottom 
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4.2.8 CHIP preferentially ubiquitinates folded substrates 
As CHIP binding to IRF-1 is required to facilitate its ubiquitination and because 
DNA binding either sterically inhibits CHIP binding or leads to conformational 
changes that do not allow CHIP to bind, I was interested to determine whether the 
conformation of IRF-1 is an essential determinant for its ability to act as a substrate 
for CHIP. In a first step, I determined the thermostability of IRF-1. Specifically, FL 
GST-IRF-1 was incubated for 5 or 15 minutes at 30, 40, 50, 60, 70 or 80°C either in 
the presence or absence of C1 DNA and subsequently its ability to bind to C1 DNA 
was determined using an EMSA (Fig 4-16). The results of this assay show that IRF-1 
in an unbound conformation is less thermostable than when associated with DNA 
and looses its DNA binding activity at temperatures over 40°C, with complete loss at 
a temperature over 50°C. IRF-1 bounds to its cognate DNA sequence, on the other 
hand, exhibits higher stability and remains active for DNA binding at temperatures 
up to 50°C. The tumour suppressor protein p53 is extremely thermo-unstable and 
looses DNA binding ability at a temperatures over 37°C in vitro [332]. 
Conventional wisdom would suggest that the unfolded, soluble protein should be an 
ideal substrate for CHIP due to its role in the protein triage pathway, where it targets 
misfolded proteins for degradation. In order to investigate how unfolding affects 
IRF-1’s and p53's ability to act as a substrate for CHIP mediated ubiquitination, first 
the ability of CHIP to interact with heat inactivated, soluble IRF-1 or p53 was 
determined using a protein-protein interaction assay. CHIP was coated onto a 
microtiter plate and incubated with a titration of GST-IRF-1 or p53, which had been 
pre-incubated at either 4, 42 or 52°C (Fig 4-17a) and then centrifuged at high speed 
to ensure that the protein was soluble rather than denatured aggregates. Interestingly, 
CHIP preferentially binds to folded proteins, with a loss in binding correlated to 
heating temperature of IRF-1 or p53. To determine if this loss in binding is reflected 
in the ability of CHIP to act as E3 ligase, in vitro ubiquitination assays were 
assembled, using CHIP as the E3 ligase and GST-IRF-1 or p53, folded or heat 
inactivated, as substrates. Results of this assay (Fig 4-18) show a positive correlation 
between the decrease in CHIP's ability to facilitate ubiquitination of IRF-1 and p53 
and the temperature at which the proteins had been incubated prior to the assay. It 
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has to be noted that strong ubiquitination can lead to the formation of high molecular 
mass adducts that can not be detected on the gel and therefore ubiquitination can 
results in loss of the protein signal on the gel (see Fig 4-18, lane 2+3 for IRF-1 and 
p53).  
The above result are surprising, as CHIP has been described as a major player in the 
cell's triage decision, targeting proteins that are denatured, beyond the possibility to 
be refolded by chaperones, for degradation. We would, therefore, expect CHIP to be 
able to bind to and ubiquitinate substrates in their unfolded conformation. As CHIP 
works both as a direct binding ligase and as a chaperone associated E3 ligase (see 
Chapter 3), we were interested to find out if the Hsp70/Hsp40 chaperones had an 
effect on CHIP's ability to act as an E3 ligase for heat inactivated substrates. In vitro 
ubiquitination assays were assembled as above, with IRF-1 and p53 pre-incubated at 
4 or 52°C, CHIP as the E3 ligase and a titration of Hsp70/Hsp40 (ratio 1:10). The 
results of the assay show that whereas Hsp70/40 inhibit ubiquitination of both IRF-1 
and p53 by CHIP, when the substrates are in their native conformation (discussed in 
detail in Chapter 3), they had no inhibitory activity and in the case of p53 even 
increase ubiquitination, when the unfolded proteins were provided to CHIP as the 
substrate. This suggests two distinct roles of CHIP as an E3 ligase (i) it acts as a 
direct E3 ligase on folded substrates (as shown for IRF-1 by Narayan et al.[130]) and 
(ii) it ubiquitinates unfolded substrates in a Hsp70 dependent manner as part of the 
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Figure 4-16 IRF-1 is more temperature sensitive in its free, DNA unbound 
conformation 
GST-IRF-1 was incubated in the absence or presence of C1 done at increasing temperature 
(incubation time and temperature as indicated), subsequently the ability of 100 ng IRF-1 to 
bind a 32P-labelled DNA probe of C1 was determined using in an EMSA.  
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Figure 4-17 CHIP preferentially binds and ubiquitinates folded IRF-1 and p53 protein 
(a) His-CHIP was immobilised on a microtiter plate and incubated with increasing amounts 
of GST-IRF-1 (left panel) or p53 (right panel) that had been pre-incubated at the indicated 
temperatures for 5 minutes. Binding of the two proteins was detected using an IRF-1 or p53 
mAbs respectively. (b) In vitro ubiquitination assay with GST-IRF-1 (left panel) or p53 
(right panel), that was pre-incubated for 5 minutes at the indicated temperatures, with CHIP 
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Figure 4-18 Hsp70 inhibits ubiquitination of folded, but not denatured CHIP substrates 
In vitro ubiquitination assay with CHIP, a titration of Hsp70/40 (ratio 1:10) (3, 6, 15 µM 
Hsp70) and IRF-1 (upper panel) or p53 (lower panel) that were pre-incubated at 4 or 52°C 
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Figure 4-19 Model of interplay between DNA binding of IRF-1 and 
binding/ubiquitination by its E3 ligases 
The Mf2 domain is a multi E3-ligase-docking site in close proximity to the DBD of IRF-1. 
Binding of E3 ligases to the Mf2 domain results in ubiquitination of the proximal DBD and 
this leads to the proteasomal degradation of IRF-1. In complex with DNA or in a denatured 
conformation, however, IRF-1 is unable to bind E3 ligases, is not ubiquitinated and thus 
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4.3 Discussion  
In recent years ubiquitination has been linked to a wide variety of cellular effects and 
it is now apparent that ubiquitin modification is involved in not only the proteasomal 
degradation system, but also serve as a molecular signal in a wide variety of cellular 
pathways [6, 8]. This raises the question of how the ubiquitin reaction is controlled to 
lead to different outcomes. Differences in the result of ubiquitination can be achieved 
by two factors, the linkage and length of the ubiquitination chain and the position of 
the target lysine in the acceptor protein [28]. However, how interplay between E3 
and E2 leads to ubiquitination of specific residues remains largely unclear. One 
proposed mechanism is that the E3 positions the charged E2 in close proximity to the 
target lysine and thereby determines which residue is subject to modification [28]. 
Analysis of the UbcH5c - ubiquitin complex by both NMR and SAXS [333] has 
shown that the conjugate is very flexible and can exhibit a range of conformations in 
solution, explaining how one E3 ligase can result in ubiquitination of different lysine 
within one target protein. Here, the flexibility of the E2 enzyme could be restricted 
by binding of an E3 and thus result in targeting of specific lysines in the substrate. 
The data presented in this chapter is in good agreement with this mechanism, we 
propose that IRF-1 ubiquitination is specific to its DBD and that this is achieved 
through docking of E3 ligases to its Mf2 domain followed by ubiquitination of the 
lysine residues in close proximity. I can reason that the E3 ligase-docking site on the 
substrate defines which lysines are modified, and that this is achieved purely by 
steric determents. Lysines within the Mf2 itself and other DBD lysines are not 
subject to ubiquitination, suggesting that ubiquitination of these residues is sterically 
unfavourable or occluded by the E3 itself. It is interesting that binding of CHIP and 
MDM2 to the same site on IRF-1 can result in distinct Lys specificity with MDM2 
able to ubiquitinate Lys95, but not Lys78, whereas no CHIP-dependent modification 
of Lys95 was detected. I can conclude that the E3 ligase-docking-site on the substrate 
defines the lysines that can be modified but that there must be additional 
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We identified five residues in the IRF-1 DBD to be modified by either CHIP or 
MDM2, in vitro ubiquitination assay results utilising an ubiquitin mutant that 
exclusively leads to monoubiquitination, show that no more than three single 
ubiquitins are attached to IRF-1 at any one time. This, together with the fact that 
single point mutations at the IRF-1 ubiquitination sites to arginine do not change the 
efficiency of IRF-1 monoubiquitination, and molecular modelling results that predict 
ubiquitination of sites Lys39, Lys50 and Lys78 resulting in the ubiquitin molecule 
occupying the same three dimensional space, suggest that not all target lysines can be 
ubiquitinated at any given time, but that ubiquitination of the sites is mutually 
exclusive. This suggests a mechanism where ubiquitination is specific to a certain 
protein domain, where several, but not all, lysine residues of this domain can be 
targeted resulting in the same molecular signal. We speculate that once the E3 ligase 
forms a complex with the charged E2 and the substrate, any lysine which lies in close 
proximity to the complex can be linked to the activated ubiquitin, this leads to 
specific modification of the lysines in a favourable position for the E3-E2 interaction 
site. This is in line with the fact that many substrates have been shown to be modified 
at several residues within a distinct domain [28].  
Why and how, a specific lysine residue can be targeted or whether IRF-1 
ubiquitination is purely domain specific remains unclear. One possibility is that 
through the involvement of other proteins in the ubiquitination enzyme complex 
ubiquitin could be sterically targeted towards one specific residue. The fact that 
MDM2 and CHIP ubiquitinate two different residues and that not all lysines in the 
DBD are subject to modification suggests that E3 ligases target specific residues in 
addition to protein domains. This could be controlled by the exact positioning of the 
E3 on the substrate only allowing access of certain target lysines to the ubiquitin 
loaded E2.  
The observation that DNA binding protects IRF-1 from ubiquitination is intriguing as 
it suggests a mechanism by which turnover of this transcription factor might decrease 
when it is in an active state, i.e. when part of a pre-initiation complex. In recent 
years, it has become clear that the ubiquitin–proteasome system and the 
transcriptional machinery are intimately linked, and that ubiquitin-mediated 
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proteolysis can enhance the activity of TAs (transcriptional activators). This is 
known as the ‘activation by destruction’ mechanism [334] and was first indicated by 
the observation that the transactivation domain and the region required for 
degradation (degron) overlap in many TAs, including IRF-1 [335]. This led us to 
think it would be interesting to investigate the exact interplay between IRF-1 
activation and ubiquitination (chapter 5).   
The Mf2 domain is a multi protein binding interface on IRF-1, DNA binding 
abolishes interactions between IRF-1 and several of its Mf2 domain binding partner, 
resulting in a subset of IRF-1 interactions partner that can only take place when IRF-
1 is ligand free, and inactive. We propose that the Mf2 domain is a docking site for 
multiple E3 ligases and that, since docking is required for ubiquitination, ligand 
bound IRF-1, is protected from ubiquitination and subsequent degradation (see 
model, 4-19). This suggests a mechanism by which ubiquitination of IRF-1 is 
regulated through its DNA binding state, in its active, DNA bound conformation 
IRF-1 is not recognised by its E3 ligases, however, as soon as it dissociates from the 
DNA, IRF-1 can be targeted for ubiquitination and degradation, resulting in fine 
regulation of the protein levels in the nucleus. In this way even though active DNA 
bound IRF-1 is not ubiquitinated, it could be turned over quickly once it dissociates 
from the promoter of target genes.  
The most popular hypothesis to explain the connection between degradation and TA 
function in gene expression is based on a ‘suicide’ model where activator 
degradation is somehow required as part of the activation mechanism and potentially 
also to terminate the signal [91]. Implicit in this model is that the TA is not subject to 
degradation prior to completing its function or when part of an active DNA-bound 
complex [91]. Here I show that DNA-bound IRF-1 has an inaccessible E3-binding 
site, and that a non-DNA binding mutant of IRF-1 is hyperubiquitinated in 
comparison to the wild-type protein (see model, Fig 4-19). The data therefore 
support the idea that IRF-1 is protected from degradation when it is part of an active 
pre-initiation complex, but can be rapidly degraded when it is not functional or when 
it has completed its function. 
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We have previously shown that the E3 ligase CHIP has two distinct functions (see 
chapter 3 for details), as a chaperone depended ligase that targets Hsp70/90 client 
proteins for degradation and as a chaperone independent ligase that directly binds to 
and ubiquitinates its substrates. Here, I demonstrate the importance of CHIP 
substrate binding for ubiquitination, in its role as a "direct E3 ligase". If IRF-1 is in a 
DNA bound or heat denatured conformation, CHIP is unable to directly interact with 
the protein. As discussed in chapter 3 (Fig 3-1, 4-18), Hsp 70 inhibits ubiquitination 
of folded IRF-1 and p53 protein, however, in their unfolded conformation Hsp70 
does not reduce CHIP mediated ubiquitination and, for p53, even activates 
ubiquitination in vitro. This gives further evidence for two distinguished roles of 
CHIP function, while it is reported to preferentially target unfolded substrates that 
are presented by Hsp70, in its direct role, conversely it shows lower affinity and 
conversion rate for unfolded substrates in the absence of Hsp70. In a cellular context 
it would be energetically more favourably to refold a protein, rather than for it to be 
degrades and re-expressed. It is therefore possible, that unfolded proteins are not 
directly recognised by CHIP, to initially allow binding by the chaperone Hsp70 and 
only if a protein is misfolded beyond refolding by Hsp70 will it be presented to CHIP 
and targeted for degradation.  
In conclusion, I report here that ubiquitination of specific residues is achieved 
through the E3 ligase binding site on the substrate and that this is likely to result in 
modification of several residues in close proximity of the docking site on the 
substrate; making the modification specific to a subset of lysines residues in a 
specific domain or region of the protein. Docking of the E3 to its substrate is 
therefore not only required for ubiquitination but also determines the specificity of 
the reaction. If the E3 cannot bind to its substrate, for example when IRF-1 is bound 
to DNA or unfolded, it is not able to mediate DBD ubiquitination. The fact that DNA 
bound IRF-1 is not recognised and ubiquitinated by its two E3 ligases MDM2 and 
CHIP suggests a mechanism by which an active pool of IRF-1 is protected from 
degradation in cells. 
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Chapter 5: The role of monoubiquitination in 
the control of p53 and IRF-1 transactivation 
activity 
 
5.1 Introduction  
5.1.1 Ubiquitination in transcriptional control  
Regulating the rate of gene transcription is fundamentally important in the control of 
normal cellular development, differentiation and homeostasis. Therefore, levels and 
activity of transcription factors are regulated very tightly ensuring fine control of 
gene expression. Recently the importance of the ubiquitin-proteasome system in 
regulating transcription factor activity has been illustrated; this can be achieved by 
proteolytic as well as non-proteolytic functions of both ubiquitin and the proteasome 
[91].  
Most transcription factors have a very short half-life, allowing tight regulation of 
their steady state cellular levels by small changes in the rate of synthesis and/or 
degradation. Levels of p53 are kept low by constant ubiquitination followed by 
degradation in unstressed cells, only in response to certain cellular signals, p53 E3 
ligases are prevented from ubiquitinating their target, leading to an increase in p53 
levels and its activity. However, the well-studied control of transcription factor 
activity by destruction is only one of several mechanisms by which the ubiquitin 
proteasome machinery is involved in transcription control. Several recent studies 
have highlighted the role of the UPS in the control of different factors of the 
transcription machinery via non-proteolytic activities. One of the first links between 
transcription factor activity and ubiquitination was made by Salghetti et al. in 1999 
[336, 337], and showed that the TAD and degron of the transcription factor Myc are 
functionally connected, with an overlap of the region that signals for ubiquitin-
mediated proteolysis and that which is required to activate transcription. Subsequent 
studies showed that degron function was a general feature of many activation 
domains that are rich in acidic residues, and that transcriptional activation potential 
correlates closely with degron function [91]. There are at least thirty transcription 
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factors with an overlapping TAD and degron, including IRF-1 and p53 (Fig 5-1) and 
everal transcription factors are now known to be most active when less abundant. 
These observations have led to an 'activated by destruction' model of transcription 
factor activity and taken together these studies suggest a strong link between TA 
stability and activity. In line with this are results by Salgehtti at al.[338], which 
showed that activation of the synthetic activator LexA-VP16 in yeast is dependent on 
the E3 ligase Met30, which leads to LexA-VP16 ubiquitination and destruction. This 
observation is intriguing as one would predict that blocking the E3 ligase that leads 
to destruction of a specific transcription factor, would increase its levels and thus its 
activity. However, blocking Met30 inhibits LexA-VP16 activity and this can be 
rescued by fusion of an ubiquitin molecule to the N-terminus of the protein, 
demonstrating that ubiquitination of LexA-VP16 is directly required for its activity. 
The Met30 study therefore indicates a direct connection between ubiquitin 
modification and enhanced function of transcription factor activity. Several other 
transcription factor have now also been shown to require activity of their respective 
E3 enzyme in order to be fully active, including Myc, HPV E2, Gal-4 and Tat [338-
341]. The exact mechanism by which ubiquitination can enhance the transactivation 
potential of a given transcription factor remains elusive. Several different 
mechanisms have been proposed, including recruitment of parts of the proteasome to 
the site of transcription, which in turn are suggested to function as activators. An 
example of this is the transactivator Tat, encoded by the human immunodeficiency 
virus type 1 (HIV-1). Activity of Tat is dependent on ubiquitination by MDM2, and 
this was suggested to mediate recruitment of the 19S particle to the HIV-1 promoter, 
activating Tat-mediated transcription [340]. Another possible mechanism of how 
ubiquitination could facilitate transcription is through the recruitment of different 
factors to the site of transcription initiation. For example monoubiquitination of the 
transcriptional co-activator CIITA, which associates with MHC II transcription 
factors and the MHC class II promoter to form an active enhanceosome, positively 
regulates its assembly at the promoter [342].  
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As ubiquitination can both activate and degrade a number of transcription factors a 
'licensing model' was proposed [338], where monoubiquitination leads to activation 
of the proteins transactivation potential, but is inevitably followed by 
polyubiquitination and degradation of the protein. This could lead to instant 
activation of the transcription factor in response to stimuli and also ensure 
termination of the activity after the signal has ended. However, more research is 
needed to reveal the physiological significance of this model and to show which 
factors might be controlled in such a manner. In summary, posttranslational 
modification of transcription factors by ubiquitin appears to play a major role in 
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Figure 5-1 Transcriptional regulators with overlapping TAD and degron [91] 
Numerous transcription factors with an overlap in the domains involved in their degradation 
and transactivation have been identified, highlighting the close relationship between these 
two, seemingly contradictory, functions.  
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5.2 Results 
5.2.1 p53 pathways activation induces its monoubiquitination  
The previous chapter of this thesis has focused on the control of the ubiquitination 
event by accessibility of the E3 ligase. In this chapter I will move on to dissect the 
effects that ubiquitination has on the transcriptional activity of the tumour 
suppressors p53 and IRF-1. Novel non-proteolytic functions of ubiquitination are 
constantly identified, however, the knowledge of how ubiquitination can affect the 
activity of the transcription factors p53 and IRF-1, besides signalling degradation, is 
limited. Strikingly, Maki et al. have shown in 1997 [230] that IR leads to an increase 
in ubiquitinated p53 adducts in the cell. Furthermore, the Ball group previously 
showed that high molecular weight adducts of p53 are induced in cells by treatment 
with the small molecular activator of p53, Nutlin-3 [198], which leads to an increase 
in both p53 levels and its transcriptional activity (Fig 5-2), resulting in cell cycle 
arrest or apoptosis [343]. Nutlins were found in a screen to identify small molecules 
that could inhibit binding of the MDM2 hydrophobic pocket to a peptide from p53 
(Fig 5-2a). Nutlin-3 binds to a p53 binding site in MDM2's hydrophobic pocket, and 
is generally believed to thereby inhibit MDM2 mediated ubiquitination and 
degradation of p53 [344]. 
Intrigued by the possibility of a role of ubiquitination in the p53 activations 
pathways, I, in a first step, set out to determine the ubiquitination state of 
transcriptionally active p53. To examine the ubiquitination status of the endogenous 
proteome under conditions where the p53 pathway is engaged, I started by capturing 
substrates ubiquitinated in the presence of a His-ubiquitin construct in cells. Briefly, 
A375 cells, a human malignant melanoma cell line with wild-type p53, were 
transfected with His-ubiquitin and treated with either the small molecule p53 
activator Nutlin-3 or X-ray radiation (IR), both of which are well-characterised 
activators of the p53-pathway response. Results of the assays show that endogenous 
p53 ubiquitination is increased in response to activating signals, as several higher 
molecular weight bands appear following radiation and Nutlin-3 treatment (Fig 5-3). 
Increase in the levels of p53 transcriptional targets, p21 and MDM2, as a readout of 
pathway activation could also be observed. These results confirmed the previous 
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observations made by Maki et al. that showed an increase in p53 ubiquitination upon 
X-Ray and demonstrated that the high molecular weight bands, observed by the Ball 
group in response to Nutlin-3 treatment, represent ubiquitinated p53.  
Interestingly, under these conditions, p53 activation led not only to an increase in the 
total amount ubiquitinated protein, but also shifted the type of ubiquitination to 
mainly mono or multi-mono ubiquitinated forms with the first three ubiquitination 
bands being predominantly present when compared to the control lane (compare lane 
4 and 5, Fig 5-2a). This was confirmed by quantifying the first and second 
monoubiquitin bands (Fig 5-3a; Ub1 and Ub2) relative to the control samples (lane 2 
with lane 5; lane 3 with lane 4) in both Nutlin-3 and IR treated cells. This showed 
(Fig 5-3b) that there was a 5.4- and 3.4-fold increase in the first and second ubiquitin 
bands in IR-treated cells, respectively; whereas the fold increase in unmodified p53 
and the fifth p53-ubiquitin band (Ub5) was 1.5- and 2.3-fold, respectively. Thus, 
although there is greater increase in the monoubiquitination of p53 in the presence of 
Nutlin-3 (9.7-fold for Ub1 and 14.1-fold for Ub2, verses 2.2-fold for unmodified p53 
and 0.9-fold for Ub5), IR also reproducibly favours the generation of p53-
monoubiquitin adducts. 
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Figure 5-2 Nutlin-3 binds to the E3 ligase MDM2 and thereby activates p53  
(a) The small molecular p53 activator nultin-3 (indicated by yellow sticks) crystallised 
bound to the hydrophobic pocket of MDM2 (shown as surface). (b) A375 cells were treated 
with 10 µM Nutlin-3 for 8 hours, lysed in Triton-X lysis buffer and analysed by SDS-
PAGE/immunoblot with p53, p21, MDM2 and GAPDH monoclonal antibodies. The GI 50 
for Nutlin-3 in melanoma cells was shown to be between 5-30 µM [345], therefore a 
relatively low concentration of Nutlin-3 (10 µM) was used throughout this chapter to reduce 
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Figure 5-3 p53 is ubiquitinated in response to activation by X-Ray or Nutlin-3 
treatment 
(a) A375 cells were transfected with His- ubiquitin (0.5 µg) as detailed. Post transfection (24 
hours) cells were treated with Nutlin-3 (10 µM) for 8 hours or radiated (5 Gy) and recovered 
for 3 hours. Subsequently histidine-labelled ubiquitinated protein was isolated using Ni-NTA 
chromatography and analysed by SDS/PAGE and immunoblot using p53, p21, MDM2 and 
GAPDH mAb. His-ubiquitinated p53 (upper panel) and total p53, p21, MDM2 and GAPDH 
in the samples lysed in Tritom-X lysis buffer (lower panel) are shown. (b) Quantification of 
results from (a) using Image J. The fold increase of unmodified p53 and p53 attached to 1, 2 
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5.2.2 p53 and MDM2 form complexes in the presence of 
Nutlin-3 in cells 
In the previous section, I showed that Nutlin-3 leads to a significant increase in p53 
monoubiquitination. As Nutlin-3 was previously described as an inhibitor of 
MDM2's E3 ligase activity, that could prevent the formation of p53:MDM2 
complexes and thereby inhibit ubiquitination of p53 by MDM2, we were interested 
to gain insight into the mechanism by which Nutlin-3 leads to an accumulation of 
ubiquitinated p53 protein in cells. Therefore, I set out to investigate the effect of 
Nutlin-3 on binding and ubiquitination of p53 by MDM2 in vitro and in cells. To 
assess the effect of Nultin-3 on binding of p53 to MDM2 in vitro, recombinant p53 
was coated onto a microtiter plate and incubated with constant amounts of MDM2 
that had been pre-incubated with increasing amounts of Nutlin-3. Results of this 
experiment show that Nutlin-3 interfered with the formation of MDM2:p53 
complexes and decreased binding of the two proteins by about 40% in vitro (Fig 5-
4a, left panel). MDM2 and p53 interact through two distinct motifs. The higher 
affinity interaction is mediated through residues in the BOX-I motif in p53's N-
terminus and the hydrophobic pocket of MDM2, whereas the second weaker binding 
site is facilitated by the BOX-V motif in the core domain of p53 and the acid domain 
of MDM2. Interestingly, this second binding site serves as an ubiquitination signal 
and interaction at this site is required for efficient ubiquitination [198]. As I observed 
a decrease in binding of p53 and MDM2 in the presence of Nutlin-3 I was interested 
to determine of this loss is due to disruption of binding at both or one of these 
interactions sites. Therefore, I carried out peptide binding assays with the BOX-1 or 
BOX-V p53 peptide immobilised on a streptavidin coated microtiter plate with 
MDM2, pre-incubated with increasing amounts of Nutlin-3, in the mobile phase. 
Results of this assay, shown in Figure 5-4a (right panel), are in agreement with 
previous observations of the Ball group [198] and show that Nutlin-3 inhibits binding 
of BOX-1 to MDM2, but not between the second binding site of MDM2 and the 
BOX-1 motif in the p53 core domain, which is required for ubiquitination (Fig 5-6). 
In fact a small, but reproducible, increase in binding of BOX-V to MDM2 in the 
presence of Nutlin-3 can be observed. This is an interesting observation as it suggests 
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that even though Nutlin-3 weakens the interaction between MDM2 and p53, it does 
not abolish it completely, but shifts binding from one site to another.  
To test the effect of Nutlin-3 on the formation of p53:MDM2 complexes in cells, I 
asked whether MDM2 was detectable in a complex with p53 after Nultin-3 treatment 
in cells. Specifically, A375 cells were treated with Nutlin-3 for 8 hours, subsequently 
cells were lysed, and p53 protein was immunoprecipitated from the lysate using a 
p53 polyclonal antibody. The lysate and immunoprecipitate were analysed by 
immunoblot, probed for p53 and MDM2. Nutlin-3 treatment resulted in a strong 
increase in p53 and MDM2 protein levels and MDM2 could be detected in complex 
with p53 in both control and Nutlin-3 treated cells (Fig 5-4b). The results of the cell 
based binding assay show that more p53:MDM2 complexes are present in the cell 
after treatment with Nutlin-3, when compared to control conditions, and that the 
decrease in binding affinity observed in in vitro binding assay is not sufficient to 
abolish binding of the two proteins in vivo. It is difficult to determine if there is a 
change in relative formation of p53:MDM2 complexes after Nutlin-3 treatment, as 
the latter results in multiple fold increase of  both p53 and MDM2. Taken together 
these data suggest that binding of p53 to MDM2 by the BOX-V motif, which is 
stimulated by Nutlin-3, is sufficient for the formation of MDM2/p53 complexes in 
cells in the presence of Nutlin-3.  
In order to investigate whether the increase of p53 ubiquitination is a direct effect of 
Nutlin-3 binding to MDM2, I assembled an in vitro ubiquitination assay with all 
components of the reaction as purified components and tested the effect of Nutlin-3 
on p53 ubiquitination by MDM2 in vitro. As shown in Figure 5-5a, Nutlin-3 does not 
affect the ability of MDM2 to ubiquitinate p53 in vitro (under condition where acid 
domain binding aptamers do inhibit MDM2-activity, right panel). This is in contrast 
to data obtained in cells, where a time course of Nutlin-3 treatment (50 µM) leads to 
a gradual increase in p53 ubiquitination (Fig 5-5b), and to the in cell ubiquitination 
assays, where Nutlin-3 dramatically increases the amount of mono- and 
diubiquitinated p53 compared to control conditions. Taken together the data 
demonstrate a novel role for Nutlin-3 in the induction of accumulation of ubiquitin-
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p53 adducts in a monoubiquitinated form rather than as polyubiquitin chains. And let 
me to refine a previous model by the Ball group, where Nutlin-3 acts as an allosteric 
activator of MDM2-mediated p53 ubiquitination [198], to reflect the fact that Nutlin-
3 specifically enhances monoubiquitination, rather than polyubiquitination, of p53 
and that Nutlin-3 stimulates the interaction between the acid domain of MDM2 and 
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Figure 5-4 Nutlin-3 disrupts the formation of p53:MDM2 complexes in vitro, but not 
cells 
 (a) p53 (100 ng/well) was immobilized on a microtiter plate and incubated with constant 
amounts of MDM2 (100 ng) and a titration of Nutlin-3 (0-1 µM). Binding of MDM2 to p53 
was detected using an anti-MDM2 mAb (2A10) (b) Co-immunoprecipitation of p53:MDM2 
complexes (left panel). Biotin-tagged p53 Box-I (PPLSQETFSDLWKLLP) and Box V 
(RNSFEVRVCACGRD) peptides were immobilized on a microtitre plate and incubated with 
100 ng of MDM2 and a titration of Nutlin-3 (0-8 mM). MDM2 binding to the peptides was 
detected using an anti-MDM2 mAb (right panel). (b) A375 cells were treated with 10 µM 
Nutlin-3 for 8 hours and lysed in IP lysis buffer (not denaturing). Lysate was pre-cleared 
using Sepharose beads and incubated with protein A beads and anti- p53 pAb (CM1) 
overnight. After washing, proteins bound to the beads were eluted by heating in SDS sample 
buffer and both lysate and eluate were analysed by SDS-PAGE followed by immunoblotting 






























0                                            1   M
(a)
(b)
Input                          p53  pull-­down
Nutlin-­3
p53  pAb
      -­    +    -­    +




































5. Results  192 
 
Figure 5-5 Nutlin-3 enhances p53 ubiquitination in cells, but not in vitro 
(a) In vitro ubiquitination assay with p53 as the substrate and a titration of Nutlin-3 (0 -50 
µM) (left panel) or a titration (0.5, 5, 10 µM) of Rb1 peptide 
(DQIMMCSDMYGICKVKNIDLK) and Nutlin-3 (right panel) and MDM2 as the E3 ligase. 
(b) A375 cells were treated with 10 µM Nultin-3 for 0-8 hours, lysed in urea lysis buffer and 
analysed by SDS-PAGE/immunoblot using anti- p53 mAb. (c) A375 cells were transfected 
with His–ubiquitin (0.5 µg) as shown. Post-transfection (20 hours), cells were lysed and 
histidine-ubiquitinated protein was isolated using Ni-NTA chromatography. Samples were 
analysed by SDS/PAGE and immunoblotting with the mAbs indicated. Total amounts of 
p53, MDM2 and GAPDH in the sample extracted using Triton-X lysis buffer (bottom panel) 
and modified p53 (top panel) are shown. 
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Figure 5-6 Model of Nutlin-3's effect on the p53:MDM2 interaction [198] 
MDM2 interacts with two distinct motifs on p53, BOX-I (I) and BOX-V (II). The Box I 
interaction is of higher affinity, while the interaction through the Box V motif serve as a 
ubiquitination signal and is required for MDM2 mediated ubiquitination of p53. Nutlin-3 
binds to the hydrophobic pocket of MDM2, which interacts with the Box I motif, thereby 
inhibiting the high affinity interactions. Interaction of the second binding site, which serve as 
a ubiquitination signal is, however, not affected, and even though the binding affinity is 
reduced, MDM2 can still stimulate ubiquitination of p53 in the presence of Nutlin-3. In cells, 
Nutlin-3 treatment shifts the ubiquitination pattern of p53 from polyubiquitination to 
monoubiquitination. It is known that binding of Nutlin-3 leads to conformational changes in 
MDM2 [198], one possibility is that this change in conformation could directly shift MDM2 
E3 ligase activity towards monoubiquitination. Another possibility is that Nutlin-3 binding 
alters the set of proteins that interact with MDM2, for example E4 enzymes, and thereby 
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5.2.3 p53 ubiquitination and degradation can be uncoupled 
The best-studied role of ubiquitination in p53 control, is its role in proteasomal 
degradation, I therefore asked how activation dependent ubiquitination of p53 
affected its half-life. To determine the half-life of p53 under control and activating 
conditions, cells were treated with the protein synthesis inhibitor cycloheximide and 
the loss of the protein over a time course of 0 to 90 minutes was followed. Cells were 
lysed in either Triton X-100 lysis buffer to determine steady state levels or under 
denaturing conditions in 8 M urea lysis buffer (Fig 5-7a). Lysis in urea buffer 
preserves the ubiquitinated forms of p53, presumably by inhibiting the activity of 
DUBs in the lysate. Consistent with observations by others, DNA damage and 
Nutlin-3 treatment increase the half-life of p53 from 20 ± 5 minutes to over 90 
minutes. Strikingly, and as detected in the previous experiment p53 ubiquitination 
increases after both X-Ray and Nutlin-3 treatment as visible in samples lysed in urea 
lysis buffer (Fig 5-7a, lower panel), this time in the absence of His-ubiquitin. These 
results suggest that p53 ubiquitination can be uncoupled from its proteolytic 
degradation under conditions where p53 is active. Strikingly, the mono- and multi-
monoubiquitinated forms of p53 detected in the presence of Nutlin-3 were not 
subject to turnover and were stable over the 90 minutes course of the experiment (Fig 
5-7a; Nutlin-3), whilst, consistent with a mixed population of mono- and 
polyubiquitinated p53 (Fig 5-7) the higher molecular weight forms of p53 in X-Ray 
treated cells were degraded whereas the monoubiquitin-adducts persisted.  
To expand on this observation, A375 cells were treated with the proteasomal 
inhibitor lactacystin and lysed under denaturing conditions. In unstressed cells, levels 
of p53 protein increased and accumulated in an ubiquitinated form, as expected for a 
short-lived protein that is degraded by the ubiquitin-proteasome pathway. Following 
p53 pathway activation, however, lactacystin treatment did not lead to the 
accumulation of Nutlin-3 or IR induced p53 forms, but reproducibly decreased p53 
ubiquitination (Fig 5-7b). Proteasome inhibitors are known to lead to 
deubiquitination of specifically mono- and not polyubiquitinated proteins [346]. Loss 
of p53 ubiquitination in radiated and Nutlin-3 treated cells, but not control cells, 
therefore gives further support to the idea that p53 activation results in its 
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monoubiquitination. Furthermore, this supports the concept that the ubiquitination 
observed after activation is not coupled to p53 degradation, as otherwise blocking the 
degradation pathway would lead to an increase in radiation or Nutlin-3 induced 
ubiquitinated forms of p53.  
Taken together, these experiments show that p53 is ubiquitinated, but not degraded, 
after engagement of the p53 pathway by Nutlin-3 and X-Rays, suggesting a direct 
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Figure 5-7 p53 ubiquitination in response to activating agents is uncoupled from its 
degradation  
(a) A375 cells were treated with Nutlin-3 (10 µM, 8 hours) or radiated with 5 Gy (3 hours 
recovery) and additionally treated with 30 µg/ml Cycloheximide prior to harvest at the times 
shown. Samples were lysed in either Triton-X or urea lysis buffer and analysed by SDS-
PAGE/immunoblot, p53 was detected using anti- p53 mAb (lower panel). (b) A375 cells 
were treated with 10 µM Lactacystin for 4 hours and simultaneously with 10 µM Nutlin-3 (8 
hours) or 5 Gy X-radiation followed by 3 hours recovery, as indicated. Cells were lysed in 
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5.2.4 p53 ubiquitination in response to X-Ray is a direct 
downstream event in the ATM signalling pathway 
IR induced DNA damage leads to activation of p53 by the ATM signalling pathway, 
to test whether ubiquitination of p53 in response to X-Ray is a direct downstream 
event of ATM kinase activation, cells were treated with an ATM-Inhibitor and 
radiated or treated with Nutlin-3. As shown in Figure 5-8, ATM activity is required 
for increased p53 ubiquitination and p53 dependent expression of p21 and MDM2, 
after X-Ray, but not Nutlin-3 treatment. This indicates, that ubiquitination of p53 
after DNA damage is an event downstream of the ATM signalling pathway. The 
effect of Nutlin-3 on p53 ubiquitination is not altered by the ATM inhibitor, 
indicating that Nultin-3, other than radiation, does not lead to activation of this 
signalling pathway, but rather acts by a direct mechanism through binding to MDM2 





























Figure 5-8 ATM Kinase activity is required for increased ubiquitination after X-Ray 
but not Nutlin-3 treatment 
A375 cells were treated with either Nutlin-3 (10 µM, 8 hours) or X-Ray (5 Gy, 3 hours 
recovery) and ATM inhibitor (KU-55933, 20 µM, 4 hours) and lysed in urea lysis buffer. 
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5.2.5 Ubiquitinated p53 accumulates in the nucleus in 
response to Nutlin-3 
If p53 was ubiquitinated when in its active form, I would expect it to be located in 
the nucleus, where p53 functions as a transcriptional activator. As there are no 
antibodies available that specifically recognise ubiquitinated p53 and as ubiquitin is 
conjugated to a vast range of cellular proteins, it is not feasible to carry out 
conventional co-localisation studies to determine the localisation of ubiquitinated 
p53 following Nutlin-3 treatment. To overcome this technical challenge I used an in 
situ proximity ligation assay (PLA) to detect endogenous p53 and ubiquitin that were 
within 40 nm of each other. For this anti-p53 polyclonal (CM1) and anti-ubiquitin 
monoclonal antibodies were used together with secondary antibodies conjugated to 
unique short DNA strands, which when in close proximity are amplified and using 
Duo-link system to produce a fluorescent signal. As a negative control, only one of 
the primary antibodies was used. To test the functionality of the assay with respect to 
detection of p53-ubiquitin conjugates, it was carried out in A375 cells that had been 
treated with Lactacystin an inhibitor of proteasomal degradation that leads to 
accumulation of ubiquitinated p53 protein in cells. Figure 5-9 shows that whereas in 
control cells the level of PLA signal is just above the single antibody control 
background, Lactacystin treatment led to a marked increase in the total number of 
fluorescent spots, which correspond to ubiquitinated p53. This indicates that the 
assay is indeed able to detect ubiquitinated p53 in cells. I went on to investigate the 
effect of Nutlin-3 on the presence of ubiquitinated p53 in the nucleus using this 
technique. Following Nutlin-3 treatment, a significant increase in the total number of 
fluorescent spots was detected, and a majority of the signal was located in the nuclear 
compartment of the cell. This was in contrast to Lactacystin treatment were the 
majority of spots were located in the cytoplasm (compare Fig 5-9 and 5-10). As an 
additional control the assay was carried out in HCT-116 p53 wt and HCT-116 p53 -/- 
cells. No signal was observed in p53 null cells while Nutlin-3 led to an increase in 
fluorescent signal in HCT-116 p53 wt cells (Fig 5-11). This further supports that the 
assay specifically detects ubiquitinated p53.  
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To establish that the nuclear pool of ubiquitinated p53 detected by PLA in the 
Nutlin-3 treated cells was monoubiquitinated I carried out cellular fractionation. 
Figure 5-12 shows a pool of monoubiquitinated p53 protein in the nuclear fraction 
from Nutlin-treated cells. (Note, this assay is not carried out under denaturing 
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Figure 5-9 Accumulated ubiquitinated p53 in response to lactacystin treatment can be 
detected using the PLA system 
 A375 cells were treated with 10 µM Lactacystin for 4 hours, and a proximate ligation assays 
using either only anti-ubiquitin or both anti-ubiquitin and anti-p53 antibodies was performed. 
Cells were stained with DAPI (1:5000 in mounting media) and visualised using an 
Axioplan2 (Zeiss) fluorescent microscope (100 x magnification). Representative PLA 
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Figure 5-10 Nutlin-3 treatment leads to accumulation of ubiquitinated p53 in the 
nucleus  
(a) A375 cells were treated with 10 µM Nultin-3 for 8 hours, and a proximate ligation assays 
using either only anti-ubiquitin or both anti-ubiquitin and anti-p53 antibodies were 
performed. Cells were stained with DAPI (1:5000 in mounting media) and visualised using 
an Axioplan2 (Zeiss) fluorescent microscope (100 x magnification). Representative PLA 
images are shown. (b) The numbers of spots in at least 100 cells were counted; the average 
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Figure 5-11 The PLA system detects ubiquitinated p53 in HCT-116 p53 wt but not p53 
-/- cells 
HCT-116 p53 wt or p53 -/- cells were treated with 10 µM Nultin-3 for 8 hours, and a 
proximate ligation assays using either only anti-ubiquitin or both anti-ubiquitin and anti-p53 
antibodies were performed. Cells were stained with DAPI (1:5000 in mounting media) and 
visualised using an Axioplan2 (Zeiss) fluorescent microscope (100 x magnification). 
Representative PLA images are shown.  
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Figure 5-12 Nutlin-3 induces monoubiquitination in nuclear p53 
Fractionation of A375 cells treated with Nutlin-3 (10 µM) or DMSO for 8 hours and 
analysed by Immunoblot with anti p53 and MDM2 (4B2) mAb. The fractionations were 
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5.2.6 Chromatin associated p53 is ubiquitinated 
The experiment described above shows that monoubiquitinated p53 accumulated in 
the nucleus following Nutlin-3 treatment, however it does not tell us whether this 
pool of protein is associated with the chromosomal DNA or if it is present in the 
soluble nuclear fraction. As chromatin is insoluble in the buffer conditions used any 
protein that is associated with the chromatin will be in the insoluble fraction, while 
chromatin unbound nuclear protein will be present in the soluble fraction. As such I 
performed a simple fractionation experiments, separating the soluble from the 
insoluble cellular fraction using hypertonic lysis conditions. To confirm that all the 
DNA and thus the chromatin was present in the insoluble fraction, DNA content of 
both fractions was analysed after sonication and RNase treatment of the samples. As 
expected all DNA was present in the insoluble fraction (Fig 5-13a compare lane 
S=soluble to P-insoluble fraction). Additionally, analysis of the proteins in the 
fractions by SDS-PAGE showed that histone-H1, which is associated with the 
chromatin, was mainly present in the insoluble fraction, providing further 
confirmation that chromatin associated proteins can be separated from free protein by 
this method. 
To determine if ubiquitinated p53 is associated with the chromatin, MCF7 or A375 
cells were treated with Nutlin-3 or X-Ray respectively; subsequently p53 protein in 
the soluble and insoluble fraction was analysed. After Nutlin-3 treatment an increase 
in p53 levels together with an increase in the appearance of higher molecular weight 
bands, indicative ubiquitinated forms of p53, was observed in the soluble and 
insoluble fraction (Fig 5-13a). Furthermore, radiation (5 Gy) of A375 cells led to the 
accumulation of ubiquitinated p53 protein in both fractions and this was dependent 
on ATM kinase activity (Fig 5-13b). This experiment indicates that after engagement 
of the p53 pathway, ubiquitinated forms of the transcription factor were associated 
with the chromatin containing fractions. To verify that the higher molecular weight 
bands represent p53 protein modified by ubiquitin, fractions of radiated samples 
were incubated with the p53 deubiquitinase HAUSP for 5 minutes at 37°C. The 
results show a significant decrease in high molecular weight bands in the HAUSP 
treated samples, when compared to control samples. This confirms that the higher 
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molecular weight bands correspond to ubiquitinated p53 (Fig 5-13c). It has to be 
noted that other cellular DUBs are present in the lysates and most likely partially 
deubiquitinate p53-ubiquitin conjugates present in the sample. The actual ratio of 
ubiquitinated to unmodified p53 in both fractions is therefore probably 
underrepresented in the experimental results.  
To further confirm that the modified protein is chromatin associated and not in the 
insoluble fraction through for example membrane association or aggregation, I set up 
an assay to specifically look at the ubiquitination status of chromatin associated p53 
using a 10-50% isokinetic sucrose gradient. Sucrose gradient sedimentation has 
previously been used to analyse chromatin structures as the sedimentation rate is 
determined by the mass and hydrodynamic shape of the chromatin fibres [347, 348]. 
Here, I have adapted this technique to determine whether ubiquitinated p53 is 
associated with the chromatin structures or present in the free nuclear fraction (See 
Fig 5-14 for experimental outline).  
The nuclei from control, Nutlin-3 and X-ray-irradiated cells were isolated and 
chromosomal DNA was briefly digested using micrococcal nuclease. After RNase 
treatment of the samples, to remove any RNA, the nuclei were lysed and the lysate 
was fractionated using sucrose density gradient centrifugation. UV monitoring and 
examination of the DNA content of each fraction following phenol/chloroform 
extraction and subsequent agarose gel analysis, revealed that the chromosomal DNA, 
and therefore protein associated with it, was mainly present in fractions 6-8 (Fig 5-
14b), whereas earlier fractions (1-3) contain nuclear protein that is not associated 
with chromatin and the remaining fractions contains proteins that are only loosely 
associated with the chromatin.  
Protein analysis of the samples using ethanol precipitation followed by SDS-PAGE, 
shows that p53 is present in both the soluble nuclear and chromatin associated 
fraction under all conditions, however, strikingly ubiquitinated protein can only be 
detected in fractions that are tightly associated with the chromatin and only under 
conditions where p53 is activated i.e. after Nutlin-3 treatment or radiation. Up to two 
ubiquitin bands are observed, suggesting that the protein is mono- and diubiquitin 
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modified or multi mono-ubiquitination (Fig 5-15). Again, the ratio of ubiquitinated to 
unmodified protein is most likely underrepresented due to activity of DUBs in the 
lysates.  
Taken together, the results presented in this chapter so far show that agents as Nutlin-
3 or X-Ray that engage the p53 activation pathway, lead to monoubiquitination of 
p53, which is uncoupled from its proteolytic degradation. Furthermore, ubiquitinated 
forms of p53 were shown to be located in the nucleus, associated with the chromatin, 
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Figure 5-13 Ubiquitinated p53 is present in the insoluble nuclear fraction 
 (a) MCF7 cells were lysed under hypertonic lysis conditions. The DNA content of the 
soluble and insoluble fraction was prepared using phenol/chloroform extraction and 
separated on an agarose gel. Proteins were analysed by SDS-PAGE/immunoblot using anti-
p53 and Histone H1 antibodies. (b) MCF7 or A375 cells were treated with 10 µM Nutlin-3 
for 0-16 hours (left panel) or 5 Gy followed by 3 hours recovery ± 10 µM ATM inhibitor for 
4 hours (right panel) respectively. Cells were fractionated into soluble and insoluble protein 
and analysed by SDS-PAGE/immunoblot using an anti-p53 antibody. (c) A375 cells were 
irradiated with 5 Gy of IR, insoluble and soluble fractions were isolated and treated with 
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Figure 5-14 Experimental outline of nuclei fractionation using sucrose gradient 
centrifugation 
 (a) A375 cells are grown in a tissue culture dish, treated as indicated and harvested at 
around 90% confluency. Nuclei were isolated, RNA was removed in an RNase step and 
chromosomal DNA partially digested using micrococcal nuclease. Following digestions, 
cells were lysed and the lysate was separated using a 10-50% sucrose gradient and ten 0.5 ml 
fractions collected using a fraction collector. During fraction collection a UV profile of the 
fractions was recorded. (b) Typical UV trace of a fractionation experiment (left panel), 
agarose gel representing DNA content of the ten fractions obtained (right panel). DNA was 
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Figure 5-15 X-radiation and Nutlin-3 treatment specifically leads to ubiquitination of 
chromatin-associated p53 
Nuclei of A375 cells treated with 5 Gy IR followed by recovery for 3 hours (a) or with 10 
µM Nutlin-3 for 8 hours (b) were fractionated as described in Fig 5-23 and analysed by SDS-
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5.2.7 Molecular modeling suggests that direct interactions 
between ubiquitin and DNA stabilises the TA:DNA 
complex 
The data presented above demonstrate that, following pathway activation, stably 
monoubiquitinated p53 is in the nucleus where it is tightly associated with chromatin 
(Fig 5-10 and 5-15). In a next step I therefore to asked whether monoubiquitination 
directly affected the ability of p53 to bind DNA. We hypothesised that ubiquitin 
acceptor lysine residues located in the DBD of p53 [349] may be of most interest in 
respect to DNA-binding, however, multiple ubiquitin acceptor sites have been 
mapped in a number of p53 domains [232]. Thus, it is difficult to study DBD 
monoubiquitination in isolation from other p53 ubiquitination events. On the other 
hand I have shown (chapter 4) that IRF-1 is ubiquitinated exclusively in its DBD 
(Fig 5-16) making it a good model to study the effects of domain specific 
monoubiquitination on TA DNA-binding activity. 
Interestingly, the DBD ubiquitination sites of both p53 and IRF-1 lie very close to or 
within the DNA binding interface, suggesting that modification of these residues 
would affect TA's ability to interact with DNA. To gain insight into the mechanism 
by which DBD ubiquitination would affect the affinity of their TAs to DNA, I started 
by generating in silico models of the DBD of both transcription factors in an 
ubiquitinated state bound to DNA using the Haddock webserver [271, 297]. Models 
were created for lysine residues that are present in the crystal structure of the DBD of 
IRF-1 (Lys39, Lys50 and Lys78, which I identified as ubiquitin acceptor lysines in 
chapter 4) and for p53 (Lys164 and Lys292) and the C-terminal glycine residue of 
ubiquitin as active contact residues. The three best structures of the four clusters with 
the best HADDOCK scores were analysed (see Fig 4-5 for IRF-1 and 5-18 for p53 
models). The models were generated in the absence of DNA and later overlaid with 
the DNA from the respective crystal structure, all complexes exhibiting a major clash 
between the position of ubiquitin and DNA were discarded, and the models with the 
best HADDOCK scores were taken forward for subsequent analysis. It should be 
noted that as shown in Figure 5-18b, even though for the Lys292 model the structures 
with a clash between DNA and ubiquitin were discarded (left panel, upper two 
molecules), and the remaining one was chosen for MD analysis, during the 
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simulation the ubiquitin molecule underwent gross movement and resulted in a 
position very close to the DNA interface and in a similar three dimensional space to 
the ubiquitin molecules in the other two models (right panel, blue molecule). This 
shows that the HADDOCK model has to be seen as merely a starting structure, 
which is refined during the simulation process. Molecular dynamic simulations of the 
DBD-ubiquitin-DNA complexes were carried out for 40 ns, the complex after the 
simulation is shown in Figure 5-17 and 5-19. The simulations were run in triplicate 
for p53 and in duplicate for IRF-1. Interestingly, ubiquitin is positioned at the DNA 
binding interface in all models and ubiquitin residues directly interact with the DNA 
in the simulations. An electrostatic surface analysis of the complex using APBS 
shows that addition of ubiquitin to the DBD strongly increases the positively charged 
surface area of the transcription factors that faces and binds DNA (Fig 5-17 and 5-
19). This suggests that the ubiquitin molecule can contribute to the binding between 
the transcription factor and DNA and thereby favours the interaction. In fact, analysis 
of the buried surface on the DNA by the protein shows an increase of 38 – 53 % in 
the ubiquitinated models when compared to the DBD alone (Fig 5-17 and 5-19). 
Additionally, the simulations were used to calculate the binding energies between 
DNA and the p53 DBD, either free or bound to ubiquitin, and this showed a 
significant decrease in ΔGB of ubiquitinated compared to unmodified TA DBD  (Fig 
5-17c and 5-19b; left panel). As p53 can be polyubiquitinated in cells, I was 
interested to examine if addition of more ubiquitins to p53 would further increase the 
positive surface area. The model of p53 ubiquitinated at Lys292 was used as the basis 
to generate models of tetraubiquitinated p53 with chains linked by K11, K48 or K63. 
Models of chains linked by K11 and K48 indicate that there might be further 
interactions between the second ubiquitin molecule, however, there are also steric 
clashes between the ubiquitin chain and the DNA (Figure 5-20, upper and middle 
panel). In a model of p53 ubiquitinated by a K63 linked chain, only the first ubiquitin 
molecule appears to be able to form interaction with DNA (lower panel). Taken 
together, the models of polyubiquitinated p53, suggest that only the first and possibly 
the second, but no further ubiquitin molecules, would interact with p53 bound DNA 
and strengthen the interaction. 
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Figure 5-16 Ubiquitination sites on IRF-1 and p53  
Domain and crystal structure of (a) IRF-1 and (b) p53 with lysines that are subject to 
ubiquitination indicated in blue.  
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Figure 5-17 Moiecular model of an IRF-1 DBD:DNA:ubiquitin complex 
(a) Model of the IRF-1:ubiquitin:DNA complex generated by superimposing the IRF-
1:ubiquitin (Fig 3-5) model onto the IRF-1DBD:DNA crystal structure. (b) Electrostatic 
surface analysis of the ubiquitin:TA model was carried out using the APBS Pymol plugin. 
Blue indicates positively charged surface, while red shows negatively charged protein 
surface. (c) Molecular Dynamic Simulations were carried out on the complex of IRF-1 
DBD:DNA (PDB:1IF1) and the IRF-1 DBD:DNA:ubiquitin model. The simulations were 
used to compute the free binding free energy (in kcal/mol) of DNA with IRF-1 DBD +/- 
ubiquitin (lower panel). (d) The buried surface on IRF-1 DBD alone and in complex with 
ubiquitin (modeled on Lys78) was calculated using Pymol.  
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Figure 5-18 Model of monoubiquitinated p53 
(a) Ubiquitin was modelled onto the p53 DBD at the ubiquitin receptor lysine residue 292 
using the HADDOCK web server. From the results obtained, the four best structures from 
the three best clusters (1-3) were analysed. The position of ubiquitin (green or blue ribbon) 
in respect to p53 (white ribbon) in the three models is shown with ubiquitin in structures 
obtained from different clusters in different green shades. 
(b) Models in position 2 and 3 were discarded as they displayed clashes with the DNA. 
Model 1 was used for subsequent MD simulations (left panel). The ubiquitin molecule 
underwent conformational changes during the simulation (blue ribbon) that brought it into 
close proximity to the DNA and in an orientation similar to that of the structures from the 
other two HADDOCK output clusters  (2,3) (right panel), thus suggesting a conversion of 
the HADDOCK solutions. 
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Figure 5-19 Molecular model of a p53 DBD:DNA:ubiquitin complex 
 (a) Model of the p53:ubiquiti:DNA complex generated by superimposing the p53:ubiquitin 
model onto the p53:DNA crystal structure (PDB). Electrostatic surface analysis of the 
ubiquitin:TA model was carried out using the APBS Pymol plugin. Blue indicates positively 
charged surface, while red shows negatively charged protein surface. (b) The buried surface 
on p53 was calculated using Pymol (left panel). Binding free energy (in kcal/mol) of DNA 
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Figure 5-20 Polyubiquitination does not dramatically increase the positive surface area 
of the p53 DBD:ubiquitin complex 
Models of polyubiquitinated p53 were generated on the basis of structures from ubiquitin 
linked to p53 Lys292 (Fig 5-8) and models of tetraubiquitin chains obtained from the 

























p53  DBD p53  DBD
p53  DBD
p53  DBD
p53  DBD p53  DBD





5. Results  218 
5.2.8 IRF-1 and p53 bind DNA more stably when in their 
ubiquitinated form 
In silico modelling suggested a novel role for monoubiquitination in the direct 
stabilisation of the TA:DNA complex, leading to transcriptional activation. To study 
this hypothesis experimentally, I first carried out in vitro DNA binding assays with 
recombinant IRF-1 and p53 protein that had been modified by ubiquitin in an in vitro 
ubiquitination reaction containing all components of the ubiquitination cascade as 
purified compounds. The ubiquitination reactions were carried out with either wild-
type ubiquitin, that can result in formation of mono- and polyubiquitination chains or 
with an ubiquitin mutant, where all lysines are mutated to arginine (NoK), which is 
unable to form polyubiquitin chains linked by internal ubiquitin lysines (Fig 5-21 and 
Fig 5-22a). As a control, AMP instead of ATP was added to the in vitro reaction 
(preliminary experiments showed that ADP could in part support ubiquitination 
where AMP could not). The sequence specific DNA binding ability of either IRF-1 
or p53 was examined using an electrophoric mobility shift assay (EMSA) followed 
by quantification of the resulting bands using Image J. To confirm that the observed 
bands corresponded to p53 or IRF-1 binding to the probe, anti p53 or IRF-1 
antibodies were added to the samples to supershift the protein:DNA complex. For 
IRF-1, which binds DNA to give a diffuse band in an EMSA, I also set up additional 
binding assays. Specifically, biotin labelled oligonucleotides that are known to bind 
to IRF-1 (Chapter 4), were immobilised onto a streptavidin coated microtiter plate, 
then incubated with a titration of either unmodified or ubiquitinated IRF-1 protein. 
DNA bound protein was detected using an anti-IRF-1 antibody (Fig 5-21c). In case 
of p53 the ubiquitination pattern with WT and NoK ubiquitin is relatively similar as 
MDM2 predominantly acts as a monoubiquitin ligase (Fig 5-23a). Results of the 
DNA binding assays show that, as predicted by in silico modelling, both IRF-1 and 
p53 have enhanced DNA-binding activity, when in an ubiquitinated form and that 
monoubiquitination is sufficient for an increase in DNA binding (Fig 5-21 to 5-23). 
The increase in DNA binding activity appears to be greater for proteins modified by 
WT ubiquitin compared to those modified by the NoK ubiquitin mutant. However, 
the ubiquitin mutant appears to be a poor substrate for the ubiquitination reaction 
compared to WT ubiquitin and its addition results in less conversion of unmodified 
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IRF-1 or p53 to the modified product, making a direct comparison of the effects of 
WT and mutant ubiquitin difficult. Yet, the assays shows very clearly that 
monoubiquitination of both transcription factors leads to an increase in DNA 
binding. We can therefore conclude that addition of a single ubiquitin molecule at a 
given site, rather than a polyubiquitin chain, is sufficient to increase the binding 
affinity of the transcription factors to their respective consensus sequence. To further 
confirm that the increase in DNA binding is due to the modification of the TAs by 
ubiquitin, a timecourse of the ubiquitination reaction for p53 was carried out with 
incubation times of either 0, 10 or 45 minutes and subsequent DNA binding analysis 
of the protein was performed by EMSA. As shown in Figure 5-23a the increase in 
DNA binding activity corresponds to the increase of ubiquitination at a longer 
incubation time. To determine if this increase in DNA binding activity is exclusive 
for binding of p53 to the p21 promoter sequence, or if it is a more general 
phenomenon, the ability of unmodified and ubiquitinated p53 to bind to sequences 
from the promoter of p21, BAX, MDM2 and PUMA were compared. As shown in 
Figure 5-24 ubiquitination leads to an increase in binding to all four promoters, 
indicating that ubiquitination of p53 generally increases the affinity for its target 
promoters. Taken together, these data provide strong evidence that ubiquitination of 
p53 and IRF-1 leads to an increase in their ability to bind to DNA and thus function 
as transcriptional regulators.  
The modelling together with DNA binding data thus suggests a direct role for 
ubiquitin in stabilising the interaction of the DBD with DNA. To identify the main 
ubiquitin residues that are involved in DNA interactions, I generated an overlay of 
the position of ubiquitin in respect to DNA in all models (Fig 5-25a). Analysis of the 
models revealed that ubiquitin contacts the DNA in all models with the same 
'positively charged patch', consisting of mainly residues Lys6, Arg42 and Lys48 (Fig 5-
25). Next I wanted to determine, if this positively charged surface is indeed involved 
in DNA interactions. Therefore, I mutated these three residues and replaced them 
with either a neutral or negatively charged residue to test if this affected the ability of 
the mutant to stabilise the p53:DNA complex. A single point mutation of either Lys48 
or Arg42 to either Ala or Gln almost completely abolished the ability of ubiquitin to 
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serve as a substrate for in vitro ubiquitination reactions (Fig 5-25c). Mutation at Lys6 
to Ala or Gln resulted in a substantial decrease in the ubiquitination efficiently, but 
some ubiquitination could still be observed, especially with the Ala mutant. Studies 
in the Hay lab have subsequently shown that all three residues Lys6, Arg42 and Lys48 
are involved in interactions with the E2 in the ubiquitin:E2:E3 complex (structure 
solved by Plechanonova [46] Figure 1-4) and mutation of these residues most likely 
disrupts the E2:ubiquitin interaction and thereby prevent the formation of an active 
complex. Since, I observed some ubiquitination using the lysine 6Ala mutant, I 
adapted the conditions of the in vitro ubiquitination reaction to get a similar amount 
of ubiquitination with wt and 6Ala ubiquitin, to achieve this both reaction were 
incubated at 30°C for 45 minutes, but ATP was added to the reaction with WT 
ubiquitin only for the last 10 minutes, while ATP was present in the reaction with 
6Ala ubiquitin for the whole incubation time. The ability of p53 ubiquitinated with 
either WT or 6Ala ubiquitin to bind to the p21 or Bax promoter was determined using 
an EMSA. As expected, results of the DNA binding assay show enhanced binding 
with wt ubiquitin, while ubiquitination with the mutant does not affect binding of 
p53 to DNA (Fig 5-25c). Because the ubiquitin mutant is not a good substrate for the 
reaction, the overall ratio of modified to unmodified p53 is quite low and thus the 
increase in DNA binding of ubiquitinated p53. Therefore, even though the results 
show a reproducible increase with wt ubiquitin and no increase with the ubiquitin 
mutant, indicating that interactions between the positively charged Lys and DNA are 
indeed involved in stabilisation of the DBD:ubiquitn:DNA complex, further 
experiments are necessary to confirm the role of these specific ubiquitin residues in 
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Figure 5-21 (Mono)-ubiquitination increases IRF-1's ability to bind to DNA 
(a) IRF-1 was ubiquitinated in an in vitro reaction with either wild-type ubiquitin or an 
ubiquitin mutant  (NoK) with all lysines mutated to arginine that cannot form polyubiquitin 
chains. The reaction was incubated for 45 minutes with 60 ng of His-CHIP and 150 ng of 
GST-IRF-1 in each reaction. (b) Binding of modified IRF-1 compared to unmodified IRF-1 
(from a) to C1 DNA was tested in an EMSA (electrophoretic mobility shift assay) with 100 
ng of ubiquitinated or unmodified IRF-1 per reaction, bands were quantified using Image J 
and are presented in a graph in form of Arbitrary Units (right panel). (c) Binding of the 
samples (from a) to DNA was determined using a DNA binding assay on a microtiter plate, 
the plate was saturated with biotin tagged C1 oligonucleotide and incubated with increasing 
amounts of IRF-1 (0-40 ng) in the mobile phase. Bound IRF-1 was detected using an anti-
IRF-1 mAb. (NS = non-specific band) 
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Figure 5-22 (Mono)-ubiquitination increases p53's ability to bind to DNA 
(a) p53 was ubiquitinated in an in vitro reaction with either wild-type ubiquitin or an 
ubiquitin mutant (NoK) with all lysines mutated to arginine that cannot form polyubiquitin 
chains. The reaction was incubated for 45 minutes with 60 ng of MDM2 and 250 ng of p53 
in each reaction. (b) Binding of modified compared to unmodified p53 (from a) to p21 
promoter DNA was determined by EMSA with 500 ng of ubiquitinated or unmodified p53 
per reaction. Where indicated a p53 mAb was added to the sample to supershift the 
p53:DNA complex. Bands on the EMSA gel were quantified using Image J and are 
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Figure 5-23 Increase in DNA binding ability of p53 correlates with an increase in 
ubiquitination 
(a) p53 was ubiquitinated in an in vitro reaction. The reaction was incubated for 0, 10 or 45 
minutes with 60 ng of MDM2 and 250 ng of p53 in each reaction. (b) Binding of modified 
compared to unmodified p53 (from a) to p21 promoter DNA was tested by EMSA with 500 
ng of ubiquitinated or unmodified p53. Bands were quantified using Image J and are 
presented in a graph (lower panel). 
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Figure 5-24 Ubiquitination of p53 leads to an increase of binding affinity to several 
promoters 
EMSA comparing binding of 500 ng of in vitro ubiquitinated p53 and unmodified p53 to 
consensus sequences from the p53 target promoters: p21, MDM2, BAX and PUMA. p53 
was ubiquitinated in an in vitro ubiquitination reaction for 45 minutes with 60 ng MDM2 and 
250 ng p53, for the unmodified control AMP instead of ATP was added to the reaction. 
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Figure 5-25 Specific residues on the surface of ubiquitin are involved in DNA 
interaction 
(a) Overlay of ubiquitin in all five TA:ubiqutin:DNA models with respect to the DNA 
sequence. (b) Surface of the ubiquitin facing the DNA in the models. Positively charged 
residues that appear to interact with the DNA in the MD simulations are highlighted. (c) 
EMSA comparing binding of 500 ng p53, ubiquitinated with either ubiquitinWT or ubiquitin6A 
in an in vitro ubiquitination assay, to consensus sequences from the p53 target promoters p21 
and BAX. p53 was ubiquitinated in an in vitro ubiquitination reaction for 45 minutes with 60 
ng MDM2 and 250 ng p53. To obtain similar amounts of ubiquitinated p53, ATP was only 
added to the reaction for the last 10 minutes in the ubiquitinWT sample. For the unmodified 
control AMP instead of ATP was added to the reaction. Bands on the EMSA gel were 
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5.2.9 Mutation of ubiquitin acceptor residues impairs the 
transcriptional of p53 and IRF-1  
Results from experimental and in silico approaches have provided evidence that 
monoubiquitination at specific DBD Lys residues of p53 and IRF-1 will increase the 
ability of these TAs to form stable complexes with DNA and this is supported by the 
observation that monoubiquitinated p53 is tightly associated with chromatin. If the 
increase in DNA-binding activity and enhanced chromatin association result in a gain 
of TA function we would expect that loss of key ubiquitin acceptor Lys would 
adversely affect the TA activity of p53 and IRF-1. To investigate this, I asked 
whether the lysine residues within the DBDs of the two proteins that are subject to 
ubiquitination are required for full transcriptional activity in cells. In detail, I tested 
the transcriptional activity of both p53 and IRF-1 mutants that contain a mutation 
from lysine to arginine, at all residues that were shown to be ubiquitinated, in a dual 
luciferase reporter assay. A mutation from lysine to arginine preserves the charge of 
the amino acid, but does not allow its modification by ubiquitin.  
The ability of the mutants and wild type proteins to modulate the rate of transcription 
from p21, Bax, PUMA and MDM2 promoters or TRAIL and CDK promoters was 
tested for p53 and IRF-1 respectively. Therefore, H1299 cells were cotransfected 
with Renilla luciferase, the reporter construct of interest fused to Firefly luciferase 
and either p53 or IRF-1. p53 contains ubiquitination sites in both its DNA binding 
and C-terminal domains. I, therefore, started of by determining the effect of 
mutations of all four lysines in the DBD and all six C-terminal lysines of p53, on its 
ability to promote transcription from the Bax and p21 promoters. Strikingly, while 
mutation of all six C-terminal lysines to arginine did not have any effect on the 
transcriptional activity of p53, mutation of residues in the DBD almost completely 
abolished p53 activity using both promoter reporters (Fig 5-26a-d). To investigate 
exactly which lysines residues were responsible for this effect, single point mutants 
at all for sites in the DBD were generated and tested in the assay. As shown in Fig 5-
26a-d the most significant effect is observed with the mutant that carries a mutation 
at Lys292, reduced activity was also observed for the protein with a mutation at Lys164 
whereas and mutation of residues Lys305 or Lys101 lead to only very small decreases 
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in p53 transcriptional activity. This implies that ubiquitination of residues Lys292 and 
Lys164 is required for p53 activation. Interestingly the Lys164 to Arg mutant displayed 
a significant reduction in TA activity when assayed using MDM2 or BAX reporters, 
however this mutant was not impaired on the p21-reporter suggesting that there 
could be some promoter context specificity in the effects with respect to modification 
at a given DBD site. It is noteworthy, that these are the same sites that were used to 
model the p53:DNA complex in silico and where ubiquitin linkage lead to an 
increase in positively charged surface area that interacts wit DNA. 
Results for IRF-1 showed that a mutation from Lys78 to Arg abolished its 
transactivation potential on the TRAIL promoter almost completely (Fig 5-26e). 
Moreover, the mutant was not able to repress transcription from the CDK2 promoter, 
where IRF-1 functions as a transcriptional repressor (Fig 5-26f). Single site 
mutations at the other residues lead to only a small change it IRF-1 dependent 
transactivation/repression, suggesting that ubiquitination at Lys78 is important for 
transcriptional control of IRF-1 under these conditions.  
Taken together, the data on p53 and IRF-1 indicate that ubiquitination of the DBD 
domains in required for full transcriptional activity of both proteins. Furthermore, the 
results demonstrate that ubiquitination of p53 and IRF-1 can lead to an increase in 
their affinity for DNA and modelling results suggest that this is due to stabilising 
interactions between ubiquitin and the promoter DNA. Overall, the results presented 
in this chapter indicate a complex role for ubiquitination in the control of p53 and 

























Figure 5-26 Mutation of the ubiquitin acceptor lysines in p53’s and IRF-1 DBD 
decrease their transcriptional activity 
 (a) H1299 cells were co-transfected with either WT p53 or mutants with all four ubiquitin 
acceptor lysine in the DBD (4R) or all six C-terminal lysines (6R) mutated to arginine, and a 
p21 or Bax reporter construct. As a control, promoter activity of a renilla promoter construct 
was measured. Results are plotted as the normalized firefly luciferase activity over the value 
of Renilla luciferase and represent the mean of two independent experiments together with 
standard deviations in relative light units (RLU). (b-d) H1299 cells were transfected with 
either p53 WT or p53 with a mutation from lysine to arginine at Lys101, Lys164, Lys292, Lys305 
or with 4R together with a (b) p21, (c) MDM2, or (d) Bax reporter plasmid. Dual luciferase 
assays were carried out as described above and the transcriptional activity of p53 WT and 
mutants was compared. (e+f) H1299 cells were co-transfected with 100 ng of either IRF-1 
WT or IRF-1 with a mutation from lysine to arginine at Lys39, Lys50, Lys78, Lys95 or Lys117 
and the (e) TRAIL or (f) CDK2 reporter plasmid and renilla. The activity of IRF-1 to 
activate transcription of the promoter was determined using the dual luciferase assay and 
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5.3 Discussion 
Tight control of gene expression is critical for maintenance of cellular homeostasis 
and thus the prevention of disease development. Therefore, transcription is one of the 
most highly regulated processes in the eukaryotic cell, including tight control of 
transcriptional regulator activity. Ubiquitination and subsequent degradation by the 
proteasome is known to be the primary mechanism by which the stability, and 
thereby activity, of the transcription factors p53 and IRF-1 is regulated. Here, I 
demonstrate that (i) the ability of IRF-1 and p53 to bind DNA is increased upon 
ubiquitination, and that monoubiquitination is sufficient for this gain of function, (ii) 
increase in p53 ubiquitination occurs in response to activating stimuli and this 
uncoupled from its degradation, (iii) ubiquitinated forms of p53 are chromatin 
associated following p53-pathway activation. These results suggest an additional role 
of ubiquitination in the regulation of the two transcription factors IRF-1 and p53, 
besides signalling their degradation (see model, Fig 5-27). 
A strong link between the UPS and control of several aspects of transcription has 
become evident in recent time. Ubiquitination of the two viral transcriptional 
regulators Tat (human immunodeficiency virus type 1) and Human Papillomavirus 
E2 by MDM2 was shown to be essential for their transactivation function [340, 341]. 
Fusion of a single ubiquitin molecule to the C-terminal end of Tat bypasses the 
requirement for MDM2 and provides a fully activate TA, indicating that 
monoubiquitination by MDM2 is required for the function of Tat as a transcriptional 
regulator [340]. Additionally, the transcription factors Gal-4 and Myc need to be 
ubiquitinated in order to be fully active [336, 350, 351]. Several mechanisms have 
been proposed to explain the link between ubiquitination and TA activation, these 
mainly involve the recruitment of co-factors to the site of transcriptional initiation, 
e.g. of the 19S regulatory particle of the proteasome, which exhibits ubiquitin 
binding ability and is important in transcription elongation by RNA polymerase II 
[97, 340, 352]. Additionally, it has been argued that in certain cases 
monoubiquitination can protect promoter bound activators from the unfolding 
activities of proteasomal ATPases by disrupting TA:ATPase complexes [339]. 
Ubiquitin can aid in the formation of active enhanceosomes, as seen for the 
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transcriptional co-regulator CIITA, which in its ubiquitinated form, acts as a 
scaffold, recruiting several other factors to the site of transcription [342]. Finally, the 
destruction of the TA as a requirement for further rounds of gene transcription was 
described by Geng et al. (2012) [91] in a model where the TA is phosphorylated by 
kinases that are associated with the transcriptional machinery. This phosphorylation 
not only marks the TA as spent and unable to stimulate further rounds of 
transcription, but also recruits E3 ligases that ubiquitinate the TA leading to its 
destruction. If ubiquitination/degradation of the TA is inhibited, the inactive TA 
blocks the promoter binding site, preventing other active regulators to bind and 
initiate further rounds of transcription [91, 353-355].  
Here, I propose an additional mechanism for the activation of TAs by ubiquitin (see 
model, Fig 5-27). I show that ubiquitination of residues within p53 and within IRF-1 
DBD stabilises the interaction of these 2 TAs with their respective consensus 
sequences. A mutational analysis of ubiquitin acceptor residues in both proteins, 
indicates that ubiquitination of specific lysine residues within their respective DBD's 
may be required for full transactivation. Models of the DBD:ubiquitin:DNA complex 
were computed to get an insight into the binding interface of the apo- compared to 
the ubiquitinated protein. The computational modelling, together with molecular 
dynamic simulations, suggests that ubiquitinated residues, mainly Lys6, Arg42 and 
Lys48, directly interact with the promoter DNA, thereby stabilising the 
protein:ubiquitin:DNA complex. This is confirmed by electrostatic surface analysis 
of the models, which shows that monoubiquitination leads to a dramatic increase of 
the positively charged surface area that interacts with the promoter DNA. This 
observation is intriguing, as even though the role of ubiquitination in promoting 
protein-protein interactions by providing part of the binding interface is well 
established, to our knowledge no example has been described where ubiquitin 
stabilises a DNA-protein interactions by forming part of the protein:DNA interface.  
Based on these observations, I propose a mechanism where ubiquitin can directly 
enhance the affinity of a TA for its target promoter, I also speculate that sequence 
specificity is determined through the DBD of the TA and that ubiquitin strengthens 
TA:DNA binding by DNA sequence unspecific electrostatic interactions involving a 
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highly charged positively patch on its surface. However, even though the modelling 
data strongly suggest a direct contribution of ubiquitin residues in the TA:DNA 
interactions, I can not rule out that ubiquitination can lead to conformational changes 
in the TAs, which increases the affinity of the DBD for DNA through an allosteric 
mechanism or a combination of direct interactions of ubiquitin with DNA and 
allosteric changes in the TAs. 
The modelling data indicate that the increase of DNA binding is mostly mediated by 
the first and possibly by the second ubiquitin molecule, but that any further chain 
elongation would not lead to additional stabilisation of the complex (Fig 5-20). 
Indeed does ubiquitination of IRF-1 or p53, by an ubiquitin mutant that can only 
form monoubiquitination, result in an increase in DNA binding, suggesting that 
(multi) mono/ or di-ubiquitination is sufficient to enhance binding of the 
transcription factors to DNA. This is in line with my observation, that p53 
ubiquitination following its activation does not lead to its degradation. It is 
commonly believed that at least four ubiquitin molecules are required to mediate 
degradation, while shorter chains (or chains with different linkages) have been 
associated with other cellular signals. Nutlin-3 treatment leads to the formation of 
mainly mono- or di ubiquitinated p53, indicating that under activating conditions p53 
ubiquitination can be 'switched' from polyubiquitination linked to degradation to 
monoubiquitination involved in p53 activation. Nutlin-3 was identified as a small 
molecular inhibitor of the MDM2-p53 interaction, by binding to the hydrophobic 
pocket of MDM2 and blocking binding to the Box I motif on p53 [344]. 
Subsequently, Nutlin-3 was shown to activate p53, leading to apoptosis and it is 
currently being tested in clinical trials as a novel anti-cancer drug. However, the 
mechanism by which Nutlin activates the p53 pathway remained a subject of 
discussion. The most widely accept hypothesis is that Nutlin, by binding to the 
hydrophobic pocket of MDM2, disrupts its interaction with p53 and thereby inhibits 
MDM2 mediated ubiquitination and degradation of p53, stabilising its levels and 
leading to increased transcription of p53 target genes. Conflictingly, however, 
complete knock-down of MDM2 does not result in an increase of p53 steady state 
level comparable to the striking up regulation of p53 levels/activity observed in 
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Nutlin-3 treated cells [356]. This indicates that pure inhibition of MDM2 is not 
sufficient to explain the activating effect of Nutlin-3 on p53 function. The Ball group 
has previously reported that Nutlin-3, despite disrupting the high affinity interaction 
between MDM2 and p53 and releasing the trans-repression activity of MDM2 on 
p53 [357], Nutlin-3 does not inhibit p53 ubiquitination. In fact they suggested that it 
leads to conformational changes in MDM2 that can promote interactions between a 
second MDM2 binding site in the core domain of p53 by the acid domain of MDM2, 
and that furthermore this interaction is sufficient to facilitate MDM2 mediated 
ubiquitination of p53. In other words Nutlin-3 acts as an allosteric activator. Here, I 
built on this model and show that Nutlin-3 can both enhance p53 ubiquitination and 
modify the ubiquitination pattern, resulting in a pool of monoubiquitinated, active 
p53 that is localised in the chromatin bound fraction of the nucleus. Even though 
Nutlin-3 can partially inhibit p53:MDM2 complex formation in vitro, more 
p53:MDM2 complexes can be detected in Nutlin-3 treated cells compared to control 
cells. This most likely reflects the striking increase in p53 and MDM2 levels in 
Nutlin-3 treated cells, and shows that interaction of MDM2 with p53's ubiquitination 
signal in its core domain is sufficient for MDM2:p53 complex formation in cells. As 
I detect mainly monoubiquitinated p53 in Nutlin-3 treated cells, I postulate that the 
MDM2:p53 complexes detected lead to p53 monoubiquitination. It would be 
interesting to determine if a specific ubiquitin-conjugating enzyme preferably 
interacts with MDM2 in its Nutlin-3 bound conformation, leading to a change in the 
ubiquitination pattern or if Nutlin-3 can affect the engagement of possible E4 
enzymes in p53 ubiquitination.  
Ubiquitination of chromatin associated p53 after radiation, but not Nutlin-3 
treatment, is dependent on the ATM kinase. ATM is the primary regulator of the 
double strand break response in cells and leads to p53 activation. It has been shown 
to directly phosphorylate p53 at Ser15 during activation. Furthermore, ATM directly 
phosphorylates MDM2 at Ser395 and indirectly mediates phosphorylation of Tyr394 
via the c-Abl kinase [358]. It remains to be investigated whether phosphorylation of 
p53, MDM2 or both by ATM mediate increased ubiquitination of p53. The 
requirement for ATM function in order for DNA damage to mediate p53 
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ubiquitination shows that ubiquitination is direct downstream effect of p53 activation 
via the ATM-pathway.  
Interestingly and in line with our results, the E3 ligase E4F1 was shown to lead to 
p53 polyubiquitination but not degradation [359]. Remarkably, E4F1 promotes p53 
dependent transcription of factors involved in cell cycle arrest rather than apoptosis. 
It would be interesting to determine if ubiquitination of specific residues or by other 
UBL modifications can change the affinity of p53 for a specific set of promoters and 
thereby, distinguish between different cellular responses to p53 under specific stress 
conditions. 
The data presented here, suggest that p53 and IRF-1 are members of the class of 
transcription factors that are activated by ubiquitination, and that this is due to 
stabilisation of the TA:DNA complex by ubiquitin linked to residues in the proteins 
DNA binding domain. The importance of the on and off rate of TA binding to their 
target promoter, in contrast to the pure promoter occupancy, has recently been 
highlighted by Lickwar et al. [360]. This study demonstrates that long residence and 
thus lower dissociation rates strongly correlate with TA function, while fast binding 
turnover correlates with shorter residence at the promoter and lower transcriptional 
activity. We can speculate therefore could that ubiquitin increases promoter 
occupancy by stabilising the interaction once the transcription factor is bound to 
DNA and thereby prolonging the residence at the promoter, thus increasing the 
chances of transcription initiation. A 'licensing' or 'kamikaze model' has also been 
proposed [137]; where monoubiquitination of TAs lead to their activation but at the 
same time inevitably results in polyubiquitination and thus TA destruction. In our 
observations, however, ubiquitinated forms of p53, especially after Nutlin-3 
treatment, are very stable and do not appear to lead to polyubiquitination and hence 
to degradation. This, additionally, shows that active p53 is not ubiquitinated in order 
to be degraded and 'vacate' a promoter binding site for binding of 'fresh' activators 
that can initiate another round of transcription, as proposed in the model by Geng et 
al. [91], described earlier. Rather, the results presented here show that under certain 
conditions p53 ubiquitination can be completely uncoupled from its degradative 
function and serve purely to activate its transcriptional activity. p53 is an unusual 
 
5. Results  235 
transcription factor in the sense that its level are almost exclusively regulated through 
degradation and not by expression. As degradation of p53 is almost completely 
halted under activating conditions, it is possible that the complete uncoupling of p53 
monoubiquitination from degradation forms an exception of TA activation. The 
levels of the transcription factor IRF-1, on the other hand, are regulated through both, 
the rate of expression as well degradation. Moreover, the Ball group has previously 
shown that a reduction in its half-life marks IRF-1 more active [136], making it a 
bona fide example for a transcription factor that is regulated by the 'kamikaze model'. 
Additionally I showed, in chapter 4, that IRF-1, when in a DNA bound conformation, 
does not get ubiquitinated (further). It would thus be possible that 
monoubiquitination stimulates IRF-1 to bind to specific promoters, then, while 
initiating transcription, IRF-1 is protected from polyubiquitination, and only after 
DNA dissociation its DBD is accessible for polyubiquitination by E3 ligases that 
leads to its degradation terminating the signal. To confirm these speculations and to 
gain complete understanding of the role of monoubiquitination in the control of TA 
activity and its link to polyubiquitination and degradation, the effects of 
monoubiquitination on the activity and stability of these and other TAs, as well the 
E3, E4 and DUB enzymes involved in the process, will have to be studied in more 
detail.  
In summary, I report, for the first time, that ubiquitination of the DNA binding 
domain of transcription factors can directly enhance binding of the protein to their 
respective consensus DNA. Furthermore, I show that ubiquitination is involved in 
activation of p53 and that this can be exploited by the small molecular drug Nutlin-3, 
which leads to an increase in p53 mono- or multiubiquitination resulting in its 
association with chromatin and thus activation. More research is necessary to 
determine how the fate of ubiquitinated p53 is determined. Most likely chain 
topology and length as well as the specific residue targeted on p53 are involved in 
determining the outcome of p53 ubiquitination. Importantly, this study highlights the 
need to further study the role of ubiquitination in the control of p53 activity to fully 
understand how the UPS is involved in p53 control. Development of small molecular 
drugs that target p53 E3 ligases to inhibit degradation of the tumour suppressor p53 
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is a main research interest, however, as shown here modification rather than 
complete blockage of p53 ubiquitination, as seen for Nutlin-3, might be a more 
successful approach to restore or activate the tumour suppressive function of p53. In 
conclusion, the data presented in this chapter indicate a complex role of 
ubiquitination in the control of the activity of the transcription factors IRF-1 and p53.  
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Chapter 6: Conclusion and future directions  
This thesis aimed to expand our understanding of IRF-1 and p53 ubiquitination by 
studying two main areas, (i) regulation of the activity and specificity of their E3 
ligases (ii) and the implications of ubiquitination on their transcriptional activity. 
And to thereby gain insight into how ubiquitination of these tumour suppressor 
proteins is controlled under different conditions to regulate their function. 
I presented a novel mechanism by which ubiquitination can be directly involved in 
the activation of transcription factors by stabilising the interactions with their cognate 
DNA sequence at target promoters. The fact that both transcription factors studied 
during my PhD bind DNA more stably when in their ubiquitinated form is intriguing, 
and indicates that this could be a more general mechanism that is the property of a 
number of transcriptional regulators. Indeed, several other transcription factors have 
been shown to require modification by ubiquitin in order to be fully active, including 
other substrates of MDM2 [340, 361]. It would be interesting to determine if 
ubiquitination of these transcriptional regulators can stabilise their DNA interactions 
in a manner similar to that seen of IRF-1 and p53. Further research is necessary to 
gain an understanding of a possible link between monoubiquitination observed in 
transcriptional active transcription factors and polyubiquitination leading to their 
degradation. The 'Kamikaze model' which proposes that ubiquitination could act as a 
licencing event which activates a TA and at the same time targets it for degradation 
[137], provides an interesting idea in which a transcription factor is particularly 
active when very short lived, thus allowing tight control of its activity. This idea is 
supported by data showing that several transcriptional regulators are most active, 
when their half-life is reduced, as seen for IRF-1 [136], and that transactivation and 
degron domains overlap in numerous proteins [91]. The results obtained as part of 
this study, however, did not reveal a direct link between p53 ubiquitination as part of 
its activation and that, which signals its destruction. Conversely, I showed that the 
half-life of active, ubiquitinated p53 is strikingly increased compared to control 
conditions, implying that the relationship between mono- and polyubiquitination is 
complex and that once monoubiquitination has occurred, polyubiquitination and 
 
6. Conclusion and future directions  238 
degradation do not inevitably follow. p53 was shown to be targeted by different 
DUBs, including HAUSP [215]; and it would be interesting to study the role of DUB 
activity in the regulation of p53 activation. Another question that remains elusive is 
how the cell controls the outcome of p53 ubiquitination, especially if the same E3 is 
involved in activation as well as degradation. In the case of MDM2, it has been 
proposed that the ratio of MDM2 to MDM4 protein, as well as the concentration of 
MDM2, is involved in the regulation of its activity, tilting MDM2 activity either 
towards poly- or monoubiquitination [215, 362]. Additionally, ligand binding could 
influence the outcome of an ubiquitination event. Nutlin-3 induced 
monoubiquitination of p53 by MDM2 shown here is an example for this. The roles of 
MDM2, MDM4, other E3 ligases and different E2 enzymes in the activation of p53 
upon DNA damage need to be examined in more detail to attain complete 
understanding of the process. I have carried out preliminary experiments with the 
aim to identify E3 ligases that are involved in p53 monoubiquitination in response to 
physiological stress signals. Therefore, chromatin associated proteins were isolated 
from nuclei of irradiated cells (IR) by sucrose gradient fractionation and analysed by 
mass spectrometry. The results, which revealed chromatin associated E3 ligases, will 
need to be validated carefully and the possible implications of these E3 ligases in the 
control of p53 monoubiquitination remain to be investigated. 
 
One of the main challenges of studying ubiquitination in a cellular context are the 
limitations to detect specific chain linkages as well to introduce a protein that is 
ubiquitinated at a specific residue into cells. In contrast to phosphorylation, where a 
mutation with a negatively charged side chain can be utilised to study its effects in 
vivo, no such modification is available to study ubiquitination. Different studies have 
utilised ubiquitin fusions protein to either the N- or C-terminus of proteins [363, 
364], results of these studies, however, have to be interpreted carefully. It is now 
clear that different patches on the surface of ubiquitin play distinct roles in 
interactions with specific ubiquitin binding proteins and that these often interact with 
residues of both ubiquitin and residues on the surface of the target proteins [8]. Thus, 
site specificity and orientation of the ubiquitin molecule are important factors in 
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ubiquitin signalling. In the case of a C-terminal fusion protein, the ubiquitin 
molecule has a free C-terminus, which is normally linked to a residue on the target 
protein, while its N-terminal methionine is attached to the target protein. This results 
in a completely different orientation of the ubiquitin molecule, than if it was linked to 
a lysine residue on the substrate. Studys by the Gu and Vousden laboratories, for 
example, suggested that monoubiquitination of p53 signals nuclear export [362-364]; 
these observations, however, heavily relied on the use of transfected C-terminal 
ubiquitin fusion proteins in the absence of activating signals.  
In my studies, I found it difficult to recapitulate the endogenous p53 pathway using 
transfections in general, this is most likely due to the fact that introduction of p53 
into cells causes growth arrest in the absence of any additional stress signals. To 
overcome this difficulty, I adapted methods that allowed the detection of the 
endogenous ubiquitination system, for example sucrose gradient fractionation to 
study chromatin bound endogenous p53 and PLA to investigate the localisation of 
endogenous, ubiquitinated p53. Unfortunately, the reagents available to study IRF-1 
are not as sensitive as for p53 e.g. antibodies, and it was therefore more difficult to 
study endogenous ubiquitination of IRF-1 in cells, leading me to focus on p53 at this 
part of the project.  
 
New technologies are emerging that allow the construction of ubiquitinated proteins 
or peptides in vitro. Most of these advances focus on the introduction of an ubiquitin 
molecule by chemical modification residues in both a recombinant acceptor protein 
and the C-terminus of ubiquitin [51]. These techniques could give additional insight 
into outcomes of ubiquitination at specific lysine residues on a target protein. So 
could a p53 or IRF-1 construct linked to ubiquitin at specific lysines give insight into 
how ubiquitination at these exact residues affects its ability to interact with DNA, 
and furthermore it could reveal if this modification stimulated or inhibited interaction 
with other proteins. Constructing a CHIP or MDM2 protein that is linked to ubiquitin 
at one of the acceptors sites I identified using mass spectrometry, could show if and 
how this modification affects its activity i.e. chain, substrate and E2 specificity. 
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The study of site-specific ubiquitination in vivo remains challenging, linkage- or site-
specific antibodies are being developed to investigate effects of specific linkages and 
ubiquitination at distinct sites, e.g. for H2B [365]. It would be worthwhile generating 
antibodies that can detect p53 or IRF-1 protein that is specifically ubiquitinated at 
DBD residues, which are implicated to play a role in their transcriptional control. 
Studying the relationship between DNA binding and ubiquitination of IRF-1 further 
revealed that IRF-1 does not interact with the two ligases MDM2 and CHIP when in 
a DNA bound conformation and is thus protected from ubiquitination and destruction 
when in an active conformation. Furthermore, it is unable to interact with other 
proteins that also bind to its Mf2 domain. This is intriguing and it would be useful to 
compare the interactome of IRF-1 in a DNA bound compared to a DNA unbound 
conformation. Other Mf2 binding proteins have regulatory effects on IRF-1 and it 
would be interesting to determine, if these effects on IRF-1 are inhibited by DNA in 
a similar manner to that of E3 ligases. It will also be worthwhile to study, if DNA 
binding introduces allosteric changes in IRF-1, which in addition to blocking 
interactions with a specific set of proteins, allows other proteins to bind and regulate 
IRF-1 activity or assists its function. 
Lysine acetylation and ubiquitination are two mutual exclusive modifications. Lys78 
of IRF-1 has previously been shown to be acetylated by the CBP acetyltransferase 
[325]. The fact that this site is subject to both ubiquitination and acetylation implies 
that these two posttranslational modifications have interdependent roles, where 
acetylation could act as a regulator of ubiquitination and vice versa. It would be 
worthwhile to study the interplay between these two modifications further.  
Work presented in this thesis identified ubiquitination sites that were mapped using 
an in vitro mass spectrometry approach. I have evaluated the results for sites 
identified on IRF-1, but not CHIP and MDM2. It would be useful to verify the 
autoubiquitination sites on these proteins by a mutational study. The in vitro 
technique to map ubiquitination sites is limited, as it does not give information about 
how the ubiquitination pattern is regulated by cellular stresses or stimuli. Recently a 
di-glycine antibody has become available that can be used to isolate peptides that 
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contain a remnant di-glycine, which is representative for ubiquitinated proteins after 
trypsin digestion [366]. Using this antibody, ubiquitinated peptides can be enriched 
from a complex sample, like cell lysates. The antibody however, does not distinguish 
between modification with ubiquitin and some ubiquitin like modifier, including 
NEDD8 and ISG 15, which also result in a remnant di-glycine when digested by 
trypsin [367]. To specifically study the ubiquitinated proteome it would therefore be 
necessary to isolate ubiquitin modified proteins in an intermediate step before trypsin 
digestion. This approach would allow a more systematic study of ubiquitination sites 
from proteins isolated both from cell lysate and in vitro reactions and could provide a 
more detailed understanding of how proteins are modified by ubiquitin under 
different cellular conditions. It would be worthwhile to dissect how proteins like p53 
are ubiquitinated under different conditions to gain an insight into the effect of 
stimuli like ionising radiation or Nutlin-3 on both the ubiquitination pattern and the 
lysines residues modified. In vitro studies using ligands that bind to E3 ligases and 
modulate their activity, including the ones presented in this thesis i.e. Hsp70 to CHIP 
and Nutlin-3 to MDM2 could help us gain understanding of how binding proteins 
regulate the specificity of E3 ligases. Furthermore, the di-glycine antibody could be 
employed for a systematic study to detect ubiquitinated transcription factor 
associated with chromatin and reveal if these are ubiquitinated within or adjacent to 
their DBD.  
In conclusion, in the work presented here, I have started to dissect the complex 
relationship of E3 ligase regulation and the cellular signal of the modification on the 
target protein. However, many question on the control and effects of p53 and IRF-1 
ubiquitination and how these could possibly be exploited in the use of therapeutics 
remain to be investigated in future studies. 
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Appendix 1.1 The TPR-domain of Cyp40 regulates its 
Peptidyl Prolyl Isomerise Activity 
As the TPR domain of CHIP allosterically regulates its activity through inter domain 
communication, we were interested to find out, whether this is a general mechanism 
by which TPR domains can control enzyme activity or whether this is a phenomenon 
specific to the E3 ligase CHIP. We therefore, chose to investigate the effects of TPR 
modulation on the dynamics and activity of Cyp40 (Cyclophilin40), in collaboration 
with Prof Malcolm Walkinshaw's group (School of Biological Science, University of 
Edinburgh). Cyp40 is comprised of two domains, an N-terminal PPIase domain and a 
C-terminal TPR domain, which are joined by a flexible linker. Like CHIP, Cyp40 is 
known to interact with Hsp90 [1, 2].  
I began by modelling a Hsp90-bound form of Cyp40 by superimposing the TPR-
domain of the Hsp90-bound CHIP crystal structure (2C2L) onto the TPR domain of 
Cyp40 (PBD: 1IHG[3]) (Fig A1-1a, right panel) and comparing it to both the wild-
type conformation and a mutant form in which Lys227 (equivalent to Lys30 of CHIP, 
Fig A1-12a; left panel) was replaced by Ala. MD simulations were performed on all 
three structures, and the averaged fluctuation of each amino acid over the simulation 
was analysed. Simulations showed that, similar to CHIP, Cyp40 displays most 
flexibility when in an unliganded wild-type conformation (Fig A1-1b; left panel). 
Furthermore, mutation of Lys227, or ligand binding, led to an overall ‘tightening’ of 
the structures of both the TPR- and PPIase-domains (Fig A1-1b; centre and right 
panel). This suggests that modulation of the TPR-domain influences the dynamics of 
Cyp40’s catalytic PPIase domain in a relationship similar to that seen for the U-box 
and TPR-domains of CHIP. To determine if there was evidence of inter-domain 
communication I analysed the correlated motions between the averaged fluctuations 
for all amino acids. A correlated movement between the first α-helix of the TPR-
domain and a β-sheet in the PPIase-domain was observed in the case of apo-Cyp40 
(Fig A1-2 a left panel, movement A), but this was greatly reduced or lost in the 
ligand bound and K227A mutant form of Cyp40 (Fig A1-2 a, middle and right 
panel). Additionally, anti-correlated motions within the first three α-helices of the 
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TPR-domain were detected, again only in the unliganded form of Cyp40 (Movement 
B and C). Together the MD data suggest inter-domain cross-talk in Cyp40 and that 
this is dependent on the status of the TPR-domain. In the case of the E3 ligase CHIP, 
TPR mediated changes in the flexibility of the protein affects the activity of the U-
box domain. To explore, if changes in the dynamics of the Cyp40 PPIase domain 
observed in MD simulations, effects its catalytic activity in a similar manner to 
CHIP, Cyp40 wild type or mutant protein, with a single mutation in its TPR domain 
from Lys to Ala at 227 or 305, were purified and its cis-trans prolyl isomerase 
activity was tested using a Kofron’s optimised peptidyl-prolyl isomerase assay with 
suc-Ala-Leu-Pro-Phe-pNA as the substrate. Results of this experiment show that the 
introduction of a mutation at the TPR domain of Cyp40 increases it catalytic activity 
when compared to the wild type protein. Hence, modulation of the TPR domain of 
Cyp40, which affects its overall flexibility, modulates the activity of its catalytic 
domain in a similar manner as observed for CHIP. We speculate that ligands binding 
to TPR domains of proteins can act as allosteric regulators, changing the dynamic 
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Figure A1-1 Mutation or peptide binding to the Cyp40 TPR leads to an overall loss of protein 
flexibilty  
(a) Crystal structure of Cyp40 shown as cartoon (PBD: 1IHG[3]) with K308 and K227 indicated in pink. 
Also shown is a structure of Cyp40 associated with Hsp90 peptide, which was obtained by 
superimposing the TPR-domain of Hsp90-bound CHIP (from PDB 2C2L) onto the available structure 
for Cyp40 (PDB 1IHG). (b) Root mean square fluctuation (RMSF) of Cα obtained from the 
trajectories of 40 ns MD simulations of Cyp40 wild-type ± Hsp90 peptide and the K227A mutant. The 
score of the positional fluctuation analysis averaged over a 5 ns time frame for each amino acid were 
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Figure Error! No text of specified style in document.1-2 Modulation of Cyp40's TPR domain 
inhibits inter-domain communication and stimulates Cyp40's catalytic activity 
(a) Dynamic cross-correlation maps of Cα atoms for Cyp40 in the presence or absence of Hsp90 
peptide and with a K227A point mutation. Correlated movements of the TPR-domain and PPIase-
domain [A] and anti-correlated movements within the first three helices of the TPR-domain [B, C] can 
be seen for the wild-type Cyp40 protein, but are strongly decreased upon Hsp90 peptide binding and 
in the Lys227 mutant. Sections of the wild-type protein coloured in red or blue. (b) Results from a 
Kofron's optimised peptidyl-prolyl isomerase assay with suc-Ala-Leu-Pro-Phe-pNA as substrate and 
the indicated Cyp40 proteins. Graphs show PPIase activity normalised to standard error of mean. (b - 
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Appendix 1.2 Chaperone mediated allosteric 
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Tetratricopeptide repeats (TPRs) are best characterised as scaffolds for the 
assembly of multiprotein complexes in essential processes such as cell cycle 
control, host defence and proteostasis. The current study addresses the role of the 
TPR in regulation of CHIP, a chaperone associated E3-ubiquitin ligase linking 
molecular chaperones to the ubiquitin proteasome system. We reveal the TPR-
domain of CHIP as a binding site for allosteric modulators involved in determining 
the dynamic conformation and activity of CHIP as an E3-ligase. Molecular dynamic 
simulations support biochemical and biophysical evidence demonstrating that 
Hsp70 binding to the TPR, or Hsp70 mimetic mutations, negatively regulates CHIP-
mediated ubiquitination of p53 and IRF-1 by preventing U-box catalysed discharge 
of ubiquitin from UbcH5. Using a second TPR-domain protein, the peptidyl-prolyl 
isomerase cyclophilin 40, we show that chaperone mediated allostery can activate, 
as well as inhibit, cochaperone function. Defining chaperone-associated TPR-
domains as managers of inter-domain allosteric communication highlights the 
potential for scaffolding modules to regulate, as well as assemble, complexes that 
are fundamental to the control of proteostasis by the core molecular chaperone 
machinery. 
 
Tetratricopeptide repeats are versatile structural modules conserved from E.coli to 
man which function in fundamental processes such as transcriptional control, kinase 
signalling, protein folding and immunity (Cerveny et al, 2012; D'Andrea & Regan, 
2003; Zeytuni & Zarivach, 2012). TPR-domains are composed of two anti-parallel α-
helices (containing a total of 34 amino acids) packed in tandem arrays to create a 
characteristic fold and binding cleft. Cleft formation facilitates protein:protein 
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interactions and underpins the role of TPR-domains as molecular scaffolds for the 
assembly of multi-protein complexes (Andrade et al, 2001; Smith, 2004). Although 
crystallographic studies originally led to the conclusion that TPR-domains were 
relatively rigid structures with an invariant conformation on ligand binding, a more 
recently study on bacterial Rap proteins suggests that TPR-domain binding can 
induce gross conformational changes in the protein as a whole (Parashar et al, 2013). 
Using NMR (Cliff et al, 2006), CD (Cliff et al, 2005) and HX-MS (Graf et al, 2010) the 
flexible character of the apo-TPR has been uncovered and this has pointed to an 
essential role for unstructured or intrinsically disordered TPR-domain regions in a 
coupled fold-on-binding mechanism. This suggests that flexible TPR-domain 
structures may be an advantage when it comes to setting up protein interaction 
networks (Dunker et al, 2005).  
 
A subset of the TPR-domain proteins is known to associate with the Hsp70/Hsp90 
family of molecular chaperones through interaction with a conserved C-terminal 
(EEVD) motif and act as cochaperones. CHIP (Carboxy-terminus of Hsc70-interacting 
protein) is an E3-ligase with three TPRs within its N-terminus, a central charged 
domain and a C-terminal U-box that is required for E2-conjugating enzyme binding 
and E3-ligase activity. CHIP functions as an Hsp70 co-chaperone (Ballinger et al, 
1999) that can also interact with Hsp90, and links the molecular chaperones to the 
ubiquitin proteasome system. In addition CHIP can interact directly with native 
substrates to facilitate docking dependent ubiquitination13. The Cyp40 (cyclophilin-
40) cochaperone, comprises an N-terminal peptidyl-prolyl isomerase (PPIase) 
domain joined by a flexible linker to TPR repeats situated in the C-terminus. Like 
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CHIP, the TPR-domain of Cyp40 is made up of three helix-turn-helix motifs arranged 
in pairs to form a super-helical structure that provides a concave binding surface, 
which in the case of Cyp40, binds preferentially to Hsp90 (Carrello et al, 2004). 
 
Here a dynamic role for TPR-domains in the regulation of co-chaperone structure 
and function is proposed. By studying CHIP we have defined the TPR-domain as a 
modulator site for allosteric effectors of its U-box function and E3-ligase activity 
using physiologically relevant substrates such as p53 and IRF-1 (Narayan et al, 2011; 
Tripathi et al, 2007). The wider utility of the TPR as a regulatory module that can be 
employed by the chaperone machinery to maintain protein homeostasis is 
demonstrated using the immunophilin Cyp40 where stabilisation of TPR-domain 
conformation stimulates cis-trans isomerisation catalysed by the PPIase domain. We 
discuss inherent flexibility of a TPR-domain and its role in establishing dynamic 
motions within ensemble proteins and how this can mediate negative and positive 
allosteric regulation of protein activity in response to chaperone interactions. 
 
Results 
Hsp70 Modulates the E3-Ligase Activity of CHIP 
We are interested in the role for TPR-domain proteins in maintaining protein 
homeostasis and particularly in whether the TPR-domain of CHIP plays a role in 
determining its E3-ligase activity and specificity. CHIP binds to a well-defined 
consensus motif in the C-terminus of Hsp70/Hsp90 and recent solution studies 
suggest that the CHIP-TPR attains a more stable conformation on Hsp70 binding 
whereas in an unliganded state it is highly flexible (Graf et al, 2010). How changes in 
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conformation affect the activity of CHIP however have not been addressed. 
Experiments therefore concentrated on determining the E3-ligase activity of CHIP in 
the apo-form compared to CHIP in which the TPR-domain was stabilised through 
binding to Hsp70. When the effect of Hsp70 on CHIP-mediated ubiquitination was 
determined, using a range of well-defined substrates (Demand et al, 2001; Esser et 
al, 2005; Narayan et al, 2011) and an Hsp70 free in vitro ubiquitination assay 
(Narayan et al, 2011), we found that Hsp70, alone or together with its physiological 
partner Hsp40 (present at a ratio of 1:10 with Hsp70), could either inhibit or activate 
CHIP function dependent on the substrate (Fig 1A, B and C). Hsp70 inhibited the 
ubiquitination of p53 and IRF-1 (1A and 1B; this is not due to binding site 
competition as native IRF-1 and p53 bind to ΔTPR-CHIP; Narayan et al, 2011; Tripathi 
et al, 2007) under conditions where it stimulated the modification of BAG-1s (1C). In 
addition, Hsp70 inhibited CHIP auto-ubiquitination in the presence of either IRF-1 or 
p53, whereas no inhibition of CHIP auto-ubiquitination was detected in the BAG-1s 
assay.  
 
The above data suggest that the mechanism by which Hsp70 effects CHIP-mediated 
ubiquitination may differ dependent on the substrate however interpretation of the 
data is complicated by the fact that Hsp70 can bind directly to p53, IRF-1 and BAG-1s 
(Fourie et al, 1997; Narayan et al, 2009; Takayama et al, 1997a) in the absence of 
CHIP. To extend our analysis we therefore used a C-terminal peptide from Hsp70 
(634GPTIEEVD641) that binds exclusively to the TPR-domain of CHIP (Fig 1D and Fig S1) 
and not to its substrates. When added to the ubiquitination assays, the Hsp70 
peptide inhibited ubiquitination of IRF-1, and a mutant peptide with reduced CHIP 
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binding activity (see Fig S1) also had reduced inhibitory activity (Fig 1E). Ubiquination 
of p53 (Fig 1F) and CHIP auto-ubiquitination (Fig  1E and F) were also inhibited by the 
Hsp-peptide mimetic. Interestingly, the Hsp70 peptide was not sufficient to mimic 
the stimulatory effect of full-length Hsp70/40 on the ubiquitination of BAG-1s and 
furthermore, Hsp70/40 stimulated ubiquitination of BAG-1s was overcome by the 
Hsp70 peptide (Fig 1G). Together the data suggest that the mechanism by which 
Hsp70 promotes the ubiquitination of BAG-1s can be uncoupled from binding to the 
TPR-domain of CHIP and that it most likely relies on the ability of Hsp70 to bind 
directly to BAG-1s (Hohfeld & Jentsch, 1997; Takayama et al, 1997b). As a control for 
peptide specificity in binding to CHIP we show that it has no effect on the activity of 
the MDM2 E3-ligase in a p53 ubiquitination assay (Fig 1H) where all the components 
of the assay (with the exception of the E3) were identical to those in Fig 1F. 
 
CHIP-K30A has an Intrinsic Defect in E3-Ubiquitin Ligase Activity 
We reasoned that mutation of certain TPR-domain residues to Ala, a residue that 
encourages helix formation (Pace & Scholtz, 1998b), may mimic the stabilising effect 
of Hsp70-binding on the TPR-domainwhen22. Lys30 of CHIP is one of two basic 
residues (the other being Lys95) that are required to form a dicarboxylate clamp 
around the C-terminal Asp of Hsp70/90 (Fig 2A), and mutation of this residue to Ala 
has been predicted to prevent Hsp70 binding. We therefore reasoned that a 
Lys30→Ala (K30A) point mutant protein may provide a tool to study the effect of 
stabilising the TPR-domain in the absence of added ligand.  
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Following expression, purification and normalization of K30A and wild-type CHIP (Fig 
S2A), we verified that the K30A mutant was folded and dimeric using a variety of 
biophysical techniques, we then asked whether the K30A mutation produced protein 
that was deficient in binding to Hsp70. CHIP-K30A protein was unable to bind to a C-
terminal peptide from Hsp70 (Fig 2B) in a real-time AlphaScreen assay under 
conditions where the wild-type protein bound with a high affinity.  As CHIP-K30A 
constructs have been used extensively in cell-based assays to study the chaperone-
dependence of CHIP (Bonvini et al, 2004; Xu et al, 2002; Zhang et al, 2007) we next 
determined the effect of the Lys30 substitution on IRF-1 modification in cells. In-cell 
ubiquitination assays showed that wild-type CHIP significantly enhanced IRF-1 
modification by ubiquitin (Fig 2C, compare lanes 6 and 3) whereas CHIP-K30A did 
not, rather the mutant had some dominant-negative activity towards endogenous 
E3-ligases. This result could be interpreted as a requirement for Hsp70 in enhanced 
substrate ubiquitination, however we also noted that CHIP-K30A did not undergo 
auto-ubiquitination (Fig 2C; Ub-CHIP) suggestive of differences in its intrinsic activity 
in a way which, as we predicted, might reflect a stabilisation of the TPR-domain 
structure by Ala. 
 
To determine if CHIP-K30A E3-ligase activity was affected by the TPR-domain 
mutation it was assayed alongside that of the wild-type protein. To rule out an effect 
of the N-terminal His-tag on the structure and activity of the TPR-domain, these 
experiments were carried out using untagged CHIP (Fig S2B). Strikingly, CHIP-K30A 
displayed a significant reduction in its E3-ligase activity compared to the wild-type 
protein using either IRF-1 (Fig 2D) or p53 (Fig 2E) as the substrate. In addition, in 
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keeping with the cell-based assays (Fig 2C), the CHIP-K30A mutant was severely 
restricted in its ability to undergo auto-ubiquitination (Fig 2F). As the in vitro 
ubiquitination assay does not contain Hsp70/90 the decrease in CHIP-K30A E3-
activity is not due to loss of Hsp70 binding potential.  
 
Evidence of TPR-Mediated Changes in CHIP Conformation 
Data presented above suggest that the TPR-domain plays an active role in the 
regulation of CHIP and that modulation by ligand binding or the introduction of 
structure stabilising amino acids may result in a shift in the protein ensemble that 
impacts on the activity of the U-box which is require to bind and allosterically 
activate the E2-enzyme component of the ubiquitination pathway (Jiang et al, 2001; 
Ozkan et al, 2005). In addition, as Hsp70 and Hsp70-peptide, or the introduction of a 
Lys30 point mutation within the TPR, have similar effects on the activity of CHIP, we 
hypothesised that the CHIP-K30A mutation might ‘mimic’ binding of Hsp70/90 to the 
ligase. To test our hypothesis we investigated whether CHIP-K30A had different 
dynamic properties and if these were similar to those of Hsp70-bound CHIP.   
 
We started by determining whether peptide binding and/or Lys30 substitution 
affected the melting temperature (Tm) of full-length CHIP using fluorescence-based 
thermal shift assays as a measure of TPR secondary-structure and folding. CHIP had a 
higher melting temperature when bound to the Hsp70 peptide than in the un-
liganded state (Fig 3A and B; Tm unbound (DMSO) = 43.5
oC, and bound [wt peptide; 
GPTIEEVD] = 45.5oC) or in the presence of the low affinity mutant peptide (Hsp70 
mutant peptide; GAAAEEVD, see Fig S1). Strikingly, when wild-type CHIP was 
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compared to CHIP-K30A, the mutation (Fig 3A and B), like ligand binding, made the 
protein more resistant to melting, with a Tm for CHIP-K30A of 46
oC. The data suggest 
that substituting Lys30 with Ala encourages a more structured or folded 
conformation to be adopted by the CHIP TPR-domain. 
 
Next, limited proteolysis was used to probe for differences in the conformation of 
liganded- and apo-CHIP compared to the CHIP-K30A mutant protein. Conditions from 
preliminary experiments (Fig S3) were used to compare wt- and CHIP-K30A proteins 
to CHIP in the presence of the active Hsp70- or mutant-peptides (Fig 3C). The results 
showed a striking similarity between the banding pattern seen over-time for the 
CHIP-K30A mutant and for liganded CHIP i.e. full-length protein was more resistant 
to cleavage and no band 2 was generated. On the other hand, the bands generated 
for the wt protein in the absence of ligand or in the presence of control peptide were 
similar, with band 2 appearing between 15 and 30 min. Similar data were obtained 
using trypsin as the protease (Fig S3). Together the data suggest that the CHIP-K30A 
and Hsp70 peptide bound forms of CHIP have less structural flexibility and are in a 
more ‘ordered’ or compact form than wild-type CHIP when in solution.  
 
Striking Similarity between the Structures of Liganded and Mutant CHIP 
To gain further insight into how the TPR-domain might mediate changes in the 
activity and structure of CHIP, MD simulations were carried out using information 
derived from the crystal structure of mouse CHIP (residues 25-304) with an Hsp90 
peptide-bound (PDB code: 2C2L; Fig 5A). To relate the modelling to our experimental 
data, five mutations were introduced into the crystal structure to obtain human 
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CHIP. Simulations were run on dimeric CHIP wild-type protein with and without 
Hsp90 peptide and on the Lys30 mutant. Simulations where one CHIP protomer was 
Hsp90 peptide bound and the other was unbound and where the Hsp90 peptide was 
replaced with the peptide from Hsp70 (Fig S4) were also run. The results of the 
simulations demonstrate that the conformation of CHIP in its liganded (Fig 4B; CHIP 
wt + Hsp90 peptide) or mutant state (Fig 4B; CHIP-K30A) are very similar to each 
other and are different from the apo-state (Fig 4B; CHIP wt). In the apo-state, the 
protein adopts a more linear and extended conformation with gross outwards 
movement of both TPR-domains (supplementary video). In contrast, in both its 
mutant and peptide bound states the protein adopts a closed conformation that is 
similar the crystal structure (Fig 4C). 
  
Averaging the fluctuation of each residue in the CHIP structure showed that wild-
type unliganded-CHIP (Fig 4D; left panel) was characterized by larger and more 
widespread fluctuations than peptide-bound (centre panel) or Lys30-mutant CHIP 
(right panel), suggesting that the dynamics of the apo-state are different from the 
dynamics of the ligand-bound or mutant states, which in turn are similar to each 
other. This is in good agreement with HX-MS data showing that apo-CHIP protein is 
more flexible than the Hsp peptide-bound forms (Graf et al, 2010). Thus, MD agrees 
with experimental observations showing that CHIP has a lower melting point and is 
more susceptible to limited proteolysis in its unliganded form, whereas it is more 
thermostable and less susceptible to proteolysis in the presence of a Lys30 mutation 
or TPR-domain binding ligands. 
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The striking similarity between CHIP when it is bound to Hsp70/Hsp90 peptides or 
when it contains an Ala substitution at Lys30 confirms that although CHIP-K30A has 
been studied as a non-chaperone binding mutant of CHIP (Bonvini et al, 2004; Xu et 
al, 2002; Zhang et al, 2007), its properties are in fact like those of a constitutively 
Hsp-bound form. The side-chain of Lys30 does not appear to make any hydrogen 
bonds with other protein atoms during the MD simulations and is instead well 
hydrated. We speculate that, consistent with studies showing alanine residues 
favour the formation of ordered helical structures (Pace & Scholtz, 1998a), mutation 
of Lys30 to the much smaller and more hydrophobic Ala, will make this region less 
hydrated and more likely to fold into an ordered structure which is more similar to 
the peptide bound structure than to the flexible, less ordered structure described for 
the apo-TPR (Graf et al, 2010).   
 
The TPR-Domain is an Allosteric Modulatory Site which Affects U-Box Activity 
When the correlations between the fluctuations for residues in all three of the CHIP 
simulations (Fig 4D) were examined, a striking anti-correlated movement (Fig 5A) 
was seen between the TPR-domain of one CHIP wild-type protomer with the U-
boxes of both dimer components. This motion was strongly suppressed upon 
peptide binding and almost completely lost in CHIP-K30A.  Additionally, correlated 
motions were observed between the two U-box domains of the dimer (Fig 5B) in the 
wild-type conformation and again these were attenuated upon peptide binding or 
substitution of Lys30. The MD simulations therefore provide strong support for a 
model where cross-talk between distinct domains of CHIP is likely to underpin its 
function. Previous studies have concluded that the CHIP dimer is asymmetric and 
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that the U-box of one of the protomers is unavailable for E2 binding due to the 
location of its cognate TPR-domain, whereas the U-box from the other protomer 
remains accessible to the E2 (Zhang et al, 2005) (with only one E2 charged U-box 
required for CHIP E3-activity). Our MD simulations suggest that changes in TPR-
domain and U-box motion would not affect the ratio of E2-binding. We conclude 
therefore that the loss of anti-correlated motions of the two U-box domains with 
one of the TPR domains (Fig 5) upon peptide binding or Lys30 mutation is evidence 
that the TPR-domain is acting as a binding-site for allosteric effectors which 
negatively regulate CHIP activity. In our model loss of anti-correlated motion would 
impact on the dynamic nature of the U-box rather than altering the accessibility of 
one, or other, of the U-boxes at any given time.  
 
To seek experimental evidence to support allosteric regulation of the U-box through 
the TPR-domain of CHIP, E2-binding and E2~Ub-discharge assays were used. The E2-
enzyme UbcH5 can act as the catalytic module for CHIP as binding to the U-box (Fig 
6A) generates allosteric changes in the UbcH5 which facilitate substrate 
ubiquitination or the transfer of ubiquitin to other ubiquitin molecules (Pruneda et 
al, 2012; Xu et al, 2008). To determine if TPR-domain-initiated changes in CHIP 
conformation and dynamic structure are transmitted to the U-box, we set up an E2-
discharge assay and followed the loss of ubiquitin from thiolester-linked E2-ubiquitin 
(E2~Ub) in response to CHIP (Fig 6B; Cartoon). Whereas increasing amounts of wild-
type CHIP stimulated ubiquitin discharge from UbcH5 (Fig 6B; lanes 4 and 5) the 
CHIP-K30A mutant protein had a significantly reduced ability to stimulate ubiquitin 
loss from the E2~Ub complex. In fact the activity of the CHIP-K30A mutant was 
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intermediate between that of wild-type CHIP and a U-box mutant (H260Q) that can 
no longer interact with the E2.  Similarly, whereas ubiquitin was discharged from 
UbcH5~Ub by CHIP in the presence of both DMSO and a mutant Hsp70 peptide that 
has a reduced affinity for CHIP (D641A peptide) the wild-type Hsp70-peptide 
prevented CHIP mediated discharge (Fig 6C).   
 
To ask whether decreased E2 discharge by CHIP-K30A represented a change in the 
affinity of the U-box for UbcH5, we carried out AlphaScreen assays where binding of 
UbcH5-donor beads to CHIP-acceptor beads (Fig 6D) was determined at equilibrium. 
The assays demonstrated that the loss of activity in the ubiquitin-discharge assay for 
the CHIP-K30A protein (Fig 6B) was due to a significant reduction in the ability of the 
mutant protein to bind the E2 when compared to wild-type CHIP. The experimental 
data on E2-discharge and CHIP:E2 binding therefore support a role for the TPR-
domain of CHIP as an allosteric modulator site, occupation of which can generate 
long range inter-domain changes in the affinity and activity of the U-box inhibiting 
the ability of UbcH5 to catalyse ubiquitin discharge (Fig 6E). 
 
The TPR-domain of Cyp40 Stimulates its Peptidyl Prolyl Isomerise Activity 
We next set ourselves the task of determining whether CHIP was an isolated 
example of a cochaperone protein whose activity could be regulated through the 
TPR-domain, or whether dynamic conformational changes are more widely 
employed as a mechanism to affect intra-domain communication in TPR-domain 
proteins that function in association with Hsp70/Hsp90. A list of proteins that show 
homology to CHIP was compiled by aligning its TPR-sequence to all human 
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sequences in the Uniprot Knowledgebase (UniProtKB), and ranking them for 
homology using five iterations of PSI-BLAST (Altschul et al, 1997). We noted that the 
top hits were rich in proteins known to act as cochaperones by binding to the C-
terminus of Hsp70/Hsp90 (Fig 7A).  Once the list was filtered for proteins where 
structural details were available and that, like CHIP, had 3 TPR repeats plus 
additional domains with measurable activity, we had prioritized four co-chaperone 
proteins, namely the protein phosphatase PPP5 plus three immunophilins; Cyp40, 
FK506 binding protein-51 (FKBP51) and FK506 binding protein-52 (FKBP52). 
Importantly, all four of these proteins also had conserved Lys residues (equivalent to 
Lys30 and Lys95 of CHIP), which form part of a dicarboxylate clamp (Fig 7B). Of these, 
Cyp40 was an attractive candidate for further analysis as it has a relatively simple 
two domain structure (Taylor et al, 2001) comprising a C-terminal TPR-domain linked 
to a catalytically active peptidyl-prolyl isomerase (PPIase) domain (Fig 7C) that is 
amenable to biochemical characterisation. 
We began by modelling an Hsp90-bound form of Cyp40 by superimposing the TPR-
domain of the Hsp90-bound CHIP crystal structure onto the TPR-domain of Cyp40 
(Fig 7C; lower panel) and comparing it to both the wild-type conformation and a 
mutant form in which Lys227 (equivalent of Lys30 of CHIP, Fig 7B and C; upper panel) 
was replaced by Ala. MD simulations were performed on all three structures and the 
averaged fluctuation of each amino acid over the simulation was analysed. The 
simulations showed that, similar to CHIP, Cyp40 displays most flexibility when in an 
unliganded wild-type conformation (Fig 7D; left panel). Furthermore, mutation of 
Lys227, or ligand binding, led to an overall ‘tightening’ of both the TPR- and PPIase-
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domains (Fig 7D; centre and right panel). This suggests that modulation of the TPR-
domain influences the dynamics of Cyp40’s catalytic PPIase-domain in a relationship 
similar to that seen for the U-box and TPR-domains of CHIP.  
As the MD simulations suggested that TPR-domain status could influence the PPIase-
domain, we generated Cyp40-K227A (Lys227Ala) to determine if predicted changes 
in the flexibility and motion of the PPIase-domain affected its cis-trans prolyl 
isomerase activity. Using a Kofron’s optimised peptidyl-prolyl isomerase assay 
(Kofron et al, 1991) with suc-Ala-Leu-Pro-Phe-pNA as the substrate, we determined 
that the K227A-Cyp40 protein exhibited increased activity compared to the wild-type 
protein (153±22% of wt; Fig 7E). We sought to confirm the data by generating a 
Cyp40-K308A mutant (the second dicarboxylate clamp-forming Lys Fig 7B and C). 
Like the Cyp40-K227A protein, a Cyp40-K308A protein had enhanced PPIase activity 
displaying 180±16% of wild-type protein activity (Fig 7E).  
 
The increase in PPIase activity for two independent TPR-domain Cyp40-mutant 
proteins is consistent with the concept that changes in TPR-domain flexibility 
regulate distinct cochaperone functions. Further, we have provided evidence that 
restricting the conformational flexibility of TPR-domain structures can act as a 
positive regulatory signal, as in the case of Cyp40, or, as with CHIP, can negatively 





TPR-domains are protein interaction modules present across diverse kingdoms 
spanning bacteria to mammals that have been studied as scaffolds for the assembly 
of multiprotein complexes. We demonstrate that the presence of an N- or C-terminal 
TPR-domain can pave the way for allosteric regulation of distinct cochaperone 
activities or associated catalytic polypeptides through modulation of conformational 
dynamics and correlated motions. Thus, in keeping with recent conceptual advances 
on the potential of scaffolds and intrinsic disorder to support allosteric control of 
signalling complexes (Motlagh et al, 2012; Nussinov et al, 2013) we show that TPR-
flexibility impacts on protein ensembles to regulated cochaperone activity in 
proteostasis. 
 
Recent biophysical analysis has uncovered a degree of intrinsic disorder or dynamic 
flexibility in some TPR-domains when they are free in solution or if they are situated 
within the N-terminus of a protein (Cliff et al, 2006; Graf et al, 2010). Solution studies 
on the TPR-domain of PP5 using NMR and CD have suggested a mechanism of fold-
on-binding to Hsp90 leading to the concept that changes in TPR-structure could 
contribute to the activation of the enzyme (Cliff et al, 2006; Cliff et al, 2005). 
However these studies were carried out on the isolated TPRs and have not been 
confirmed using full-length PP5. Recent crystallographic analysis of the Rap proteins 
from gram negative bacteria questions the widely held view that TPR domains have 
an invariant structure on ligand binding by showing that interaction of the RapJ TPR 
with PhrC generates  large changes in the conformation of the protein as a whole 
(Parashar et al, 2013). Analyse of the TPR-domain in full-length CHIP using HX-MS 
shows it is ‘loosely folded’ and that the first 60 amino acids are intrinsically 
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disordered (Graf et al, 2010). A flexible TPR-domain structure that is readily able to 
take part in ‘fold-on-binding interactions’ leading to a change in the conformation 
and dynamic motions of the protein as a whole is supported by the current study. 
Fluctuation measurements for individual residues using MD simulations (Fig 4 and 7) 
for the TPR-domains of both CHIP and Cyp40 reveal a high degree of flexibility which 
is significantly reduced upon ligand binding or the introduction of structure 
stabilizing amino acids. In addition we see extensive correlations in motions between 
groups of residues and protein domains. In CHIP, correlated motions (motion 
occurring with the same phase) between one TPR and the U-box domains of the 
dimer and anti-correlated motion (motion occurring in opposite phases) between 
the two U-box domains (Fig 5) take place. As correlated and anti-correlated motions 
are linked to mechanisms of enzyme catalysis and protein allostery it is striking that 
TPR-domain binding suppresses motions within the TPR itself as well as in the U-
boxes. Thus, loss of coordinated motion and intrinsic flexibility appear to be key 
components of allosteric inhibition by TPR-binding ligands such as Hsp70. Although 
the TPR-domain of Cyp40 is at the C-terminus, rather than the N-terminus, it still has 
a high degree of flexibility, especially in helix 1, 2 and 7 (Fig 7). In addition, atomic 
fluctuations suggest that the PPIase-domain of Cyp40 is affected by TPR status. 
PPIase domains are thought to undergo coordinated conformation changes that are 
correlated with enzymatic activity (Ramanathan & Agarwal, 2011). The β-barrel core 
of the PPIase-domain must provide a rigid scaffold to conserve hydrophobic 
interactions holding proline in the active site whilst loops proximal to the active site 
must be flexible enough to accommodate proline moving from cis to trans. Thus, a 
change in flexibility within the PPIase-domain is likely to influence enzyme activity. 
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Dynamic protein motion and flexibility are emerging as potential hallmarks of E3-
ligase mediated ubiquitination. Studies on cullin-RING E3-ligases have shown that 
flexibility in substrate-binding proteins and Rbx subunits is required for efficient 
polyubiquitination. Moreover, the cullins, have recently been described as 
conformationally labile. Together, the flexible components of the cullin-RING E3-
ligase complexes function to facilitate a shortening of the distance between the E2 
and the substrate to initiate ubiquitination and an increase in the E2-substrate 
distance to accommodate polyubiquitination (Liu & Nussinov, 2012). In another 
model, flexible regions of the yeast E3-ligase San1 (Rosenbaum et al, 2011) and the 
ribosome-associated ligase Ltn1 (Lyumkis et al, 2013) aid in substrate selection by 
facilitating the recognition of misfolded or defective nascent-polypeptides. Here, we 
describe a third route by which E3-ligase structural flexibility can regulate 
ubiquitination. In this case, changes in the degree of TPR-domain secondary 
structure, flexibility and motion are transmitted to the U-box of CHIP and impact on 
the ability of CHIP to form complexes with UbcH5, an E2 catalytic partner. As E2/E3 
interactions are critical to the generation of allosteric changes in the E2 which 
activate the thiolester-linked (Liu & Nussinov, 2012; Ozkan et al, 2005; Plechanovova 
et al, 2012), CHIP in which the TPR has been stabilized is deficient in its ability to 
discharge ubiquitin from the E2~Ub thiolester (Fig 6).  Thus, the TPR-domain in CHIP 
appears to provide the plasticity it requires to act as an E3-ligase but can also act as 
an ‘allosteric switch’ where the introduction of a more ordered stable structure can 
‘turn off’ its E3-function. Our study therefore supports the hypothesis that site-to-
site allosteric coupling is optimized when ID domains are present and when a fold-
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on-binding mechanism is employed (Hilser & Thompson, 2011; Ma & Nussinov, 
2009), it also demonstrates that intrinsic disorder, scaffolding and allostery can all be 
linked in a single polypeptide chain as well as in multiprotein complexes. 
 
The current study provides compelling evidence that Hsp70 is not simply acting as a 
targeting moiety for CHIP in the canonical protein quality control/chaperoning 
pathways, but is intimately linked to the control of CHIP activity. Support for this 
comes from studies on Smad1/5 (Wang et al, 2011) where Hsp70 inhibits CHIP-
mediated ubiquitination and from α-synuclein where suppression of mono-
ubiquitination by BAG-5 is Hsp70-mediated (Kalia et al, 2011). Our data is consistent 
with the concept that Hsp70 might hold CHIP in an inactive form until a favourable 
substrate is identified, at which stage CHIP would dissociate and bind directly to its 
target substrate (Narayan et al, 2011). The cochaperone function of Cyp40 is the cis 
to trans isomerisation of Xaa-proline isopeptide bonds (where Xaa is any amino acid) 
this is a rate limiting step in protein folding, thus the ability of TPR-stabilizing 
mutations to enhance its PPIase activity suggests that it could be allosterically 
activated by Hsp90. Alternatively, as Cyp40, has an intrinsic chaperone activity (Mok 
et al, 2006) misfolded or nascent polypeptides could bind directly to its TPR-domain 
leading to allosteric auto-activation.  
 
Broadening the function of TPR-domains to include allosteric regulatory roles offers 
the opportunity to modulate the activity of rate-limiting steps in protein homeostasis 
pathways that are key to healthy aging and which play a significant role in preventing 
the development of neurodegenerative diseases and cancer. The ability of TPR-
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domains to accommodate ligands with diverse primary and secondary structures 
(Brinker et al, 2002; Ramsey et al, 2009; Zeytuni & Zarivach, 2012), should encourage 
us to think that TPR directed biologics and/or small molecules will be identified for 
specific proteins offering the potential for allosteric drug development.  
 
Methods and Materials 
Chemicals, antibodies and peptides 
Antibodies were used at 1 μg/ml and were anti-IRF-1 mAb (BD Biosciences), anti-p53 
DO- 1, anti-Mdm2 4B2 and anti-CHIP v3.1 mAbs (Moravian Biotechnology), anti-CHIP 
N-terminal pAb (Sigma), anti-Hsp70 pAb (Stressgen) and anti-His mAb (Novagen). 
Secondary antibodies were purchased from Dako Cytomation. MG-132 (Calbiochem) 
was dissolved in DMSO to 10 mM and used as indicated. Peptides were from Chiron 
Mimotopes and were synthesized with a Biotin-tag and an SGSG spacer at the N-
terminus; peptides were solubilized in DMSO. ATP was purchased from Calbiochem 
and creatine phosphate from Sigma. 
 
Plasmids and purified proteins 
pDEST-15-codon optimized IRF-1 (GST-IRF-1) and pET15b-CHIP (His-CHIP; wt, K30A 
and ΔTPR) were purified using glutathione-sepharose (Amersham GE) and Ni2+-NTA 
agarose (Qiagen) respectively, according to the manufacturer’s instructions. An NdeI-
codon optimized IRF-1-EcoRI fragment was amplified from pDEST-15-IRF-1, ligated 
into pCOLDI (TaKaRa Bio) to give pCOLDI-IRF-1 (His-IRF-1) and purified as above 
following expression at 15oC for 15 min by addition of IPTG (1mM). pET3a-CHIP 
(untagged CHIP; wt and K30A mutant) was sub-cloned from pET15b-CHIP using NdeI 
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and BamHI. Recombinant untagged p53 was purified as previously described50. 
Purified recombinant Hsp70 was purchased from Stressgen, ubiquitin and UBE1 from 
Boston Biochem and creatine phosphokinase from Sigma. Purified His-UbcH5a and 
His-tag cleaved UbcH5a were produced in house. pcDNA3-IRF-1, pcDNA3-CHIP and 
His-Ub are as previously described13. Purification of untagged CHIP is described in 
detail in the supplemental text. 
 
Cell Culture 
H1299 cells were cultured in RPMI-1640 (Roswell Park Memorial Institute 1640; 
Invitrogen) supplemented with 10% (v/v) fetal bovine serum (Autogen Bioclear) and 
1% (v/v) penicillin-streptomycin mix (Invitrogen), and were maintained at 37°C/5% 
CO2. Cells were seeded 24 hours before transfection and DNA transfected into the 
cells using Attractene (Qiagen) according to the manufacturer’s recommendations. 
 
Binding Assays 
Purified protein (Hsp70 or UbcH5a; 100 ng) was immobilized on microtitre plates in 
0.1 M NaHCO3 (pH 8.6) overnight at 4°C. Following washing in PBS plus 0.1% (v/v) 
Tween-20, non-reactive sites were blocked using 3% (w/v) BSA in PBS. A titration of 
the protein of interest (usually 0-100 ng) was added in 1x ELISA Buffer (25 mM 
HEPES, pH 7.5, 50 mM KCl, 10 mM MgCl2, 5% (v/v) glycerol, 0.1% (v/v) Tween-20) for 
1 h at RT. Binding was detected using anti-His mAb and HRP-tagged anti-mouse 2o or 
anti-CHIP pAb and HRP-tagged anti-rabbit 2o, and electrochemical luminescence was 
quantified using a luminometer. For peptide binding assays, microtitre plates were 
coated with streptavidin (1 μg/well in PBS) and incubated with enough biotin-tagged 
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peptide to saturate the streptavidin (~60 pmol). Unbound peptide was removed and 
non-reactive sites blocked as above. A titration of His-CHIP (wt or K30A or ΔTPR as 
stated) in 1x ELISA buffer was added for 1 h at RT. Washing and detection was as 
above using anti-His mAb. 
 
AlphaScreen 
Amplified Luminescent Proximity Homogeneous Assays (AlphaScreen) were carried 
out in white half-area microtitre plates according to the manufacturer’s 
recommendations. In brief, biotin-tagged Hsp70 peptide (GPTIEEVD; 6.25 ng) was 
linked to streptavidin donor beads (20 µl) diluted 1:100 and incubated with a 
titration (0-100 ng in 10 µl volume) of His-CHIP wt or K30A mutant conjugated to 
protein-A acceptor beads (20 µl of 1:100 dilution) using anti-His mAb. The reaction 
mix was incubated for 1 h at room temperature and quantified using an EnVision 
fluorescence detector (Perkin Elmer). For His-UbcH5:untagged CHIP AlphaScreen, the 
assay was performed as above except that His-tagged UbcH5a (50 ng) was anchored 
onto Nickel-chelate donor beads and a titration (0-100 ng) of untagged CHIP wt or 
K30A onto protein-A acceptor beads using anti-CHIP N-terminal pAb.  
 
Ubiquitination and PPIase Assays 
Cell-based ubiquitination assays were carried out as previously described (Pion et al, 
2009). In vitro ubiquitination assays (Wallace et al, 2006) were started with His-CHIP 
(50-100 nM) or untagged CHIP (100-200 nM), incubated for up to 20 min as indicated 
at 30°C, and stopped by the addition of SDS-PAGE sample buffer. Samples were 
analyzed using 4–12% NuPAGE gels in a MOPS buffer system/immunoblot. If 
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required, Hsp70 (1:1 molar ratio with CHIP unless stated otherwise) and/or Hsp40 
(at 1:10 ratio of Hsp40:Hsp70) or peptides were added to the ubiquitination mix (see 
figure legends for details) immediately prior to the incubation at 30°C. Cyp40 was 
analysed using Kofron’s optimised peptidyl-prolyl isomerase assay(Kofron et al, 
1991). A solution of 6 mg/ml α-chymotrypsin (CalBiotech) in 10 mM hydrochloric 
acid was prepared and kept on ice. α-chymotrypsin solution (100 μL ) was added to 
870 μL of Cyp40 in 50 mM HEPES, pH8, 100 mM NaCl, 1 mM DTT and 0.5 mM EDTA, 
gently mixed and rapidly added to a cuvette containing 4 mM substrate (30 μL; suc-
Ala-Leu-Pro-Phe-pNA; Bachem, UK). The final solution contained 20 nM Cyp40, 0.6 
mg/mL α-chymotrypsin, 120 μM substrate, 14 mM lithium chloride, 3% (v/v) 2,2,2-
trifluoroethanol. Absorbance at 400 nM was recorded every 0.1 s for 120 s on a 
JascoV550 UV/VIS spectrophotometer (ε400nm = 10,050 M
-1∙cm-1; p-nitroaniline). The 
rate of the turnover reaction was determined during the steady-state phase.  
 
E2 Discharge Assay 
Reactions contained 25 mM HEPES pH 8.0, 10 mM MgCl2, 350 nM ATP, 0.5 mM DTT, 
0.05% (v/v) Triton X-100, 0.25 mM benzamidine, 10 µM ubiquitin, 100 nM UBE1 and 
1 μM UbcH5a (E2). The E2 was charged for 15 min at 30°C after which His-CHIP (0-
200 nM; ±Hsp70 peptide as required) was added and reactions were incubated for a 
further 15 min at 30°C to discharge the E2. To stop the reaction, SDS-PAGE sample 
buffer (without DTT, but with 2.5 mM N-ethylmaleimide) was added and the 
reactions analysed on 4–12% NuPAGE gels/immunoblot. 
 
Thermal Unfolding Assay 
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SYPRO Orange was diluted to 50X in Buffer S (20 mM Tris, pH 8, 150 mM NaCl) and 
used at 5X. His-CHIP wt or K30A was diluted to 5 μM in Buffer S before the addition 
of SYPRO Orange. Hsp70 peptides (or a DMSO control) were added to a final 
concentration of 5 μM. Samples were loaded on a 96-well PCR plate (50 μl per 
reaction) and sealed. Unfolding was measured using an iCycler iQ Real-Time PCR 
system (Bio-Rad) by heating samples from 25°C to 60°C at 1°C increments with a 30 
second incubation at each increment. Fluorescence intensity was measured in 
relative fluorescent units (RFU) using excitation/emission wavelengths of 
485 nm/575 nm. 
 
Limited Proteolysis 
CHIP protein (2 µg; plus 4 µg peptide if required) was incubated with Glu-C (Roche; 
40 ng) in 25 mM ammonium carbonate (pH 7.8) at room temperature as indicated. 
Reactions were stopped by addition of sample buffer and heating at 85°C for 5 min. 
Samples were analysed by 4-12% NuPAGE gels and stained with InstantBlue 
(Expedeon). For tryptic digests, 500 ng CHIP proteins, 5 ng trypsin (Roche) and 1 µg 
peptide was used, and the incubation carried out in 100 mM Tris-HCl (pH 8.5) at 4°C.  
 
MD Simulations 
The crystal structure of mouse CHIP in complex with Hsp90 peptide (PDB code 2C2L, 
resolved at 3.3 Å(Zhang et al, 2005)) was used as the initial structure for simulations. 
Five mutations (P77H, T167S, H188D, G192S, I194V - mouse numbering) were 
introduced into the crystal structure to obtain human CHIP using the WHATIF 
(http://swift.cmbi.ru.nl/whatif/) program. Simulations were then run on three 
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systems: the CHIP dimer with Hsp90 pep (chains A,B,E,F from 2C2L where chains A 
and B are the CHIP dimer and chains E and F are the peptides bound to chains A and 
B respectively), the CHIP dimer without peptide (chains A,B) and the CHIP dimer with 
Lys30 mutated to Ala (chains A,B). For simulations on Cyp40, the crystal structure of 
bovine Cyclophilin 40 in its monoclinic form was used (PDB code 1IHG, resolved at 
1.8 Å35). A mutation was introduced at Lys227 to Ala and a Hsp90 peptide bound form 
was modelled by superimposing the CHIP structure bound to the Hsp90 peptide 
(2C2L Chain A and E) onto the Cyp40 TPR using Pymol (The PyMOL Molecular 
Graphics System, Version v1.4.1, Schrödinger, LLC). Simulations were run on the 
three systems: Cyp40 WT, Cyp40 K227A and Cyp40 bound to Hsp90 (obtained from 
Chain E of 2C2L). For details of the analyses see supplementary text. 
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Figure 1. Hsp70 differentially modulates CHIP-dependent ubiquitination. (A) 
Immunoblot of in vitro ubiquitination reactions assembled using ATP, ubiquitin, 
UBE1, UbcH5a, His-CHIP and GST-IRF-1 in the presence of a titration  of Hsp70 
and/or Hsp40 (at either a 1:1 and 1:2 molar ratio of Hsp70 with CHIP) as indicated. 
(B, C) Immunoblot of in vitro ubiquitination assays assembled as in (A) except using 
untagged p53 (B) or GST-BAG-1s (C) as substrate, in the presence of Hsp70 and 
Hsp40. (D) Snapshot of the crystal structure of mCHIP dimer (protomers in shades of 
grey) in complex with Hsp90 peptide (yellow sticks; PDB code 2C2L) generated using 
PyMOL v1.4.1. Lys30 is highlighted in blue. (E, F) Immunoblot of in vitro 
ubiquitination reactions assembled using ATP, ubiquitin, UBE1, UbcH5a, His-CHIP 
and His-IRF-1 (E) or untagged p53 (F) in the presence of a titration of Hsp70 peptides 
as indicated (wt: GPTIEEVD; mut: GAAAEEVD). A carrier only control (DMSO) was 
included. (G) As above except that GST-BAG-1s was used as the substrate and both 
full-length Hsp70/Hsp40 as well as Hsp70 wt peptides were included in the assay as 
indicated. (H) As in (F) except using GST-Mdm2 as the E3 ligase. 
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Figure 2. CHIP-K30A is intrinsically defective in E3-ligase activity. (A) Close-up of the 
Hsp90 binding site on CHIP extracted from the crystal structure of mCHIP dimer 
(protomers in shades of grey) in complex with Hsp90 peptide (yellow sticks; PDB 
code 2C2L) generated using PyMOL v1.4.1. Lys30 on CHIP and Asp732 on Hsp90 are 
highlighted in blue and green respectively. (B) An AlphaScreen assay was set up (see 
cartoon) to measure binding dynamics of His-CHIP wt or K30A mutant with biotin-
tagged Hsp70 peptide (GPTIEEVD) in solution. (C) Ubiquitination of exogenous IRF-1 
in H1299 cells transiently transfected with plasmids encoding CHIP wt or K30A 
mutant and His-ubiquitin. Immunoblots show ubiquitinated protein (His-pulldown) 
and total protein (direct lysis). (D, E) In vitro ubiquitination assays were assembled 
using ATP, ubiquitin, UBE1, UbcH5a, untagged CHIP wt or K30A, and His-IRF-1 (D) or 
untagged p53 (E) as substrate. Reactions were analyzed by 4-12% 
NuPAGE/immunoblot. (F) Immunoblot of in vitro ubiquitination assays assembled as 
above except in the absence of substrate to study auto-ubiquitination of untagged 
CHIP wt or K30A proteins over time. 
 
Figure 3. CHIP-K30A and Hsp70-bound CHIP are conformationally distinct from the 
wild-type protein. (A) Graph showing the unfolding of His-CHIP wt or K30A mutant 
(left panel) or His-CHIP wt pre-incubated with the indicated peptides based on Hsp70 
(right panel) as a function of temperature change measured by the uptake of the 
fluorescent dye SYPRO Orange. Shown is the mean ± standard error of mean of 3 
experiments. (B) Table listing the mid-point temperature of phase transition (Tm) of 
each sample in (A) that was calculated by plotting the gradient of protein unfolding 
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against the temperature gradient [d(RFU)/dT]. (C) InstantBlue stained gel of 
untagged CHIP wt or K30A (left panel) digested with Glu-C. FL is the full-length 
protein and band 1 is a cleavage product that persists in the K30A mutant. Band 2 is 
only observed in digests of the wt protein. Also shown is a Glu-C digest of His-CHIP 
wt protein in complex with wt or mutant Hsp70 peptides (right panel). 
 
Figure 4. CHIP-K30A and Hsp70-bound CHIP have similar equilibrium structures. (A-
D) Images were generated using PyMOL v.1.4.1. (A) Crystal structure of murine CHIP 
dimer (monomers in shades of blue) in complex with Hsp90 peptide (pink sticks; 
adapted from PDB 2C2L). (B) Overlay of the CHIP dimer before (blue ribbon) and 
after (grey mesh) 20 ns MD simulations for unliganded CHIP wt (left), CHIP wt in 
complex with Hsp90 peptide (centre) and CHIP-K30A (right). (C) Overlaid snapshots 
of the CHIP dimer in apo and liganded forms and with Lys30 mutated to Ala after 20 
ns MD simulations (from (B)). (D) Root mean square fluctuation (RMSF) of Cα 
obtained from the trajectories of the 20 ns simulations of CHIP wt ± peptide and the 
CHIP-K30A mutant. The score of the positional fluctuation analysis averaged over 
amino acid were colour coded and indicated on the crystal structure.  
 
Figure 5. Coordinated movements between the TPR and U-box domains of CHIP are 
reduced when Hsp90 binds to the TPR domain. (A) Dynamic cross-correlation map 
(left panel) of Cα atoms for the un-liganded wt CHIP dimer. Correlated motions are 
represented above the diagonal in blue and anti-correlated below in red. Correlated 
movements of the CHIP U-boxes are indicated by a blue box. Anti-correlated 
movements of the TPR domain (right panel in brown) with both U-boxes (right panel 
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in green) are indicated with red boxes. Cartoon of CHIP dimer (right panel) was 
generated using PyMOL v.1.4.1. (B) As above except the dynamic cross-correlation 
maps of Cα atoms are for Hsp90 peptide bound wt CHIP dimer (left panel) and the 
K30A mutant CHIP dimer (right panel). 
 
Figure 6. Modulation of the TPR-domain of CHIP affects U-box function. (A) Snapshot 
of the crystal structure of zebrafish CHIP-Ubox in complex with UbcH5 (from PDB 
2OXQ) superimposed onto the crystal structure of mouse CHIP (from PDB 2C2L). The 
image, showing a single CHIP monomer, was generated using PyMOL v1.4.1. Blue 
ribbon: CHIP; red ribbon: UbcH5; TPR tetratricopeptide repeat. (B) His-UbcH5a was 
charged with ubiquitin (Ub~E2; thiolester linkage) by incubating with UBE1 and 
ubiquitin in the presence of ATP, following which ubiquitin discharge from the E2 by 
His-CHIP wt or K30A mutant was monitored. The E2-binding-defective mutant 
H260Q was included as a control. Shown is an immunoblot probed for CHIP and the 
E2. (C) Immunoblot of E2 discharge assay as above except using a titration of His-
CHIP wt protein that had been pre-incubated with a fixed amount (3 µM) of Hsp70 
wt peptide or D641A mutant peptide or DMSO control prior to addition into the 
assay. Ub~E2 represents the E2:Ub species linked by a thiolester bond while * 
indicates the E2:Ub species linked by an isopeptide bond (Ub-E2 or ubiquitinated E2). 
(D) An AlphaScreen assay was set up (see cartoon) to measure binding dynamics of 
untagged CHIP wt or K30A mutant with His-tagged UbcH5a in solution. (E) A model 
for CHIP regulation where the whole of the apo-protein (i) is more flexible and where 
there are regions of intrinsic disorder in the TPR(Graf et al, 2010). Upon binding to 
the E2~Ub complex the U-box of apo-CHIP generates a conformational change in 
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UbcH5 that facilitates Ub discharge. Alternatively (ii), when the TPR-domain binds to 
certain ligands (or is stabilised by mutations) it becomes more ridged and there is a 
decrease in dynamic motions throughout the whole protein. In the ligand bound 
form of CHIP the U-box is less able to for complexes with UbcH5 and Ub is therefore 
discharged inefficiently. 
 
Figure 7. The TPR-domain of Cyp40 allosterically enhances its peptidyl proline 
isomerase activity. (A) List of human TPR-containing proteins in the UniProt 
Knowledgebase bearing homology to CHIP's TPR domain and ranked for homology 
using five iterations of PSI-BLAST. Proteins that, like CHIP, had three TPR motifs 
based on available structural information and additional domains with measurable 
enzymatic activity are highlighted in bold. (B) Sequence alignment of the three TPR 
motifs in the indicated proteins with the highly conserved Lys residues that interact 
with the dicarboxylate clamp of Hsp70/Hsp90 marked in blue. (C) Snapshot of the 
crystal structure of Cyp40 (PBD 1IHG ; upper panel) with the dicarboxylate clamp 
residues K227 and K308 in pink. Also shown is a snapshot of the structure obtained 
by superimposing the TPR-domain of Hsp90-bound CHIP (from PDB 2C2L) onto the 
available structure for Cyp40 (PDB 1IHG ; lower panel). (D) Root mean square 
fluctuation (RMSF) of Cα obtained from the trajectories of 40 ns MD simulations of 
Cyp40 wt ± Hsp90 peptide and the K227A mutant. The score of the positional 
fluctuation analysis averaged over amino acid were colour coded and indicated on 
the crystal structure. (E) Results from a Kofron's optimised peptidyl-prolyl isomerase 
assay with suc-Ala-Leu-Pro-Phe-pNA as substrate and the indicated Cyp40 proteins. 
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 Protein Uniprot No.TPR Protein evidence Function/Enzymatic activity Hsp90  
 CHIP Q9UNE7 3 YES E3 ubiquitin-ligase YES 
SGTA-beta  Q96EQ0 4 YES co-chaperone YES 
2 SGTA-alpha  O43765 3 YES co-chaperone YES 
3 PPP5C P53041 3 YES serine/threonine phosphatase YES 
4 TTC12 Q9H892 3 NO not know n  
5 UNC-45A Q9H3U1 3 YES co-chaperone YES 
6 RPAP3 Q9H6T3 7 YES chaperone/scaffolding protein for RNA polymerase YES 
7 Cyp40 Q08752 3 YES peptidyl-prolyl isomerase, co-chaperone YES 
8 TOMM34 Q15785 6 YES import of preproteins into mitochondria YES 
9 SPAG1 Q07617 9 YES GTPase activity  
10 TTC3 P53804 4 YES E3 ubiquitin-ligase   
11 LONRF3 Q496Y0 4 YES not know n  
12 TTC31 Q49AM3 3 NO not know n  
13 UNC45B Q8IWX7 3 NO not know n  
14 TTC28 Q96AY4 28 YES not know n  
15 HOP P31948 9 YES co-chaperone YES 
16 WDTC1 Q8N5D0 2 YES associates with proteins of Ub-prot. system  
17 TOMM70A O94826 10 YES component of mitochondrial translocase complex YES 
18 TTC1 Q99614 3 YES interacts w ith GAP domain of NF1  
19 TANC1 Q9C0D5 3 YES scaffold protein?  
20 Wisp39 Q9UIM3 3 YES regulates p21 protein stability by binding to Hsp90 YES 
21 FKBP51 Q13451 3 YES peptidyl-prolyl isomerase, co-chaperone YES 
22 FKBP52 Q02790 3 YES peptidyl-prolyl isomerase, co-chaperone YES 
23 OGT O15294 13 YES N-acetylglucosamine transferase  
24 TANC2 Q9HCD6 3 YES not know n  
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DNA-binding regulates site-specific ubiquitination of IRF-1
Vivien LANDRÉ*, Emmanuelle PION*1, Vikram NARAYAN*, Dimitris P. XIRODIMAS† and Kathryn L. BALL*2
*Cell Signalling Unit, Edinburgh Cancer Research Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Rd South, Edinburgh EH4 2XR, U.K., and
†Centre de Recherche de Biochimie Macromoléculaire, UMR 5237, CNRS, Montpellier, France
Understanding the determinants for site-specific ubiquitination by
E3 ligase components of the ubiquitin machinery is proving to be
a challenge. In the present study we investigate the role of an E3
ligase docking site (Mf2 domain) in an intrinsically disordered
domain of IRF-1 [IFN (interferon) regulatory factor-1], a short-
lived IFN! -regulated transcription factor, in ubiquitination of
the protein. Ubiquitin modification of full-length IRF-1 by E3
ligases such as CHIP [C-terminus of the Hsc (heat-shock cognate)
70-interacting protein] and MDM2 (murine double minute 2),
which dock to the Mf2 domain, was specific for lysine residues
found predominantly in loop structures that extend from the
DNA-binding domain, whereas no modification was detected
in the more conformationally flexible C-terminal half of the
protein. The E3 docking site was not available when IRF-1
was in its DNA-bound conformation and cognate DNA-binding
sequences strongly suppressed ubiquitination, highlighting a strict
relationship between ligase binding and site-specific modification
at residues in the DNA-binding domain. Hyperubiquitination of a
non-DNA-binding mutant supports a mechanism where an active
DNA-bound pool of IRF-1 is protected from polyubiquitination
and degradation.
Key words: C-terminus of the heat-shock cognate 70-interacting
protein (CHIP), DNA binding, interferon regulatory factor
1 (IRF-1), murine double minute 2 (MDM2), transcription,
ubiquitination.
INTRODUCTION
Protein ubiquitination was first described as part of the
proteasomal degradation pathway and has since been shown to
play a major role in regulating a wide range of cellular pathways.
Cell-cycle progression, DNA damage and repair, and transcription
are all subject to fine control by the ubiquitin pathway. The
ubiquitin transfer cascade comprises three enzymes, E1, E2
and E3. In the initial step, ubiquitin is activated by the E1
(ubiquitin-activating enzyme) and subsequently transferred to
the E2 (ubiquitin-conjugating enzyme) which forms a complex
with the E3 (ubiquitin ligase) and the substrate [1]. The main
class of E3 ligases [RING including PHD (plant homeodomain)
and U-box domain proteins] act by facilitating the transfer of
ubiquitin from the E2 to one, or several, lysine residues in the
substrate. The outcome of ubiquitination depends on the type of
modification (mono- compared with poly-), the configuration
of the chain linkages and the position of the modified residue
in the primary amino acid sequence of the protein. The E3 is
believed to determine substrate specificity and interplay between
the E3 and E2 results in different chain linkages [2]. Ubiquitin
contains seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33,
Lys48 and Lys63); any one of these lysine residues, in addition
to the N-terminal methionine residue, can be connected to
another ubiquitin molecule resulting in the formation of di- or
poly-ubiquitin chains with a variety of different linkages [2,3].
Additionally, ubiquitin chains with mixed linkages and branches
have been observed, adding to the overall complexity of the system
[4]. While Lys48 chains are associated with protein degradation,
Lys63 has roles in processes such as the response to stress,
membrane trafficking and endocytosis. Lys11 signals proteasomal
degradation and can alter subcellular localization, cell division
and protein activity [5]. Although progress is being made on
understanding the cellular roles of linkage-specific ubiquitination,
the mechanisms involved in ubiquitin transfer, and particularly the
selection of specific ubiquitin-acceptor residues, remain elusive.
In contrast with phosphorylation, where specific peptide motifs
are known to serve as phosphorylation signals for different
kinases, no such definite sequence motifs have been identified
for E3 ligases and prediction of lysine residues that are subject to
modification remains difficult [6].
IRF-1 [IFN (interferon) regulatory factor-1] is an IFN-regulated
transcription factor and a key effector of IFN! -activated changes
in gene expression. IRF-1 has a strong link to human health with
loss of function leading to the development of some cancers [7,8],
whereas its overexpression is associated with chronic autoimmune
diseases [9–12]. Like many other transcription factors, IRF-1 is
turned over very rapidly, with a half-life of approximately 20–
30 min in cultured cells, and it is degraded via the ubiquitin–
proteasome pathway [13,14]. We formerly reported that CHIP [C-
terminus of the Hsc (heat-shock cognate) 70-interacting protein]
binds to a central intrinsically disordered domain (Mf2 domain)
of IRF-1 and mediates its ubiquitination under certain stress
conditions [15]. This led us to ask (i) whether ligase docking
plays a role in selecting lysine residues for modification, and
(ii) what would be the outcome if the E3 could no longer dock
to the Mf2 domain. We report in the present paper that IRF-
1 ubiquitination by CHIP is proximal to its binding site and that
only selected lysine residues in the structured DBD (DNA-binding
domain) of IRF-1 were able to act as ubiquitin-acceptor sites.
We characterize MDM2 (murine double minute 2) as a second
Mf2-domain-binding ligase and show that it also mediates DBD
Abbreviations used: CHIP, C-terminus of the Hsc (heat-shock cognate) 70-interacting protein; DBD, DNA-binding domain; DTT, dithiothreitol; EMSA,
electrophoretic mobility-shift assay; GST, glutathione transferase; IFN, interferon; IRF-1, IFN regulatory factor-1; mAb, monoclonal antibody; MDM2, murine
double minute 2; MS/MS, tandem MS; Ni-NTA, Ni2 + -nitrilotriacetate; NP40, Nonidet P40; pAb, polyclonal antibody; TA, transcriptional activator; TRAIL,
TNF (tumour-necrosis-factor)-related apoptosis-inducing ligand; WT, wild-type.
1 Present address: Centre de Recherche de Biochimie Macromoléculaire, UMR 5237, CNRS, Montpellier, France.
2 To whom correspondence should be addressed (email Kathryn.Ball@igmm.ed.ac.uk).
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ubiquitination. In addition, we show that IRF-1 is only available
for E3 docking and ubiquitination when in a DNA-unbound state,
leading us to propose a mechanism by which IRF-1 degradation
is partly controlled by its ability to bind DNA.
MATERIALS AND METHODS
Cell culture, transfection, FLAG pull-down, half-life and
immunoblotting
HCT-116 cells were maintained in McCoy’s medium (Invitrogen).
Medium was supplemented with 5% (v/v) FBS (fetal
bovine serum; Biosera) and 1% (v/v) penicillin/streptomycin
(Invitrogen), and cells were grown at 37 !C with 5% CO2. At 80%
confluence, cells were transfected using Attractene (Invitrogen)
following the manufacturer’s instructions. FLAG pull-down and
half-life determination was carried out as described previously
[13,16]. Immunoblotting was performed as described previ-
ously [17].
Reagents, plasmids and protein preparation
The antibodies used were anti-IRF-1 mAb (monoclonal antibody)
(BD Biosciences) and anti-IRF-1 C20 pAb (polyclonal anti-
body) (Santa Cruz Biotechnology), DO1 mAb (anti-p53;
Moravian Biotechnology), anti-FLAG M2 mAb (Sigma), 4B2
mAb (anti-MDM2) and anti-CHIP 3.1 (a gift from Dr Borek
Vojtesek, Masaryk Memorial Cancer Institute, Brno, Czech
Republic). Secondary antibodies were purchased from Dako.
Antibodies were used at the concentrations indicated by the
supplier and at 1 µg/ml for DO1 and anti-CHIP. pDEST15-
IRF-1 [GST (glutathione transferase)–IRF-1] mutants were
constructed using a QuikChange® site-directed mutagenesis kit
(Stratagene) with primers designed for a codon change from
tryptophan to arginine or lysine to arginine (Sigma). GST–IRF-
1 and GST–MDM2 were purified using glutathione–Sepharose
(GE Healthcare) following the manufacturer’s instructions. The
GST tag was cleaved off MDM2 using Prescission Protease
(GE Healthcare) following the manufacturer’s instructions. His–
CHIP, His–UbcH5 and His–SET (pET-26b-SET was from J.
Libermann and T. Tuschi via Addgene [18]) were purified using
Ni-NTA (Ni2 + -nitrilotriacetate) agarose (Qiagen) following the
manufacturer’s instructions. Kap-1 was purified as described
previously [16] (pGEX-4T1-Kap-1 was a gift from Dr A. Ivanov,
West Virginia University, Morgantown, West Virginia, U.S.A.
[19]). Untagged p53 purified from insect cells was a gift from Dr
Jennifer Fraser and Professor Ted Hupp (both from the University
of Edinburgh, Edinburgh, Scotland, U.K.).
Ubiquitination assay
In vitro ubiquitination assays were performed as described
previously [20] using 25 ng of substrate [GST–IRF-1WT, GST–
IRF-1W11R or p53 as indicated; WT is wild-type] and His–CHIP
or MDM2 as indicated. Reactions were incubated at 30 !C for
15 min unless otherwise indicated. The reactions were terminated
by the addition of SDS sample buffer and analysed on a 4–12 %
NuPAGE gel in a Mops buffer system (Invitrogen) followed by
immunoblotting.
In vivo ubiquitination assays were carried out as described
previously [20]. Briefly, HCT-116 cells were transfected with the
indicated amounts of His–ubiquitin, IRF-1 and MDM2 or CHIP
and treated with 50 µM MG-132 for 4 h. Cells were harvested and
20% was lysed directly in 0.1% NP40 (Nonidet P40) lysis
buffer [25 mM Hepes (pH 7.5), 0.1% NP40, 150 mM KCl, 5 mM
DTT (dithiothreitol), 50 mM NaF and protease inhibitor mix] and
separated by PAGE (12 % gel) followed by immunoblot analysis;
for the remaining cells, His–ubiquitin conjugates were isolated
using Ni-NTA agarose as described previously [20].
EMSA (electrophoretic mobility-shift assay) and ELISA
EMSAs were carried out as described previously [21].
Briefly, 100–300 ng of GST–IRF-1WT or GST–IRF-1W11R was
incubated with either 40 ng of 32P-labelled C1 probe [21],
the ISRE (IFN-stimulated response element) sequences from the
promoter sequences of caspase 8 [22], ISG-15 [23], ISG-20
[24], TRAIL [TNF (tumour-necrosis-factor)-related apoptosis-
inducing ligand] [25] or an oligonucleotide from the p53-
binding site on the 21 promoter [26] in EMSA buffer [20
mM Hepes (pH 7.5), 50 mM KCl, 5% glycerol, 0.4 mM DTT,
0.1 mg/ml BSA, 0.5% Triton X-100, 0.125 mg/ml poly(dI-
dC) and 0.04 mg/ml salmon sperm DNA] for 30 min at room
temperature (24 !C). After the addition of 6! loading buffer
samples were analysed by PAGE (5% gel) and radiolabelled
bands were detected using a Storm840 phosphoimager (GE
Healthcare).
Protein-binding assays (ELISAs) detecting protein–protein or
protein–peptide binding were carried out as described previously
[15].
MS analysis
Samples were analysed by 4–12% gradient SDS/PAGE. The gel
track was excised and divided into approximately 15 sections.
Each section was cut into 1 mm cubes. These were then subjected
to in-gel digestion using trypsin; samples were loaded on to
a C18 column in 0.05 % TFA (trifluoroacetic). Peptides were
eluted using acetonitrile in formic acid (2% acetonitrile in
0.01% formic acid to 90% acetonitrile in 0.08% formic acid).
The eluate was sprayed on to an Ultimate 3000 nLC (Dionex)
column coupled to a LTQ Orbitrap XL (Thermo Scientific) and
the Top 5 Method was used: FT (Fourier transform)-MS plus
five IT (ion trap)-MS/MS (tandem MS) (95 min acquisition).
Orbitrap XL RAW data files were extracted with Raw2MSM
(Version 1.7.2007.04.11) to generate a Mascot generic file (.msm).
Extracted data was searched against the IPI (International Protein
Index) human database (date 20100502) using the Mascot search
engine (version 2.2). The following parameters were used:
type of search, MS/MS ion search; enzyme, trypsin/P; fixed
modifications, carbamidomethyl (C); variable modifications,
acetyl (N-term), dioxidation (M), Gln"pyro-Glu (N-term Q),
GlyGly (K), GlyGly (N-term), oxidation (M); mass values,
monoisotopic; protein mass, unrestricted; peptide mass tolerance,
+#10 p.p.m. (#13C = 2); fragment mass tolerance, +#0.6 Da; and
maximum missed cleavages, two. Hits with a Mascot score under
ten were discarded. Two separate analyses, using different batches
of CHIP-ubiquitinated IRF-1, were carried out in the proteomics
facility in the College of Life Sciences, University of Dundee,
Dundee, U.K.
Generation of models using HADDOCK
The ‘Easy Interface’ of the HADDOCK web server [27,28]
was used to generate models of the IRF-1 DBD conjugated to
ubiquitin. The C-terminal glycine residue of ubiquitin (Gly76)
was selected as the active residue on ubiquitin (structure obtained
from PDB code 1UBQ, chain A [29]) and either Lys39, Lys50,
Lys78 or Lys95 was chosen on the DBD as the active residue in
the IRF-1 structure PDB code 1IF1, chain B. No passive residues
c$ The Authors Journal compilation c$ 2013 Biochemical Society
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Figure 1 MDM2 can act as an E3 ligase for IRF-1 in vitro and in cells
(A) Alignment of the two MDM2-binding motifs on IRF-2 with the homologous regions from IRF-1. (B) HCT-116 cells were co-transfected with 2 µg of pcDNA3-MDM2 or pcDNA3-empty vector
and 2 µg of FLAG–IRF-1WT, IRF-1! Mf2 or empty vector. FLAG conjugates were immunoprecipitated using anti-FLAG-M2 agarose. After elution, samples and lysate (25 µg) were analysed by
immunoblotting using an anti-MDM2 mAb and anti-FLAG mAb. (C) GST–IRF-1 (100 ng) was immobilized on a microtitre plate and incubated with a titration (0–100 ng) of MDM2. Protein binding
was detected using an anti-MDM2 mAb and the protein amount against binding is expressed as relative light units (RLU). The results are representative of at least three independent experiments.
(D) Biotin-tagged IRF-1 peptides (20 amino acids with a five amino acid overlap) were immobilized on a microtitre plate and incubated with 100 ng of MDM2. MDM2 binding to the peptides was
detected using an anti-MDM2 mAb. The data are representative of three individual experiments. (E) An in vitro ubiquitination assay was carried out using GST–IRF-1 as the substrate and increasing
amounts of MDM2 as the E3 ligase (0–160 ng) and incubated for 15 min. The samples were analysed using SDS/PAGE and immunoblotting with an anti-IRF-1 mAb. Results are representative of two
separate experiments. (F) HCT-116 cells were co-transfected with pcDNA3-IRF-1 (0.5 µg), His–ubiquitin (0.5 µg) and pcDNA3-MDM2 (2 µg) as shown. Post-transfection (20 h), cells were treated
with MG132 (50 µM) for 4 h and histidine-labelled ubiquitinated protein was isolated using Ni-NTA chromatography. Samples were analysed by SDS/PAGE and immunoblotting using an anti-IRF-1
mAb. Total amounts of IRF-1 in the sample (bottom panel) and modified IRF-1 (top panel) are shown. The results are representative of three individual experiments. (G) Immunoblot analysis of
HCT-116 cells transfected with the indicated amounts of pcDNA3-MDM2 following cycloheximide (30 µg/ml) treatment. Cells were harvested at the times shown and analysed (60 µg/lane) by
SDS/PAGE (10 % gel) and immunoblotting. IRF-1 was detected using an anti-IRF-1 mAb. Results are representative of at least three separate experiments. IP, immunoprecipitation; ub, ubiquitin.
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Figure 2 IRF-1 is ubiquitinated specifically in its DBD
(A) Time course (0–30 min) of an in vitro ubiquitination assay of IRF-1 modified by His–CHIP (50 ng) (left-hand panel) and MDM2 (80 ng) (right-hand panel). Results are representative of at
least three separate experiments. (B) Schematic illustration of the procedure used to map the ubiquitination sites on IRF-1 by MS (top panel). GST–IRF-1 was ubiquitinated using an in vitro
ubiquitination assay with CHIP as the E3 ligase and isolated from the reaction mix using glutathione beads. A Colloidal-Blue-stained gel before band excision for MS analysis (bottom left-hand panel)
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were selected. The best four structures in the three clusters with
the best HADDOCK score were analysed.
RESULTS
MDM2 can act as an E3 ligase for IRF-1 in vitro and in cells
CHIP, a U-box E3 ligase, docks to a multi-protein-binding
interface in the intrinsically disordered Mf2 domain of IRF-1 and
this interaction is required for efficient modification of IRF-1 by
CHIP in cells [16]. Interestingly, a domain with homology with
the Mf2 is involved in ubiquitination of IRF-2 (Figure 1A), a close
relative of IRF-1, by the RING E3 ligase MDM2 [30], suggesting
that the Mf2 may comprise a general docking site for IRF-1 and
IRF-2 E3 ligases. Thus, in order to acquire additional E3 ligase
tools to study the role of the Mf2 in ubiquitination, we determined
whether MDM2 could act as a docking-dependent ligase for
IRF-1.
We first overexpressed FLAG–IRF-1 in HCT-116 cells and
asked whether MDM2 was detectable after isolation of IRF-
1 complexes using a FLAG pull-down, and whether loss of
the Mf2 domain affected binding. The results show that WT
IRF-1 forms a complex containing MDM2 in cells (Figure 1B,
lanes 2 and 5), whereas an IRF-1 Mf2 mutant (!106–140)
is not associated with MDM2 (lanes 3 and 6). To establish
whether MDM2 could bind directly to IRF-1 or whether other
cellular factors were required for complex formation, protein
interaction assays were carried out using purified components.
GST–IRF-1 was immobilized on a microtitre plate and incubated
with a titration of MDM2 in the mobile phase. Results of this
assay showed that MDM2 bound to IRF-1 in a dose-dependent
manner (Figure 1C). To identify the binding interface between
MDM2 and IRF-1, a peptide–protein interaction assay was used.
An overlapping IRF-1 peptide library (Supplementary Figure
S1 at http://www.biochemj.org/bj/449/bj4490707add.htm) was
immobilized and incubated with a constant amount of MDM2 in
the mobile phase; binding was then detected using an anti-
MDM2 antibody. MDM2 bound to an IRF-1 peptide from within
the Mf2 domain (peptide 8, VRVYRMLPPLTKNQRKERKS;
Figure 1D) with homology with the MDM2-binding site-I of IRF-
2 (Figure 1A).
Whether formation of MDM2–IRF-1-containing complexes
was sufficient to signal IRF-1 ubiquitination was determined using
in vitro and cell-based approaches. Using a minimal ubiquitination
assay employing only purified components, we established that
IRF-1 could act as a substrate for MDM2 and that there was a
positive correlation between the efficiency of IRF-1 ubiquitination
and the concentration of MDM2 added to the assay (Figure 1E).
In-cell ubiquitination assays using His–ubiquitin, IRF-1 and
MDM2 (Figure 1F) were assembled in HCT-116 cells. After
isolation and analysis of His-ubiquitinated proteins, an increase
in the amount of ubiquitinated IRF-1 was seen in the presence
of MDM2 (Figure 1F; compare lane 7 with lane 8). It should be
noted that ubiquitination of IRF-1 seen in lane 7 (Figure 1F) is
mediated by endogenous E3-ligase activity. To determine whether
ubiquitination of IRF-1 by MDM2 had an effect on its half-life,
HCT-116 cells were transfected with MDM2 and treated with
the protein synthesis inhibitor cycloheximide. The loss of IRF-1
protein was then monitored over time by immunoblot analysis
(Figure 1G). The results show that MDM2 overexpression did not
lead to a decrease in the half-life of IRF-1, rather it gave a slight,
but reproducible, increase in its half-life. This is in agreement
with the idea that MDM2 is a monoubiquitin ligase that can only
polyubiquitinate its substrates under specific conditions or in the
presence of an E4 ligase [31]; it also suggests that MDM2 may
be involved in the regulation of IRF-1 activity rather than its rate
of degradation.
Mf2 docking directs DBD ubiquitination by CHIP and MDM2
In order to investigate whether binding of E3 ligases to the Mf2
domain facilitates ubiquitination at specific lysine residues, IRF-1
ubiquitin-acceptor sites modified in the presence of either CHIP
or MDM2 were determined using MS. First, optimal conditions
for IRF-1 ubiquitination were established by performing a time
course of ubiquitination in vitro over 30 min with either CHIP
(Figure 2A, left-hand panel) or MDM2 (right-hand panel).
For identification of ubiquitination sites by MS, IRF-1 was
ubiquitinated for either 10 or 45 min and discrete ubiquitinated
intermediates were excised and subjected to in-gel digestion using
trypsin (Figure 2B). Ubiquitin-modified residues are protected
from trypsin cleavage, resulting in a distinct cleavage pattern for
the ubiquitinated protein. Furthermore, ubiquitin that is attached
to the protein is cleaved off at a C-terminal arginine residue
leaving a di-glycine peptide remnant that adds 114.043 Da to the
ubiquitinated peptide. The modified cleavage pattern, together
with the mass additions, facilitate identification, by MS, of
peptides that have been ubiquitinated (Figure 2B).
Although there are a total of 23 lysine residues in the primary
amino acid sequence of IRF-1, only a subset of those were detected
by MS as being ubiquitin-acceptor sites for the Mf2-binding
ligases CHIP or MDM2 (Figures 2C and 2D). Strikingly, IRF-1
was predominantly ubiquitinated in, or adjacent to, the DBD and
no modified residues from within the C-terminal half of the protein
were detected with either of the E3 ligases. Although both MDM2
and CHIP modified Lys39, Lys50 and Lys117, in the two independent
analyses of CHIP-ubiquitinated IRF-1 Lys95 modification was
not detected, whereas this residue was modified when MDM2
provided the E3 activity. Similarly, Lys78 was detected only
in the CHIP-ubiquitinated samples. Although this difference in
specificity remains to be confirmed using a second analytical
technique, the existing data suggest that although Mf2-directed
ubiquitination of IRF-1 is specific for the DBD, there could be
subtle differences in the exact residues targeted by MDM2 and
CHIP.
and immunoblot analysis of the samples blotted for IRF-1 and CHIP (bottom right-hand panel) are shown. CHIP was co-purified from the reaction with IRF-1 as a result of IRF-1–CHIP protein
interactions. Results are indicative of two separate experiments utilising CHIP and MDM2 as E3 ligases for the ubiquitination reaction. (C) Results of MS analysis of modified peptides in IRF-1. Lysine
residues that were shown to be modified by ubiquitin are highlighted in red. (D) Modified lysine residues are indicated on a schematic IRF-1 domain structure. Lysine residues that are modified by
only MDM2 or CHIP are shown in red, whereas residues that are modified by both are shown in black. (E) Model of ubiquitinated IRF-1. Ubiquitin was modelled on to the available crystal structure
of the IRF-1 DBD (PDB code 1IF1) (white) using the HADDOCK web server at Lys39 (green), Lys50 (yellow), Lys78 (red) and Lys95 (blue), the structure that obtained the highest score for each site
(left-hand panel) and the three structures obtaining the highest score in one of the three best clusters for each site (right-hand panel) are shown. (F) In vitro ubiquitination of IRF-1 with CHIP and
MDM2 as E3 ligases and either WT or NoK ubiquitin (in which all lysine residues are mutated to arginine). Reactions with WT ubiquitin were incubated for 10 min, whereas the reactions with no E3
ligase and NoK ubiquitin were incubated for 60 min. The results are representative of two independent experiments. (G) In vitro ubiquitination assay with GST–IRF-1 containing the indicated mutation
at one of the ubiquitin-acceptor lysine residues, NoK ubiquitin and CHIP as the E3 ligase; the reactions were incubated for 45 min. Immunoblots were probed with an anti-IRF-1 pAb. ub, ubiquitin.
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Using the HADDOCK web server [27,28], a model of
the ubiquitinated IRF-1 DBD was generated with ubiquitin
docked to the ubiquitin-acceptor sites identified (only sites
present in the crystal structure [32], amino acids 7–
111 are shown; Figure 2E and Supplementary Figure S2
at http://www.biochemj.org/bj/449/bj4490707add.htm). Interest-
ingly, modelling suggests that modification at three of the five
ubiquitination sites identified (Lys39, Lys50 and Lys78) would result
in ubiquitin occupying an overlapping three-dimensional space.
Thus ubiquitination at any one of these three sites could potentially
block ubiquitination at the other two sites. In order to investigate
this model experimentally in vitro ubiquitination assays, using
either WT ubiquitin or an ubiquitin mutant in which all of the
lysine residues were mutated to arginine (NoK ubiquitin), were
used. For the majority of E3 ligases NoK ubiquitin can only
result in the formation of monoubiquitinated residues as chain
elongation is not possible (linear ubiquitin chain formation by
SHARPIN [33] is an exception to this). We found that the ubiquitin
mutant was, in general, a poor substrate for in vitro ubiquitination
with slower conversion of IRF-1 into its monoubiquitinated form
than is seen in the presence of WT ubiquitin. However, when
assay conditions were adapted to facilitate ubiquitination we saw
that monoubiquitination provided a maximum of three ubiquitins
added per IRF-1 molecule, and in the case of MDM2 a single
ubiquitinated form was predominant (Figure 3E, bottom panel;
compare lanes 3 and 5 with lanes 2 and 4), suggesting that
a maximum of three out of the five ubiquitin-acceptor sites
identified can be modified at any one time.
If the modelling is correct we would predict that mutation of
Lys39, Lys50 and Lys78 individually would not be sufficient to
affect IRF-1 DBD monoubiquitination. Therefore to complement
the above approach a series of IRF-1 point mutant proteins was
generated in which Lys39, Lys50 and Lys78 were individually
mutated to arginine. When the mutant proteins were used as
substrates for CHIP in the presence of NoK ubiquitin, loss
of Lys39 and Lys78 did not produce qualitative or quantitative
changes in monoubiquitination of IRF-1, consistent with the idea
that ubiquitination at either one of these residues produces a
similar outcome and that ubiquitination at these two sites is
mutually exclusive. Although mutation of Lys50 did have an
effect on monoubiquitination, with loss of the slowest migrating
ubiquitinated form of IRF-1, this mutant was susceptible to
cleavage during expression and the cleavage product was also
a substrate for CHIP, making the data difficult to interpret.
Unfortunately, we were not able to test the modelling data using
double and triple mutants as the introduction of multiple lysine
point mutations produced proteins that were extremely susceptible
to cleavage during expression.
Taken as a whole, the data in this section support the modelling
data and suggest that ubiquitination of Lys39 and Lys78, and
potentially Lys50, are mutually exclusive and might therefore
result in the generation of a very similar ‘molecular signature’.
DNA-bound IRF-1 is protected from ubiquitination in vitro
When the ubiquitin-modified residues were mapped on to the
available IRF-1 DBD crystal structure, we found that Lys39,
Lys50 and Lys95 were located in exposed loops (L1, L2 and
L3), whereas Lys78 was positioned within the !3-helix which
forms the second helix of the HTH (helix–turn–helix) homologous
motif (Figure 3A). As the ubiquitin-acceptor sites are all located
within the DBD, with Lys78 and Lys95 being at the DNA-binding
interface (Figure 3A), we reasoned that modification may be
affected by the sequence-specific DNA-binding activity of IRF-1.
To test this, IRF-1 was pre-incubated with a consensus site DNA
oligonucleotide (C1), which we show can bind to GST–IRF-1WT
(Figure 3B, lanes 3–5), but not a DNA-binding mutant, IRF-1W11R
(lanes 6–9), in an EMSA and is supershifted by an anti-IRF-1
mAb. A control oligonucleotide that does not interact with
IRF-1 (p21c) was used as a negative control (Figure 3B, lanes 7–
10). Whereas control DNA (p21c) had no significant effect on the
ubiquitination of IRF-1 by CHIP (Figure 3C, left-hand panel) or
MDM2 (right-hand panel), addition of IRF-1 consensus site DNA
(C1) almost completely suppressed ubiquitination. To control
for non-specific effects of DNA on IRF-1 we used a non-DNA-
binding mutant (IRF-1W11R; Figure 3B) and asked whether this was
refractive to the effects of DNA. Figure 3(C) shows that whereas
C1 oligonucleotides inhibit the ubiquitination of wild-type IRF-1
(lanes 4 and 5) they had no significant effect on the ubiquitination
of IRF-1W11R (lanes 9 and 10). As an additional control we showed
that C1 DNA did not affect CHIP activity directly as there was
no effect on the ability of CHIP to mediate autoubiquitination
(Figure 3C, bottom panel). Ubiquitination of p53, a second well-
characterized substrate for both CHIP (Figure 3D, left-hand panel)
and MDM2 (Figure 3D, right-hand panel), was not affected by p53
binding to DNA from the p21 promoter (p21c DNA), suggesting
that protection of IRF-1 from ubiquitination by DNA is not a
property of all transcription factors (Figure 3D).
To expand on the observation described above, which used
an optimized IRF-1 consensus DNA oligonucleotide, a range
of oligonucleotide probes based on naturally occurring binding
elements from IRF-1 target gene promoters was examined.
Elements from all of the IRF-1 target genes tested were able
to inhibit CHIP- and MDM2-mediated ubiquitination and there
was good agreement between the ability of IRF-1 to bind DNA
in an EMSA (Figure 3E, bottom panel) and the ability of the
oligonucleotide to inhibit ubiquitination of IRF-1 in an in vitro
ubiquitination assay (Figure 3E, top panels). For example, IRF-
1 binds only weakly to an oligonucleotide based on the TRAIL
promoter and this probe is a weak inhibitor of IRF-1 ubiquitination
(Figure 3E, bottom panel, lane 5).
IRF-1 bound to DNA is unable to associate with proteins that
interact with its Mf2 domain
We reasoned that there were two possible mechanisms to explain
the loss of IRF-1 ubiquitination when in its DNA-bound form;
first the targeted lysine residues may be ‘cryptic’ and therefore
inaccessible to the ligases, or secondly, the ability of IRF-1 to bind
to CHIP or to MDM2 may be impaired. As the available structural
data for the DBD of IRF-1 bound to its cognate DNA element [32]
suggests that at least some of the required lysine residues are still
available for ubiquitination (Figure 3A; for example Lys50), we
concentrated on the second option, i.e. a change in the affinity
of IRF-1 for Mf2-binding proteins. To address the effects of
IRF-1 DNA binding on its ability to interact with components
of the ubiquitination system, we used protein-interaction assays
to measure CHIP binding to IRF-1 protein that had been pre-
incubated with either C1 oligonucleotide or control DNA (p21c).
Initial titrations demonstrated binding of native unliganded IRF-
1 in solution to immobilized CHIP in a dose-dependent manner
(Figure 4A, left-hand panel). On the basis of this assay a
fixed amount of CHIP was immobilized and incubated with
a constant amount of IRF-1 that had been pre-incubated with a
titration of either C1 or p21c. Figure 4(A) (right-hand panel)
shows that whereas IRF-1 binding to CHIP was largely unaffected
by p21c, titration of C1 into the assay inhibited CHIP binding. The
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Figure 3 DNA-bound IRF-1 is protected from ubiquitination in vitro
(A) Crystal structure of the IRF-1 DBD (PDB code 1IF1) with lysine residues that were shown to be modified indicated by sticks. (B) EMSA showing binding of a titration (100 and 300 ng) of purified
GST–IRF-1WT or of the DNA-binding mutant GST–IRF-1W11R to a 32P-labelled DNA probe of C1 DNA (left-hand panel) or binding of GST-IRF-1WT to the C1 probe compared with the non-binding
control probe (p21c) (right-hand panel). When indicated an anti-IRF-1 mAb was added to the reaction to supershift the protein–DNA complex. (C) In vitro ubiquitination assay using GST–IRF-1WT
and GST–IRF-1W11R as substrate with a titration of either C1 oligonucleotides or p21c DNA (0.25 and 1 µM) using CHIP (left-hand panel) or MDM2 (right-hand panel) as the E3 ligase. Results
are representative of at least three separate experiments. (D) In vitro ubiquitination assay with p53 as the substrate and a titration of p21 promoter DNA (10 nm–1 µM) or C1 DNA (500 nM) with
either CHIP (left-hand panel) or MDM2 (right-hand panel) as the E3 ligase. (E) The effects of oligonucleotides from promoters of different IRF-1-inducible genes (3 µM) were tested on the in vitro
ubiquitination of IRF-1 by CHIP (top left-hand panel) and MDM2 (top right-hand panel) and compared with the ability of GST–IRF-1 (300 ng) to bind to the oligonucleotides in a band-shift assay
(bottom panel). Where indicated, an anti-IRF-1 antibody was added to the reaction to supershift the complex. The results are representative of two independent experiments.
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Figure 4 IRF-1 bound to DNA is unable to associate with proteins that interact with its Mf2 domain
(A) His–CHIP (100 ng) was immobilized on a microtitre plate and incubated with either a titration of purified GST–IRF-1 alone (0–100 ng) (left-hand panel) or with constant amounts of GST–IRF-1
(100 ng) and a titration of C1 DNA or p21c DNA (right-hand panel). Results are representative of at least three separate experiments. (B) MDM2 (100 ng) was immobilized on a microtitre plate and
incubated with GST–IRF-1 (100 ng) and C1 or p21c DNA (100 nM). Binding was detected using an anti-IRF-1 mAb. The results are representative of two individual experiments. (C) EMSA presenting
binding of 300 ng of purified GST–IRF-1WT to a 32P-labelled DNA probe of C1 DNA in the presence of 0.3 or 1.5 µg of purified His–CHIP or MDM2 as shown. When indicated an anti-IRF-1 mAb
was added to the reaction to supershift the protein–DNA complex. (D) Different Mf2-domain-binding proteins, SET and Kap-1, were immobilized on a microtitre plate (100 ng) and incubated with
GST–IRF-1 (100 ng) and C1 or p21c DNA (100 nM). Binding was detected using an anti-IRF-1 mAb. Results are representative of at least two separate experiments. RLU, relative light unit.
results of this assay suggest that stable binding of CHIP to IRF-1
is severely restricted when IRF-1 is in its DNA-bound form.
Similarly, when we tested binding of MDM2 to IRF-1 in its
DNA-bound and -unbound form, MDM2 bound preferentially to
the unbound form of IRF-1 (Figure 4B). To test whether CHIP
and MDM2 binding had a reciprocal effect on DNA binding
we examined whether the ligases could compete with DNA for
binding to IRF-1 using an EMSA (Figure 4C). Neither CHIP nor
MDM2 had any effect on the ability of IRF-1 to bind to DNA,
suggesting that IRF-1 has a higher affinity for DNA than for the
Mf2-binding protein. As we have shown that the Mf2 domain is
a multi-protein-binding site that interacts with a number of other
IRF-1 regulators, we also tested the effect of DNA binding on
the interaction of IRF-1 with Kap-1 and SET [16]. Figure 4(D)
shows reduced binding of IRF-1 to both Kap-1 and SET when in
its DNA-bound state.
The crystal structure of the IRF-1 DBD in complex with its
cognate promoter-binding element suggests that residues from
within the Mf2 domain are not required for DNA binding [30],
thus the results of the present study can be interpreted to suggest
that access to the Mf2 interface is controlled through changes in
the conformation of IRF-1 rather than through direct competition
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for binding to DNA. However, as deletion of the Mf2 domain
prevents IRF-1 from binding to DNA (Supplementary Figure S3 at
http://www.biochemj.org/bj/449/bj4490707add.htm) we cannot
completely rule out the possibility that residues from the Mf2
contribute to binding through a direct contact with the DNA.
In summary the experiments presented here suggest that Mf2-
domain-binding partners are likely to function only on the
unliganded form of the protein. Furthermore, the observation that
neither MDM2 nor CHIP is able to ubiquitinate IRF-1 unless
they are bound to the protein lends strong support for a direct
relationship between E3-ligase binding, ubiquitination and site-
specificity.
Ubiquitination of IRF-1 in cells is enhanced in a DNA-binding
mutant
Taken together, the above observations led us to hypothesize
that IRF-1 is ‘protected’ from ubiquitination, and therefore
presumably from degradation, when it is in its transcriptionally
active DNA-bound conformation. To lend support to this
hypothesis, we determined whether a non-DNA-binding mutant
of IRF-1 was more or less prone to ubiquitination than the wild-
type protein. We first confirmed that specific DNA does not
inhibit binding of CHIP to IRF-1W11R in vitro using a protein–
protein interaction assay. CHIP was coated on to a microtitre
plate and incubated with IRF-1 and a titration of C1 DNA
(Figure 5A). As expected, C1 DNA inhibited binding of IRF-
1WT to CHIP, whereas binding of CHIP to IRF-1W11R was not
affected by the presence of DNA. To ensure that the kinetics of
ubiquitination of IRF-1WT compared with IRF-1W11R by CHIP was
not significantly different, we performed in vitro ubiquitination
assays with a titration of CHIP in the absence of any DNA.
CHIP ubiquitinated both IRF-1WT and IRF-1W11R to a similar
extent in vitro (Figure 5B). Next in vivo ubiquitination assays
were carried out in HCT-116 cells using IRF-1WT and IRF-1W11R.
When histidine-labelled ubiquitinated proteins were isolated from
cells that had been transfected with either IRF-1WT or IRF-1W11R
together with His–ubiquitin we found that the IRF-1W11R mutant
was hyperubiquitinated when compared with the WT protein
(Figure 5C, compare lanes 3 and 4), supporting the idea that IRF-1
which is not associated with the chromatin is more ‘available’ for
ubiquitination by endogenous Mf2-domain-interacting ligases.
Thus although CHIP ubiquitinates IRF-1WT and IRF-1W11R to a
similar extent in vitro, in cells the Trp11 mutant is preferentially
ubiquitinated, supporting the concept that free IRF-1 may be
turned over more rapidly than the pool of IRF-1 that is bound, or
able to bind, to DNA.
DISCUSSION
In recent years, ubiquitination has been linked to a growing
number of cellular processes and it is now apparent that ubiquitin
modification is involved not only in proteasomal degradation,
but serves as a common mechanism for executing a wide
variety of signalling events [1,2]. This raises the question of
how the ubiquitin reaction is controlled at multiple levels in
order to generate distinct outcomes. Differences in the result
of ubiquitination can be achieved by the position of the target
lysine residue in the acceptor protein [34], as well as by the
use of different linkages and length of the ubiquitin chain.
Yet, our understanding of ubiquitin-acceptor site selection lags
behind a growing structural and mechanistic understanding of
chain elongation and linkage determination [2]. One of the
mechanisms proposed for ubiquitin-acceptor site specificity is
Figure 5 Ubiquitination of IRF-1 in cells is enhanced in a DNA-binding
mutant
(A) His–CHIP (100 ng) was immobilized on a microtitre plate and incubated with constant
amounts of either GST–IRF-1WT or GST–IRF-1W11R (100 ng) and a titration of C1 or p21c probe.
The results are representative of four separate experiments. (B) In vitro ubiquitination assay using
GST–IRF-1WT or GST–IRF-1W11R as substrate with a titration of His–CHIP (0–60 ng). Results
are representative of three independent experiments. (C) HCT-116 cells were co-transfected
with pcDNA3-IRF-1WT or pcDNA3-IRF-1W11R (0.5 µg) and His–ubiquitin (0.5 µg) as shown.
At 20 h post-transfection cells were treated with MG132 (50 µM) for 4 h and histidine-labelled
ubiquitinated protein was isolated using Ni-NTA chromatography and analysed by SDS/PAGE
and immunoblotting. Total amounts of IRF-1 in the sample (bottom panel) and modified IRF-1
(top panel) are shown. The results are representative of three separate experiments.
that the E3 positions the charged E2 in close proximity to the
target lysine residue and thereby determines which residues are
subject to modification [35]. Thus while artificial ‘tethering’ of
some E2s to their targets in the absence of an E3 is sufficient
to signal substrate ubiquitination, this process is fairly non-
discriminatory leading to promiscuous modification of lysine
residues. In the presence of the E3, however, only a subset of the
lysine modified by the E2 alone are ubiquitinated [36], suggesting
that, as well as stimulating discharge of the ubiquitin from the E2
through allosteric mechanisms [37,38], E3 ligases may also act
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Figure 6 Model of interplay between DNA binding of IRF-1 and interaction with its E3 ligases followed by ubiquitination
The Mf2 domain is a multi E3-ligase-docking site in close proximity to the DBD of IRF-1. Binding of E3 ligases to the Mf2 domain results in ubiquitination of the proximal DBD and this leads to the
proteasomal degradation of IRF-1. In complex with DNA, however, IRF-1 is unable to bind E3 ligases and other Mf2-binding partners and is not ubiquitinated and thus protected from degradation.
ub, ubiquitin.
to restrain the E2, ensuring that only specific target residues are
modified. Analysis of the UbcH5c–ubiquitin complex by both
NMR and SAXS (small-angle X-ray scattering) [39] has shown
that the conjugate is very flexible and can exhibit a range of
conformations in solution, explaining how one E3 ligase can
mediate ubiquitination of several different residues within a target
protein. The results of the present study are in good agreement
with this mechanism; we propose that IRF-1 ubiquitination is
specific to its DBD and that this is achieved through docking of E3
ligases to its Mf2 domain followed by ubiquitination of the lysine
residues in close proximity. However, we also note that other DBD
lysine residues as well as lysine residues in the Mf2 domain itself
are not ubiquitinated by either MDM2 or CHIP, suggesting that
ubiquitination of these residues is sterically unfavourable.
The observation that DNA binding protects IRF-1 from
ubiquitination is intriguing as it suggests a mechanism by which
turnover of this transcription factor might decrease when it is
in an active state, i.e. when part of a pre-initiation complex. In
recent years it has become clear that the ubiquitin–proteasome
system and the transcriptional machinery are intimately linked,
and that ubiquitin-mediated proteolysis can enhance the activity
of TAs (transcriptional activators). This is known as the ‘activation
by destruction’ mechanism [40] and was first indicated by
the observation that the transactivation domain and the region
required for degradation (degron) overlap in many TAs, including
IRF-1 [41]. Furthermore, factors that affect the rate of turnover
for this group of transcription factors typically also affect their
transactivation potential [40,42]. In keeping with this we have
developed nanobodies to a negative regulatory domain of IRF-1
and, in addition to activating the TA activity of endogenous
IRF-1 by up to 8-fold, they also modulate the rate of IRF-1
degradation [40]. The most popular hypothesis to explain the
connection between degradation and TA function in gene expres-
sion is based on a ‘suicide’ model where activator degradation
is somehow required as part of the activation mechanism and
potentially also to terminate the signal [42]. Implicit in this
model is that the TA is not subject to degradation prior to com-
pleting its function or when part of an active DNA-bound
complex [42]. In the present study we show that DNA-
bound IRF-1 has a cryptic or inaccessible E3-binding site, and
that a non-DNA binding mutant of IRF-1 is hyperubiquitinated in
comparison with the WT protein (Figure 6). These data support
the idea that IRF-1 is ‘protected’ from degradation when it is part
of an active pre-initiation complex, but can be rapidly degraded
when it is not functional or when it has completed its function.
How the ‘suicide’ model fits in with recent findings that TAs take
part in ‘tread-milling’ rapidly on and off the chromatin [43] has
not been explained. It will therefore be of interest to further dissect
the role of polyubiquitination and its interplay with other forms of
post-translational modification in the regulation of IRF-1 activity
as a transcription factor.
In conclusion, in the present paper we report that ubiquitination
of residues in the DBD of IRF-1 is achieved through E3-ligase
binding to an adjacent multi-protein docking site resulting in the
selective modification of several lysine residues. Docking of
the E3 to its substrate is therefore not only required for
ubiquitination, but also determines the specificity of the reaction.
If the E3 cannot bind to its substrate, for example when IRF-1
is bound to DNA, it is not able to mediate DBD ubiquitination,
suggesting a mechanism by which an active pool of IRF-1 might
be protected from degradation in cells.
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Figure S1 IRF-1 peptides
List of the IRF-1 peptide library used in the protein–peptide binding assay in Figure 1(D) of the
main text.
Figure S2 Model of monoubiquitinated IRF-1
Ubiquitin was modelled on to the IRF-1 DBD at the ubiquitin receptor lysine residues present in
the crystal structure [Lys39 (K39), Lys50 (K50), Lys78 (K78) and Lys95 (K95)] using the HADDOCK
web server. From the results obtained the four best structures from the three best clusters were
analysed. The overlay of the ubiquitin position in respect to IRF-1 for each lysine residue are
shown, with ubiquitin in structures obtained from different clusters in different colours.
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Figure S3 An IRF-1 Mf2 domain deletion mutant is DNA-binding-deficient
EMSA showing binding of a titration (100 and 300 ng) of purified GST–IRF-1WT or
GST–IRF-1!Mf2 to a 32P-labelled DNA probe of C1 DNA; an anti-IRF-1 mAb was included in
the reaction where indicated to supershift the complex (left-hand panel). Purified GST–IRF-1WT
or GST–IRF-1!Mf2 was separated by SDS/PAGE and analysed by immunoblotting using an
anti-IRF-1 pAb.
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